13.07.2015 Views

Basic Lab Procedures in Clinical Bacteriology - J. Vandepitte

Basic Lab Procedures in Clinical Bacteriology - J. Vandepitte

Basic Lab Procedures in Clinical Bacteriology - J. Vandepitte

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Basic</strong>laboratoryprocedures<strong>in</strong> cl<strong>in</strong>icalbacteriology


<strong>Basic</strong>laboratoryprocedures<strong>in</strong> cl<strong>in</strong>icalbacteriologySecond editionJ. <strong>Vandepitte</strong> and J. VerhaegenDepartment of MicrobiologySt Rafaël Academic HospitalLeuven, BelgiumK. EngbaekDepartment of Cl<strong>in</strong>ical MicrobiologyUniversity of CopenhagenHerlev HospitalHerlev, DenmarkP. RohnerDepartment of Cl<strong>in</strong>ical MicrobiologyCantonal University HospitalGeneva, SwitzerlandP. PiotJo<strong>in</strong>t United Nations Programme on HIV/AIDSGeneva, SwitzerlandC. C. HeuckWorld Health OrganizationGeneva, SwitzerlandWorld Health OrganizationGeneva2003


WHO Library Catalogu<strong>in</strong>g-<strong>in</strong>-Publication Data<strong>Basic</strong> laboratory procedures <strong>in</strong> cl<strong>in</strong>ical bacteriology / J. <strong>Vandepitte</strong> . . . [et al.].—2nd ed.1.Bacteriological techniques—standards3.Manuals I.<strong>Vandepitte</strong>, J.2.<strong>Lab</strong>oratory techniques and procedures standardsISBN 92 4 154545 3 (NLM classification: QY 100)© World Health Organization 2003All rights reserved. Publications of the World Health Organization can be obta<strong>in</strong>ed from Market<strong>in</strong>gand Dissem<strong>in</strong>ation, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel:+41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.<strong>in</strong>t). Requests for permission toreproduce or translate WHO publications–whether for sale or for noncommercial distribution–shouldbe addressed to Publications, at the above address (fax: +41 22 791 4806; email:permissions@who.<strong>in</strong>t).The designations employed and the presentation of the material <strong>in</strong> this publication do not imply theexpression of any op<strong>in</strong>ion whatsoever on the part of the World Health Organization concern<strong>in</strong>g thelegal status of any country, territory, city or area or of its authorities, or concern<strong>in</strong>g the delimitationof its frontiers or boundaries. Dotted l<strong>in</strong>es on maps represent approximate border l<strong>in</strong>es for whichthere may not yet be full agreement.The mention of specific companies or of certa<strong>in</strong> manufacturers’ products does not imply that theyare endorsed or recommended by the World Health Organization <strong>in</strong> preference to others of a similarnature that are not mentioned. Errors and omissions excepted, the names of proprietary productsare dist<strong>in</strong>guished by <strong>in</strong>itial capital letters.The World Health Organization does not warrant that the <strong>in</strong>formation conta<strong>in</strong>ed <strong>in</strong> this publicationis complete and correct and shall not be liable for any damages <strong>in</strong>curred as a result of its use.The named authors alone are responsible for the views expressed <strong>in</strong> this publication.Typeset <strong>in</strong> Hong KongPr<strong>in</strong>ted <strong>in</strong> S<strong>in</strong>gapore2001/13712—SNPBest-set/SNPSpr<strong>in</strong>t—6000


ContentsPrefaceviiiIntroduction 1Quality assurance <strong>in</strong> bacteriology 2Introduction 2Def<strong>in</strong>itions 2Internal quality control 6External quality assessment 16PART IBacteriological <strong>in</strong>vestigations 19Blood 20Introduction 20When and where bacteraemia may occur 20Blood collection 20Blood-culture media 22Process<strong>in</strong>g of blood cultures 23Cerebrosp<strong>in</strong>al fluid 25Introduction 25Collection and transportation of specimens 25Macroscopic <strong>in</strong>spection 26Microscopic exam<strong>in</strong>ation 26Prelim<strong>in</strong>ary identification 28Susceptibility test<strong>in</strong>g 29Ur<strong>in</strong>e 30Introduction 30Specimen collection 30Culture and <strong>in</strong>terpretation 32Interpretation of quantitative ur<strong>in</strong>e culture results 34Identification 35Susceptibility tests 36Stool 37Introduction 37Etiological agents and cl<strong>in</strong>ical features 37Appropriate use of laboratory resources 39Collection and transport of stool specimens 40Visual exam<strong>in</strong>ation of stool specimens 41Enrichment and <strong>in</strong>oculation of stool specimens 41Media for enteric pathogens 42Primary isolation 42Prelim<strong>in</strong>ary identification of isolates 44v


CONTENTSF<strong>in</strong>al microbiological identification 50Serological identification 54Upper respiratory tract <strong>in</strong>fections 60Introduction 60Normal flora of the pharynx 60Bacterial agents of pharyngitis 61Collection and dispatch of specimens 62Direct microscopy 62Culture and identification 63Susceptibility test<strong>in</strong>g 65Lower respiratory tract <strong>in</strong>fections 66Introduction 66The most common <strong>in</strong>fections 66Collection of sputum specimens 68Process<strong>in</strong>g of sputum <strong>in</strong> the laboratory (fornon-tuberculous <strong>in</strong>fections) 68Culture for Mycobacterium tuberculosis 72Interpretation of cultures for M. tuberculosis 74General note on safety 74Sexually transmitted diseases 76Introduction 76Urethritis <strong>in</strong> men 77Genital specimens from women 79Specimens from genital ulcers 82Purulent exudates, wounds and abscesses 86Introduction 86Commonly encountered cl<strong>in</strong>ical conditions and themost frequent etiological agents 86Collection and transportation of specimens 89Macroscopic evaluation 90Microscopic exam<strong>in</strong>ation 91Culture 92Identification 93Susceptibility test<strong>in</strong>g 97Anaerobic bacteriology 98Introduction 98Description of bacteria <strong>in</strong> relation to oxygen requirement 98<strong>Bacteriology</strong> 98Antimicrobial susceptibility test<strong>in</strong>g 103Introduction 103General pr<strong>in</strong>ciples of antimicrobial susceptibility test<strong>in</strong>g 103Cl<strong>in</strong>ical def<strong>in</strong>ition of terms “resistant” and “susceptible”:the three category system 104Indications for rout<strong>in</strong>e susceptibility tests 106vi


CONTENTSChoice of drugs for rout<strong>in</strong>e susceptibility tests <strong>in</strong> thecl<strong>in</strong>ical laboratory 107The modified Kirby–Bauer method 109Direct versus <strong>in</strong>direct susceptibility tests 117Technical factors <strong>in</strong>fluenc<strong>in</strong>g the size of the zone <strong>in</strong> thedisc-diffusion method 118Quality control 120Serological tests 122Introduction 122Quality control measures 122Serological reactions 125Serological tests for syphilis 126Febrile agglut<strong>in</strong><strong>in</strong>s tests 133Antistreptolys<strong>in</strong> O test 135Bacterial antigen tests 137PART IIEssential media and reagents 141Introduction 142Pathogens, media and diagnostic reagents 143Blood 144Cerebrosp<strong>in</strong>al fluid 144Ur<strong>in</strong>e 145Stool 146Upper respiratory tract 147Lower respiratory tract 148Urogenital specimens for exclusion of sexually transmitteddiseases 149Pus and exudates 149List of recommended media and diagnostic reagentsfor the <strong>in</strong>termediate microbiological laboratory 150Selected further read<strong>in</strong>g 154Index 155vii


IntroductionCommunicable diseases cont<strong>in</strong>ue to account for an unduly high proportionof the health budgets of develop<strong>in</strong>g countries. Accord<strong>in</strong>g to The world healthreport, 1 acute diarrhoea is responsible for as many as 2.2 million deaths annually.Acute respiratory <strong>in</strong>fections (primarily pneumonia) are another importantcause of death, result<strong>in</strong>g <strong>in</strong> an estimated 4 million deaths each year.Analysis of data on lung aspirates appears to <strong>in</strong>dicate that, <strong>in</strong> develop<strong>in</strong>gcountries, bacteria such as Haemophilus <strong>in</strong>fluenzae and Streptococcus pneumoniae,rather than viruses, are the predom<strong>in</strong>ant pathogens <strong>in</strong> childhood pneumonia.b-Lactamase-produc<strong>in</strong>g H. <strong>in</strong>fluenzae and S. pneumoniae with decreasedsensitivity to benzylpenicill<strong>in</strong> have appeared <strong>in</strong> different parts of the world,mak<strong>in</strong>g the surveillance of these pathogens <strong>in</strong>creas<strong>in</strong>gly important.Sexually transmitted diseases are on the <strong>in</strong>crease. There are still threats ofepidemics and pandemics of viral or bacterial orig<strong>in</strong>, made more likely by<strong>in</strong>adequate epidemiological surveillance and deficient preventive measures.To prevent and control the ma<strong>in</strong> bacterial diseases, there is a need to developsimple tools for use <strong>in</strong> epidemiological surveillance and disease monitor<strong>in</strong>g,as well as simplified and reliable diagnostic techniques.To meet the challenge that this situation represents, the health laboratory servicesmust be based on a network of laboratories carry<strong>in</strong>g out microbiologicaldiagnostic work for health centres, hospital doctors, and epidemiologists.The complexity of the work will <strong>in</strong>crease from the peripheral to the <strong>in</strong>termediateand central laboratories. Only <strong>in</strong> this way will it be possible to gather,quickly enough, sufficient relevant <strong>in</strong>formation to improve surveillance, andpermit the early recognition of epidemics or unusual <strong>in</strong>fections and the development,application, and evaluation of specific <strong>in</strong>tervention measures.1 The world health report 2000. Geneva, World Health Organization, 2000.1


Quality assurance <strong>in</strong> bacteriologyIntroductionQuality assurance programmes are an efficient way of ma<strong>in</strong>ta<strong>in</strong><strong>in</strong>g thestandards of performance of diagnostic laboratories, and of upgrad<strong>in</strong>g thosestandards where necessary. In microbiology, quality goes beyond technicalperfection to take <strong>in</strong>to account the speed, cost, and usefulness or cl<strong>in</strong>icalrelevance of the test. <strong>Lab</strong>oratory tests <strong>in</strong> general are expensive and, withprogress <strong>in</strong> medic<strong>in</strong>e, they tend to use up an <strong>in</strong>creas<strong>in</strong>g proportion of thehealth budget.Def<strong>in</strong>itionsTo be of good quality, a diagnostic test must be cl<strong>in</strong>ically relevant, i.e. it musthelp <strong>in</strong> the prevention or treatment of disease. Other measures of quality <strong>in</strong> adiagnostic test are:• Reliability: Is the result correct?• Reproducibility: Is the same result obta<strong>in</strong>ed when the test is repeated?• Speed: Is the test rapid enough to be of use to the doctor <strong>in</strong> prescrib<strong>in</strong>gtreatment?• Cost–benefit ratio: Is the cost of the test reasonable <strong>in</strong> relation to the benefitto the patient and the community?Factors that affect the reliability and reproducibilityof laboratory resultsSources of error may <strong>in</strong>clude the follow<strong>in</strong>g:• Personnel. The performance of the laboratory worker or technician isdirectly related to the quality of education and tra<strong>in</strong><strong>in</strong>g received, theperson’s experience, and the conditions of employment.• Environmental factors. Inadequate work<strong>in</strong>g space, light<strong>in</strong>g, or ventilation,extreme temperatures, excessive noise levels, or unsafe work<strong>in</strong>g conditionsmay affect results.• Specimens. The method and time of sampl<strong>in</strong>g and the source of the specimenare often outside the direct control of the laboratory, but have a directbear<strong>in</strong>g on the ability of the laboratory to achieve reliable results. Otherfactors that the laboratory can control and that affect quality are the transport,identification, storage, and preparation (process<strong>in</strong>g) of specimens.The laboratory therefore has a role <strong>in</strong> educat<strong>in</strong>g those tak<strong>in</strong>g and transport<strong>in</strong>gspecimens. Written <strong>in</strong>structions should be made available andregularly reviewed with the cl<strong>in</strong>ical and nurs<strong>in</strong>g staff.• <strong>Lab</strong>oratory materials. The quality of reagents, chemicals, glassware, sta<strong>in</strong>s,culture media, and laboratory animals all <strong>in</strong>fluence the reliability of testresults.• Test method. Some methods are more reliable than others.• Equipment. Lack of equipment or the use of substandard or poorly ma<strong>in</strong>ta<strong>in</strong>ed<strong>in</strong>struments will give unreliable results.• Exam<strong>in</strong>ation and read<strong>in</strong>g. Hurried read<strong>in</strong>g of results, or failure to exam<strong>in</strong>ea sufficient number of microscope fields, can cause errors.• Report<strong>in</strong>g. Transcription errors, or <strong>in</strong>complete reports, cause problems.2


QUALITY ASSURANCE IN BACTERIOLOGYQuality of <strong>in</strong>terpretation of test resultsInterpretation is of particular importance <strong>in</strong> microbiology. At each stage <strong>in</strong> theexam<strong>in</strong>ation of a specimen, the results should be <strong>in</strong>terpreted <strong>in</strong> order to selectthe optimum test, <strong>in</strong> terms of speed and reliability, for the next stage of theexam<strong>in</strong>ation.Quality assurance <strong>in</strong> the microbiology laboratoryQuality assurance is the sum of all those activities <strong>in</strong> which the laboratory isengaged to ensure that test results are of good quality. It must be:— comprehensive: to cover every step <strong>in</strong> the cycle from collect<strong>in</strong>g the specimento send<strong>in</strong>g the f<strong>in</strong>al report to the doctor (Fig. 1);— rational: to concentrate on the most critical steps <strong>in</strong> the cycle;— regular: to provide cont<strong>in</strong>uous monitor<strong>in</strong>g of test procedures;— frequent: to detect and correct errors as they occur.GOOD-QUALITY LABORATORY SERVICES MEAN GOOD-QUALITYMEDICINEQuality assurance helps to ensure that expensive tests are used as economicallyas possible; it also determ<strong>in</strong>es whether new tests are valid or worthless,improves the performance of cl<strong>in</strong>ical and public health laboratories, and mayhelp to make the results obta<strong>in</strong>ed <strong>in</strong> different laboratories comparable.Types of quality assuranceThere are two types of quality assurance: <strong>in</strong>ternal and external.• Internal. This is called QUALITY CONTROL. Each laboratory has a programmeto check the quality of its own tests.Fig. 1. Steps <strong>in</strong> laboratory <strong>in</strong>vestigation of an <strong>in</strong>fected patient3


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYInternal quality control <strong>in</strong>volves, ideally:— cont<strong>in</strong>uous monitor<strong>in</strong>g of test quality;— comprehensive check<strong>in</strong>g of all steps, from collect<strong>in</strong>g the specimen (wheneverpossible) to send<strong>in</strong>g the f<strong>in</strong>al report.<strong>Lab</strong>oratories have an ethical responsibility to the patient to produce accurate,mean<strong>in</strong>gful results.INTERNAL QUALITY CONTROL IS ABSOLUTELY ESSENTIAL FORGOOD OPERATING PROCEDURE• External. This is called QUALITY ASSESSMENT. <strong>Lab</strong>oratory performanceis controlled by an external agency. In some countries, participation ismandatory (regulated by the government) and required for licensure.External quality assessment <strong>in</strong>volves:— periodic monitor<strong>in</strong>g of test quality;— spot check<strong>in</strong>g of identification tests, and sometimes of isolation techniques.Quality criteria <strong>in</strong> microbiologyCl<strong>in</strong>ical relevanceAn important criterion of quality for a microbiological test is how much itcontributes to the prevention or cure of <strong>in</strong>fectious diseases; this is called itscl<strong>in</strong>ical relevance. Cl<strong>in</strong>ical relevance can only be ensured when there isgood communication between the cl<strong>in</strong>ician and the laboratory.To illustrate cl<strong>in</strong>ical relevance, here are some examples:1. If a few colonies of Gram-negative rods are isolated from the sputum orthroat swab of a hospitalized patient, further identification and an antibiogramare of no cl<strong>in</strong>ical relevance, s<strong>in</strong>ce neither procedure will haveany effect on treatment of the patient.2. If Streptococcus pyogenes is isolated, a full antibiogram has no cl<strong>in</strong>ical relevance,s<strong>in</strong>ce benzylpenicill<strong>in</strong> is the drug of choice, and this is always active<strong>in</strong> vitro.3. If Escherichia coli is isolated from a sporadic case of non-bloody diarrhoea,identification of the serotype is of no cl<strong>in</strong>ical relevance, s<strong>in</strong>ce there is noclearly established correlation between serotype and pathogenicity.4. If a Gram-sta<strong>in</strong>ed smear shows “mixed anaerobic flora”, rout<strong>in</strong>e identificationof the anaerobes is of no cl<strong>in</strong>ical relevance. It would be costly <strong>in</strong> timeand materials, and would not affect treatment of the patient.5. If a yeast is isolated from a respiratory tract specimen, an identification testfor Cryptococcus should be done. Further identification tests have no cl<strong>in</strong>icalrelevance, s<strong>in</strong>ce they would have no effect on patient management.4


QUALITY ASSURANCE IN BACTERIOLOGYIn summary, a test of good quality is one that is accurate and gives usefulresults for the prevention or cure of <strong>in</strong>fection. It is not necessary to isolate andidentify all the different types of organism <strong>in</strong> the sample.ReliabilityFor tests that give quantitative results, reliability is measured by how closethe results are to the true value. Some examples of tests of this k<strong>in</strong>d are:— antibiotic assay of serum;— measurement of m<strong>in</strong>imal <strong>in</strong>hibitory concentration (MIC) values of antibiotics<strong>in</strong> vitro;— serum antibody titrations.For tests that give qualitative results, reliability is measured by whether theresult is correct. Some examples of tests of this k<strong>in</strong>d are:— identification of pathogens;— antibiotic susceptibility test<strong>in</strong>g of isolates by the disc method.Standard term<strong>in</strong>ology for microorganisms is essential to reliability. Internationallyrecognized nomenclature should always be used. For example:Staphylococcus aureus, NOT “pathogenic staphylococci”; Streptococcus pyogenes,NOT “haemolytic streptococci”.Use of uniform, approved methods is essential. For example, disc susceptibilitytests should be performed with an <strong>in</strong>ternationally recognized technique,such as the modified Kirby–Bauer test (page 109).ReproducibilityThe reproducibility or precision of a microbiological test is reduced by twoth<strong>in</strong>gs:1. Lack of homogeneity. A s<strong>in</strong>gle sample from a patient may conta<strong>in</strong> more thanone organism. Repeat cultur<strong>in</strong>g may therefore isolate different organisms.2. Lack of stability. As time passes, the microorganisms <strong>in</strong> a specimen multiplyor die at different rates. Repeat cultur<strong>in</strong>g may therefore isolate differentorganisms. To improve precision, therefore, specimens should be testedas soon as possible after collection.EfficiencyThe efficiency of a microbiological test is its ability to give the correct diagnosisof a pathogen or a pathological condition. This is measured by twocriteria:1. Diagnostic sensitivitySensitivity =total number of positive resultstotal number of <strong>in</strong>fected patientsThe greater the sensitivity of a test, the fewer the number of false-negativeresults.5


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYFor example, the sensitivity of MacConkey agar is poor for the isolation ofSalmonella typhi from stool. This important enteric pathogen is often missedbecause of overgrowth by nonpathogenic <strong>in</strong>test<strong>in</strong>al bacteria.2. Diagnostic specificitySpecificity =The greater the specificity of a test, the fewer the number of false-positiveresults.For example:total number of negative resultstotal number of unifected patients• Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g of sputum is highly specific for diagnos<strong>in</strong>gtuberculosis, because it gives only a few false-positive results.• Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g of ur<strong>in</strong>e is much less specific, because it givesmany false-positive results (as a result of atypical mycobacteria).• The Widal test has a very low specificity for the diagnosis of typhoidfever, because cross-agglut<strong>in</strong>at<strong>in</strong>g antibodies rema<strong>in</strong><strong>in</strong>g from past<strong>in</strong>fections with related salmonella serotypes give false-positive results.The sensitivity and specificity of a test are <strong>in</strong>terrelated. By lower<strong>in</strong>g the levelof discrim<strong>in</strong>ation, the sensitivity of a test can be <strong>in</strong>creased at the cost of reduc<strong>in</strong>gits specificity, and vice versa. The diagnostic sensitivity and specificity ofa test are also related to the prevalence of the given <strong>in</strong>fection <strong>in</strong> the populationunder <strong>in</strong>vestigation.Internal quality controlRequirementsAn <strong>in</strong>ternal quality control programme should be practical, realistic, andeconomical.An <strong>in</strong>ternal quality control programme should not attempt to evaluate everyprocedure, reagent, and culture medium on every work<strong>in</strong>g day. It should evaluateeach procedure, reagent, and culture medium accord<strong>in</strong>g to a practicalschedule, based on the importance of each item to the quality of the test as awhole.<strong>Procedures</strong>Internal quality control beg<strong>in</strong>s with proper laboratory operation.<strong>Lab</strong>oratory operations manualEach laboratory should have an operations manual that <strong>in</strong>cludes the follow<strong>in</strong>gsubjects:— clean<strong>in</strong>g of the work<strong>in</strong>g space,— personal hygiene,— safety precautions,— designated eat<strong>in</strong>g and smok<strong>in</strong>g areas located outside the laboratory,— handl<strong>in</strong>g and disposal of <strong>in</strong>fected material,6


QUALITY ASSURANCE IN BACTERIOLOGY— appropriate vacc<strong>in</strong>ations for workers, e.g. hepatitis B,— care of equipment,— collection of specimens,— registration of specimens,— elim<strong>in</strong>ation of unsuitable specimens,— process<strong>in</strong>g of specimens,— record<strong>in</strong>g of results,— report<strong>in</strong>g of results.The operations manual should be carefully followed, and regularly revisedand updated.Care of equipmentIt is particularly important to take good care of laboratory equipment. Goodquality tests cannot be performed if the equipment used is either of poorquality or poorly ma<strong>in</strong>ta<strong>in</strong>ed.Table 1 is a schedule for the rout<strong>in</strong>e care and ma<strong>in</strong>tenance of essential equipment.Equipment operat<strong>in</strong>g temperatures may be recorded on a form such asthe one shown <strong>in</strong> Fig. 2.Culture mediaCulture media may be prepared <strong>in</strong> the laboratory from the basic <strong>in</strong>gredientsor from commercially available dehydrated powders, or they may be purchasedready for use. Commercial dehydrated powders are recommendedbecause they are economical to transport and store, and their quality is likelyto be higher than media prepared <strong>in</strong> the laboratory. For best results, carefulattention is required to the po<strong>in</strong>ts itemized below.Selection of mediaAn efficient laboratory stocks the smallest possible range of media consistentwith the types of test performed. For example, a good agar base can be usedas an all-purpose medium for prepar<strong>in</strong>g blood agar, chocolate agar, andseveral selective media.One highly selective medium (Salmonella–Shigella agar or deoxycholate citrateagar) and one less selective medium (MacConkey agar) are necessary for theisolation of pathogenic Enterobacteriaceae from stools.A special culture medium should be added for the recovery of Campylobacterspp.Order<strong>in</strong>g and storage of dehydrated media1. Order quantities that will be used up <strong>in</strong> 6 months, or at most 1 year.2. The overall quantity should be packed <strong>in</strong> conta<strong>in</strong>ers that will be used up<strong>in</strong> 1–2 months.3. On receipt, tighten caps of all conta<strong>in</strong>ers securely. Dehydrated mediaabsorb water from the atmosphere. In a humid climate, seal the tops ofconta<strong>in</strong>ers of dehydrated media with paraff<strong>in</strong> wax (fill the space betweenthe lid and conta<strong>in</strong>er with molten wax, and let it harden).7


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYTable 1. Quality control of equipmentEquipment Rout<strong>in</strong>e care Monitor<strong>in</strong>g Technical ma<strong>in</strong>tenanceand <strong>in</strong>spectionAnaerobic jar Clean <strong>in</strong>side of jar each week Use methylene blue <strong>in</strong>dicator Inspect gasketReactivate catalyst after each strip with each run seal<strong>in</strong>g <strong>in</strong> therun (160 ∞C, 2h) Note and record decolorization lid weeklyReplace catalyst every 3 months time of <strong>in</strong>dicator each weekAutoclave Clean and change water Check and adjust water level Every 6 monthsmonthlybefore each runRecord time and temperatureor pressure for each runRecord performance withspore-strips weeklyCentrifuge Wipe <strong>in</strong>ner walls with antiseptic Replace brushessolution weekly or afterannuallybreakage of glass tubes orspillageHot-air oven Clean <strong>in</strong>side monthly Record time and Every 6 monthsfor sterilizationtemperature for each runof glasswareIncubator Clean <strong>in</strong>side walls and Record temperature at the Every 6 monthsshelves monthlystart of each work<strong>in</strong>g day(allowance 35 ± 1∞C)Microscope Wipe lenses with tissue or lens Check alignment of Annuallypaper after each day’s work condenser monthlyClean and lubricate mechanical Place a dish of blue silicastage weeklywith the microscope underProtect with dust cover when the dust cover to preventnot <strong>in</strong> usefungal growth <strong>in</strong> humidclimatesRefrigerator Clean and defrost every 2 Record temperature every Every 6 monthsmonths and after power failure morn<strong>in</strong>g (allowance 2–8 ∞C)Water-bath Wipe <strong>in</strong>side walls and change Check water level daily Every 6 monthswater monthlyRecord temperature on firstday of each week (allowance55–57 ∞C)4. Write the date of receipt on each conta<strong>in</strong>er.5. Store <strong>in</strong> a dark, cool, well-ventilated place.6. Rotate the stock so that the older materials are used first.7. When a conta<strong>in</strong>er is opened, write the date of open<strong>in</strong>g on it.8. Discard all dehydrated media that are either caked or darkened.9. Keep written records of media <strong>in</strong> stock.Preparation of media1. Follow strictly the manufacturer’s <strong>in</strong>structions for preparation.2. Prepare a quantity that will be used up before the shelf-life expires (seebelow).8


9Fig. 2. Record of equipment operat<strong>in</strong>g temperature


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYStorage of prepared media1. Protect aga<strong>in</strong>st sunlight.2. Protect aga<strong>in</strong>st heat. Media conta<strong>in</strong><strong>in</strong>g blood, other organic additives, orantibiotics should be stored <strong>in</strong> the refrigerator.3. The shelf-life of prepared media, when stored <strong>in</strong> a cool, dark place, willdepend on the type of conta<strong>in</strong>er used. Typical shelf-lives are:— tubes with cotton-wool plugs, 3 weeks;— tubes with loose caps, 2 weeks;— conta<strong>in</strong>ers with screw-caps, 3 months;— Petri dishes, if sealed <strong>in</strong> plastic bags, 4 weeks.Quality control of prepared media1. pH test<strong>in</strong>g. The pH of the prepared medium need not be checked rout<strong>in</strong>elywhen it is correctly prepared from dehydrated powder. If the medium isprepared from basic <strong>in</strong>gredients, it should be allowed to cool before thepH is tested. Solid media should be tested with a surface electrode or aftermaceration <strong>in</strong> distilled water. If the pH differs by more than 0.2 units fromthe specification, adjust with acid or alkali or prepare a new batch.2. Sterility test<strong>in</strong>g. Carry out rout<strong>in</strong>e sterility tests on media to which bloodor other components have been added after autoclav<strong>in</strong>g. Take 3–5% of eachbatch and <strong>in</strong>cubate at 35 ∞C for 2 days. Refrigerate the rest. If more thantwo colonies per plate are seen, discard the whole batch.3. Performance test<strong>in</strong>g. The laboratory should keep a set of stock stra<strong>in</strong>s formonitor<strong>in</strong>g the performance of media. A suggested list of stock stra<strong>in</strong>s isgive <strong>in</strong> Table 2. These stra<strong>in</strong>s can be obta<strong>in</strong>ed through rout<strong>in</strong>e work, orfrom commercial or official sources. Recommendations for the ma<strong>in</strong>tenanceand use of stock stra<strong>in</strong>s are given on page 14.A list of performance tests for commonly used media is given <strong>in</strong> Table 3.Table 2. Suggested stock stra<strong>in</strong>s for quality control aGram-positive cocciEnterobacteriaceaeEnterococcus faecalis (ATCC 29212 Citrobacter freundiior 33186)Enterobacter cloacaeStaphylococcus aureus (ATCC 25923) Escherichia coli (ATCC 25922)Staphylococcus epidermidisKlebsiella pneumoniaeStreptococcus agalactiaeProteus mirabilisStreptococcus mitisSalmonella typhimuriumStreptococcus pneumoniaeSerratia marcescensStreptococcus pyogenesShigella flexneriGram-negative fastidious organisms Yers<strong>in</strong>ia enterocoliticaMoraxella catarrhalisOther Gram-negative rodsHaemophilus <strong>in</strong>fluenzae type bAc<strong>in</strong>etobacter lwoffib-lactamase-negative Pseudomonas aerug<strong>in</strong>osa (ATCC 27853)b-lactamase-positiveVibrio cholerae (non-01)Haemophilus para<strong>in</strong>fluenzaeFungiNeisseria gonorrhoeaeCandida albicansNeisseria men<strong>in</strong>gitidisAnaerobesBacteroides fragilisClostridium perfr<strong>in</strong>gensa The stra<strong>in</strong>s most relevant to the needs of the laboratory should be selected.10


QUALITY ASSURANCE IN BACTERIOLOGYTable 3. Performance tests on commonly used mediaMedium Incubation Control organism Expected resultBile–aescul<strong>in</strong> agar 24h Enterococcus faecalis Growth and blacken<strong>in</strong>ga-HaemolyticNo growth, with haemolysisStreptococcusBlood agar 24h, CO 2 Streptococcus Growth and b-haemolysispyogenesS. pneumoniae Growth and a-haemolysisChocolate agar 24h, CO 2 Haemophilus <strong>in</strong>fluenzae GrowthDecarboxylase (cover with sterileoil)— lys<strong>in</strong>e 48h Shigella typhimurium PositiveShigella flexneriNegative— ornith<strong>in</strong>e 48h S. typhimurium PositiveKlebsiella pneumoniae NegativeDihydrolase— arg<strong>in</strong><strong>in</strong>e 48h S. typhimurium PositiveProteus mirabilis NegativeGelat<strong>in</strong>ase (rapid tests) 24h Escherichia coli NegativeSerratia marcescens PositiveKligler iron agar (see Triple sugariron agar)MacConkey agar with crystal 24h E. coli Red coloniesviolet P. mirabilis Colourless colonies (no swarm<strong>in</strong>g)E. faecalis No growthMalonate broth 24h E. coli Negative (green)K. pneumoniae Positive (blue)Mannitol salt agar 24h Staphylococcus aureus Yellow coloniesStaphylococcus Rose coloniesepidermidisE. coli No growthMethyl red/Voges–Proskauer 48h E. coli Positive/negativeK. pneumoniae Negative/positiveMueller–H<strong>in</strong>ton agar 24h E. coli ATCC 25922S. aureus ATCC 25923 Acceptable zone sizesPseudomonas (Table 24, p. 110)aerug<strong>in</strong>osa ATCC27853Nitrate broth 24h E. coli PositiveAc<strong>in</strong>etobacter lwoffi NegativeOxidation/fermentation 24h P. aerug<strong>in</strong>osa Oxidation at the sufacedextrose (without oil) A. lwoffi No changePeptone water (<strong>in</strong>dole) 24h E. coli PositiveK. pneumoniae NegativePhenylalan<strong>in</strong>e deam<strong>in</strong>ase/ 24h E. coli Negativeferrichloride P. mirabilis PositiveSalmonella–Shigella agar or 24h E. coli No growthdeoxycholate citrate agar S. typhimurium Colourless coloniesYers<strong>in</strong>a enterocolitica Colourless coloniesS. flexneri Colourless coloniesSelenite broth 24h S. typhimurium Growth after subcultureE. coli No growth after subcultureSimmons citrate agar (<strong>in</strong>cubate 48h E. coli No growthwith loose screw-cap) K. pneumoniae Growth, blue colour11


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYThiosulfate citrate bile salts 24h Vibrio spp. (non- Yellow coloniesagaragglut<strong>in</strong>at<strong>in</strong>g)Thayer–Mart<strong>in</strong> agar 24h, CO 2 Neisseria men<strong>in</strong>gitidis GrowthNeisseria gonorrhoeae GrowthStaphylococcus spp. No growthE. coli No growthC. albicans No growthThioglycollate broth 24h Bacteroides fragilis GrowthTriple sugar iron agar (depth of 24h Citrobacter freundii A/A gas a + H 2 Sbutt should be at least 2.5cm; S. typhimurium K/A gas a + H 2 S<strong>in</strong>cubate with loose screw-cap) S. flexneri K/A gas aA. lwoffi No changeUrea medium 24h E. coli NegativeP. mirabilis Positive (p<strong>in</strong>k)Voges–Proskauer (see Methylred/Voges–Proskauer)aA/A: acid slant; K/A: alkal<strong>in</strong>e slant.Table 3 (cont<strong>in</strong>ued)Medium Incubation Control organism Expected resultThe procedures to be followed when carry<strong>in</strong>g out performance tests on newbatches of media are:1. Prepare a suspension of the stock stra<strong>in</strong> with a barely visible turbidity,equivalent to that of the barium sulfate standard used <strong>in</strong> the modifiedKirby–Bauer method (McFarland 0.5) (see page 109) and use 1 loopful as<strong>in</strong>oculum.2. Incubate for the length of time used rout<strong>in</strong>ely. Read the plates <strong>in</strong> the usualway.3. Keep proper records of results.Sta<strong>in</strong>s and reagentsRecommendations for test<strong>in</strong>g a number of reagents are given <strong>in</strong> Table 4.Test<strong>in</strong>g should be carried out:— each time a new batch of work<strong>in</strong>g solution is prepared;— every week (this is critical for the cold Ziehl–Neelsen sta<strong>in</strong>: the classicalsta<strong>in</strong> has a shelf-life of several months).Sta<strong>in</strong>s and reagents should be discarded when:— the manufacturer’s expiry date is reached;— visible signs of deterioration appear (turbidity, precipitate, discoloration).Diagnostic antigens and antiseraIn order to obta<strong>in</strong> the best results from antigens and antisera:• Always follow the manufacturer’s <strong>in</strong>structions.• Store at the recommended temperature. Some serological reagents do nottolerate freez<strong>in</strong>g.12


QUALITY ASSURANCE IN BACTERIOLOGYTable 4. Performance tests on commonly used reagentsReagent or sta<strong>in</strong> Species suitable for test<strong>in</strong>g MediumPositiveNegativeBacitrac<strong>in</strong> disc S. pyogenes (zone) E. faecalis Blood agarCatalase S. aureus E. faecalis Tryptic soy agarCoagulase plasma S. aureus S. epidermidis Tryptic soy agarb-Glucuronidase (PGUA) a E. coli K. pneumoniae Tryptic soy agarGram sta<strong>in</strong> Staphylococcus spp E. coli Mixed <strong>in</strong> smearONPG b E. coli S. typhimurium Triple sugar iron agaror Kligler iron agarOptoch<strong>in</strong> disc S. pneumoniae (zone) Streptococcus mitis Blood agarOxidase Pseudomonas aerug<strong>in</strong>osa E. coli Tryptic soy agarTellurite disc E. faecalis (no zone) Streptococcus Blood agaragalactiae (zone)V-factor (disc or strips) Haemophilus para<strong>in</strong>fluenzae Haemophilus <strong>in</strong>fluenzae Tryptic soy agarXV-factor (disc or strips) H. <strong>in</strong>fluenzae Tryptic soy agarZiehl–Neelsen sta<strong>in</strong> Mycobacterium tuberculosis Mixed non-acid-fast Sputum smear cfloraa4-Nitrophenyl-b-D-glucopyranosiduronic acid. (PGUA)b o-Nitrophenyl-b-D-galactopyranoside.c Prepare a number of smears from known positive and negative patients. Fix by heat, wrap <strong>in</strong>dividually <strong>in</strong> paper, andstore <strong>in</strong> the refrigerator.• Avoid repeated freez<strong>in</strong>g and thaw<strong>in</strong>g. Before freez<strong>in</strong>g, divide antiserum<strong>in</strong>to aliquot portions sufficient for a few tests.• Discard when the manufacturer’s expiry date is reached.• To test agglut<strong>in</strong>at<strong>in</strong>g antisera, always use fresh pure cultures of knownreactivity.• Always <strong>in</strong>clude a serum control of known reactivity <strong>in</strong> each batch of tests.The serum may be from a patient, or from a commercial source.• If possible, the potency of the control serum should be expressed <strong>in</strong> InternationalUnits per millilitre.• Paired sera from the same patient, taken dur<strong>in</strong>g the acute and convalescentphases of the disease, should be tested with the same batch ofreagents.• For the serological diagnosis of syphilis, only nationally or <strong>in</strong>ternationallyrecognized procedures should be used.• Each batch of serological tests should <strong>in</strong>clude:— a negative serum (specificity control);— a weakly reactive serum (sensitivity control);— a strongly reactive serum (titration control), which should read with<strong>in</strong>one dilution of its titre when last tested.• Always record all control serum titres.Antibiotic susceptibility testsThe rout<strong>in</strong>e use of the modified Kirby–Bauer method is recommended(page 109). To avoid errors, the follow<strong>in</strong>g guidel<strong>in</strong>es should be used:• Discs should be of correct diameter (6.35mm).• Discs should be of correct potency (Table 24, page 110).• The stock supply should be stored frozen (-20∞C).13


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGY• The work<strong>in</strong>g supply should be kept no longer than 1 month <strong>in</strong> a refrigerator(2–8 ∞C).• Only Mueller–H<strong>in</strong>ton agar of performance-tested quality should be used.• Correct pH (7.2–7.4) of the f<strong>in</strong>ished medium is essential for some antibiotics.• The <strong>in</strong>oculum should be standardized aga<strong>in</strong>st the prescribed turbiditystandard (page 111).• Zone sizes should be measured exactly.• Zone sizes should be <strong>in</strong>terpreted by referr<strong>in</strong>g to a table of critical diameters.Zone diameters for each organism should fall with<strong>in</strong> the limits given<strong>in</strong> Table 24 (page 110).• The three standard control stra<strong>in</strong>s are: 1— Staphylococcus aureus (ATCC 25923; NCTC 6571);— Escherichia coli (ATCC 25922; NCTC 10418);— Pseudomonas aerug<strong>in</strong>osa (ATCC 27853; NCTC 10622).• Tests should be carried out with the three standard stra<strong>in</strong>s:— when a new batch of discs is put <strong>in</strong>to use;— when a new batch of medium is put <strong>in</strong>to use;— once a week, <strong>in</strong> parallel with the rout<strong>in</strong>e antibiograms.• Use the quality control chart shown <strong>in</strong> Fig. 16 (page 121) for record<strong>in</strong>g andevaluat<strong>in</strong>g performance tests.Ma<strong>in</strong>tenance and use of stock culturesSelection and orig<strong>in</strong>Select the stra<strong>in</strong>s so that the maximum number of morphological, metabolic,and serological characteristics can be tested with the m<strong>in</strong>imum number of cultures;a suggested list is given <strong>in</strong> Table 2. These stra<strong>in</strong>s can be obta<strong>in</strong>ed froma comb<strong>in</strong>ation of the follow<strong>in</strong>g sources:— properly documented isolates from cl<strong>in</strong>ical specimens;— official culture collections;— commercial producers;— external quality assessment surveys;— reference laboratories.PreservationLong-term preservationLong-term preservation methods permit <strong>in</strong>tervals of months or even yearsbetween subcultures. The best methods are lyophilization (freeze-dry<strong>in</strong>g), orstorage at -70∞C or below, <strong>in</strong> an electric freezer or <strong>in</strong> liquid nitrogen. Alternativemethods are described below.Glycerol at -20 ∞C1. Grow a pure culture on an appropriate solid medium.2. When the culture is fully developed, scrape it off with a loop.3. Suspend small clumps of the culture <strong>in</strong> sterile neutral glycerol.1These stra<strong>in</strong>s can be obta<strong>in</strong>ed from: American Type Culture Collection (ATCC), 10801 UniversityBoulevard, Manassas, VA 20110, USA; or National Collection of Type Cultures (NCTC), PHLSCentral Public Health <strong>Lab</strong>oratory, 61 Col<strong>in</strong>dale Avenue, London NW9 5HT, England.14


QUALITY ASSURANCE IN BACTERIOLOGY4. Distribute <strong>in</strong> quantities of 1–2ml <strong>in</strong> screw-capped tubes or vials.5. Store at -20∞C. Avoid repeated freez<strong>in</strong>g and thaw<strong>in</strong>g. Transfer after 12–18months.M<strong>in</strong>eral oil at room temperature 11. Prepare tubes of heart <strong>in</strong>fusion agar with a short slant. For fastidiousorganisms, add fresh native or heated blood.2. Sterilize m<strong>in</strong>eral oil (liquid petrolatum) <strong>in</strong> hot air (170 ∞C for 1 hour).3. Grow a pure culture on the agar slant.4. When good growth is seen, add sterile m<strong>in</strong>eral oil to about 1cm above thetip of the slant.5. Subculture when needed by scrap<strong>in</strong>g growth from under the oil.6. Store at room temperature. Transfer after 6–12 months.Stab cultures at room temperature (use for non-fastidious organismsonly, such as staphylococci and Enterobacteriaceae)1. Prepare tubes with a deep butt of carbohydrate-free agar. Tryptic soy agar(soybean case<strong>in</strong> digest agar) is recommended.2. Stab the organism <strong>in</strong>to the agar.3. Incubate overnight at 35 ∞C.4. Close tube with screw-cap or cork. Dip cap or cork <strong>in</strong>to molten paraff<strong>in</strong>wax to seal.5. Store at room temperature. Transfer after 1 year.Stab cultures <strong>in</strong> cyst<strong>in</strong>e trypticase agar (CTA) (for Neisseria andstreptococci)1. Prepare tubes of CTA basal medium.2. Stab the organism <strong>in</strong>to the medium.3. Incubate overnight at 35 ∞C.4. Close tube with screw-cap or cork. Dip cap or cork <strong>in</strong>to molten paraff<strong>in</strong>wax to seal.5. For Neisseria, store at 35 ∞C, and transfer every 2 weeks. For streptococci,store at room temperature, and transfer every month.Cooked-meat medium for anaerobes1. Inoculate tubes.2. Incubate overnight at 35 ∞C.3. Close tube with screw-cap or cork.4. Store at room temperature. Transfer every 2 months.Short-term preservationWork<strong>in</strong>g cultures for daily rout<strong>in</strong>e tests can be prepared <strong>in</strong> the follow<strong>in</strong>g ways.Rapid-grow<strong>in</strong>g organisms1. Inoculate on tryptic soy agar slants <strong>in</strong> screw-capped tubes.2. Incubate overnight at 35 ∞C.3. Store <strong>in</strong> a refrigerator. Transfer every 2 weeks.1Morton HE, Pulaski EJ. The preservation of bacterial cultures. Journal of <strong>Bacteriology</strong>, 1938,38:163–183.15


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGYStreptococci1. Inoculate on blood agar slants <strong>in</strong> screw-capped tubes.2. Incubate overnight at 35 ∞C.3. Store <strong>in</strong> a refrigerator. Transfer every 2 weeks.Men<strong>in</strong>gococci and Haemophilus1. Inoculate on chocolate agar slants or plates.2. Incubate overnight at 35 ∞C.3. Store at room temperature. Transfer twice a week.Gonococci1. Inoculate on chocolate agar.2. Incubate and store at 35 ∞C. Transfer every 2 days.3. Replace the quality control stra<strong>in</strong> by each new cl<strong>in</strong>ical isolate.Use of reference laboratoriesThe follow<strong>in</strong>g categories of specimen should be submitted to a regional orcentral reference laboratory:— specimens for <strong>in</strong>frequently requested or highly specialized tests (e.g. virology,serodiagnosis of parasitic <strong>in</strong>fections);— occasional duplicate specimens, as a check on the submitt<strong>in</strong>g laboratory’sown results;— specimens need<strong>in</strong>g further confirmation, specification, group<strong>in</strong>g, or typ<strong>in</strong>gof pathogens of great public health importance (e.g. Salmonella, Shigella,Vibrio cholerae, Brucella, men<strong>in</strong>gococci, and pneumococci).Reference laboratories should be able to supply reference cultures for qualitycontrol and tra<strong>in</strong><strong>in</strong>g needs, and standard sera and reagents for comparisonwith those <strong>in</strong> use <strong>in</strong> the referr<strong>in</strong>g laboratory.If no external quality assessment programme exists, the reference laboratoryshould be asked to supply bl<strong>in</strong>d, coded specimens and cultures so thatthe referr<strong>in</strong>g laboratory may test its own proficiency <strong>in</strong> isolation andidentification.External quality assessmentThis section gives <strong>in</strong>formation on what is <strong>in</strong>volved <strong>in</strong> participation <strong>in</strong> an externalquality assessment scheme (sometimes known as a “proficiency test<strong>in</strong>gscheme”).PurposesThe purposes of a quality assessment programme are:— to provide assurance to both physicians and the general public that laboratorydiagnosis is of good quality;— to assess and compare the reliability of laboratory performance on anational scale;— to identify common errors;— to encourage the use of uniform procedures;16


QUALITY ASSURANCE IN BACTERIOLOGY— to encourage the use of standard reagents;— to take adm<strong>in</strong>istrative measures (which may <strong>in</strong>clude revocation of theoperat<strong>in</strong>g licence) aga<strong>in</strong>st substandard laboratories;— to stimulate the implementation of <strong>in</strong>ternal quality control programmes.OrganizationA quality assessment programme consists of a number of surveys <strong>in</strong> whichcoded specimens are distributed by mail to participat<strong>in</strong>g laboratories. Thesespecimens should be <strong>in</strong>corporated <strong>in</strong>to the laboratory rout<strong>in</strong>e, and handledand tested <strong>in</strong> exactly the same way as rout<strong>in</strong>e cl<strong>in</strong>ical specimens.The surveys should be conducted <strong>in</strong> accordance with the follow<strong>in</strong>grecommendations:— surveys should be carried out at least 4 times a year;— a m<strong>in</strong>imum of 3 specimens should be <strong>in</strong>cluded <strong>in</strong> each survey;— the report<strong>in</strong>g period should be short, for example 2 weeks follow<strong>in</strong>greceipt of the specimens;— <strong>in</strong>structions and report forms should be <strong>in</strong>cluded with each survey andthe report sheet should be <strong>in</strong> duplicate, with a clearly stated deadl<strong>in</strong>e.CulturesCultures should be <strong>in</strong>cluded for identification and for susceptibility test<strong>in</strong>gaga<strong>in</strong>st a limited range of antibiotics; they may be pure cultures or mixturesof two or more cultures.Cultures should represent at least the first 3 of the follow<strong>in</strong>g 6 categories:1. Bacterial species that are of great public health potential, but which arenot often seen <strong>in</strong> rout<strong>in</strong>e practice, for example Corynebacterium diphtheriae,Salmonella paratyphi A.NOTE: Brucella and Salmonella typhi should not be used for quality assessmentschemes, s<strong>in</strong>ce they may give rise to serious accidental <strong>in</strong>fections.2. Abnormal biotypes that are often misidentified, for example H 2 S-positiveEscherichia coli, lactose-negative E. coli, urease-negative Proteus.3. Newly recognized or opportunistic pathogens, for example Yers<strong>in</strong>ia enterocolitica,Vibrio parahaemolyticus, Burkholderia, Pseudomonas cepacia.4. A mixture of Shigella, Citrobacter, E. coli, and Klebsiella may be used to testthe skill of a laboratory <strong>in</strong> isolat<strong>in</strong>g pathogenic microorganisms from anumber of commensal organisms.5. A mixture of nonpathogenic organisms may be used to test for ability torecognize negative specimens.6. Bacteria with special resistance patterns, for example meticill<strong>in</strong>-resistant S.aureus (MRSA).SeraSerological tests for the follow<strong>in</strong>g <strong>in</strong>fections should be part of an externalquality assessment programme <strong>in</strong> bacteriology:— syphilis— rubella— brucellosis17


BASIC LABORATORY PROCEDURES IN CLINICAL BACTERIOLOGY— streptococcal <strong>in</strong>fections— typhoid fever.Rat<strong>in</strong>g and report<strong>in</strong>g of resultsAs soon as all reports of results are received from participat<strong>in</strong>g, the correctanswers should be sent to the laboratories. With<strong>in</strong> one month after that, a f<strong>in</strong>alreport should be sent to the laboratories with an analysis of the results. A performancescore is given to each laboratory. Each laboratory should have a codenumber known only to itself. Thus it can recognize its own performance <strong>in</strong>relation to others, but the other laboratories rema<strong>in</strong> anonymous.18


Part IBacteriological <strong>in</strong>vestigations


BloodIntroductionBlood is cultured to detect and identify bacteria or other cultivable microorganisms(yeasts, filamentous fungi). The presence of such organisms <strong>in</strong> theblood is called bacteraemia or fungaemia, and is usually pathological. Inhealthy subjects, the blood is sterile. However, there are a few exceptions: transientbacteraemia often occurs shortly after a tooth extraction or other dentalor surgical manipulation of contam<strong>in</strong>ated mucous membranes, bronchoscopy,or urethral catheterization. This type of transient bacteraemia is generally dueto commensal bacteria and usually resolves spontaneously through phagocytosisof the bacteria <strong>in</strong> the liver and spleen.Septicaemia is a cl<strong>in</strong>ical term used to describe bacteraemia with cl<strong>in</strong>icalmanifestations of a severe <strong>in</strong>fection, <strong>in</strong>clud<strong>in</strong>g chills, fever, malaise, toxicity,and hypotension, the extreme form be<strong>in</strong>g shock. Shock can be caused bytox<strong>in</strong>s produced by Gram-negative rods or Gram-positive cocci.When and where bacteraemia may occurBacteraemia is a feature of some <strong>in</strong>fectious diseases, e.g. brucellosis, leptospirosisand typhoid fever. Persistent bacteraemia is a feature of endovascular<strong>in</strong>fections, e.g. endocarditis, <strong>in</strong>fected aneurysm and thrombophlebitis.Transient bacteraemia often accompanies localized <strong>in</strong>fections such as arthritis,bed sores, cholecystitis, enterocolitis, men<strong>in</strong>gitis, osteomyelitis, peritonitis,pneumonia, pyelonephritis, and traumatic or surgical wound <strong>in</strong>fections.It can arise from various surgical manipulations, but usually resolvesspontaneously <strong>in</strong> healthy subjects.Bacteraemia and fungaemia may result from the iatrogenic <strong>in</strong>troduction ofmicroorganisms by the <strong>in</strong>travenous route: through contam<strong>in</strong>ated <strong>in</strong>travenousfluids, catheters, or needle-puncture sites. Both types of <strong>in</strong>fection may develop<strong>in</strong> users of <strong>in</strong>travenous drugs and <strong>in</strong> immunosuppressed subjects, <strong>in</strong>clud<strong>in</strong>gthose with human immunodeficiency virus/the acquired immunodeficiencysyndrome (HIV/AIDS). They are often caused by “opportunistic” microorganismsand may have serious consequences. Table 5 shows the most commoncauses of bacteraemia or fungaemia.Blood collectionTim<strong>in</strong>g of blood collectionWhenever possible, blood should be taken before antibiotics are adm<strong>in</strong>istered.The best time is when the patient is expected to have chills or a temperaturespike. It is recommended that two or preferably three blood cultures beobta<strong>in</strong>ed, separated by <strong>in</strong>tervals of approximately 1 hour (or less if treatmentcannot be delayed). More than three blood cultures are rarely <strong>in</strong>dicated. Theadvantages of repeated cultures are as follows:— the chance of miss<strong>in</strong>g a transient bacteraemia is reduced;— the pathogenic role of “saprophytic” isolates (e.g. Staphylococcus epidermidis)is confirmed if they are recovered from multiple venepunctures.20


BACTERIOLOGICAL INVESTIGATIONSTable 5. Common causes of bacteraemia or fungaemiaGram-negative organismsGram-positive organismsEscherichia coliStaphylococcus aureusKlebsiella spp.S. epidermidisEnterobacter spp.a-Haemolytic (viridans) streptococciProteus spp.Streptococcus pneumoniaeSalmonella typhi E. faecalis (group D)Salmonella spp. other than S. typhi S. pyogenes (group A)Pseudomonas aerug<strong>in</strong>osa S. agalactiae (group B)Neisseria men<strong>in</strong>gitidisListeria monocytogenesHaemophilus <strong>in</strong>fluenzaeClostridium perfr<strong>in</strong>gensBacteroides fragilis (anaerobe)Peptostreptococcus spp. (anaerobes)Brucella spp.Candida albicans and other yeast-Burkholderia (Pseudomonas) pseudomallei like fungi (e.g. Cryptococcus(<strong>in</strong> certa<strong>in</strong> areas)neoformans)It is important that blood specimens for culture are collected before <strong>in</strong>itiat<strong>in</strong>gempirical antimicrobial therapy. If necessary, the choice of antimicrobial canbe adjusted when the results of susceptibility tests become available.Quantity of bloodBecause the number of bacteria per millilitre of blood is usually low, it isimportant to take a reasonable quantity of blood: 10ml per venepuncture foradults; 2–5ml may suffice for children, who usually have higher levels of bacteraemia;for <strong>in</strong>fants and neonates, 1–2ml is often the most that can beobta<strong>in</strong>ed. Two tubes should be used for each venepuncture: the first a ventedtube for optimal recovery of strictly aerobic microorganisms, the second anon-vented tube for anaerobic culture.Sk<strong>in</strong> dis<strong>in</strong>fectionThe sk<strong>in</strong> at the venepuncture site must be meticulously prepared us<strong>in</strong>g a bactericidaldis<strong>in</strong>fectant: 2% t<strong>in</strong>cture of iod<strong>in</strong>e, 10% polyvidone iod<strong>in</strong>e, 70%alcohol, or 0.5% chlorhexid<strong>in</strong>e <strong>in</strong> 70% alcohol. The dis<strong>in</strong>fectant should beallowed to evaporate on the sk<strong>in</strong> surface before blood is withdrawn. If t<strong>in</strong>ctureof iod<strong>in</strong>e is used, it should be wiped off with 70% alcohol to avoid possiblesk<strong>in</strong> irritation.Even after careful sk<strong>in</strong> preparation, some bacteria persist <strong>in</strong> the deeper sk<strong>in</strong>layers and may ga<strong>in</strong> access to the blood, e.g. S. epidermidis, Propionibacteriumacnes, and even spores of Clostridium. Pseudobacteraemia (false-positive bloodculture) may result from the use of contam<strong>in</strong>ated antiseptic solutions,syr<strong>in</strong>ges, or needles. The repeated isolation of an unusual organism (e.g. Burkholderia(Pseudomonas) cepacia, Pantoea (Enterobacter) agglomerans, or Serratiaspp.) <strong>in</strong> the same hospital must raise suspicion of a nosocomial <strong>in</strong>fection andpromote an <strong>in</strong>vestigation. Another source of contam<strong>in</strong>ation is contact of theneedle with non-sterile vials (or solutions), if the same syr<strong>in</strong>ge is first used toprovide blood for chemical analysis or measurement of the erythrocyte sedimentationrate.21


BLOODAnticoagulantThe use of sodium polyanethol sulfonate (SPS) as an anticoagulant is recommendedbecause it also <strong>in</strong>hibits the antibacterial effect of serum and phagocytes.If the blood is immediately added to a sufficient volume (50ml) of brothand thoroughly mixed to prevent clott<strong>in</strong>g, no anticoagulant is needed. It isrecommended that blood-culture bottles be available at all hospitals and majorhealth centres. If blood-culture bottles are not available, blood may be transportedto the laboratory <strong>in</strong> a tube conta<strong>in</strong><strong>in</strong>g a sterile anticoagulant solution(citrate, hepar<strong>in</strong>, or SPS). Upon receipt <strong>in</strong> the laboratory, such blood samplesmust be transferred immediately to blood-culture bottles us<strong>in</strong>g a strict aseptictechnique. Where blood is taken without anticoagulant, the clot can be asepticallytransferred to broth <strong>in</strong> the laboratory and the serum used for certa<strong>in</strong>serological tests (e.g. Widal).Blood-culture mediaChoice of broth mediumThe blood-culture broth and tryptic soy broth (TSB) should be able to supportgrowth of all cl<strong>in</strong>ically significant bacteria.Quantity of brothIdeally, the blood should be mixed with 10 times its volume of broth (5ml ofblood <strong>in</strong> 50ml of broth) to dilute any antibiotic present and to reduce thebactericidal effect of human serum.Blood-culture bottlesBlood-culture bottles (125ml) with a pre-perforated screw-cap and a rubberdiaphragm must be used. Fill the bottle with 50ml of medium and then loosenthe screw-cap half a turn. Cover the cap with a square piece of alum<strong>in</strong>iumfoil, and autoclave the bottle for 20 m<strong>in</strong>utes at 120 ∞C. Immediately afterautoclav<strong>in</strong>g, while the bottle and the medium are still hot, securely tightenthe cap without remov<strong>in</strong>g the alum<strong>in</strong>ium foil (otherwise the cap will notbe sterile). As the medium cools, a partial vacuum will be created <strong>in</strong> thebottle, which will facilitate <strong>in</strong>jection of a blood specimen through thediaphragm.The top of the cap must be carefully dis<strong>in</strong>fected just before the bottle is<strong>in</strong>oculated.Prior to distribution and before use, all blood-culture bottles should becarefully exam<strong>in</strong>ed for clarity. Any medium show<strong>in</strong>g turbidity should not beused.If strictly aerobic bacteria (Pseudomonas, Neisseria) or yeasts are suspected, thebottle should be vented as soon as it is received <strong>in</strong> the laboratory, by <strong>in</strong>sert<strong>in</strong>ga sterile cotton-wool-plugged needle through the previously dis<strong>in</strong>fecteddiaphragm. The needle can be removed once the pressure <strong>in</strong> the bottle reachesatmospheric pressure. Commercial blood-culture bottles often also conta<strong>in</strong>carbon dioxide, which has a stimulat<strong>in</strong>g effect on growth.22


BACTERIOLOGICAL INVESTIGATIONSIn countries where brucellosis is prevalent, the use of a diphasic blood-culturebottle, with a broth phase and a solid-slant phase on one of the flat surfacesof the bottle (Castaneda bottle), is recommended for the cultivation of Brucellaspp. The presence of carbon dioxide is needed for the isolation of most stra<strong>in</strong>sof B. abortus.Process<strong>in</strong>g of blood culturesIncubation timeBlood-culture bottles should be <strong>in</strong>cubated at 35–37∞C and rout<strong>in</strong>ely <strong>in</strong>spectedtwice a day (at least for the first 3 days) for signs of microbial growth. A sterileculture usually shows a layer of sedimented red blood covered by a paleyellow transparent broth. Growth is evidenced by:— a floccular deposit on top of the blood layer— uniform or subsurface turbidity— haemolysis— coagulation of the broth— a surface pellicle— production of gas— white gra<strong>in</strong>s on the surface or deep <strong>in</strong> the blood layer.Whenever visible growth appears, the bottle should be opened aseptically, asmall amount of broth removed with a sterile loop or Pasteur pipette, and aGram-sta<strong>in</strong>ed smear exam<strong>in</strong>ed for the presence of microorganisms.Subcultures are performed by streak<strong>in</strong>g a loopful on appropriate media:— for Gram-negative rods: MacConkey agar, Kligler iron agar, motility<strong>in</strong>dole–urease(MIU) medium, Simmons citrate agar;— for small Gram-negative rods: blood agar;— for staphylococci: blood agar, mannitol salt agar;— for streptococci: blood agar with optoch<strong>in</strong>, bacitrac<strong>in</strong>, and tellurite discs,sheep blood agar for the CAMP test, and bile–aescul<strong>in</strong> agar.For rout<strong>in</strong>e exam<strong>in</strong>ations, it is not necessary to <strong>in</strong>cubate blood culturesbeyond 7 days. In some cases, <strong>in</strong>cubation may be prolonged for an additional7 days, e.g. if Brucella or other fastidious organisms are suspected, <strong>in</strong> cases ofendocarditis, or if the patient has received antimicrobials.Bl<strong>in</strong>d subcultures and f<strong>in</strong>al process<strong>in</strong>gSome microorganisms may grow without produc<strong>in</strong>g turbidity or visiblealteration of the broth. Other organisms, e.g. pneumococci, tend to undergoautolysis and die very rapidly. For this reason some laboratories performrout<strong>in</strong>e subcultures on chocolate agar after 18–24 hours of <strong>in</strong>cubation. A bl<strong>in</strong>dsubculture may be made at the end of 7 days of <strong>in</strong>cubation, by transferr<strong>in</strong>gseveral drops of the well-mixed blood culture (us<strong>in</strong>g a sterile Pasteur pipette)<strong>in</strong>to a tube of thioglycollate broth, which <strong>in</strong> turn is <strong>in</strong>cubated and observedfor 3 days.23


BLOODAntibiogramWhen staphylococci or Gram-negative rods are suspected, precious time canbe saved by perform<strong>in</strong>g a direct, non-standardized antibiogram us<strong>in</strong>g thepositive broth as an <strong>in</strong>oculum. A sterile swab is dipped <strong>in</strong>to the turbid broth,excess fluid is expressed, and the swab is used to <strong>in</strong>oculate Mueller–H<strong>in</strong>tonmedium as <strong>in</strong> the standard method (see page 110). A provisional read<strong>in</strong>g canoften be made after 6–8 hours of <strong>in</strong>cubation. In 95% of cases the resultsobta<strong>in</strong>ed with this method are <strong>in</strong> agreement with the standardized test.Contam<strong>in</strong>antsContam<strong>in</strong>ation of blood cultures can be avoided by meticulous sk<strong>in</strong> preparationand by adherence to strict aseptic procedures for <strong>in</strong>oculation and sub<strong>in</strong>oculation.However, even <strong>in</strong> ideal conditions, 3–5% of blood cultures grow“contam<strong>in</strong>ants” orig<strong>in</strong>at<strong>in</strong>g from the sk<strong>in</strong> (S. epidermidis, P. acnes, Clostridiumspp., diphtheroids) or from the environment (Ac<strong>in</strong>etobacter spp., Bacillus spp.).Such organisms, however, may occasionally behave as pathogens and evencause endocarditis. A true <strong>in</strong>fection should be suspected <strong>in</strong> the follow<strong>in</strong>gsituations:— if the same organism grows <strong>in</strong> two bottles of the same blood specimen;— if the same organism grows <strong>in</strong> cultures from more than one specimen;— if growth is rapid (with<strong>in</strong> 48 hours);— if different isolates of one species show the same biotypes and antimicrobial-susceptibilityprofiles.All culture results should be reported to the cl<strong>in</strong>ician, <strong>in</strong>clud<strong>in</strong>g the presumedcontam<strong>in</strong>ants. However, for the latter no antibiogram need be performed andappropriate mention should be made on the report slip, e.g. Propionibacteriumacnes (sk<strong>in</strong> commensal), Staphylococcus epidermidis (probable contam<strong>in</strong>ant). Itis to the advantage of all concerned to establish good communication betweenphysicians and laboratory personnel.The identification of two or more agents may <strong>in</strong>dicate polymicrobial bacteraemia,which can occur <strong>in</strong> debilitated patients, but may also be due to contam<strong>in</strong>ation.“Anaerobic” bacteraemia is often caused by multiple pathogens;for example, one or more anaerobes may be associated with one or more aerobes<strong>in</strong> severe fulm<strong>in</strong>at<strong>in</strong>g bacteraemia associated with severe trauma or surgery<strong>in</strong>volv<strong>in</strong>g the large <strong>in</strong>test<strong>in</strong>e.24


Cerebrosp<strong>in</strong>al fluidIntroductionThe exam<strong>in</strong>ation of cerebrosp<strong>in</strong>al fluid (CSF) is an essential step <strong>in</strong> thediagnosis of bacterial and fungal men<strong>in</strong>gitis and CSF must always be consideredas a priority specimen that requires prompt attention by the laboratorystaff.Normal CSF is sterile and clear, and usually conta<strong>in</strong>s three leukocytesor fewer per mm 3 and no erythrocytes. The chemical and cytological compositionof CSF is modified by men<strong>in</strong>geal or cerebral <strong>in</strong>flammation, i.e. men<strong>in</strong>gitisor encephalitis. Only the microbiological exam<strong>in</strong>ation of CSF willbe discussed here, although the CSF leukocyte count is also of paramountimportance.The most common causal agents of men<strong>in</strong>gitis are listed <strong>in</strong> Table 6 accord<strong>in</strong>gto the age of the patient, but it should be kept <strong>in</strong> m<strong>in</strong>d that some overlapexists.Collection and transportation of specimensApproximately 5–10ml of CSF should be collected <strong>in</strong> two sterile tubes bylumbar or ventricular puncture performed by a physician. In view of thedanger of iatrogenic bacterial men<strong>in</strong>gitis, thorough dis<strong>in</strong>fection of the sk<strong>in</strong> ismandatory. Part of the CSF specimen will be used for cytological and chemicalexam<strong>in</strong>ation, and the rema<strong>in</strong>der for the microbiological exam<strong>in</strong>ation. Thespecimen should be delivered to the laboratory at once, and processed immediately,s<strong>in</strong>ce cells dis<strong>in</strong>tegrate rapidly. Any delay may produce a cell countthat does not reflect the cl<strong>in</strong>ical situation of the patient.Table 6. Common causes of bacterial and fungal men<strong>in</strong>gitisIn neonates (from birth to 2 months)Escherichia coliListeria monocytogenesOther Enterobacteriaceae: Salmonella spp., Citrobacter spp.Streptococcus agalactiae (group B)In all other age groupsHaemophilus <strong>in</strong>fluenzae (capsular type b) aNeisseria men<strong>in</strong>gitidisStreptococcus pneumoniaeMycobacterium tuberculosisListeria monocytogenes bCryptococcus neoformans bStaphylococci ca Uncommon after the age of 5 years.b In immunocompromised patients (<strong>in</strong>clud<strong>in</strong>g those with acquired immunodeficiency syndrome (AIDS)).c Associated with neurosurgery and postoperative dra<strong>in</strong>s.25


CEREBROSPINAL FLUIDMacroscopic <strong>in</strong>spectionThe appearance of the CSF should be noted and recorded as: clear, hazy,turbid, purulent, yellow (due to haemolysis or icterus), or blood-t<strong>in</strong>ged, withfibr<strong>in</strong> web or pellicle.Microscopic exam<strong>in</strong>ationPreparation of specimenIf, on gross exam<strong>in</strong>ation, the CSF is purulent (very cloudy), it can be exam<strong>in</strong>edimmediately without centrifugation. In all other cases, the CSF shouldbe centrifuged <strong>in</strong> a sterile tube (preferably a 15-ml conical tube with screwcap)at 10000 g for 5–10 m<strong>in</strong>utes. Remove the supernatant us<strong>in</strong>g a sterilePasteur pipette fitted with a rubber bulb, and transfer it to another tubefor chemical and/or serological tests. Use the sediment for further microbiologicaltests.Direct microscopyExam<strong>in</strong>e one drop of the sediment microscopically (¥400), between a slide andcoverslip, for:— leukocytes (polymorphonuclear neutrophils or lymphocytes)— erythrocytes— bacteria— yeasts.If the yeast-like fungus Cryptococcus neoformans is suspected, mix a loopful ofthe sediment with a loopful of India <strong>in</strong>k on a slide, place a coverslip on top,and exam<strong>in</strong>e microscopically for the typical, encapsulated, spherical, budd<strong>in</strong>gyeast forms.In areas where African trypanosomiasis occurs, it will also be necessary tosearch carefully for actively motile, flagellated trypanosomes.A rare and generally fatal type of men<strong>in</strong>gitis is caused by free-liv<strong>in</strong>g amoebaefound <strong>in</strong> water (Naegleria fowleri) which enter through the nose and penetratethe central nervous system. They may be seen <strong>in</strong> the direct wet preparationas active motile amoebae about the size of neutrophilic leukocytes.Gram-sta<strong>in</strong>ed smearsAs the causative agent of bacterial men<strong>in</strong>gitis may often be observed <strong>in</strong> aGram-sta<strong>in</strong>ed smear, this exam<strong>in</strong>ation is extremely important. Air-dry thesmear, fix with gentle heat, and sta<strong>in</strong> it by Gram’s method. Exam<strong>in</strong>e at ¥1000(oil-immersion) for at least 10 m<strong>in</strong>utes, or until bacteria are found. Table 7 listsimportant diagnostic f<strong>in</strong>d<strong>in</strong>gs that are associated with different forms ofmen<strong>in</strong>gitis.26


BACTERIOLOGICAL INVESTIGATIONSTable 7. Cerebrosp<strong>in</strong>al fluid f<strong>in</strong>d<strong>in</strong>gs associated with men<strong>in</strong>gitisObservationType of men<strong>in</strong>gitisBacterial Tuberculous Fungal Viral(“aseptic”)Elevated leukocyte Segmented Mononuclear Mononuclear Mononuclearcount polymorphonuclear (young neutrophils)neutrophilsGlucose Very low: Low: Low: Normal:0.28–1.1mmol/l 1.1–2.2mmol/l 1.1–2.2mmol/l 3.6–3.9mmol/lProte<strong>in</strong> Elevated Elevated Elevated Slightlyelevated <strong>in</strong>early stage of<strong>in</strong>fectionSta<strong>in</strong>ed smear Bacteria usually Rarely positive Usually positive Negativeseen (Gram) (acid-fast) (India <strong>in</strong>k)Table 8. Choice of culture media for CSF specimens accord<strong>in</strong>g to the results ofthe Gram smear aObservation Gram-negative rods Gram-positive cocci Gram-negative Gram-positive No organismscocci rods seenIn neonates In other In neonates In other agesagesBlood agar b + + + + with + + +optoch<strong>in</strong> discBlood agar with + + +S. aureus streak bChocolate agar (+) (+) (+)MacConkey agar + + + + + + +Tryptic soy broth + + + + + + +a +=Use; (+) = optional use.b Incubate <strong>in</strong> an atmosphere rich <strong>in</strong> CO 2 (candle jar).Acid-fast sta<strong>in</strong> (Ziehl–Neelsen)Although its sensitivity is not high, exam<strong>in</strong>ation of an acid-fast-sta<strong>in</strong>ed preparationof the sediment or of the fibr<strong>in</strong> web is <strong>in</strong>dicated when tuberculous men<strong>in</strong>gitisis suspected by the physician. Carefully exam<strong>in</strong>e the acid-fast-sta<strong>in</strong>edpreparation for at least 15 m<strong>in</strong>utes. If the result is negative, the microscopic<strong>in</strong>vestigation should be repeated on a fresh specimen on the follow<strong>in</strong>g day.CultureIf bacteria have been seen <strong>in</strong> the Gram-sta<strong>in</strong>ed smear, the appropriate culturemedia should be <strong>in</strong>oculated (Table 8). If no organisms have been seen, or ifthe <strong>in</strong>terpretation of the Gram smear is unclear, it is desirable to <strong>in</strong>oculatea full range of media, <strong>in</strong>clud<strong>in</strong>g blood agar with a streak of Staphylococcus27


CEREBROSPINAL FLUIDaureus to promote growth of H. <strong>in</strong>fluenzae. Blood agar and chocolate agar platesshould be <strong>in</strong>cubated at 35∞C <strong>in</strong> an atmosphere enriched with carbon dioxide.All media should be <strong>in</strong>cubated for 3 days, with daily <strong>in</strong>spections.When tuberculous men<strong>in</strong>gitis is suspected, at least three tubes of Löwenste<strong>in</strong>–Jensen medium should be <strong>in</strong>oculated with a drop of the sediment and <strong>in</strong>cubatedfor 6 weeks. For the first 2–3 days the tubes should be <strong>in</strong>cubated <strong>in</strong> ahorizontal position with the screw-cap loosened half a turn. Tubes should be<strong>in</strong>spected for growth at weekly <strong>in</strong>tervals. Smears from any suspicious growthshould be prepared, preferably <strong>in</strong> a bacteriological safety cab<strong>in</strong>et, air-dried,heat-fixed, and sta<strong>in</strong>ed by the Ziehl–Neelsen method. The presence of acidfastrods is consistent with the diagnosis of tuberculosis. All isolates shouldbe forwarded to a central laboratory for confirmation and for susceptibilitytest<strong>in</strong>g.When Cryptococcus neoformans is suspected, either from the India <strong>in</strong>k preparationor on cl<strong>in</strong>ical grounds, the sediment should be <strong>in</strong>oculated on two tubesof Sabouraud dextrose agar, and <strong>in</strong>cubated at 35 ∞C for up to 1 month. C.neoformans also grows on the blood agar plate, which should be <strong>in</strong>cubatedat 35∞C for 1 week, if <strong>in</strong>dicated.Prelim<strong>in</strong>ary identificationGrowth on MacConkey agar is suggestive of Enterobacteriaceae and shouldbe further identified us<strong>in</strong>g the methods and media recommended for entericpathogens.Colonies of Gram-positive cocci with a narrow zone of b-haemolysis may beS. agalactiae (group B streptococci). This should be confirmed with the reverseCAMP test (page 101).Flat colonies with a concave centre and a slight green zone of a-haemolysisare probably S. pneumoniae. For confirmation, a 6-mm optoch<strong>in</strong> disc should beplaced on a blood agar plate heavily <strong>in</strong>oculated with a pure culture of the suspectedstra<strong>in</strong>. After overnight <strong>in</strong>cubation, pneumococci will exhibit an <strong>in</strong>hibitionzone of 14 mm or more around the optoch<strong>in</strong> disc. The best results areobta<strong>in</strong>ed after <strong>in</strong>cubation on sheep blood agar <strong>in</strong> a carbon-dioxide-enrichedatmosphere. If the read<strong>in</strong>g of this test on the primary blood agar plate is <strong>in</strong>conclusive,the test should be repeated on a subculture.Colonies of H. <strong>in</strong>fluenzae will grow only on chocolate agar, and as satellitecolonies <strong>in</strong> the vic<strong>in</strong>ity of the staphylococcal streak on blood agar. Furtheridentification may be accomplished us<strong>in</strong>g H. <strong>in</strong>fluenzae type b antiserum <strong>in</strong>the slide agglut<strong>in</strong>ation test.Gram-negative diplococci grow<strong>in</strong>g on blood and chocolate agar, and giv<strong>in</strong>g arapidly positive oxidase test, may be considered to be men<strong>in</strong>gococci. Confirmationis accomplished by group<strong>in</strong>g with appropriate N. men<strong>in</strong>gitidis antisera(A, B, C) <strong>in</strong> the slide agglut<strong>in</strong>ation test. A negative agglut<strong>in</strong>ation test doesnot rule out men<strong>in</strong>gococci as there are at least four additional serogroups. Ifthe agglut<strong>in</strong>ation test is negative, carbohydrate utilization tests should be performedand the culture sent to a central reference laboratory. A prelim<strong>in</strong>aryreport should be given to the physician at each stage of identification (Gramsta<strong>in</strong>,growth, agglut<strong>in</strong>ation, etc.), not<strong>in</strong>g that a f<strong>in</strong>al report will follow.Colonies of Gram-positive rods with a narrow zone of b-haemolysis on bloodagar may be Listeria monocytogenes. The follow<strong>in</strong>g confirmatory tests are28


BACTERIOLOGICAL INVESTIGATIONSsuggested: positive catalase reaction, motility <strong>in</strong> broth culture or <strong>in</strong> MIU,growth and black discoloration on bile–aescul<strong>in</strong> agar.Susceptibility test<strong>in</strong>gFor Gram-negative rods and staphylococci, the standardized disc-diffusionmethod (Kirby–Bauer) should be used.No susceptibility test<strong>in</strong>g is needed for Listeria monocytogenes, S. agalactiae orN. men<strong>in</strong>gitidis s<strong>in</strong>ce resistance to ampicill<strong>in</strong> and benzylpenicill<strong>in</strong> is extremelyrare.All stra<strong>in</strong>s of pneumococci should be tested on blood agar for susceptibilityto chloramphenicol and benzylpenicill<strong>in</strong>. For the latter, the oxacill<strong>in</strong> (1mg) discis recommended (see page 66, “Lower respiratory tract <strong>in</strong>fections”).Stra<strong>in</strong>s of H. <strong>in</strong>fluenzae should be tested for susceptibility to chloramphenicolus<strong>in</strong>g chocolate agar or a supplemented blood agar. Most ampicill<strong>in</strong>-resistantstra<strong>in</strong>s produce b-lactamase that can be demonstrated us<strong>in</strong>g one of the rapidtests recommended for the screen<strong>in</strong>g of potential b-lactamase-produc<strong>in</strong>gstra<strong>in</strong>s of gonococci (page 79).29


Ur<strong>in</strong>eIntroductionUr<strong>in</strong>e is the specimen most frequently submitted for culture. It also presentsmajor problems <strong>in</strong> terms of proper specimen collection, transport, culturetechniques, and <strong>in</strong>terpretation of results. As with any other specimen submittedto the laboratory, the more comprehensive the <strong>in</strong>formation providedby the submitt<strong>in</strong>g physician the more able the laboratory is to provide the bestpossible culture data.The most common sites of ur<strong>in</strong>ary tract <strong>in</strong>fection (UTI) are the ur<strong>in</strong>arybladder (cystitis) and the urethra. From these sites the <strong>in</strong>fection mayascend <strong>in</strong>to the ureters (ureteritis) and subsequently <strong>in</strong>volve the kidney(pyelonephritis). Females are more prone to <strong>in</strong>fection of the ur<strong>in</strong>ary tractthan are males and also present the greater problem <strong>in</strong> the proper collectionof specimens.In both males and females, UTI may be asymptomatic, acute, or chronic.Asymptomatic <strong>in</strong>fection can be diagnosed by culture. Acute UTI is more frequentlyseen <strong>in</strong> females of all ages; these patients are usually treated on anoutpatient basis and are rarely admitted to hospital. Chronic UTI <strong>in</strong> bothmales and females of all ages is usually associated with an underly<strong>in</strong>g disease(e.g. pyelonephritis, prostatic disease, or congenital anomaly of the genitour<strong>in</strong>arytract) and these patients are most often hospitalized. Asymptomatic,acute, and chronic UTI are three dist<strong>in</strong>ct entities and the laboratory resultsoften require different <strong>in</strong>terpretation.Asymptomatic pyelonephritis <strong>in</strong> females may rema<strong>in</strong> undetected for sometime, and is often only diagnosed by carefully performed quantitative ur<strong>in</strong>eculture. Chronic prostatitis is common and difficult to cure, and is oftenresponsible for recurr<strong>in</strong>g UTI. In most UTI, irrespective of type, enteric bacteriaare the etiological agents, Escherichia coli be<strong>in</strong>g isolated far more frequentlythan any other organism. In about 10% of patients with UTI, twoorganisms may be present and both may contribute to the disease process.The presence of three or more different organisms <strong>in</strong> a ur<strong>in</strong>e culture is strongpresumptive evidence of improper collection or handl<strong>in</strong>g of the ur<strong>in</strong>e specimen.However, multiple organisms are often seen <strong>in</strong> UTI <strong>in</strong> patients with<strong>in</strong>dwell<strong>in</strong>g bladder catheters.Specimen collectionThe importance of the method of collection of ur<strong>in</strong>e specimens, their transportto the laboratory, and the <strong>in</strong>itial efforts by the laboratory to screen andculture the ur<strong>in</strong>e cannot be overemphasized. It is the responsibility of the laboratoryto provide the physician with sterile, wide-mouthed, glass or plasticjars, beakers, or other suitable receptacles. They should have tight-fitt<strong>in</strong>glids or be covered with alum<strong>in</strong>ium foil prior to sterilization by dry heat orautoclav<strong>in</strong>g.Ur<strong>in</strong>e specimens may have to be collected by a surgical procedure, e.g. suprapubicaspiration, cystoscopy, or catheterization. If not, the laboratory must<strong>in</strong>sist on a clean-catch midstream ur<strong>in</strong>e specimen, particularly <strong>in</strong> females andchildren. S<strong>in</strong>ce ur<strong>in</strong>e itself is a good culture medium, all specimens should beprocessed by the laboratory with<strong>in</strong> 2 hours of collection, or be kept refriger-30


BACTERIOLOGICAL INVESTIGATIONSated at 4 ∞C until delivery to the laboratory and processed no longer than 18hours after collection.Whenever possible, ur<strong>in</strong>e specimens for culture should be collected <strong>in</strong>the morn<strong>in</strong>g. It is advisable to ask the patient the night before to refra<strong>in</strong> fromur<strong>in</strong>at<strong>in</strong>g until the specimen is to be collected.A female outpatient should:1. Wash her hands thoroughly with soap and water and dry them with aclean towel.2. Spread the labia, and cleanse the vulva and labia thoroughly us<strong>in</strong>g sterilecotton gauze pads and warm soapy water, wip<strong>in</strong>g from front to rear. Dis<strong>in</strong>fectantsshould not be used.3. R<strong>in</strong>se the vulva and labia thoroughly with warm water and dry with asterile gauze pad. Dur<strong>in</strong>g the entire process the patient should keep thelabia separated and should not touch the cleansed area with the f<strong>in</strong>gers.4. Pass a small amount of ur<strong>in</strong>e. The patient should collect most of therema<strong>in</strong><strong>in</strong>g ur<strong>in</strong>e <strong>in</strong> a sterile conta<strong>in</strong>er, clos<strong>in</strong>g the lid as soon as the ur<strong>in</strong>ehas been collected. This is a midstream ur<strong>in</strong>e specimen.5. Hand the closed conta<strong>in</strong>er to the nurs<strong>in</strong>g personnel for prompt delivery tothe laboratory.A male outpatient should:1. Wash his hands thoroughly with soap and water and dry them with a cleantowel.2. Pull back the foresk<strong>in</strong> (if not circumcised) and wash the glans thoroughlyus<strong>in</strong>g sterile cotton gauze pads and warm soapy water. Dis<strong>in</strong>fectantsshould not be used.3. R<strong>in</strong>se the glans thoroughly with warm water and dry with a sterile gauzepad. Dur<strong>in</strong>g the entire procedure the patient should not touch the cleansedarea with the f<strong>in</strong>gers.4. Pull back the foresk<strong>in</strong> and pass a small amount of ur<strong>in</strong>e. Still hold<strong>in</strong>g backthe foresk<strong>in</strong>, the patient should pass most of the rema<strong>in</strong><strong>in</strong>g ur<strong>in</strong>e <strong>in</strong>to asterile conta<strong>in</strong>er, clos<strong>in</strong>g the lid as soon as the ur<strong>in</strong>e has been collected.This is a midstream ur<strong>in</strong>e specimen.5. Hand the closed conta<strong>in</strong>er to the nurs<strong>in</strong>g personnel for prompt delivery tothe laboratory.For bedridden patients, the same procedure is followed, except that a nursemust assist the patient or, if necessary, do the entire cleans<strong>in</strong>g procedure beforerequest<strong>in</strong>g the patient to pass ur<strong>in</strong>e.In both situations every effort must be made to collect a clean-catch ur<strong>in</strong>e specimen<strong>in</strong> a sterile conta<strong>in</strong>er and to ensure that it is delivered promptly to thelaboratory together with <strong>in</strong>formation on the patient, the cl<strong>in</strong>ical diagnosis, andthe requested procedures.Infants and childrenCollection of a clean-catch ur<strong>in</strong>e specimen from <strong>in</strong>fants and children who areill <strong>in</strong> bed or uncooperative can be a problem. Give the child water or otherliquid to dr<strong>in</strong>k. Clean the external genitalia. The child can be seated on thelap of the mother, nurse, or ward attendant, who should then encourage thechild to ur<strong>in</strong>ate and collect as much ur<strong>in</strong>e as possible <strong>in</strong> a sterile conta<strong>in</strong>er.The conta<strong>in</strong>er should then be covered and delivered to the laboratory forimmediate process<strong>in</strong>g.31


URINECulture and <strong>in</strong>terpretationAll ur<strong>in</strong>e specimens brought to the microbiology laboratory should be exam<strong>in</strong>edat once, or placed <strong>in</strong> a refrigerator at 4 ∞C until they can be exam<strong>in</strong>ed.The exam<strong>in</strong>ation procedure <strong>in</strong>cludes the follow<strong>in</strong>g steps:1. Exam<strong>in</strong>ation of a Gram-sta<strong>in</strong>ed smear.2. A screen<strong>in</strong>g test for significant bacteriuria.3. A def<strong>in</strong>itive culture for ur<strong>in</strong>e specimens found to be positive <strong>in</strong> the screen<strong>in</strong>gtest, and for all specimens obta<strong>in</strong>ed by cystoscopy, suprapubic bladderpuncture (SBP), or catheterization.4. Susceptibility tests on cl<strong>in</strong>ically significant bacterial isolates.Preparation and exam<strong>in</strong>ation of a Gram-sta<strong>in</strong>ed smear is a necessary part ofthe laboratory process. Us<strong>in</strong>g a sterile Pasteur pipette (one for each sample),place one drop of well-mixed, uncentrifuged ur<strong>in</strong>e on a slide. Allow the dropto dry without spread<strong>in</strong>g, heat-fix and sta<strong>in</strong>. Exam<strong>in</strong>e under an oil-immersionlens (¥600 or more) for the presence or absence of bacteria, polymorphonuclearleukocytes, and squamous epithelial cells.One or more bacterial cells per oil-immersion field usually implies thatthere are 10 5 or more bacteria per millilitre <strong>in</strong> the specimen. The presence of oneor more leukocytes per oil-immersion field is a further <strong>in</strong>dication of UTI.Non-<strong>in</strong>fected ur<strong>in</strong>e samples will usually show few or no bacteria or leukocytes<strong>in</strong> the entire preparation. In specimens from females, the presence of manysquamous epithelial cells, with or without a mixture of bacteria, is strongpresumptive evidence that the specimen is contam<strong>in</strong>ated with vag<strong>in</strong>al floraand a repeat specimen is necessary, regardless of the number of bacteria peroil-immersion field. If results are required urgently, the report of the Gramsta<strong>in</strong>f<strong>in</strong>d<strong>in</strong>gs should be sent to the physician with a note that the culturereport is to follow.Screen<strong>in</strong>g methodThe absence of leukocytes and bacteria <strong>in</strong> a Gram-sta<strong>in</strong>ed smear of a cleancatchur<strong>in</strong>e sample prepared as described above is good evidence that theur<strong>in</strong>e is not <strong>in</strong>fected. A ur<strong>in</strong>e specimen that is “negative” on careful exam<strong>in</strong>ationof the Gram-sta<strong>in</strong>ed smear does not need to be cultured. An alternativesimple and effective screen<strong>in</strong>g test is the test strip for leukocyteesterase/nitrate reduction. The strip is dipped <strong>in</strong>to the ur<strong>in</strong>e specimen as<strong>in</strong>structed <strong>in</strong> the package literature. Any p<strong>in</strong>k colour is a positive reaction<strong>in</strong>dicat<strong>in</strong>g the presence of leukocyte esterase and/or bacteria <strong>in</strong> excessof 10 5 per ml. Ur<strong>in</strong>e samples that are positive <strong>in</strong> the screen<strong>in</strong>g test shouldbe cultured as soon as possible to prevent possible overgrowth by nonsignificantbacteria. If the strip does not develop a p<strong>in</strong>k colour it is <strong>in</strong>terpretedas a negative screen<strong>in</strong>g test, is so reported, and no culture is <strong>in</strong>dicated. Thetest strip may not be sensitive enough to detect bacterial counts of less than10 5 per ml of ur<strong>in</strong>e.Quantitative culture and presumptive identificationTwo techniques are recommended here for quantitative culture andpresumptive identification: the calibrated loop technique and the filter-paperdip strip method.32


BACTERIOLOGICAL INVESTIGATIONSCalibrated loop techniqueThe recommended procedure uses a calibrated plastic or metal loop to transfer1 ml of ur<strong>in</strong>e to the culture medium (MacConkey agar with crystal violetand non-selective blood agar).1. Shake the ur<strong>in</strong>e gently, then tip it to a slant and with a 1-ml <strong>in</strong>oculat<strong>in</strong>gloop touch the surface so that the ur<strong>in</strong>e is sucked up <strong>in</strong>to the loop. Neverdip the loop <strong>in</strong>to the ur<strong>in</strong>e.2. Deposit 1 ml of the ur<strong>in</strong>e on a blood agar plate and streak half the plate bymak<strong>in</strong>g a straight l<strong>in</strong>e down the centre (1), followed by close passes at rightangles through the orig<strong>in</strong>al (2), and end<strong>in</strong>g with oblique streaks cross<strong>in</strong>gthe two previous passes (3) (Fig. 3).3. Inoculate the MacConkey agar <strong>in</strong> the same manner.4. Incubate the plates overnight at 35 ∞C.Blood agar and MacConkey agar can also be replaced by another nonselectivemedium (e.g. CLED 1 agar, purple lactose agar).Filter-paper dip-strip methodThe filter-paper dip-strip method of Leigh & Williams 2 is based on the absorptionand subsequent transfer of a fixed amount of ur<strong>in</strong>e to a suitable plat<strong>in</strong>gagar medium.The strips can be locally prepared us<strong>in</strong>g a specific type of blott<strong>in</strong>g-paper andshould measure 7.5cm long by 0.6cm wide (see Fig. 4). They are marked at1.2cm from one end with a pencil. The filter-paper dip strip technique shouldbe compared with the calibrated loop technique before adopt<strong>in</strong>g the strips forFig. 3. Inoculation of bacteria on culture platesFig. 4. Diagram of a dip strip1CLED: Cyst<strong>in</strong>e-Lactose-Electrolyte Deficient.2Leigh DA & Williams JD. Method for the detection of significant bacteriuria <strong>in</strong> large groups ofpatients. Journal of Cl<strong>in</strong>ical Pathology, 1964, 17: 498–503.33


URINEFig. 5. Dip-strip impressions on an agar plate, show<strong>in</strong>g conversionfrom number of colonies to number of bacteria per mlrout<strong>in</strong>e <strong>in</strong>vestigations. The strips are made <strong>in</strong> quantity, placed <strong>in</strong> a suitableconta<strong>in</strong>er and autoclaved. Sterile strips are commercially available. A sterilestrip is removed from the conta<strong>in</strong>er for each ur<strong>in</strong>e sample to be tested. Themarked end is dipped as far as the mark <strong>in</strong>to the thoroughly mixed ur<strong>in</strong>esample. The strip is withdrawn immediately and the excess ur<strong>in</strong>e is allowedto be absorbed.The area below the mark, which will bend over like the foot of an “L”, shouldthen be placed <strong>in</strong> contact with a plate of brolac<strong>in</strong> agar 1 or purple lactose agarfor 2–3 seconds. Several strips can be cultured on one plate by divid<strong>in</strong>g theundersurface of the plate <strong>in</strong>to up to 16 rectangles (Fig. 5). Be sure to identifyeach rectangular area with the number or name of the patient. Remove asecond strip from the conta<strong>in</strong>er and repeat the procedure exactly, mak<strong>in</strong>g asecond impr<strong>in</strong>t identical to the first. Once the plate is completely <strong>in</strong>oculatedwith duplicate impressions, it should be <strong>in</strong>cubated at 35–37 ∞C, and thecolonies result<strong>in</strong>g from each dip-strip impr<strong>in</strong>t counted. With the help ofFig. 5 it is possible to convert the average number of colonies for each pair ofdip-strips to the number of bacteria per ml of ur<strong>in</strong>e.Immediately follow<strong>in</strong>g the above procedure, <strong>in</strong>oculate half a plate ofMacConkey agar (with crystal violet) with the ur<strong>in</strong>e specimen us<strong>in</strong>g a sterileloop. The <strong>in</strong>clusion of a blood agar facilitates the rapid identification of Grampositivecocci. Plates should be <strong>in</strong>cubated at 35–37 ∞C overnight, and exam<strong>in</strong>edon the follow<strong>in</strong>g day for growth. Identification procedures may then be<strong>in</strong>itiated us<strong>in</strong>g well-separated colonies of similar appearance. If required, the<strong>in</strong>oculum for perform<strong>in</strong>g the disc-diffusion susceptibility test (page 97) can beprepared from either of these plates. In this way, the results of both identificationand susceptibility tests will be available on the next day.Interpretation of quantitative ur<strong>in</strong>e culture resultsFor many years, only the presence of at least 10 5 colony-form<strong>in</strong>g units (CFU)per ml <strong>in</strong> a clean-catch midstream ur<strong>in</strong>e specimen was considered cl<strong>in</strong>ically1 Bromothymol-blue lactose cyst<strong>in</strong>e agar.34


BACTERIOLOGICAL INVESTIGATIONSrelevant for a diagnosis of ur<strong>in</strong>ary tract <strong>in</strong>fection. This assumption has beenchallenged; some experts feel that 10 4 CFU or even fewer may <strong>in</strong>dicate <strong>in</strong>fection.Others believe that the presence of polymorphonuclear leukocytes playsan important role <strong>in</strong> the pathology and cl<strong>in</strong>ical manifestations of UTI. It is notpossible to def<strong>in</strong>e precisely the m<strong>in</strong>imum number of bacteria per millilitre ofur<strong>in</strong>e that is def<strong>in</strong>itely associated with UTI. General recommendations forreport<strong>in</strong>g are given below.Category 1: fewer than 10 4 CFU per ml. Report as probable absence of UTI.(Exceptions: if fewer than 10 4 CFU per ml are present <strong>in</strong> ur<strong>in</strong>etaken directly from the bladder by suprapubic puncture orcystoscopy, <strong>in</strong>; symptomatic women, or <strong>in</strong> the presence ofleukocytura, report the identification and the result of thesusceptibility test.)Category 2: 10 4 –10 5 CFU per ml. If the patient is asymptomatic, request asecond ur<strong>in</strong>e specimen and repeat the count. If the patient hassymptoms of UTI, proceed with both identification andsusceptibility tests if one or two different colony types ofbacteria are present. Bacterial counts <strong>in</strong> this range stronglysuggest UTI <strong>in</strong> symptomatic patients, or <strong>in</strong> the presence ofleukocyturia. If the count, the quality of the ur<strong>in</strong>e specimen, orthe significance of the patient’s symptoms is <strong>in</strong> doubt, asecond ur<strong>in</strong>e specimen should be obta<strong>in</strong>ed for retest<strong>in</strong>g.Report the number of CFU.Category 3: More than 10 5 CFU per ml. Report the count to the physicianand proceed with identification and susceptibility tests if oneor two different colony types of bacteria are present. Thesebacterial counts are strongly suggestive of UTI <strong>in</strong> all patients,<strong>in</strong>clud<strong>in</strong>g asymptomatic females.If more than two species of bacteria are present <strong>in</strong> ur<strong>in</strong>e samples <strong>in</strong> categories2 and 3, report as “Probably contam<strong>in</strong>ated; please submit a fresh, clean-catchspecimen”.IdentificationIdentification should be performed as rapidly as possible. S<strong>in</strong>ce the vastmajority of ur<strong>in</strong>ary tract <strong>in</strong>fections are caused by E. coli, a rapid test shouldbe used to identify red colonies from MacConkey agar.b-Glucuronidase test for rapid identificationof E. coli 1This test determ<strong>in</strong>es the ability of an organism to produce the enzymeb-glucuronidase. The enzyme hydrolyses the 4-nitrophenyl-b-dglucopyranosiduronicacid (PGUA) reagent to glucuronic acid and p-nitrophenol.The development of a yellow colour <strong>in</strong>dicates a positive reaction.1Kilian M, Borrow P. Rapid diagnosis of Enterobacteriaceae. 1. Detection of bacterialglycosidases. Acta Pathologica et Microbiologica Scand<strong>in</strong>avica, Section B, 1976, 84:245–251.35


URINEProcedure:1. Prepare a dense milky suspension of the organism to be tested <strong>in</strong> a smalltube conta<strong>in</strong><strong>in</strong>g 0.25ml of sal<strong>in</strong>e. The suspension should be prepared fromcolonies grow<strong>in</strong>g on MacConkey agar.2. Dissolve 300mg of 4-nitrophenyl-b-d-glucopyranosiduronic acid (PGUA)and 100mg of yeast extract (Oxoid L21) 1 <strong>in</strong> 20ml of phosphate buffer (Trisbuffer, pH 8.5). Adjust the pH to 8.5 ± 0.1. Pour 0.25ml of the medium <strong>in</strong>toeach of the required number of sterile tubes. Close the tubes with stoppers.<strong>Lab</strong>el the tubes PGUA and <strong>in</strong>dicate the date.3. Inoculate one tube of the PGUA medium with a dense suspension ofthe organism to be tested. Incubate the tube for 4 hours at 35∞C. The developmentof a yellow colour <strong>in</strong>dicates the presence of b-glucuronidase (positiveresult); if no colour change occurs the result is negative. The presenceof a pigmented yellow colour <strong>in</strong>dicates that the result is unreliable; <strong>in</strong> suchcases other tests must be used.Quality control organisms:Escherichia coli positive (yellow) resultShigella flexneri negative (clear) resultPGUA tablets are commercially available.Susceptibility testsSusceptibility tests (page 97) should only be performed on well-isolatedcolonies of similar appearance that are considered significant accord<strong>in</strong>g to theguidel<strong>in</strong>es presented above. Susceptibility tests are generally more importanton cultures obta<strong>in</strong>ed from patients who are hospitalized or have a history ofrecurr<strong>in</strong>g UTI. Cultures from patients a primary UTI may not require a susceptibilitytest.1Available from Oxoid Ltd, Wade Road, Bas<strong>in</strong>gstoke, Hampshire, RG24 8PW, England.36


StoolIntroductionEnteric bacterial <strong>in</strong>fections, caus<strong>in</strong>g diarrhoea, dysentery, and enteric fevers,are important health problems throughout the world. Diarrhoeal <strong>in</strong>fectionsare second only to cardiovascular diseases as a cause of death, and they arethe lead<strong>in</strong>g cause of childhood death. In develop<strong>in</strong>g countries, diarrhoeal; diseasesaccount for 1.5 million death each year among children aged 1–4 years.The risk of children <strong>in</strong> this age group dy<strong>in</strong>g from diarrhoeal disease is 600times greater <strong>in</strong> develop<strong>in</strong>g countries than <strong>in</strong> developed countries. In somedevelop<strong>in</strong>g countries, children suffer ten or more episodes of diarrhoea a year.Children are frequently <strong>in</strong>fected with multiple pathogens and even childrenwithout diarrhoea quite often carry potential pathogens <strong>in</strong> their stools. Observations<strong>in</strong> studies suggested that active immunization through repeated exposureand prolonged breastfeed<strong>in</strong>g may protect aga<strong>in</strong>st the diarrhoeageniceffect of these agents. They have also underl<strong>in</strong>ed the difficulties <strong>in</strong> determ<strong>in</strong><strong>in</strong>gthe cause of an episode of diarrhoea by culture of a s<strong>in</strong>gle stool specimen.With the <strong>in</strong>creas<strong>in</strong>g prevalence of HIV/AIDS and immunosuppressivechemotherapy, diarrhoea <strong>in</strong> immunocompromised patients has become agrow<strong>in</strong>g challenge. Patients with HIV/AIDS either present with diarrhoea orhave diarrhoea <strong>in</strong> a later stage of the disease, and the <strong>in</strong>fection is often lifethreaten<strong>in</strong>gand difficult to cure. The list of enteric bacterial <strong>in</strong>fections identified<strong>in</strong> HIV/AIDS patients is long and <strong>in</strong>cludes Campylobacter, Salmonella,Shigella, and mycobacteria. Salmonellosis has been estimated to be nearly 20times as common and 5 times more often bacteraemic <strong>in</strong> patients withHIV/AIDS than <strong>in</strong> those without the disease. In Zaire, 84% of patients withdiarrhoea of more than a month’s duration were found to be seropositive forHIV, and 40% of patients with HIV/AIDS had persistent diarrhoea.Etiological agents and cl<strong>in</strong>ical featuresThe genus Salmonella conta<strong>in</strong>s more than 2000 serotypes. Many of thesemay <strong>in</strong>fect both humans and domestic animals. In humans they cause gastroenteritis,typhoid fever, and bacteraemia with or without metastaticdisease. Salmonella gastroenteritis usually beg<strong>in</strong>s with nausea, vomit<strong>in</strong>g,abdom<strong>in</strong>al colic and diarrhoea 8–48 hours after <strong>in</strong>gestion of the contam<strong>in</strong>atedfood. The symptoms often persist for 3–5 days before resolv<strong>in</strong>g withouttherapy. Antimicrobials will not hasten cl<strong>in</strong>ical recovery, and may lengthenthe convalescence and asymptomatic carrier state. Antimicrobial susceptibilitytest<strong>in</strong>g and antimicrobial therapy are not recommended for uncomplicatedcases. Antimicrobial treatment is only <strong>in</strong>dicated if the patient appears bacteraemic.Some patients may harbour Salmonella spp. <strong>in</strong> stool or ur<strong>in</strong>e for periodsof 1 year or longer but rema<strong>in</strong> asymptomatic. Approximately 3% of patientswith typhoid fever and 0.2–0.6% of persons with non-typhoid Salmonellagastroenteritis will have positive stool cultures for more than 1 year.Shigella spp. cause a wide spectrum of cl<strong>in</strong>ical diseases, which vary fromasymptomatic <strong>in</strong>fections to diarrhoea without fever to severe dysentery.Symptoms consist of abdom<strong>in</strong>al cramps, <strong>in</strong>effectual and pa<strong>in</strong>ful stra<strong>in</strong><strong>in</strong>g topass stool (tenesmus), and frequent, small-volume, bloodsta<strong>in</strong>ed <strong>in</strong>flammatorydischarge. Shigella spp. are the ma<strong>in</strong> cause of bacillary dysentery followedby entero<strong>in</strong>vasive and enterohaemorrhagic E. coli. Many cases present as mild37


STOOLillnesses that require no specific treatment. However, for severe dysentery orwhen secondary spread is likely, antimicrobial therapy after susceptibilitytest<strong>in</strong>g is <strong>in</strong>dicated as resistance towards commonly used antimicrobials ishigh <strong>in</strong> many countries. Four groups of Shigella organisms, with a total of 39serotypes and subtypes, are recognized. Group A (S. dysenteriae), group B (S.flexneri), and group C (S. boydii) conta<strong>in</strong> multiple serotypes; there is only oneserotype for group D (S. sonnei). S. dysenteriae and S. flexneri are the most commonlyisolated Shigella species <strong>in</strong> develop<strong>in</strong>g countries, while S. sonnei is themost commonly isolated species <strong>in</strong> developed countries.At least six different classes of diarrhoea-produc<strong>in</strong>g Escherichia coli havebeen identified: enteropathogenic E. coli (EPEC), enterotoxigenic E. coli(ETEC), enterohaemorrhagic or verotox<strong>in</strong>-produc<strong>in</strong>g E. coli (EHEC or VTEC),entero<strong>in</strong>vasive E. coli (EIEC), enteroadhesive E. coli (EAEC), and enteroaggregativeE. coli (EAggEC). Four of them are common causes of diarrhoealdisease <strong>in</strong> develop<strong>in</strong>g countries. However, identification of these stra<strong>in</strong>srequires serological assays, toxicity assays <strong>in</strong> cell culture, pathogenicitystudies <strong>in</strong> animals and gene-probe techniques that are beyond the capacity of<strong>in</strong>termediate-level cl<strong>in</strong>ical laboratories. It may be possible to have a presumptiveidentification of a VTEC stra<strong>in</strong>, as the most frequent VTEC serotypeO157:H7 is characterized by be<strong>in</strong>g sorbitol-negative. However, E. fergusoniiand E. hermanii are also sorbitol-negative. A sorbitol-negative E. coli stra<strong>in</strong> willneed additional identification by serotyp<strong>in</strong>g with E. coli O157 antiserum.Demonstration of verotox<strong>in</strong> production <strong>in</strong>dicates that it is a VTEC stra<strong>in</strong>.Cholera is a typical example of a toxigenic <strong>in</strong>fection. All the symptoms can beattributed to the <strong>in</strong>test<strong>in</strong>al fluid loss caused by an enterotox<strong>in</strong> released byVibrio cholerae <strong>in</strong> the <strong>in</strong>test<strong>in</strong>e. The stool is volum<strong>in</strong>ous and watery, and conta<strong>in</strong>sno <strong>in</strong>flammatory cells. The ma<strong>in</strong> objective of treatment is fluid replacementand antimicrobials have only a secondary role.V. cholerae spreads very rapidly. It can be divided <strong>in</strong>to several serotypes onthe basis of variation <strong>in</strong> the somatic O antigen, and serotype O1 exists <strong>in</strong> twobiological variants termed “classical” and “El Tor”. Until 1992, only V. choleraeserogroup O1 (classical or El Tor) was known to produce epidemic cholera,and other serogroups were thought to cause sporadic cholera and extra<strong>in</strong>test<strong>in</strong>al<strong>in</strong>fections. However, <strong>in</strong> 1992 a large outbreak of cholera appeared onthe east coast of India and quickly spread to neighbour<strong>in</strong>g countries. This epidemicwas caused by a previously unrecognized serogroup of V. cholerae O139Bengal. Isolation of V. cholerae O139 has so far been reported from 10 countries<strong>in</strong> south-east Asia but seems to be on the decl<strong>in</strong>e.V. parahaemolyticus and several other species of Vibrio (V. fluvialis, V. hollisae,V. mimicus) and Aeromonas (A. hydrophila, A. sobria, A. caviae) cause food poison<strong>in</strong>gor gastroenteritis <strong>in</strong> persons who eat raw or undercooked seafood.Campylobacter jejuni and C. coli have emerged as major enteric pathogens thatcan be isolated as often as Salmonella and Shigella spp. <strong>in</strong> most parts of theworld. Investigations <strong>in</strong> Africa and Asia have shown <strong>in</strong>cidence rates ofbetween 19 and 38%, and asymptomatic carrier rates of between 9 and 40%,<strong>in</strong> children. The <strong>in</strong>test<strong>in</strong>al disease varies from a brief, self-limit<strong>in</strong>g enteritis toa fulm<strong>in</strong>ant enterocolitis with severe diarrhoea, abdom<strong>in</strong>al colic, fever, andmuscle pa<strong>in</strong>. The stools are at first mucoid and liquid and may progress toprofuse watery diarrhoea conta<strong>in</strong><strong>in</strong>g blood and pus. Symptoms usuallysubside with<strong>in</strong> a week. Relapse occurs <strong>in</strong> about 25% of patients, but is generallymilder than the <strong>in</strong>itial episode. The <strong>in</strong>fection is usually self-limit<strong>in</strong>gwithout antimicrobial therapy, and susceptibility test<strong>in</strong>g is usually not<strong>in</strong>dicated.38


BACTERIOLOGICAL INVESTIGATIONSArcobacter butzleri, formerly regarded as a low-temperature-grow<strong>in</strong>g Campylobacter,has recently been recognized as a cause of diarrhoeal disease <strong>in</strong>patients, ma<strong>in</strong>ly children, <strong>in</strong> develop<strong>in</strong>g countries.Human <strong>in</strong>fections with Yers<strong>in</strong>ia enterocolitica have been reported ma<strong>in</strong>ly fromnorthern Europe, Japan and the United States of America. The majority of isolateshave been identified from children with sporadic diarrhoea.Clostridium difficile is the primary cause of enteric disease related to antimicrobialtherapy. It produces a broad spectrum of diseases rang<strong>in</strong>g from milddiarrhoea to potentially fatal pseudomembranous colitis. Observation ofcolonic pseudomembranes by colonoscopy is diagnostic for pseudomembranouscolitis, <strong>in</strong> which case laboratory confirmation is unnecessary. Severalcommercial tests are available for the laboratory, <strong>in</strong>clud<strong>in</strong>g culture, latexagglut<strong>in</strong>ation for detection of a cell-associated prote<strong>in</strong>, ELISA assay for cytotox<strong>in</strong>and/or enterotox<strong>in</strong>, and cell culture toxicity assay for cytotox<strong>in</strong>. Manyhospital patients harbour the organism <strong>in</strong> the stool <strong>in</strong> the absence of symptoms,particularly if they are receiv<strong>in</strong>g broad-spectrum antimicrobials. Therefore,a culture without demonstration of tox<strong>in</strong> production has little diagnosticvalue.Rotavirus is the only non-bacterial agent to be discussed here. Other virusesare important causes of diarrhoea but rotavirus is common everywhere <strong>in</strong> theworld with similar rates <strong>in</strong> both developed and develop<strong>in</strong>g countries. Most<strong>in</strong>fections occur <strong>in</strong> children between 6 and 18 months, with a higher prevalencedur<strong>in</strong>g the cooler months of the year. The diagnosis is made either withan enzyme immunoassay (ELISA) or more simply and practically with a latexagglut<strong>in</strong>ation assay. Reagents for both assays are commercially available butare expensive.Appropriate use of laboratory resourcesThe laboratory associated with a busy hospital or cl<strong>in</strong>ic <strong>in</strong> a develop<strong>in</strong>gcountry can quickly become overwhelmed with specimens. Cultures are notrequired for effective management of the majority of cases of diarrhoea anddysentery and patients will require only rehydration and not antimicrobials.A few patients (e.g. those with typhoid fever) will need the results of a culturefor appropriate treatment. The problem of how best to utilize scarce resourcesis a constant concern.Often, the public health aspects are the most important, and the laboratorymust be able to provide data that describe the common enteric pathogens <strong>in</strong>the district and the antimicrobial susceptibility patterns of these pathogens,and <strong>in</strong>vestigate an epidemy. Cl<strong>in</strong>icians must work closely with the laboratory.A procedure that allows the laboratory to develop a valid database is thecollection of specimens from a random systematic sample of patients withdiarrhoea at the hospital or cl<strong>in</strong>ic. By test<strong>in</strong>g only a proportion of these, thenumber of specimens is reduced and a more complete <strong>in</strong>vestigation can bemade on each specimen. If the sample is a systematic one (e.g. every twentyfifthpatient), then the results can be used to estimate the <strong>in</strong>fection <strong>in</strong> the entirepopulation of patients. If a typical cl<strong>in</strong>ical syndrome is observed <strong>in</strong> a particularage group, or dur<strong>in</strong>g a particular season, the laboratory can focus its sampl<strong>in</strong>gon these specific problems.The laboratory may decide to test for only certa<strong>in</strong> enteric pathogens. Yers<strong>in</strong>iaenterocolitica is evidently rare <strong>in</strong> most tropical areas. If the organism does notoccur <strong>in</strong> the area served by the laboratory, test<strong>in</strong>g for it can be omitted. When39


STOOLthe laboratory provides a report, it should specify which organisms were<strong>in</strong>vestigated. If Salmonella and Shigella species were the only pathogens ruledout, the report should not state “No pathogens found”. Rather, it should state“Salmonella and Shigella species not found”.Collection and transport of stool specimensFaecal specimens should be collected <strong>in</strong> the early stages of the diarrhoealdisease, when pathogens are present <strong>in</strong> the highest number, and preferablybefore antimicrobial treatment is started, if appropriate. The specimen shouldbe collected <strong>in</strong> the morn<strong>in</strong>g to reach the laboratory before noon, so that it canbe processed the same day. Formed stools should be rejected. Ideally, a freshstool specimen is preferred to a rectal swab, but a rectal swab is acceptable ifthe collection cannot be made immediately or when transportation of the stoolto the laboratory is delayed.Procedure for collect<strong>in</strong>g stool samplesProvide the patient with two small wooden sticks and a suitable conta<strong>in</strong>erwith a leakproof lid (e.g. a clean glass cup, a plastic or waxed-cardboard box,or a special conta<strong>in</strong>er with a spoon attached to the lid). The use of penicill<strong>in</strong>bottles, matchboxes and banana leaves should be discouraged as they exposethe laboratory staff to the risk of <strong>in</strong>fection.Instruct the patient to collect the stool specimen on a piece of toilet tissue orold newspaper and to transfer it to the conta<strong>in</strong>er, us<strong>in</strong>g the two sticks.The specimen should conta<strong>in</strong> at least 5g of faeces and, if present, those partsthat conta<strong>in</strong> blood, mucus or pus. It should not be contam<strong>in</strong>ated with ur<strong>in</strong>e.Once the specimen has been placed <strong>in</strong> the specimen conta<strong>in</strong>er, the lid shouldbe sealed.The patient should be asked to deliver the specimen to the cl<strong>in</strong>ic immediatelyafter collection. If it is not possible for the specimen to be delivered to the laboratorywith<strong>in</strong> 2 hours of its collection, a small amount of the faecal specimen(together with mucus, blood and epithelial threads, if present) should be collectedon two or three swabs and placed <strong>in</strong> a conta<strong>in</strong>er with transport medium(Cary–Blair, Stuart or Amies) or 33mmol/l of glycerol–phosphate buffer. Forcholera and other Vibrio spp., alkal<strong>in</strong>e peptone water is an excellent transport(and enrichment) medium. Pathogens may survive <strong>in</strong> such media for up to 1week, even at room temperature, although refrigeration is preferable.Procedure for collect<strong>in</strong>g rectal swabs1. Moisten a cotton-tipped swab with sterile water. Insert the swab throughthe rectal sph<strong>in</strong>cter, rotate, and withdraw. Exam<strong>in</strong>e the swab for faecalsta<strong>in</strong><strong>in</strong>g and repeat the procedure until sufficient sta<strong>in</strong><strong>in</strong>g is evident. Thenumber of swabs to be collected will depend on the number and types of<strong>in</strong>vestigation required.2. Place the swab <strong>in</strong> an empty sterile tube with a cotton plug or screw-cap, ifit is to be processed with<strong>in</strong> 1–2 hours. If the swab must be kept for longerthan 2 hours, place it <strong>in</strong> transport medium.40


BACTERIOLOGICAL INVESTIGATIONSVisual exam<strong>in</strong>ation of stool specimens1. Exam<strong>in</strong>e the stool sample visually and record the follow<strong>in</strong>g:— its consistency (formed, unformed (soft) or liquid)— its colour (white, yellow, brown or black)— the presence of any abnormal components (e.g. mucus or blood).2. Place a small fleck of the stool specimen or rectal swab together with asmall flake of mucus (if present) <strong>in</strong> a drop of 0.05% methylene blue solutionon a clean slide and mix thoroughly.3. Place a coverslip on the sta<strong>in</strong>ed suspension, avoid<strong>in</strong>g the formation of airbubbles. Wait 2–3 m<strong>in</strong>utes to. Exam<strong>in</strong>e the slide under the microscopeus<strong>in</strong>g the high-power objective (¥100).4. Record cells that can be clearly identified as mononuclear or polymorphonuclear;ignore degenerated cells.Exam<strong>in</strong>ation of the cellular exudate of diarrhoeal stools may give an <strong>in</strong>dicationof the organism <strong>in</strong>volved:— clumps of polymorphonuclear leukocytes (>50 cells per high-powerfield), macrophages and erythrocytes are typical of shigellosis;— smaller numbers of polymorphonuclear leukocytes (


STOOLV. cholerae grows quickly <strong>in</strong> APW and will outgrow other organisms <strong>in</strong> 6–8hours. However, after 8 hours other organisms may overgrow the V. cholerae.Non-O1 V. cholerae grows more quickly than V. cholerae O1 and may overgrowthe latter when both organisms are present.Media for enteric pathogensFor Shigella spp., Salmonella spp. and Y. enterocolitica a general-purpose plat<strong>in</strong>gmedium of low selectivity and a medium of moderate or high selectivity arerecommended. MacConkey agar with crystal violet is recommended as ageneral purpose medium. For Y. enterocolitica <strong>in</strong>cubate the MacConkey agarat 35∞C for 1 day and then at room temperature (22–29 ∞C) for another day.Xylose–lys<strong>in</strong>e–deoxycholate (XLD) agar is recommended as a medium ofmoderate or high selectivity for the isolation of Shigella and Salmonella spp.Deoxycholate citrate agar (DCA), Hektoen enteric agar (HEA) or Salmonella–Shigella(SS) agar are suitable alternatives. Shigella dysenteriae type 1, S.sonnei and entero<strong>in</strong>vasive E. coli do not grow well on SS agar. However, SSagar may be used for isolat<strong>in</strong>g Y. enterocolitica when <strong>in</strong>cubated as describedfor MacConkey agar. Many laboratories <strong>in</strong>clude bismuth sulfite agar for isolat<strong>in</strong>gSalmonella typhi and other species of Salmonella.For Campylobacter spp. there are several selective media (Blaser, Butzler,Skirrow) conta<strong>in</strong><strong>in</strong>g different antimicrobial supplements. However, a bloodagar base with 5–10% sheep blood conta<strong>in</strong><strong>in</strong>g a comb<strong>in</strong>ation of a cefalospor<strong>in</strong>(15 mg/ml), vancomyc<strong>in</strong> (10mg/ml), amphoteric<strong>in</strong> B (2 mg/ml) and 0.05%ferrows sulfate–sodium metabisulfite–sodium pyruvate (FBP) is acceptable.For Vibrio spp. a selective medium is necessary although many stra<strong>in</strong>s maygrow on MacConkey agar. Thiosulfate citrate bile salts sucrose (TCBS) agar isselective for V. cholerae O1 and non-O1 and for V. parahaemolyticus, but it isexpensive. Telluride taurocholate gelat<strong>in</strong>e (TTG) agar is another selectivemedium, but it is not commercially available. Alkal<strong>in</strong>e meat extract agar(MEA) and alkal<strong>in</strong>e bile salt agar (BSA) are <strong>in</strong>expensive simple media that canbe locally prepared and give excellent results.Clostridium difficile was difficult to isolate before the development ofcefoxit<strong>in</strong>–cycloser<strong>in</strong>e–fructose agar (CCFA). Formulations us<strong>in</strong>g an egg-yolkagar base are preferally used as C. difficile is negative for both lecith<strong>in</strong>ase andlipase, while other clostridia commonly found <strong>in</strong> the gut, such as C. perfr<strong>in</strong>gens,C. bifermentans and C. sordelli are lecith<strong>in</strong>ase-positive.Primary isolationThe specimen should be exam<strong>in</strong>ed and cultured as soon as it is deliveredto the laboratory, as this gives the highest isolation rate of Shigellaand Campylobacter spp. If this is not possible, the specimen should be storedat 4∞C.A concentrated <strong>in</strong>oculum of faeces should be used with high selectivity mediaand a light <strong>in</strong>oculum of faeces with low selectivity media. In many laboratories,the plates are <strong>in</strong>oculated directly with the rectal swabs, but care shouldbe taken not to make an <strong>in</strong>oculation that is overloaded.42


BACTERIOLOGICAL INVESTIGATIONSProcedure for <strong>in</strong>oculation of primary isolation media1. Inoculate media of high selectivity with three loopfuls and those of lowselectivity with one loopful of the faecal suspension. Place the <strong>in</strong>oculum<strong>in</strong> the middle of the agar plate and streak it up and down and across theplate as shown <strong>in</strong> Fig. 6. This procedure will maximize the number of isolatedcolonies. Discrete colonies will be found <strong>in</strong> the peripheral portion ofthe plate.2. After <strong>in</strong>oculation, <strong>in</strong>cubate the agar plates. Incubate the plates for the isolationof Salmonella, Shigella and Yers<strong>in</strong>ia spp. and V. cholerae at 35∞C <strong>in</strong> anaerobic <strong>in</strong>cubator (without CO 2 ), the plates for Campylobacter spp. at 42 ∞C<strong>in</strong> an microaerophilic atmosphere with 10% CO 2 , and the plates forClostridium difficile at 35∞C <strong>in</strong> an anaerobic atmosphere.Incubation atmosphere for CampylobacterPlates for the isolation of Campylobacter spp. should be <strong>in</strong>cubated at 42–43 ∞C<strong>in</strong> a microaerophilic atmosphere conta<strong>in</strong><strong>in</strong>g 5% O 2 , 10% CO 2 and 85% N 2 .The growth of the normal faecal flora is <strong>in</strong>hibited at this temperature whilethe thermotolerant Campylobacter species are unaffected. However, if nonthermotolerantspecies are be<strong>in</strong>g <strong>in</strong>vestigated, the temperature of <strong>in</strong>cubationshould be lowered to 35–37 ∞C.• An atmosphere suitable for the growth of Campylobacter spp. may be produced<strong>in</strong> several ways. The method of choice will depend on the size andworkload of the laboratory, and the relative cost.• A candle-jar provides an atmosphere of approximately 17–19% O 2 and2–3% CO 2 . This atmosphere is not ideal for the growth of Campylobacterspp., and some stra<strong>in</strong>s will not grow <strong>in</strong> it. However, several <strong>in</strong>vestigatorshave demonstrated that <strong>in</strong>cubation at 42 ∞C on a culture medium supplementedwith FBP will improve the isolation rate. The FBP supplementenhances the oxygen tolerance of Campylobacter spp. by <strong>in</strong>activat<strong>in</strong>g super-Fig. 6. Inoculation of bacteria on culture plates43


STOOLoxides and hydrogen peroxide. Disadvantages of this system are a longer<strong>in</strong>cubation period and <strong>in</strong>hibition of some oxygen-sensitive Campylobacterspp.• Another simple and <strong>in</strong>expensive system uses a co-culture technique. Plateswith rapidly grow<strong>in</strong>g facultative anaerobic bacteria are <strong>in</strong>cubated with theplates for the isolation of Campylobacter spp. <strong>in</strong> an airtight conta<strong>in</strong>er or aplastic bag. As the facultative anaerobic bacteria grow, the oxygen contentis lowered and the CO 2 content is <strong>in</strong>creased. The disadvantage of thissystem is the longer <strong>in</strong>cubation time usually required for growth of theCampylobacter spp.• A hydrogen and CO 2 -generator envelope with a self-conta<strong>in</strong>ed catalystspecifically for the isolation of Campylobacter spp. is commercially available.The envelope is placed <strong>in</strong> an anaerobic jar, and a new envelope mustbe used each time the jar is opened. No more than six plates should bestacked <strong>in</strong> the jar to obta<strong>in</strong> maximum isolation.• A plastic bag <strong>in</strong>cubation system is also commercially available. It consistsof a plastic bag, which is collapsed two or three times by hand or vacuum,and refilled each time, with 5% O 2 , 10% CO 2 and 85% N 2 .• The evacuation–replacement system uses an anaerobic jar without a catalyst.The conta<strong>in</strong>er is evacuated twice to 38cm (15mmHg) pressure andrefilled each time with 10% H 2 and 90% N 2 mixture.Prelim<strong>in</strong>ary identification of isolatesIdentification <strong>in</strong>volves both biochemical and serological tests, the extent ofwhich will depend on the capacity of the laboratory. Flow charts for guidance<strong>in</strong> identification of important enteric bacteria are presented <strong>in</strong> Figs 7a–c.Identify well-separated colonies of typical appearance on the primary platesby mak<strong>in</strong>g a mark on the bottom of the Petri dish. These will be transferredfor further test<strong>in</strong>g. If more than one type of colony is present, process at leastone colony of each type.Lactose-nonferment<strong>in</strong>g bacteria, such as Salmonella and Shigella spp., give riseto small colourless colonies on MacConkey agar, SS agar, and DCA. Coloniesof Proteus spp. may be confused with Salmonella and Shigella spp., especiallyon MacConkey agar and DCA, because of their lactose-negative appearance.Lactose-ferment<strong>in</strong>g organisms, such as E. coli and Enterobacter/Klebsiella spp.,produce p<strong>in</strong>k to red colonies on MacConkey agar, DCA and SS agar. On XLDagar, Shigella and Salmonella spp. produce small red colonies, most stra<strong>in</strong>s ofSalmonella with a black centre. Some stra<strong>in</strong>s of Proteus spp. will also give blackcentredcolonies on XLD agar. On bismuth sulfite agar, Salmonella typhi producesblack colonies with a metallic sheen, if the colonies are well separated.Yers<strong>in</strong>ia enterocolitica grows on MacConkey and SS agars as small, pale colourlesscolonies that grow most rapidly at 22–29 ∞C.Salmonella and Shigella spp.Three differential media are recommended for <strong>in</strong>itial screen<strong>in</strong>g of isolates ofSalmonella and Shigella spp.:— urea broth, weakly buffered (UREA)— motility-<strong>in</strong>dole–lys<strong>in</strong>e medium (MIL)— Kligler’s iron agar (KIA).44


BACTERIOLOGICAL INVESTIGATIONSFig. 7a. Flow diagram for the prelim<strong>in</strong>ary identification of common EnterobacteriaceaeProcedure for <strong>in</strong>oculation and read<strong>in</strong>g of UREA1. Us<strong>in</strong>g an <strong>in</strong>oculat<strong>in</strong>g loop, collect 2–3 non-lactose-ferment<strong>in</strong>g coloniesfrom the primary plates and transfer to tube conta<strong>in</strong><strong>in</strong>g UREA.2. Incubate the tubes for 2–4 hours at 35 ∞C and observe for a change <strong>in</strong> colourto p<strong>in</strong>k (urease-positive). Discard the urease-positive tubes.3. Subculture growth from the urease-negative tubes to MIL and to KIA (seebelow), and <strong>in</strong>cubate all tubes, <strong>in</strong>clud<strong>in</strong>g the urease-negative tube conta<strong>in</strong><strong>in</strong>gUREA, overnight at 35 ∞C <strong>in</strong> an aerobic <strong>in</strong>cubator.Procedure for <strong>in</strong>oculation and read<strong>in</strong>g of MILand KIA1. Inoculate the MIL by <strong>in</strong>sert<strong>in</strong>g a straight <strong>in</strong>oculat<strong>in</strong>g needle to 2mm abovethe bottom of the tube. Withdraw the needle along the same l<strong>in</strong>e.2. Inoculate the KIA by stabb<strong>in</strong>g the agar butt with a straight <strong>in</strong>oculat<strong>in</strong>gneedle and streak<strong>in</strong>g the slant <strong>in</strong> a zigzag.3. <strong>Lab</strong>el all tubes with the number of the laboratory and <strong>in</strong>cubate overnightat 35∞C.4. Exam<strong>in</strong>e the tube of Urease-negative UREA (see above) for delayed ureasereaction. Discard the delayed urease-positive cultures.5. Exam<strong>in</strong>e the MIL medium for motility, lys<strong>in</strong>e and <strong>in</strong>dole reaction. Motileorganisms will spread out <strong>in</strong>to the medium from the l<strong>in</strong>e of <strong>in</strong>oculationand produce diffuse growth. Non-motile organisms will grow only alongthe l<strong>in</strong>e of <strong>in</strong>oculation. A positive lys<strong>in</strong>e reaction is <strong>in</strong>dicated by an alkal<strong>in</strong>ereaction (purple colour) at the bottom of the medium, and a negativereaction by an acid reaction (yellow colour) at the bottom of the medium45


STOOLFig. 7b. Flow diagram for the prelim<strong>in</strong>ary identification of anaerobic Gram-positive rods(caused by fermentation of glucose). To test for <strong>in</strong>dole production, add 3–4drops of Kovacs reagent to the medium. A red to p<strong>in</strong>k colour <strong>in</strong>dicates thepresence of <strong>in</strong>dole and the persistence of the bright yellow layer <strong>in</strong>dicatesa negative test.6. Exam<strong>in</strong>e the KIA medium. All Enterobacteriaceae ferment glucose, produc<strong>in</strong>gacid and gas or acid only, which gives a yellow slant. If gas is produced,bubbles or cracks are seen throughout the medium; the mediummay even be pushed up <strong>in</strong> the tube if a large amount of gas is produced(e.g. <strong>in</strong> the case of Enterobacter spp.). If lactose is simultaneously fermented,both the agar butt and the slant become acid, i.e. yellow (e.g. <strong>in</strong> the caseof E. coli). If lactose is not fermented (e.g. <strong>in</strong> the case of Shigella and Salmonellaspp.), the agar butt is yellow but the slant becomes alkal<strong>in</strong>e, i.e.red. Blacken<strong>in</strong>g along the stab l<strong>in</strong>e or throughout the medium <strong>in</strong>dicatesthe production of hydrogen sulfide. Record the result and make a provisionalidentification of the organism with the help of Tables 10 and 11.Salmonella stra<strong>in</strong>s are oxidase-negative, motile, and <strong>in</strong>dole-negative. They donot hydrolyse urea and—except for S. paratyphi A—are lys<strong>in</strong>e-decarboxylasepositive.On KIA agar they produce an alkal<strong>in</strong>e slant, acid butt, H 2 S, and gas,except for S. typhi, which is anaerogenic, and most stra<strong>in</strong>s of S. paratyphi A,which are H 2 S-negative. If these criteria are satisfied, report: “Salmonella isolated(provisional identification)”.Shigella stra<strong>in</strong>s are oxidase-negative, non-motile, lys<strong>in</strong>e-decarboxylasenegative,and urea is not hydrolysed. On KIA they produce an alkal<strong>in</strong>e slantand acid butt, no H 2 S, and no gas, except for S. flexneri serotype 6 (Newcastleand Manchester varieties) and S. boydii serotype 14, which are aerogenic.46


BACTERIOLOGICAL INVESTIGATIONSFig. 7c. Flow diagram for the prelim<strong>in</strong>ary identification of anaerobic Gram-negative rodsCatalase is produced except for S. dysenteriae serotype 1, which is catalasenegative.If these criteria are fulfilled, report: “Shigella isolated (provisionalidentification)”.Yers<strong>in</strong>ia enterocoliticaGrowth of small, pale or colourless colonies on MacConkey or SS agar afterovernight <strong>in</strong>cubation could be Yers<strong>in</strong>ia enterocolitica. Inoculate typical colonies<strong>in</strong>to KIA and <strong>in</strong>cubate at 25 ∞C overnight. Also <strong>in</strong>oculate suspected colonies<strong>in</strong>to two UREA and two MIL media, <strong>in</strong>cubate 1 tube of each at 25 ∞C and theothers at 35 ∞C. On KIA, typical Y. enterocolitica stra<strong>in</strong>s will produce acid butt,alkal<strong>in</strong>e slant, with no gas or H 2 S. If the stra<strong>in</strong> is motile and urease-positiveat 25 ∞C and non-motile and weakly urease-positive or urease-negative at35∞C, report: “Yers<strong>in</strong>ia isolated (provisional identification)”.Vibrio cholerae and V. parahaemolyticusVibrio stra<strong>in</strong>s grow as pale, non-lactose-ferment<strong>in</strong>g colonies on MacConkeyagar. On TCBS agar V. cholerae grows as medium-sized convex, smooth,47


STOOLTable 9. Colony morphology of common enteric bacteria on differential andselective plat<strong>in</strong>g mediaSpecies MacConkey XLD agar SS agar DCA HEAagar withcrystal violetEscherichia coli P<strong>in</strong>k to rose Large, flat, P<strong>in</strong>k to red, P<strong>in</strong>k, encircled Large, salmonyellow,<strong>in</strong>hibited, by zone of p<strong>in</strong>k to orange,opaque growth precipitate encircled by zoneof precipitateShigella spp. Colourless Red Colourless Colourless to tan Green, moist andraisedSalmonella spp. Colourless Red, with or Colourless, with Colourless to tan, Blue-green, withwithout or without with or without or without blackblack centre black centre black centre centreEnterobacter/ P<strong>in</strong>k, mucoid Yellow, mucoid P<strong>in</strong>k, <strong>in</strong>hibited Large, pale mucoid Large, salmon-Klebsiella. growth with p<strong>in</strong>k centre orangespp.Proteus/ Colourless, Red, some Colourless, with Large, colourless Blue-green orProvidencia <strong>in</strong>hibited, Proteus spp. or without to tan, with or salmon, with orspp. swarm<strong>in</strong>g have black grey-black without black without blackcentre centre centre centreYers<strong>in</strong>ia Colourless Yellow, irregular Colourless Colourless SalmonenterocoliticaEnterococci No growth No growth to No growth No growth to No growth to slightslight growth slight growth growthXLD: Xylose-Lys<strong>in</strong>e–Deoxycholate; DCA: Deoxycholate–citrate; SS: Salmonella-Shigella; HEA: Hektoen entericTable 10. Interpretation of Enterobacteriaceae reactionson Kligler’s iron agar (KIA)ReactionAcid butt (yellow) and alkal<strong>in</strong>e slant (red)Acid throughout medium (butt and slantyellow)Alkal<strong>in</strong>e throughout medium (butt andslant red)Gas bubbles <strong>in</strong> butt or cracks <strong>in</strong> themediumBlacken<strong>in</strong>g <strong>in</strong> the buttInterpretationOnly glucose fermentedGlucose and lactose fermentedNeither glucose nor lactose fermentedGas-produc<strong>in</strong>g bacteriaHydrogen sulfide (H 2 S) producedyellow colonies, whereas V. parahaemolyticus grows as large, flat, bluegreencolonies. Some stra<strong>in</strong>s of V. cholerae may also appear green or colourlesson TCBS because of delayed sucrose fermentation. On TTGA, coloniesdevelop dark centres because of telluride reduction and are surroundedby cloudy zones due to gelat<strong>in</strong>ase activity. On BSA and MEA, V. choleraecolonies are translucent, usually with a flat surface and clear-cut marg<strong>in</strong>;they are easily differentiated from colonies of Enterobacteriaceae underoblique light illum<strong>in</strong>ation or when exam<strong>in</strong>ed aga<strong>in</strong>st the day light at an48


BACTERIOLOGICAL INVESTIGATIONSTable 11. Typical reaction patterns of Enterobacteriaceaeon Kligler’s iron agar (KIA)Reaction Sugar(s) fermented Bacteria speciesButt acid Glucose: acid and gas Escherichia coliSlant acid Lactose: acid and gas KlebsiellaGas <strong>in</strong> buttEnterobacterNo H 2 SCitrobacter diversusSerratia liquefaciensButt acid Glucose: acid and gas SalmonellaSlant alkal<strong>in</strong>e Lactose: not fermented ProteusGas <strong>in</strong> buttCitrobacter freundii*H 2 S producedButt acid Glucose: acid only ShigellaSlant alkal<strong>in</strong>e Lactose: not fermented Yers<strong>in</strong>iaNo gas <strong>in</strong> buttSerratia marcescens*No H 2 SProvidencia stuartiiProvidencia rettgeri*Butt acid Glucose: acid and gas Salmonella paratyphi ASlant alkal<strong>in</strong>e Lactose: not fermented Hafnia alveiGas <strong>in</strong> buttSerratia marcescens*No H 2 SMorganella morganiButt neutral/alkal<strong>in</strong>e No sugars fermented AlcaligenesSlant alkal<strong>in</strong>ePseudomonasNo gasAc<strong>in</strong>etobacterNo H 2 S*Atypical reactions.oblique angle. Suspect colonies should be screened with oxidase and thestr<strong>in</strong>g test.Procedure for oxidase test1. Place 2–3 drops of the oxidase reagent (1% tetramethyl-paraphenylenediam<strong>in</strong>e)on a piece of filter paper <strong>in</strong> a Petri dish.2. Pick up a small amount of fresh growth from the MacConkey agar with aplat<strong>in</strong>um (not Nichrome) loop or a clean wooden stick or toothpick. Smearthe growth across the moistened part of the filter paper.3. A positive reaction is <strong>in</strong>dicated by the appearance of a dark purple colouron the paper with<strong>in</strong> 10 seconds. Among the Gram-negative rods Vibrio,Aeromonas, Plesiomonas, Pseudomonas, and Alcaligenes are oxidase-positive;all Enterobacteriaceae are oxidase-negative. The oxidase reagent should betested regularly with positive and negative control stra<strong>in</strong>s.Procedure for str<strong>in</strong>g test1. Place a drop of 0.5% aqueous solution of sodium deoxycholate on a slideand mix a small amount of growth from the MacConkey agar <strong>in</strong>to the drop.2. A positive reaction is <strong>in</strong>dicated by the suspension with<strong>in</strong> 60 seconds: itlooses its turbidity and becomes mucoid; a “mucoid str<strong>in</strong>g” can be drawnwhen the loop is slowly lifted away from the drop. A few stra<strong>in</strong>s ofAeromonas may show a weak and delayed str<strong>in</strong>g at about 60 seconds.49


STOOLIf these tests are positive, transfer a part of a colony to KIA and, after overnight<strong>in</strong>cubation, observe for a yellow butt, alkal<strong>in</strong>e slant, and no gas or H 2 Sproduction. If this is confirmed, report: “Vibrio cholerae isolated (provisionalidentification)”.Campylobacter jejuni and Campylobacter coliExam<strong>in</strong>e the Campylobacter plates after 48–72 hours of <strong>in</strong>cubation. Suspectcolonies should be screened with three presumptive tests: oxidase test, wetmount preparation under dark-field or phase-contrast microscope, and Gramsta<strong>in</strong>.If a dark-field or phase-contrast microscope is not available, coloniesmay be rapidly screened for typical cell morphology by sta<strong>in</strong><strong>in</strong>g with Gram’scrystal-violet solution. For the Gram sta<strong>in</strong> 0.3% carbol fuchs<strong>in</strong> is recommendedas countersta<strong>in</strong>. Campylobacter species are oxidase-positive, they aremotile with a dart<strong>in</strong>g, tumbl<strong>in</strong>g motility, and they appear as simple curved orspiral-shaped rods (seagull w<strong>in</strong>gs or “S”-shape). If this is confirmed, report:“Campylobacter isolated (provisional identification)”.Clostridium difficileThe C. difficile colonies on CCFA are large, yellow and ground glass <strong>in</strong> appearance.On anaerobic blood agar the colony morphology varies and other featuresshould be looked for to detect the organism. Typically, colonies are grey,opaque and non-haemolytic at 24–48 hours, but a few stra<strong>in</strong>s may be greenishblue due to a-type haemolysis. After 48–72 hours of <strong>in</strong>cubation, coloniesmay develop a dist<strong>in</strong>ctly light grey to white centre. With experience, C. difficileis easily recognized despite the colonial variability, thanks to its characteristicodour, which resembles that of horse or elephant manure. If thecolonies are lecith<strong>in</strong>ase- and lipase-negative and show yellow-green fluorescencewhen illum<strong>in</strong>ated with Wood’s lamp, report: “Clostridium difficile isolated(provisional identification)”.F<strong>in</strong>al microbiological identificationBefore the f<strong>in</strong>al report is made, the cultures should always be checked for puregrowth, and the identification should be confirmed with additional biochemicaltests.1. Pick a suspect colony well-separated from other colonies on the plate andsubculture it <strong>in</strong> nutrient broth for biochemical tests, to an agar slope forserological tests, and plate it on MacConkey agar to confirm the purity ofthe culture.2. Make additional biochemical tests accord<strong>in</strong>g to the tables. Exam<strong>in</strong>e thereactions after overnight <strong>in</strong>cubation and identify the isolate.Identification of Shigella and Salmonella may sometimes pose a problem,because some stra<strong>in</strong>s vary <strong>in</strong> their biochemical reactions and may even shareantigens with other Gram-negative organisms. Non-motile, lactose-negative,anaerogenic stra<strong>in</strong>s of E. coli are notoriously difficult to differentiate fromShigella, and identification may be further complicated by the fact that someof these stra<strong>in</strong>s may cause bacillary dysentery.50


BACTERIOLOGICAL INVESTIGATIONSSalmonellaIf the results of the prelim<strong>in</strong>ary tests are consistent with a Salmonella stra<strong>in</strong>,<strong>in</strong>oculate ornith<strong>in</strong>e decarboxylase, Simmons citrate, ONPG media, andpeptone water enriched with mannitol, rhamnose, trehalose, or xylose.Exam<strong>in</strong>e the reactions after overnight <strong>in</strong>cubation and identify the isolateaccord<strong>in</strong>g to Table 12. If the results agree with the culture of Salmonella,proceed with the serological identification.ShigellaIf the results of the prelim<strong>in</strong>ary tests are consistent with a Shigella stra<strong>in</strong>, <strong>in</strong>oculateornith<strong>in</strong>e decarboxylase, phenylalan<strong>in</strong>e deam<strong>in</strong>ase and ONPG media,and sucrose and xylose peptone water. Exam<strong>in</strong>e the reactions after overnight<strong>in</strong>cubation and identify the isolate accord<strong>in</strong>g to Table 13. If the results agreewith the culture of Shigella, proceed with the serological identification.Shigella conta<strong>in</strong>s four species, S. dysenteriae, S. flexneri, S. boydii, and S. sonnei.These are often referred to as subgroups A, B, C, and D, respectively. Someserotypes may provisionally be identified by biochemical reactions anddivided <strong>in</strong>to biotypes.Table 12. Biochemical reactions of Salmonella biotypes and other bacteriaSwarm<strong>in</strong>g H 2 S KIA Indole Lys<strong>in</strong>e Ornith<strong>in</strong>e Citrate ONPG Urease Mannitol Trehalose Rhamnose XyloseSalmonella - - - + + + - - + + + +(mostserotypes)S. choleraesuis - d - + + d - - + - + +S. arizonae - + - + + + + - + + + +S. typhi - +w - + - - - - + + - +S. paratyphi A - d- - - + - - - + + + -Edwardsiella - + + + + - - - - - - -tardaCitrobacter - + - - - + + d + + + +freundiiProteus spp. + + -/+ - +/- v - + - + - +Abbreviations: +: >95% positive; d: 26–74% positive; d-: 5–25% positive; -: 95% positive; d+: 75–95% positive; d: 26–74% positive; d-: 5–25% positive; -:


STOOLTable 14. Biochemical reactions of Shigella species and serotypesOrnith<strong>in</strong>e Fermentation: Fermentation: Catalase Glucosedecarboxylase lactose/sucrose mannitol gasShigella dysenteriaeSerotype 1 (shigae) - - - - -Serotype 2 (schmitzii) - - - + -Serotypes 3–10 - - - + -Shigella flexneriSerotype 1–5, X and Y - - + + -Serotype 6 Newcastle - - - + +Serotype 6 Manchester - - + + +Serotype 6 Boyd 88 - - + + -Shigella boydiiSerotype 1–13, 15 - - - - -Serotype 14 - - - - +Shigella sonnei + +(delayed) + + -S. dysenteriae (subgroup A) conta<strong>in</strong>s 10 serotypes. Serotype 1 is catalasenegativeand produces Shiga tox<strong>in</strong>. The other serotypes are catalase-positive.Most stra<strong>in</strong>s do not ferment mannitol and lactose.S. flexneri (subgroup B) conta<strong>in</strong>s 8 serotypes. Most stra<strong>in</strong>s ferment mannitolbut not sucrose or lactose. The Newcastle stra<strong>in</strong> of serotype 6 does not fermentmannitol, but produces gas from glucose; the Manchester stra<strong>in</strong> produces acidand gas from glucose and mannitol; the Boyd 88 stra<strong>in</strong> produces acid but nogas from glucose and mannitol.S. boydii (subgroup C) conta<strong>in</strong>s 15 serotypes. Mannitol is fermented, butlactose is not fermented.S. sonnei (subgroup D) conta<strong>in</strong>s one serotype with two “phases”: I and II.Mannitol is fermented. ONPG is positive, but fermentation of lactose andsucrose is delayed until after 24 hours. (See Table 14.)Yers<strong>in</strong>ia enterocoliticaIf the results of the prelim<strong>in</strong>ary tests are consistent with a Yers<strong>in</strong>ia stra<strong>in</strong>, <strong>in</strong>oculateornith<strong>in</strong>e decarboxylase, Voges–Proskauer, ONPG, Simmons citrateagar, and peptone water enriched with sucrose, rhamnose, mellibiose, sorbitolor cellobiose. Exam<strong>in</strong>e the reactions after overnight <strong>in</strong>cubation and identifythe isolate accord<strong>in</strong>g to Table 15. If the results agree with the culture of Y. enterocolitica,report: “Yers<strong>in</strong>ia enterocolitica”.Vibrio choleraeIf the results of the prelim<strong>in</strong>ary tests are consistent with a Vibrio stra<strong>in</strong>, <strong>in</strong>oculateornith<strong>in</strong>e decarboxylase, Simmons citrate agar, and sucrose peptonewater, and <strong>in</strong>cubate overnight. If one of these reactions is negative, test foraescul<strong>in</strong> hydrolysis, Voges–Proskauer, and fermentation of mannitol, arab<strong>in</strong>oseand arbut<strong>in</strong>. Exam<strong>in</strong>e the reactions after overnight <strong>in</strong>cubation and identifythe isolate accord<strong>in</strong>g to Table 16.52


BACTERIOLOGICAL INVESTIGATIONSTable 15. Biochemical reactions of Yers<strong>in</strong>ia enterocolitica and other non-pathogenicYers<strong>in</strong>ia speciesMIL Urease Ornith<strong>in</strong>e VP 25 ∞C Citrate Sucrose Rhamnose Mellibiose Sorbitol CellobioseY. enterocolitica +/v/- + + v - v - - +* +Y. frederiksenii +/+/- + + + d + + - + +Y. <strong>in</strong>termedia +/+/- + + + + + + + + +Y. kristensenii +/d/- + + - - - - - + +Y. pseudotuberculosis +/-/- + - - - - + + - -Abbreviations: +: >95% positive; d: 26–74% positive; -: 95% positive; d+: 75–95% positive; d: 26–74% positive; -:


STOOL2. Divide a clean glass slide <strong>in</strong>to several squares with a pencil and place aloopful (3mm) of the red cell suspension <strong>in</strong> each square.3. Place a small portion of the growth from an agar or KIA slant <strong>in</strong> each redcell suspension and mix well.Clump<strong>in</strong>g of the red cells occurs with<strong>in</strong> 30–60 seconds with stra<strong>in</strong>s of the ElTor biotype. Known haemagglut<strong>in</strong>at<strong>in</strong>g (El Tor) and non-haemagglut<strong>in</strong>at<strong>in</strong>gstra<strong>in</strong>s should be used as controls for each new suspension of red cells. Newlyisolated stra<strong>in</strong>s of classical biotypes are usually negative <strong>in</strong> the test, but oldlaboratory stra<strong>in</strong>s of the classical biotype may not always be negative <strong>in</strong> thisreaction.Polymyx<strong>in</strong> B susceptibility test1. Spread a loopful of overnight peptone water culture of the isolate on aMueller–H<strong>in</strong>ton or meat-extract agar.2. Place a susceptibility disk conta<strong>in</strong><strong>in</strong>g 50 units of polymyx<strong>in</strong> B <strong>in</strong> the middleof the culture.3. Place the plate <strong>in</strong> the refrigerator for 1 hour.4. Incubate the plate overnight at 35 ∞C.Known stra<strong>in</strong>s of classical and El Tor biotypes should always be <strong>in</strong>cluded ascontrols. Classical stra<strong>in</strong>s are sensitive to polymyx<strong>in</strong> B and a clear <strong>in</strong>hibitoryzone is observed around the disk. The El Tor stra<strong>in</strong>s are resistant and no<strong>in</strong>hibitory zone is formed.Campylobacter jejuni and Campylobacter coliOnly a few tests are available <strong>in</strong> cl<strong>in</strong>ical laboratories to identify the Campylobacterspecies and subspecies. Campylobacter species are usually divided <strong>in</strong>totwo groups on the basis of growth temperature: thermotolerant species, whichgrow at 42–43∞C, and non-thermotolerant species, which grow at 15–25∞C.The thermotolerant species are Campylobacter jejuni subsp. jejuni, C. coli, C. lari,C. upsaliensis, and some stra<strong>in</strong>s of C. hyo<strong>in</strong>test<strong>in</strong>alis. C. lari and C. hyo<strong>in</strong>test<strong>in</strong>alisare resistant to nalidixic acid; C. jejuni, C. coli and C. upsaliensis are sensitiveto it. C. jejuni subsp. jejuni, C. coli and C. lari are resistant to cefalot<strong>in</strong>;C. hyo<strong>in</strong>test<strong>in</strong>alis and C. upsaliensis are sensitive to it. The differentiation with<strong>in</strong>these groups is made on the basis of hippurate hydrolysis and the productionof hydrogen sulfide <strong>in</strong> Kligler’s iron agar.The non-thermotolerant species are C. jejuni subsp. doylei, C. fetus, andArcobacter butzleri. C. jejuni subsp. doylei will grow at neither 15 ∞C nor at25∞C; C. fetus will grow at 25 ∞C but not at 15 ∞C; A. butzleri will grow at bothtemperatures. A. butzleri is resistant to cefalot<strong>in</strong>; C. jejuni subsp. doylei and C.fetus are sensitive to it (Table 18).Serological identificationSalmonellaThe nomenclature and classification of the salmonellae have changed severaltimes and are still under discussion. Accord<strong>in</strong>g to present nomenclature, allSalmonella species belong to a s<strong>in</strong>gle genus which is subdivided <strong>in</strong> six subgroups(also called subspecies), <strong>in</strong>clud<strong>in</strong>g the former genus Arizona. Subgroup54


BACTERIOLOGICAL INVESTIGATIONSTable 18. Biochemical <strong>in</strong>dentification of Campylobacter species found <strong>in</strong> stoolGrowth at H 2 S/KIA Hippurate Nitrate Susceptible tohydrolysis a reduction Nalidixic acid b Cefalot<strong>in</strong> c15 ∞C 25∞C 42∞CCampylobacter jejuni - - + - + + S Rsubsp. jejuniC. jejuni subsp. doylei - - - - d - S SC. coli - - + + - + S RC. lari - - + - - + R RC. upsaliensis - - + - - + S SC. fetus subsp. fetus - + - - - + R SC. hyo<strong>in</strong>test<strong>in</strong>alis - + v + - + R SArcobacter butzleri d + + - - - + v RAbbreviations: +: >95% positive; d+: 75–95% positive; d: 26–74% positive; d-: 5–25% positive; -:


STOOLGroup: A B a C 1 C 2 D E 1 FAntigen: 2 4;5 6;7 6;8 9 3;10 11There are other variations <strong>in</strong> the antigenic structure: the change <strong>in</strong> colonyappearance from smooth to rough, and the presence or absence of Vi antigen.When present the Vi antigen prevents agglut<strong>in</strong>ation by homologous O antiserum.The Vi antigen is usually found <strong>in</strong> fresh isolates and is lost rapidly onstorage of the culture. The Vi antigen is important for the identification of S.typhi, which often is not agglut<strong>in</strong>ated by heterologous H antisera.Procedure for somatic O antigen analysisDirect slide agglut<strong>in</strong>ation test1. Br<strong>in</strong>g the sal<strong>in</strong>e and the reagents to room temperature before perform<strong>in</strong>gthe test.2. Place a drop of sal<strong>in</strong>e on a clean microscope slide.3. With a sterile loop, emulsify a small portion of the growth from a moistagar slope <strong>in</strong> the drop of sal<strong>in</strong>e to produce a uniform and turbidsuspension.4. Exam<strong>in</strong>e the bacterial suspensions through a hand-lens or the low-powerobjective (¥10) of a microscope to ascerta<strong>in</strong> that the suspension is not autoagglut<strong>in</strong>able<strong>in</strong> sal<strong>in</strong>e.5. With a 10-ml loop take up 1 drop of Salmonella polyvalent O antiserum (A–Iand Vi), and place it on the slide just beside the bacterial suspension.6. Mix the antiserum and bacterial suspension and tilt the slide backwardsand forwards for 1 m<strong>in</strong>ute. Look for clump<strong>in</strong>g while view<strong>in</strong>g the suspensionunder good light. Dist<strong>in</strong>ct clump<strong>in</strong>g dur<strong>in</strong>g this period is a positiveresult.7. If the result is positive, repeat the slide test with s<strong>in</strong>gle-factor antiserum.Some Salmonella possess an envelope (Vi) antigen and, <strong>in</strong> the live or unheatedform, are non-agglut<strong>in</strong>able with group C1 (O:6,7) or group D (O:9) antisera.Heat the suspension <strong>in</strong> boil<strong>in</strong>g water for 20 m<strong>in</strong>utes to remove the Vi antigen,cool, separate the bacteria by centrifugation, re-suspend <strong>in</strong> fresh sal<strong>in</strong>e, andtest with the same antisera.Procedure for H antigen analysisA prelim<strong>in</strong>ary identification of the major flagellar (H) antigen can be made bythe direct slide agglut<strong>in</strong>ation test as described for the somatic O antigens.Occasionally it is necessary to <strong>in</strong>crease the motility of the test organism bymak<strong>in</strong>g several consecutive transfers <strong>in</strong> a semi-solid nutrient medium(“swarm agar”, see below). Antisera aga<strong>in</strong>st those antigens are commerciallyavailable. However, a phase suppression is often required if identification ofboth flagellar phases is necessary for classification. This often requires a phase<strong>in</strong>version with sera designed for this purpose. 11. Prepare a semi-solid nutrient medium conta<strong>in</strong><strong>in</strong>g 0.2–0.4% agar. Add 1mlof the medium to test-tubes.2. Replace the corks from the test-tubes with cotton wool.3. Melt the agar <strong>in</strong> boil<strong>in</strong>g water and place the test-tubes with the meltedagar <strong>in</strong> a 45 ∞C water-bath for 30 m<strong>in</strong>utes.aAll Salmonellae of subgroup B conta<strong>in</strong> antigen 4, but only some conta<strong>in</strong> antigen 5.1Available from Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark.56


BACTERIOLOGICAL INVESTIGATIONSFig. 8. Serological identification of Salmonella species57


STOOL4. Write the specimen number and the H antisera (H:b, H:i, and H:1,2) oneach test-tube. Include a control test-tube.5. Add 10 ml of each phase <strong>in</strong>version heterologous H antiserum to thecorrespond<strong>in</strong>g agar, shake the test-tube carefully, and leave the agar tosolidify as a slope.6. Make a heavy suspension of isolated colonies <strong>in</strong> sal<strong>in</strong>e, streak the slopeus<strong>in</strong>g a loop, and <strong>in</strong>cubate overnight.7. With an <strong>in</strong>oculat<strong>in</strong>g loop emulsify a speck of the culture from the slope<strong>in</strong> a drop of sal<strong>in</strong>e.8. With a 10-ml loop, take up 1 drop of one of the heterologous H antiseraand place it on the slide just beside the bacterial suspension.9. Mix the antiserum and bacterial suspension and tilt the slide backwardsand forwards for 1 m<strong>in</strong>ute. Look for clump<strong>in</strong>g while view<strong>in</strong>g thesuspension under a good light. Dist<strong>in</strong>ct clump<strong>in</strong>g dur<strong>in</strong>g this period is apositive result.10. Repeat the agglut<strong>in</strong>ation test with the other heterologous antisera ifrequired, and identify the serotype with the help of the flow diagram onpage 57.Salmonella typhiTo confirm the biochemical identification, test <strong>in</strong> antisera Vi, O group D (O:D),and H:d. Cultures agglut<strong>in</strong>at<strong>in</strong>g <strong>in</strong> Vi may be negative <strong>in</strong> O:D due to obstructionby the Vi antigen. Remove the Vi antigen by heat<strong>in</strong>g the suspension for20 m<strong>in</strong>utes at 100 ∞C and test <strong>in</strong> O:D antiserum aga<strong>in</strong>. If positive <strong>in</strong> Vi, O:Dand H:d, report: “Salmonella typhi”. If positive only <strong>in</strong> O:D, report: “Salmonella,group D”.Salmonella paratyphi ATo confirm the biochemical identification, test with Salmonella group A antiserum.If positive with group A antiserum, test with H:a antiserum, and ifpositive, report: “Salmonella paratyphi A”. If negative with H:a, report:“Salmonella group A”. If non-motile, they may be S. flexneri type 6 or S. boydiitype 13 or 14, and should be tested with Shigella antisera B and D.Salmonella, other serotypesWhen the presumptive tests <strong>in</strong>dicate typical Salmonella, test with Salmonella Ogroups A, B, C, D, and E antisera.• If positive <strong>in</strong> group B, test with flagellar antiserum H:b, H:i and H:1,2. Ifpositive with H:b antiserum, the organism may be S. wien or S. paratyphiB. S. wien can be differentiated from S. paratyphi B by test<strong>in</strong>g with H:1,wand H:2 antisera (if available). S. wien reacts with H:1,w and S. paratyphi Bwith H:2.• If positive with H:i or H:1,2 antiserum, make a phase <strong>in</strong>version andtest with heterologous H antiserum. If positive, report: “S. typhimurium”.If negative, report: “Salmonella, group B”.• If positive with group C antiserum, report: “Salmonella group C”.• If positive with group D antiserum, test with Vi, H:d and H:m antisera. Ifpositive with Vi or H:d, report: “Salmonella typhi”. If positive with H:m,report: “Salmonella enteritidis”. If negative with Vi, H:d and H:m, report:“Salmonella group D”.• If biochemically the stra<strong>in</strong> is a Salmonella but is negative with all O-groupantisera, report: “Presumptive Salmonella species” and refer to NationalReference Centre.58


BACTERIOLOGICAL INVESTIGATIONSShigellaShigella can be subdivided <strong>in</strong>to serogroups and serotypes by slide and tubeagglut<strong>in</strong>ation tests with specific O-antisera. Slide agglut<strong>in</strong>ation will usuallybe sufficient, if the results are clear-cut. The antigen suspension should bemade from a non-selective medium such as a nutrient agar or KIA, and thesuspension should be observed for auto-agglut<strong>in</strong>ation before the antiserum isadded.Tests with Shigella groups A, B, C, and D antisera• If agglut<strong>in</strong>ation occurs with group A, report: “Shigella dysenteriae”.Test with S. dysenteriae type 1 antiserum. If positive, report: “S. dysenteriaetype 1”.• If agglut<strong>in</strong>ation occurs with group B, report: “Shigella flexneri”.• If agglut<strong>in</strong>ation occurs with group C, report: “Shigella boydii”.• If agglut<strong>in</strong>ation occurs with group D, report: “Shigella sonnei”.Occasionally Shigella stra<strong>in</strong>s may fail to agglut<strong>in</strong>ate <strong>in</strong> homologous antiserumdue to the presence of a K antigen. Heat<strong>in</strong>g a sal<strong>in</strong>e suspension of the stra<strong>in</strong><strong>in</strong> a boil<strong>in</strong>g water-bath for 20 m<strong>in</strong>utes and repeat<strong>in</strong>g the test may reverse this.Other Gram-negative organisms may share antigens with Shigella stra<strong>in</strong>s andgive false-positive agglut<strong>in</strong>ation with Shigella typ<strong>in</strong>g sera. Well-known examplesof bacteria show<strong>in</strong>g this cross-reaction are Plesiomonas shigelloides andShigella sonnei phase 1, and certa<strong>in</strong> stra<strong>in</strong>s of Hafnia and Shigella flexneriserotype 4a; but of greater importance is the cross-reaction with some stra<strong>in</strong>sof diarrhoeagenic E. coli.Yers<strong>in</strong>ia enterocoliticaY. enterocolitica possesses several somatic (O) antigens, which have been usedfor subdivid<strong>in</strong>g the species <strong>in</strong>to at least 17 serogroups. Most human <strong>in</strong>fections<strong>in</strong> Canada, Europe, and Japan are due to serotype O3; Infections due toserotype O9 have been reported ma<strong>in</strong>ly from the Scand<strong>in</strong>avian countries, and<strong>in</strong>fections with serotype O8 are almost exclusively from the USA. There isserological cross-reaction between Y. enterocolitica O9 and Brucella spp.59


Upper respiratory tract <strong>in</strong>fectionsIntroductionThe upper respiratory tract extends from the larynx to the nostrils and comprisesthe oropharynx and the nasopharynx together with the communicat<strong>in</strong>gcavities, the s<strong>in</strong>uses and the middle ear. The upper respiratory tract canbe the site of several types of <strong>in</strong>fection:— pharyngitis, sometimes <strong>in</strong>volv<strong>in</strong>g tonsillitis, and giv<strong>in</strong>g rise to a “sorethroat”— nasopharyngitis— otitis media— s<strong>in</strong>usitis— epiglottitis.Of all those <strong>in</strong>fections, pharyngitis is by far the most frequent; <strong>in</strong> addition, theuntreated <strong>in</strong>fection may have serious sequelae. Only pharyngitis will be consideredhere.Most cases of pharyngitis have a viral etiology and follow a self-limit<strong>in</strong>gcourse. However, approximately 20% are caused by bacteria and usuallyrequire treatment with appropriate antibiotics. As the physician is rarely ableto make a dist<strong>in</strong>ction between viral and bacterial pharyngitis on cl<strong>in</strong>icalgrounds alone, treatment should ideally be based on the result of bacteriologicalexam<strong>in</strong>ation.Bacteriological diagnosis of pharyngitis is complicated by the fact that theoropharynx conta<strong>in</strong>s a heavy, mixed, normal flora of aerobic and anaerobicbacteria. The normal flora generally outnumbers the pathogens and the roleof the bacteriologist is to dist<strong>in</strong>guish between the commensals and thepathogens. Where possible only the latter should be reported to the physician.Normal flora of the pharynxThe normal flora of the pharynx <strong>in</strong>cludes a large number of species thatshould be neither fully identified nor reported when observed <strong>in</strong> throatcultures:• viridans (a-haemolytic) streptococci and pneumococci• nonpathogenic Neisseria spp.• Moraxella (formerly Branhamella) catarrhalis (this can also be a respiratorypathogen)• staphylococci (S. aureus, S. epidermidis)• diphtheroids (with the exception of C. diphtheriae)• Haemophilus spp.• yeasts (Candida spp.) <strong>in</strong> limited quantity• various strictly anaerobic Gram-positive cocci and Gram-negative rods,spirochaetes and filamentous forms.The throats of elderly, immunodeficient, or malnourished patients, particularlywhen they have received antibiotics, may be colonized by Enterobacteriaceae(Escherichia coli, Klebsiella spp., etc.) and by the nonfermentativeGram-negative groups (Ac<strong>in</strong>etobacter spp. and Pseudomonas spp.). Suchpatients may also have <strong>in</strong> their pharynx a proliferation of S. aureus or of60


BACTERIOLOGICAL INVESTIGATIONSCandida spp., or other yeast-like fungi. Although these microorganisms do notcause pharyngitis, except <strong>in</strong> association with granulocytopenia, it is advisableto report such isolates to the cl<strong>in</strong>ician, as they occasionally <strong>in</strong>dicate the existenceof (or may sometimes give rise to) a lower respiratory tract <strong>in</strong>fection(e.g. pneumonia) or bacteraemia. However, an antibiogram should not be performedrout<strong>in</strong>ely on these coloniz<strong>in</strong>g microorganisms.Bacterial agents of pharyngitisStreptococcus pyogenes (Lancefield group A) is by far the most frequent causeof bacterial pharyngitis and tonsillitis. This <strong>in</strong>fection is particularly prevalent<strong>in</strong> young children (5–12 years). When streptococcal pharyngitis is associatedwith a characteristic sk<strong>in</strong> rash, the patient is said to have scarlet fever. In<strong>in</strong>fants, a streptococcal throat <strong>in</strong>fection may often <strong>in</strong>volve the nasopharynxand be accompanied by a purulent nasal discharge.Non-group-A, b-haemolytic streptococci (e.g. groups B, C and G) are uncommoncauses of bacterial pharyngitis and if detected should be reported. Pharyngeal<strong>in</strong>fections due to S. pyogenes, if not properly treated, may give rise tosequelae such as rheumatic fever, and, less often, glomerulonephritis. Specificidentification of, and antibacterial treatment directed aga<strong>in</strong>st, S. pyogenes areprimarily <strong>in</strong>tended to prevent the occurrence of rheumatic fever.Corynebacterium diphtheriae is the cause of diphtheria, a disease that is endemic<strong>in</strong> many countries. It can reach epidemic proportions <strong>in</strong> countries where thevacc<strong>in</strong>ation programme has been <strong>in</strong>terrupted. Characteristically (with a fewexceptions), C. diphtheriae causes a typical form of <strong>in</strong>fection, characterized bya greyish-white membrane at the site of <strong>in</strong>fection (pharynx, tonsils, nose, orlarynx). Diphtheria is a serious disease and the diagnosis is made on the basisof cl<strong>in</strong>ical f<strong>in</strong>d<strong>in</strong>gs. The physician would then generally make a specificrequest to culture for diphtheria bacilli.Gonococcal pharyngitis has been recognized with <strong>in</strong>creas<strong>in</strong>g frequency <strong>in</strong>some countries, with rates that parallel the <strong>in</strong>cidence of cervical and urethralgonorrhoea. Culture of throat swabs for gonococci should be done on specificrequest from the cl<strong>in</strong>ician, us<strong>in</strong>g the appropriate selective medium (modifiedThayer–Mart<strong>in</strong> medium).Necrotiz<strong>in</strong>g ulcerative pharyngitis (V<strong>in</strong>cent ang<strong>in</strong>a) is a rare condition characterizedby a necrotic ulceration of the pharynx with or without formationof a pseudomembrane. It is associated, at the site of <strong>in</strong>fection, with a heavymixed flora of strict anaerobes dom<strong>in</strong>ated by Gram-negative fusiform rodsand spirochaetes, generally referred to as Fusobacterium spp. and Treponemav<strong>in</strong>centii, and possibly others. Although both species belong to the normalmouth flora, their presence <strong>in</strong> large numbers <strong>in</strong> a Gram-sta<strong>in</strong>ed smear of ulceratedlesions should be reported as a “fusospirochaetal complex”. This microscopicdiagnosis need not be confirmed by anaerobic culture, which is difficultand time-consum<strong>in</strong>g. However, the presence of this complex does not excludethe need to search for other pathogens, particularly S. pyogenes.Although small numbers of C. albicans or other Candida species may be partof the normal oral flora, oral candidiasis results when the number of organisms<strong>in</strong>creases considerably <strong>in</strong> certa<strong>in</strong> pathological conditions, e.g. <strong>in</strong> malnourishedpremature babies, <strong>in</strong> immunodeficient adults (e.g. patients withHIV/AIDS), or <strong>in</strong> patients who have received broad-spectrum antimicrobialsor cancer therapy. The affected area—tongue, tonsils, throat or buccal mucosa—may be extremely red, or covered with white patches or a confluent grey-61


UPPER RESPIRATORY TRACT INFECTIONSwhite membrane (thrush). The diagnosis of candidiasis is best made byf<strong>in</strong>d<strong>in</strong>g numerous yeast cells, some of them form<strong>in</strong>g long mycelium-like filaments,<strong>in</strong> a Gram-sta<strong>in</strong>ed smear of the exudate.Swabs from the upper respiratory tract may be submitted to the laboratory,not for the diagnosis of a cl<strong>in</strong>ical <strong>in</strong>fection, but to detect a potential pathogen<strong>in</strong> a healthy subject, a pharyngeal or a nasal “carrier”. This should only bedone as part of well-def<strong>in</strong>ed epidemiological surveys. The follow<strong>in</strong>gpathogens can give rise to a carrier state <strong>in</strong> the upper respiratory tract:• Staphylococcus aureus. Sampl<strong>in</strong>g of patients and staff for nasal carriers issometimes performed as part of an <strong>in</strong>vestigation of hospital outbreaks ofMeticill<strong>in</strong>-resistant S. aureus (MRSA).• Neisseria men<strong>in</strong>gitidis. Carriage of men<strong>in</strong>gococci may be very prevalent(20% or more) even at non-epidemic times. Identification of pharyngealcarriers of men<strong>in</strong>gococci is rarely needed, and need not be performed priorto the adm<strong>in</strong>istration of prophylactic antibiotics to family or other closecontacts of patients with men<strong>in</strong>gococcal disease.• Streptococcus pyogenes. Carriage of this organism <strong>in</strong> low numbers may beprevalent, especially among schoolchildren (20–30%).• Corynebacterium diphtheriae. The carrier rate of the diphtheria bacillus ishigh <strong>in</strong> non-vacc<strong>in</strong>ated populations. In such communities, it may be justifiedto identify and treat carriers among the close contacts of a patient withproven diphtheria. Carriers are rare when an immunization programme iscorrectly implemented.Collection and dispatch of specimensIdeally, specimens should be collected by a physician or other tra<strong>in</strong>ed personnel.The patient should sit fac<strong>in</strong>g a light source. While the tongue is keptdown with a tongue depressor, a sterile cotton-wool swab is rubbed vigorouslyover each tonsil, over the back wall of the pharynx, and over any other<strong>in</strong>flamed area. Care should be taken not to touch the tongue or buccal surfaces.It is preferable to take two swabs from the same areas. One can be usedto prepare a smear, while the other is placed <strong>in</strong>to a glass or plastic conta<strong>in</strong>erand sent to the laboratory. Alternatively, both swabs may be placed <strong>in</strong> the conta<strong>in</strong>erand dispatched to the laboratory. If the specimen cannot be processedwith<strong>in</strong> 4 hours, the swab should be placed <strong>in</strong> a transport medium (e.g. Amiesor Stuart).Direct microscopyThe fusospirochaetal complex of necrotiz<strong>in</strong>g ulcerative pharyngitis (V<strong>in</strong>centang<strong>in</strong>a) and Candida are best recognized on a Gram-sta<strong>in</strong>ed smear, whichshould be prepared if the physician makes a special request. The Gramsta<strong>in</strong>edsmear is not useful for the detection of streptococci or Neisseria spp.Moreover, the direct smear has poor sensitivity and specificity for the detectionof the diphtheria bacillus, unless the specimen has been collected withcare and is exam<strong>in</strong>ed by an experienced microbiologist. In the absence of aphysician’s request or of cl<strong>in</strong>ical <strong>in</strong>formation, a Gram-sta<strong>in</strong>ed smear shouldnot be made for throat swabs.62


BACTERIOLOGICAL INVESTIGATIONSCulture and identificationCulture for Streptococcus pyogenesImmediately upon receipt <strong>in</strong> the laboratory, the swab should be rubbed overone-quarter of a blood agar plate, and the rest of the plate streaked with asterile wire loop. The blood agar should be prepared from a basal agarmedium without glucose (or with a low glucose content), e.g. tryptic soy agar(TSA). Acidification of glucose by S. pyogenes <strong>in</strong>hibits the production ofhaemolys<strong>in</strong>. Blood from any species, even human blood (fresh donor blood),can be used at a concentration of 5%. The plates should be filled to a depthof 4–5mm. Sheep blood is preferred because it does <strong>in</strong>dicate haemolysis ofsome commensal Haemophilus spp. and it gives no haemolysis with the zymogenesvariant of Enterococcus faecalis.The recognition of b-haemolytic colonies can be improved, and their presumptiveidentification hastened, by plac<strong>in</strong>g a co-trimoxazole disc (as usedfor the susceptibility test) and a special low-concentration bacitrac<strong>in</strong> disc overthe <strong>in</strong>itial streaked area. Because S. pyogenes is resistant and many other bacteriaare susceptible to co-trimoxazole, this disc improves the visibility ofb-haemolysis. Incubation <strong>in</strong> a candle-jar will detect most b-haemolytic streptococci.A simple way to <strong>in</strong>crease haemolysis is to stab the agar surface perpendicularlyby <strong>in</strong>sert<strong>in</strong>g the loop deep <strong>in</strong>to the medium to encourage growthof subsurface colonies. After 18 hours and aga<strong>in</strong> after 48 hours of <strong>in</strong>cubationat 35–37∞C, the blood plates should be exam<strong>in</strong>ed for the presence of small(0.5–2mm) colonies surrounded by a relatively wide zone of clear haemolysis.After Gram-sta<strong>in</strong><strong>in</strong>g to verify that they are Gram-positive cocci, thecolonies should be submitted to specific identification tests for S. pyogenes. Forcl<strong>in</strong>ical purposes, presumptive identification of S. pyogenes is based on its susceptibilityto a low concentration of bacitrac<strong>in</strong>. For this purpose, a special differentialdisc is used conta<strong>in</strong><strong>in</strong>g 0.02–0.05 IU of bacitrac<strong>in</strong>. The ord<strong>in</strong>ary discsused <strong>in</strong> the susceptibility test, with a content of 10 units, are not suitable foridentification. A b-haemolytic streptococcus show<strong>in</strong>g any zone of <strong>in</strong>hibitionaround the disc should be reported as S. pyogenes. If the haemolytic coloniesare sufficiently numerous, the presence or absence of an <strong>in</strong>hibition zone maybe read directly from the primary blood agar plate. If the colonies are lessnumerous, one or two should be picked from the primary plate, streaked onone-fifth of another plate to obta<strong>in</strong> confluent growth, and each <strong>in</strong>oculated areacovered with a bacitrac<strong>in</strong> disc. After overnight <strong>in</strong>cubation, the subculturesshould be read for <strong>in</strong>hibition zones.In some laboratories this presumptive identification is confirmed by serologicaldemonstration of the specific cell wall polysaccharides. This can be doneeither by the classical precipit<strong>in</strong> method, or more rapidly by us<strong>in</strong>g a commercialkit for the rapid slide coagglut<strong>in</strong>ation or latex agglut<strong>in</strong>ation tests. Ifdesirable, bacitrac<strong>in</strong>-resistant b-haemolytic streptococci can be further identifiedus<strong>in</strong>g some simple physiological tests (see Table 19). M<strong>in</strong>ute colonies ofb-haemolytic streptococci may be encountered, which, when grown and serologicallygrouped, react with group A antiserum. These streptococci are notconsidered to be S. pyogenes and are not associated with the serious <strong>in</strong>fectionscaused by group A streptococci.In report<strong>in</strong>g the presence of S. pyogenes <strong>in</strong> a throat culture, a semiquantitativeanswer should be given (rare, +, ++, or + ++). Patients with streptococcalpharyngitis generally show massive growth of S. pyogenes, with colonies overthe entire surface of the plate. Plates of carriers generally show fewer than 20colonies per plate. Even rare colonies of b-haemolytic streptococci should beconfirmed and reported.63


UPPER RESPIRATORY TRACT INFECTIONSTable 19. Differentiation of b-haemolytic streptococciSpecies S. pyogenes S. agalactiae E. faecalis Othersvar. zymogenes aLancefield group A B D C, G, FHaemolysis b b b b bZone around the differentialbacitrac<strong>in</strong> disc + 0 c 0 c 0 dBile–aescul<strong>in</strong> agar(growth & blacken<strong>in</strong>g) 0 0 + 0Reverse CAMP test 0 + 0 0Co-trimoxazole e susceptibility 0 0 0 +PYR test f + 0 + 0aE. faecalis var. zymogenes produces b-haemolysis only on horse-blood agar.b5% are non-haemolytic.c5% are positive.d10% are positve.eSame disc as <strong>in</strong> the Kirby–Bauer method.fPYR: pyrrolidonyl-b-naphtylamide.Culture for Corynebacterium diphtheriaeAlthough the diphtheria bacillus grows well on ord<strong>in</strong>ary blood agar, growthis improved by <strong>in</strong>oculat<strong>in</strong>g one or two special media:• Löffler coagulated serum or Dorset egg medium. Although not selective, bothof these media give abundant growth of the diphtheria bacillus afterovernight <strong>in</strong>cubation. Moreover, the cellular morphology of the bacilli ismore “typical”: irregularly sta<strong>in</strong>ed, short to long, slightly curved rods,show<strong>in</strong>g metachromatic granules, and arranged <strong>in</strong> a V form or <strong>in</strong> parallelpalisades. Metachromatic granules are more apparent after sta<strong>in</strong><strong>in</strong>g withmethylene blue or Albert sta<strong>in</strong> than with the Gram sta<strong>in</strong>.• A selective tellurite blood agar. This medium facilitates isolation when thebacilli are few <strong>in</strong> number, as is the case for healthy carriers. On thismedium, colonies of the diphtheria bacillus are greyish to black and arefully developed only after 48 hours. Suspicious colonies, consist<strong>in</strong>g ofbacilli with a coryneform morphology on the Gram-sta<strong>in</strong>ed smear, shouldbe subcultured to a blood agar plate to check for purity and for “typical”morphology. It should also be remembered that colonies of the mitisbiotype of C. diphtheriae, which is the most prevalent, show a marked zoneof b-haemolysis on blood agar.A presumptive report on the presence of C. diphtheriae can often be given atthis stage. However, this should be confirmed or ruled out by some simplebiochemical tests and by demonstration of the toxigenicity. As the latterrequires <strong>in</strong>oculation of gu<strong>in</strong>ea-pigs or an <strong>in</strong> vitro toxigenic test (Elek) and hasto be performed <strong>in</strong> a central laboratory, only rapid biochemical identificationwill be covered here. C. diphtheriae is catalase- and nitrate-positive. Urea is nothydrolysed. Acid without gas is produced from glucose and maltose, generallynot from saccharose. The fermentation of glucose can be tested on Kliglermedium. Urease activity can be demonstrated on MIU and nitrate reduction<strong>in</strong> nitrate broth <strong>in</strong> the same way as for Enterobacteriaceae. For the fermentationof maltose and saccharose, Andrade peptone water can be used as a basewith a 1% f<strong>in</strong>al concentration of each carbohydrate. Results can usually beread after 24 hours, although it may be necessary to re<strong>in</strong>cubate for one night.64


BACTERIOLOGICAL INVESTIGATIONSIt must be emphasized that the microbiology laboratory’s role is to confirmthe cl<strong>in</strong>ical diagnosis of diphtheria. Therapy should not be withheld pend<strong>in</strong>greceipt of laboratory reports. More detailed <strong>in</strong>formation on the isolation andidentification of C. diphtheriae is found <strong>in</strong> Guidel<strong>in</strong>es for the laboratory diagnosisof diphtheria. 1Susceptibility test<strong>in</strong>gRout<strong>in</strong>e susceptibility tests on throat or pharyngeal isolates are most often notrequired, and may even be mislead<strong>in</strong>g. The major pathogens <strong>in</strong>volved <strong>in</strong>bacterial pharyngitis are S. pyogenes and C. diphtheriae benzylpenicill<strong>in</strong> anderythromyc<strong>in</strong> are considered as the antimicrobials of choice to treat both typesof <strong>in</strong>fection. In cases of diphtheria, treatment with antitox<strong>in</strong> is also <strong>in</strong>dicated.1 Begg N. Manual for the management and control of diphtheria <strong>in</strong> the European region. Copenhagen,WHO Regional Office for Europe, 1994.65


Lower respiratory tract <strong>in</strong>fectionsIntroductionLower respiratory tract <strong>in</strong>fections (LRTI) are <strong>in</strong>fections occurr<strong>in</strong>g below thelevel of the larynx, i.e. <strong>in</strong> the trachea, the bronchi, or <strong>in</strong> the lung tissue (tracheitis,bronchitis, lung abscess, pneumonia). Sometimes, <strong>in</strong> pneumonia, theadjacent membranous cover<strong>in</strong>g of the lung is <strong>in</strong>volved, result<strong>in</strong>g <strong>in</strong> roughen<strong>in</strong>g(pleurisy) and sometimes production of fluid <strong>in</strong> the pleural cavity (pleuraleffusion).A special form of LRTI is pulmonary tuberculosis, which is common <strong>in</strong> manycountries. The patient may cough up aerosols conta<strong>in</strong><strong>in</strong>g tubercle bacilli(Mycobacterium tuberculosis) which can be <strong>in</strong>haled by other people. This formof the disease (“open” tuberculosis) is easily spread from person to person,and is therefore a serious communicable disease.Many patients with LRTI cough up purulent (pus-conta<strong>in</strong><strong>in</strong>g) sputum that isgenerally green or yellowish <strong>in</strong> colour; this sputum may be cultured andexam<strong>in</strong>ed grossly and microscopically.There are other <strong>in</strong>fections <strong>in</strong> which little or no sputum is produced: Legionnairedisease (caused by Legionella pneumophila), pneumonia due toMycoplasma pneumoniae (“primary atypical pneumonia”), and Chlamydiapneumonia. These diseases require specialized techniques (serology and isolationon special cultures) for their diagnosis and will not be discussed furtherhere. Apart from pulmonary tuberculosis (see below), most requests forsputum microscopy and culture concern patients with respiratory <strong>in</strong>fectionsassociated with purulent sputum.The most common <strong>in</strong>fectionsAcute and chronic bronchitisIn patients with acute bronchitis (usually follow<strong>in</strong>g an acute viral <strong>in</strong>fection,such as a common cold or <strong>in</strong>fluenza), sputum is not usually cultured unlessthe patient fails to show signs of cl<strong>in</strong>ical improvement.Chronic bronchitis is a long-last<strong>in</strong>g, disabl<strong>in</strong>g respiratory disease with periodicacute attacks. Most patients generally cough up sputum every day, which isusually grey and mucoid; the disease also has episodes when the conditionof the patient becomes worse and obviously purulent sputum is coughed up.This is termed an acute exacerbation of chronic bronchitis. The typical respiratorypathogens (Haemophilus <strong>in</strong>fluenzae, Streptococcus pneumoniae, or lessoften Moraxella (Branhamella) catarrhalis) are frequently found <strong>in</strong> sputumsamples.Lung abscessAn abscess may form <strong>in</strong> the lung follow<strong>in</strong>g the <strong>in</strong>halation of a foreign body,of the stomach contents, or of upper respiratory tract (mouth or throat) secretions.This is sometimes termed “aspiration pneumonia”. Attempts may bemade to culture coughed-up sputum (which is often extremely foul-smell<strong>in</strong>g),66


BACTERIOLOGICAL INVESTIGATIONSbut when there is an abscess (as demonstrated by radiography) the pus conta<strong>in</strong>ed<strong>in</strong> it should be exam<strong>in</strong>ed microscopically and cultured. Unfortunately,there is no medical agreement on how this pus should be obta<strong>in</strong>ed, but directpuncture and withdrawal of pus is one of the possibilities. Anaerobic bacteriasuch as Prevotella melan<strong>in</strong>ogenica (formerly Bacteroides melan<strong>in</strong>ogenicus) andPeptostreptococcus spp., derived from the mouth or throat flora, are often veryimportant causative agents. Pus should be collected, transported, and exam<strong>in</strong>edaccord<strong>in</strong>g to standard methods for anaerobic culture of pus (see p. 86and pp. 98–102).Pneumonia and bronchopneumoniaAcute lobar pneumonia usually affects only a s<strong>in</strong>gle lobe of the lung. This<strong>in</strong>fection is nearly always caused by S. pneumoniae. This form of pneumoniaoccasionally occurs <strong>in</strong> epidemic form. A rare cause of a rather similar form ofpneumonia is Klebsiella pneumoniae.While a few patients <strong>in</strong>fected with S. pneumoniae or K. pneumoniae will haveclassical pneumonia, the most frequent form of the disease is bronchopneumonia,with patches of <strong>in</strong>filtration and <strong>in</strong>flammation (termed “consolidation”)distributed over one or often both lungs.Many different k<strong>in</strong>ds of viruses or bacteria can be associated with bronchopneumonia.Apart from S. pneumoniae, and sometimes H. <strong>in</strong>fluenzae, Staphylococcusaureus is a cause of bronchopneumonia, particularly dur<strong>in</strong>g <strong>in</strong>fluenzaor measles epidemics. Gram-negative rods (<strong>in</strong> particular, E. coli and K. pneumoniae)and P. aerug<strong>in</strong>osa are also frequently found. These <strong>in</strong>fections are allcommon <strong>in</strong> <strong>in</strong>tensive-care departments, especially when broad-spectrumantibiotics are widely used or mechanical respiration is carried out, and are<strong>in</strong>dicative of <strong>in</strong>discrim<strong>in</strong>ate use of antibiotics and failure to monitor patientscarefully for early signs of <strong>in</strong>fection.If there is a pleural effusion, the fluid should be exam<strong>in</strong>ed microscopicallyand cultured accord<strong>in</strong>g to the procedures described for pus and exudates.Pulmonary tuberculosisThe sputum of patients with pulmonary tuberculosis is usually not highlypurulent, but should not be rejected for tuberculosis <strong>in</strong>vestigation because ofthis. An acid-fast sta<strong>in</strong>ed smear (Ziehl–Neelsen) should be exam<strong>in</strong>ed microscopicallyto detect immediately any patients who have acid-fast bacteria <strong>in</strong>their sputum 1 . After the smear has been sta<strong>in</strong>ed, the sputum should be treatedby a decontam<strong>in</strong>ation procedure (see p. 72) <strong>in</strong> order to kill as many of the nonmycobacterialorganisms as possible and to leave the tubercle bacilli viableand thus suitable for culture on Löwenste<strong>in</strong>–Jensen medium.Because the bacteriological procedures for the diagnosis of pyogenic respiratory<strong>in</strong>fections, such as bronchitis and pneumonia, are so fundamentallydifferent from those for tuberculosis, they will be considered separately.The physician must make it clear to the laboratory whether he or she wishesexam<strong>in</strong>ations for:1See Manual of basic techniques for a health laboratory, 2nd ed. Geneva, World HealthOrganization, 2003.67


LOWER RESPIRATORY TRACT INFECTIONS• pyogenic bacteria (H. <strong>in</strong>fluenzae, S. pneumoniae, etc.),• tubercle bacteria (M. tuberculosis), or• both types of bacteria.Collection of sputum specimensThe collection of good sputum specimens is an art <strong>in</strong> itself and has beendescribed <strong>in</strong> other books 1 . Exam<strong>in</strong>ation of a badly collected sputum specimencan give mislead<strong>in</strong>g results because of contam<strong>in</strong>ation with the normal bacterialflora present <strong>in</strong> the mouth and throat; “sputum” consist<strong>in</strong>g of saliva andfood particles should not be exam<strong>in</strong>ed.The sputum should be collected <strong>in</strong> a sterile wide-mouthed conta<strong>in</strong>er with asecure, tight-fitt<strong>in</strong>g cover and sent to the laboratory without delay. If thesputum is allowed to stand after collection, overgrowth of contam<strong>in</strong>at<strong>in</strong>g bacteriamay take place before the exam<strong>in</strong>ation is carried out and the results ofsmears and cultures will be highly mislead<strong>in</strong>g. For this reason, it is not recommendedthat sputum specimens be sent to the laboratory by mail. The onlyexceptions are specimens for tuberculosis exam<strong>in</strong>ation that may have to besent to a district or regional laboratory. The local and national postal regulationsfor the transmission of <strong>in</strong>fected (pathological) material must be strictlyapplied.Process<strong>in</strong>g of sputum <strong>in</strong> the laboratory (fornon-tuberculous <strong>in</strong>fections)After collection sputum must be immediately processed or kept <strong>in</strong> arefrigerator.Macroscopic evaluationThe macroscopic appearance of the sputum should be recorded. Possibledescriptions <strong>in</strong>clude:purulent, greenpurulent, yellowmucopurulent (i.e. partially mucoid and partially purulent)blood-sta<strong>in</strong>edblood-sta<strong>in</strong>ed, with green floccules*grey, mucoid*grey, frothy*white, mucoid*white, frothy*white, mucoid, with some food particles*watery (i.e. only saliva present)*watery, with some food particles1Specimen collection and transport for microbiological <strong>in</strong>vestigation. Alexandria, WHO RegionalOffice for the Eastern Mediterranean, 1995 (WHO Regional Publications, Eastern MediterraneanSeries 8).Manual of basic techniques for a health laboratory, 2nd ed. Geneva, World Health Organization,2003.Technical guide for sputum exam<strong>in</strong>ation for tuberculosis by direct microscopy. Bullet<strong>in</strong> of theInternational Union Aga<strong>in</strong>st Tuberculosis and Lung Disease, 4th ed. 1996.68


BACTERIOLOGICAL INVESTIGATIONSSputum specimens marked with an asterisk should not normally be exam<strong>in</strong>edfor non-tuberculous <strong>in</strong>fections.Microscopic exam<strong>in</strong>ationA portion of the purulent or mucopurulent sputum should be used for thepreparation of a Gram-sta<strong>in</strong>ed smear.If no floccules of pus can be seen (e.g. <strong>in</strong> a grey mucoid sputum sample), theGram-sta<strong>in</strong>ed smear may show only the presence of large, rather square, squamousepithelial cells, frequently covered with masses of adherent bacteria.This is an <strong>in</strong>dication that the specimen consists ma<strong>in</strong>ly of mouth or throatsecretions, and culture should not be carried out as it is not relevant, andusually highly mislead<strong>in</strong>g. An accepted guidel<strong>in</strong>e is to reject, for culture, anyspecimen that conta<strong>in</strong>s fewer than 10 polymorphonuclear neutrophils perepithelial cell 1 .In many patients with acute respiratory <strong>in</strong>fections (e.g. pneumonia) and purulentsputum, the emergency exam<strong>in</strong>ation of a Gram-sta<strong>in</strong>ed smear mayprovide guidance to the cl<strong>in</strong>ician <strong>in</strong> the choice of antimicrobial chemotherapy.Possible results <strong>in</strong>clude:• Gram-positive diplococci surrounded by an empty space from theunsta<strong>in</strong>ed capsules (suggestive of S. pneumoniae);• small Gram-negative coccobacilli (probably H. <strong>in</strong>fluenzae);• Gram-negative diplococci, <strong>in</strong>tracellular and extracellular (suggestive ofMovaxella catarrhalis;• Gram-positive cocci <strong>in</strong> grape-like clusters (suggestive of S. aureus);• Gram-negative rods (suggestive of the presence of Enterobacteriaceae orPseudomonas spp.);• large Gram-positive yeast-like cells, often with mycelia (suggestive of thepresence of Candida spp.).Cultural procedures and <strong>in</strong>terpretationWhen microscopy of the specimen demonstrates an acceptable quality of thesputum, select a floccule of purulent material (or of the most nearly purulentmaterial available) us<strong>in</strong>g a sterile swap or loop and <strong>in</strong>oculate on to the variousculture plates.A suggested rout<strong>in</strong>e set of culture media is as follows:• blood agar, with a streak of S. aureus to facilitate satellite growth of H.<strong>in</strong>fluenzae, and with an optoch<strong>in</strong> disc placed <strong>in</strong> the middle of the secondarystreak<strong>in</strong>g,• chocolate agar,• MacConkey agar.The blood agar and chocolate agar plates are <strong>in</strong>cubated at 35–36 ∞C <strong>in</strong> anatmosphere conta<strong>in</strong><strong>in</strong>g extra carbon dioxide (e.g. <strong>in</strong> a candle jar) and theMacConkey plate is <strong>in</strong>cubated <strong>in</strong> air.1 He<strong>in</strong>emann HS & Radano RR. Acceptability and cost sav<strong>in</strong>gs of selective sputum microbiology<strong>in</strong> a community teach<strong>in</strong>g hospital. Journal of Cl<strong>in</strong>ical Microbiology, 1979, 10: 567–573.69


LOWER RESPIRATORY TRACT INFECTIONSIf grape-like clusters of Gram-positive cocci were present <strong>in</strong> the sta<strong>in</strong>ed smear,an extra mannitol salt agar (MSA) plate is suggested. The presence of Grampositive,yeast-like structures <strong>in</strong> the sta<strong>in</strong>ed smear may be an <strong>in</strong>dicationfor the <strong>in</strong>oculation of a tube of Sabouraud dextrose agar (which needs to be<strong>in</strong>cubated for at least 3 days at 35–37 ∞C). MSA and Sabouraud cultures donot need to be done rout<strong>in</strong>ely for all sputum specimens.Cultures should be <strong>in</strong>spected after <strong>in</strong>cubation overnight (18 hours) but re<strong>in</strong>cubationfor an extra 24 hours may be <strong>in</strong>dicated when growth is less than expectedfrom the microscopic f<strong>in</strong>d<strong>in</strong>gs, or when only t<strong>in</strong>y colonies are present.Typical f<strong>in</strong>d<strong>in</strong>gs <strong>in</strong>clude the follow<strong>in</strong>g:• Flat, clear colonies with concave centres and zones of green (a-) haemolysis,as well as a zone of <strong>in</strong>hibition of growth around the optoch<strong>in</strong> disc,may be S. pneumoniae. If the read<strong>in</strong>g of the optoch<strong>in</strong> test result on theprimary plate is <strong>in</strong>conclusive, the test should be repeated on a subculture.It should not be forgotten that other a-haemolytic colonies (the so-calledviridans streptococci) are normally present <strong>in</strong> the flora of the mouth andthroat.• T<strong>in</strong>y, water-drop colonies grow<strong>in</strong>g as non-haemolytic satellite colonies onthe blood agar plate, but much larger clear colonies on the chocolate agaror enriched blood agar plates, suggest the presence of H. <strong>in</strong>fluenzae. Thesecolonies are usually present <strong>in</strong> large numbers, generally more than 20 perplate. Some laboratories choose to confirm this by X and V factor dependencetests, but these have to be very carefully controlled and are notstrictly necessary. Serological typ<strong>in</strong>g of respiratory stra<strong>in</strong>s is usually nothelpful, as most of them are “rough” and untypable.• Brittle, dry, grey-white colonies on blood agar and chocolate agar platesthat can be moved <strong>in</strong>tact with a loop may <strong>in</strong>dicate M. catarrhalis. If desired,a set of sugar degradation tests may be set up (all test results negative),but most laboratories do not do this. Moraxella organisms are stronglyoxidase-positive, and their colonial and microscopic appearance is highlycharacteristic. As the morphologcal appearance of Moraxella resemblesNeisseria spp. the tributyr<strong>in</strong> test may be used for differentiation, s<strong>in</strong>ceMoraxella hydrolyses tributyr<strong>in</strong>.• Medium-sized, golden-buff colonies are formed by S. aureus. The coagulaseand the mannitol fermentation tests are positive, although the slidecoagulase test (“bound” coagulase test) is occasionally negative. If there isa contradiction between the appearance of the colonies and the slide test,then a tube coagulase (“free” coagulase) test should be performed.• Colonies on MacConkey agar suggest that Enterobacteriaceae orPseudomonas spp. or Ac<strong>in</strong>etobacter spp. are present.• Whitish, round, matt colonies on the blood agar and chocolate agar platesmay be Candida albicans, which will also grow with<strong>in</strong> 2–3 days on aSabouraud dextrose agar culture.It should be stressed that rare colonies of any of the above organisms eitherstem from the normal commensal flora of the respiratory tract, or are a resultof colonization (e.g. coliforms, yeasts). As they may not be relevant to themanagement of the patient, they should not be reported, or should be reportedas coloniz<strong>in</strong>g flora.Susceptibility test<strong>in</strong>gSusceptibility tests should be performed only when the amount of growth isconsidered significant, and not on every bacterial species present <strong>in</strong> small70


BACTERIOLOGICAL INVESTIGATIONSTable 20. Interpretation of susceptibility test results offastidious organisms aTotal zone diameter (mm)Resistant Intermediate SusceptibleS. pneumoniae (Mueller–H<strong>in</strong>tonwith 5% sheep blood <strong>in</strong> 5%CO 2 <strong>in</strong>cubationOxacill<strong>in</strong> (1mg) (for benzylpenicill<strong>in</strong>) 19 b — 20Tetracycl<strong>in</strong>e (30 mg) 18 19–22 22Erythromyc<strong>in</strong> (15 mg) 15 16–20 21Chloramphenicol (30mg) 20 — 21Co-trimoxazole (25mg) 15 16–18 19M. catarrhalis (Mueller–H<strong>in</strong>ton)Tetracycl<strong>in</strong>e (30 mg) 14 15–18 19Erythromyc<strong>in</strong> (15 mg) 13 14–22 23Co-trimoxazole (25mg) 10 11–15 16aNational Committee for Cl<strong>in</strong>ical <strong>Lab</strong>oratory Standards (NCCLS). Performance standards for antimicrobial susceptibilitytest<strong>in</strong>g. M100-S8. Vol 18, 1998.bResistant or <strong>in</strong>termediate.numbers <strong>in</strong> the culture. Interpretations of some possible results are presented<strong>in</strong> Table 20.For Enterobacteriaceae and staphylococci the standardized disc-diffusionmethod (Kirby–Bauer) should be used. Stra<strong>in</strong>s of S. pneumoniae should betested on Mueller–H<strong>in</strong>ton agar, supplemented with 5% sheep blood, for susceptibilityto tetracycl<strong>in</strong>e, chloramphenicol, erythromyc<strong>in</strong>, and benzylpenicill<strong>in</strong>.Conventional blood agar can also be used. For benzylpenicill<strong>in</strong>, a discconta<strong>in</strong><strong>in</strong>g 1mg of oxacill<strong>in</strong> is preferred to a disc conta<strong>in</strong><strong>in</strong>g benzylpenicill<strong>in</strong>itself as results with this oxacill<strong>in</strong> agree better with the MIC value for benzylpenicill<strong>in</strong>;it is also more stable. Benzylpenicill<strong>in</strong> discs may deteriorate rapidly<strong>in</strong> hot climates and thus produce unreliable results.H. <strong>in</strong>fluenzae stra<strong>in</strong>s should be tested for b-lactamase production, us<strong>in</strong>g, forexample, the Nitrocef<strong>in</strong> test. Rare stra<strong>in</strong>s of H. <strong>in</strong>fluenzae may be ampicill<strong>in</strong>resistantwithout produc<strong>in</strong>g b-lactamase. At this stage it is not recommendedto test H. <strong>in</strong>fluenzae for antibiotic susceptibility by the disc-diffusion technique.M. catarrhalis isolates should be tested for b-lactamase production. Test<strong>in</strong>gaga<strong>in</strong>st tetracycl<strong>in</strong>e and erythromyc<strong>in</strong> is optional.Candida albicans cultures need not be tested aga<strong>in</strong>st any antimicrobial agents.Most laboratories give a semi-quantitative assessment of the bacteria culturedon solid media, which might be presented as follows:(+) = few colonies+ = light growth++ =moderately heavy growth+++ =heavy growth.71


LOWER RESPIRATORY TRACT INFECTIONSCulture for Mycobacterium tuberculosisIn addition to the preparation of a direct, acid-fast sta<strong>in</strong>ed smear, material(usually, but not always, sputum) should be cultured for M. tuberculosis, wheneverthis disease is cl<strong>in</strong>ically suspected. Some patients, <strong>in</strong> whom pulmonarytuberculosis is suspected, may not cough up any sputum. A little sputum may,<strong>in</strong> fact, be produced but is immediately swallowed. In this case, the physicianshould collect a specimen of fast<strong>in</strong>g gastric juice (generally obta<strong>in</strong>ed early <strong>in</strong>the morn<strong>in</strong>g) and neutralize the material us<strong>in</strong>g sodium bicarbonate (100mg)before send<strong>in</strong>g it to the laboratory. The gastric juice should be treated <strong>in</strong> thesame way as sputum. It is expensive to culture all sputum samples rout<strong>in</strong>elyfor tubercle bacilli (although some unsuspected patients would be discovered);therefore this is not rout<strong>in</strong>ely recommended.Concentration–digestion–decontam<strong>in</strong>ationproceduresSputum from patients with tuberculosis <strong>in</strong>fection often conta<strong>in</strong>s solid particlesof material from the lungs and this material should be selected for culture,whenever it is found. However, as tuberculous sputum is coughed up throughthe throat and mouth, contam<strong>in</strong>ation with the normal flora of the pharynxis <strong>in</strong>evitable. The contam<strong>in</strong>at<strong>in</strong>g bacteria must be killed if the Löwenste<strong>in</strong>–Jensen culture media are not to become overgrown. A concentrationdigestion-decontam<strong>in</strong>ationprocedure of any specimen collected from a sitewhere there are normal flora is therefore recommended. The follow<strong>in</strong>g threeprocedures are widely used:— Sodium hydroxide (NaOH) (Petroff);— N-acetyl-l-cyste<strong>in</strong>e–sodium hydroxide (NALC–NaOH); and— Zephiran–trisodium phosphateSodium hydroxide procedure (Petroff)This procedure liquifies the sometimes mucoid sputum while destroy<strong>in</strong>g thecontam<strong>in</strong>at<strong>in</strong>g organisms. However, sodium hydroxide is also toxic formycobacteria, and care must be taken when us<strong>in</strong>g the method to ensure that:— the f<strong>in</strong>al concentration of NaOH does not exceed 2%;— the tubercle bacilli are not exposed to sodium hydroxide for more than 30m<strong>in</strong>utes, <strong>in</strong>clud<strong>in</strong>g centrifugation time.1. Mix equal volumes of sputum and 4% sodium hydroxide 40g/l (previouslysterilized by autoclav<strong>in</strong>g) <strong>in</strong> a sterile, leak-proof, 50-ml glass bottleor jar, or plastic conical centrifuge tube.2. Incubate at room temperature (25–30 ∞C) for 15 m<strong>in</strong>utes, shak<strong>in</strong>g themixture carefully every 5 m<strong>in</strong>utes us<strong>in</strong>g a mechanical shaker. In hot climatessome cool<strong>in</strong>g may be needed or the reaction time may be reducedto 10–15 m<strong>in</strong>utes.3. Centrifuge immediately or dilute the mixture to the 50-ml mark with distilledwater or phosphate buffer (pH 6.8) to stop the action of the NaOH.4. After 15 m<strong>in</strong>utes, centrifuge the specimen at 3000g for 15 m<strong>in</strong>utes. Discardthe supernatant carefully <strong>in</strong>to a splash-proof conta<strong>in</strong>er filled with a suitabledis<strong>in</strong>fectant (phenol- or glutaraldehyde-based). Neutralize the sedimentdrop by drop with a 2-mol/l HCl solution conta<strong>in</strong><strong>in</strong>g 2% of phenolred, comb<strong>in</strong>ed with shak<strong>in</strong>g, until the colour changes persistently from redto yellow. Alternatively add one drop of <strong>in</strong>dicator solution and then addHCl drop by drop while shak<strong>in</strong>g cont<strong>in</strong>uously.72


BACTERIOLOGICAL INVESTIGATIONS5. If the media is to be <strong>in</strong>oculated immediately, suspend the neutralizeddeposit <strong>in</strong> 1–2ml of sterile 0.85% NaCl or sterile distilled water. Otherwise,suspend the sediment <strong>in</strong> 1–2ml of sterile bov<strong>in</strong>e album<strong>in</strong> fraction V.N-acetyl-L-cyste<strong>in</strong>e–sodium hydroxide procedureA lower concentration of NaOH <strong>in</strong> the presence of a mucolytic agent like N-acetyl-l-cyste<strong>in</strong>e (NALC) is less aggressive aga<strong>in</strong>st tubercle bacilli. Neither the<strong>in</strong>cubation time nor the temperature are as crucial as <strong>in</strong> the NaOH procedure.However, the short shelf-life of no more than 24 hours of the NALC–NaOHwork<strong>in</strong>g solution requires daily preparation.1. Comb<strong>in</strong>e equal volumes of sodium citrate solution (29g sodium citratedihydrate per litre of distilled water) and 4% sodium hydroxide (40g/l),and autoclave the mixture. The solution may be stored at roomtemperature.2. Just prior to use, add 0.5g NALC to 100ml of NaOH–sodium citratesolution.3. Depend<strong>in</strong>g on the number of specimens that must be decontam<strong>in</strong>ated,prepare 2.5g of NALC <strong>in</strong> 500ml of NaOH–sodium citrate solution or 5gNALC <strong>in</strong> 1000ml of NaOH–sodium citrate solution. After 24 hours thereagent must be discarded.4. Add an equal volume of NALC–NaOH work<strong>in</strong>g solution to the specimen<strong>in</strong> a sterile, leak-proof, 50-ml glass bottle or jar, or plastic conical centrifugetube. Securely tighten the screw-cap, <strong>in</strong>vert the tube and shake it gentlyfor no longer than 30 seconds.5. Let the tube stand for 15 m<strong>in</strong>utes at room temperature (20–25 ∞C).6. Dilute the mixture to the 50-ml mark with distilled water or with67mmol/l phosphate buffer (pH 6.8) to stop the action of the NaOH.Discard the supernatant carefully <strong>in</strong>to a splash-proof conta<strong>in</strong>er filled witha suitable dis<strong>in</strong>fectant (phenol- or glutaraldehyde-based).7. If the media is to be <strong>in</strong>oculated immediately, suspend the deposit <strong>in</strong>1–2ml of sterile 0.85% NaCl or sterile distilled water. Otherwise, suspendthe sediment <strong>in</strong> 1–2ml of sterile bov<strong>in</strong>e album<strong>in</strong> fraction V.Zephiran–trisodium phosphate procedureMycobacteria can withstand prolonged treatment with this more gentle procedure.Therefore, <strong>in</strong>cubation time and temperature are not critical.1. Prepare 1kg of trisodium phosphate (Na 3 PO 4 ◊12H 2 O) <strong>in</strong> 4 litres of hotdistilled water, add 7.5ml of 17% benzalkonium chloride (Zephiran),mix well, and store at room temperature.2. Mix an equal volume of sputum (up to 10ml) with the Zephiran–trisodiumphosphate solution <strong>in</strong> a 50-ml sterile, leak-proof centrifugation glass bottle.Tighten the cap and vigorously shake the mixture manually or us<strong>in</strong>g amechanical shaker for 30 m<strong>in</strong>utes.3. Leave the mixture to stand for an additional 30 m<strong>in</strong>utes.4. Centrifuge at 3000 g for 15 m<strong>in</strong>utes. Discard the supernatant carefully<strong>in</strong>to a splash-proof conta<strong>in</strong>er filled with a suitable dis<strong>in</strong>fectant (phenol- orglutaraldehyde-based), and re-suspend the sediment <strong>in</strong> 20ml of neutraliz<strong>in</strong>gphosphate buffer, pH 6.6 1 .1 Preparation of neutraliz<strong>in</strong>g phosphate buffer 67mmol/l.Stock solutions:A. Dissolve 9.47g of anhydrous disodium phosphate <strong>in</strong> 1 litre of distilled water.B. Dissolve 9.07g of anhydrous monopotassium phosphate <strong>in</strong> 1 litre of distilled water.For pH 6.8 buffers: mix 50ml of stock solution A with 50ml of stock solution B.For pH 6.6 buffers. mix 37.5ml of stock solution A with 62.5ml of stock solution B.Check the pH. Add solution A to raise the pH, or solution B to lower the pH as necessary.73


LOWER RESPIRATORY TRACT INFECTIONS5. Centrifuge once aga<strong>in</strong> at 3000 g for 15 m<strong>in</strong>utes. Discard the supernatantand <strong>in</strong>oculate the sediment onto the media.Culture1. Inoculate 3 drops (about 0.1ml) of the sediment onto at least three platesof Löwenste<strong>in</strong>–Jensen medium or equivalent.2. Determ<strong>in</strong>e the contam<strong>in</strong>ation rate of the <strong>in</strong>cubated media regularly andrecord the number of contam<strong>in</strong>ated plates.The rate of contam<strong>in</strong>ation should be 3–5%. Excessive contam<strong>in</strong>ation (over 5%)of the Löwenste<strong>in</strong>–Jensen cultures usually <strong>in</strong>dicates that the decontam<strong>in</strong>ationprocedure was not effective enough. Contam<strong>in</strong>ation rates of


BACTERIOLOGICAL INVESTIGATIONSlaboratory personnel and appropriate occupational health procedures shouldbe applied. 1Transportation of cultures of M. tuberculosis by mail to the national referencelaboratory presents special risks <strong>in</strong> the event of accidents or breakage of theconta<strong>in</strong>er. Only approved conta<strong>in</strong>ers and dispatch materials conform<strong>in</strong>g topostal requirements should be used.1<strong>Lab</strong>oratory services <strong>in</strong> tuberculosis control Part I: Organization and management. Geneva,World Health Organization, 1998 (unpublished document WHO/TB/98.258).75


Sexually transmitted diseasesIntroductionThe number of microorganisms known to be sexually transmitted or transmissible,and the spectrum of cl<strong>in</strong>ical syndromes associated with these agents,have expanded enormously dur<strong>in</strong>g the past twenty years. Table 21 listsselected sexually transmissible microorganisms and the diseases they cause.The etiological diagnosis of some of these conditions is a major challenge tothe cl<strong>in</strong>ical microbiology laboratory. A laboratory diagnosis is an essentialcomponent <strong>in</strong> the management and control of diseases such as gonorrhoeaand syphilis, and has implications not only for the patient but also for his orher sex partners.This section discusses briefly the identification of the most commonly occurr<strong>in</strong>gsexually transmissible microorganisms found <strong>in</strong> specimens from thefemale and male genital tract. Viruses and bacterial agents such as Ureaplasmaurealyticum, Mycoplasma hom<strong>in</strong>is, and Mobiluncus spp. will not be dealt withTable 21. Selected sexually transmissible microorganisms and related syndromesEtiological agentNeisseria gonorrhoeaeChlamydia trachomatis(serovars D–K)Chlamydia trachomatis(serovars L 1 , L 2 , L 3 ,)Treponema pallidumHaemophilus ducreyiCalymmatobacteriumgranulomatisMobiluncus spp.Human (alpha) herpesvirus(HSV I and HSV II)Cytomegalovirus (CMV)Human papilloma virus(HPV)Human immunodeficiencyvirus (HIV)Hepatitis B virus (HBV)Gardnerella vag<strong>in</strong>alisCandida albicansSyndromeBarthol<strong>in</strong>itis, cervicitis, chorio-amnionitis, conjunctivitis, dissem<strong>in</strong>atedgonococcal <strong>in</strong>fection (arthritis, dermatitis, tenosynovitis), endometritis,epididymitis, <strong>in</strong>fertility, pharyngitis, prepubertal vag<strong>in</strong>itis, perihepatitis,proctitis, prostatitis, salp<strong>in</strong>gitis, urethritisBarthol<strong>in</strong>itis, cervicitis, conjunctivitis <strong>in</strong> <strong>in</strong>fants, endometritis, epididymitis,<strong>in</strong>fant pneumonia, <strong>in</strong>fertility, otitis media <strong>in</strong> <strong>in</strong>fants, pelvic <strong>in</strong>flammatorydisease (PID), perihepatitis, prepubertal vag<strong>in</strong>itis, proctitis, Reitersyndrome, salp<strong>in</strong>gitis, urethritisLymphogranuloma venereumSyphilisChancroidGranuloma <strong>in</strong>gu<strong>in</strong>ale (donovanosis)Bacterial vag<strong>in</strong>osisGenital and orolabial herpes, men<strong>in</strong>gitis, neonatal herpes, proctitisCongenital <strong>in</strong>fectionCervical cancer, viral wartsAcquired immunodeficiency syndrome (AIDS) and AIDS-related complexHepatitis BUrethritis, vag<strong>in</strong>itisBalanoposthitis, vulvovag<strong>in</strong>itis76


BACTERIOLOGICAL INVESTIGATIONShere. For more extensive <strong>in</strong>formation, the reader is referred to the relevantWHO publication. 1Urethritis <strong>in</strong> menUrethritis <strong>in</strong> men is cl<strong>in</strong>ically characterized by a urethral discharge and/ordysuria, but asymptomatic <strong>in</strong>fection with Neisseria gonorrhoeae or Chlamydiatrachomatis occurs frequently. If untreated, gonococcal and chlamydial urethritismay progress to epididymitis. Rectal and oropharyngeal <strong>in</strong>fection withN. gonorrhoeae and C. trachomatis may occur <strong>in</strong> homosexual men.For the purpose of patient management, urethritis should be divided <strong>in</strong>togonococcal urethritis and nongonococcal urethritis (NGU). Approximatelyhalf the cases of NGU are caused by C. trachomatis, but the etiology of themajority of the rema<strong>in</strong><strong>in</strong>g cases has not been fully elucidated. Accord<strong>in</strong>g tosome studies, Ureaplasma urealyticum may be a cause of urethritis, and Trichomonasvag<strong>in</strong>alis can be found <strong>in</strong> 1–3% of cases of NGU. Intra-urethral <strong>in</strong>fectionwith human herpesvirus may yield a urethral discharge. Bacterial agentssuch as staphylococci, various Enterobacteriaceae, Ac<strong>in</strong>etobacter spp., andPseudomonas spp. can be isolated from the urethra of healthy men, but havenot been shown to cause urethritis.The exam<strong>in</strong>ation of specimens for C. trachomatis is complicated and will notbe discussed <strong>in</strong> this section. Besides isolation <strong>in</strong> cell culture systems, nonculturemethods for the detection of chlamydial antigens by enzymeimmunoassays, immunofluorescence assays and nucleic acid amplificationtests have recently become available. These methods, while promis<strong>in</strong>g, rema<strong>in</strong>prohibitively expensive.Collection and transport of specimensFor the collection of urethral specimens, a swab with a narrow diameter or asterile bacteriological loop should be <strong>in</strong>serted 3–4 cm <strong>in</strong>to the urethra andgently rotated before withdrawal. Purulent discharge can be collected directlyon a swab or on the <strong>in</strong>oculat<strong>in</strong>g loop. The composition of both the tip and theshaft of the swab is important. For the culture of N. gonorrhoeae, charcoaltreatedcotton tips or calcium alg<strong>in</strong>ate or Dacron tips are preferred. If thesespecial, commercially prepared, sampl<strong>in</strong>g swabs are not available and regularcotton swabs are used, the specimen should be <strong>in</strong>oculated immediately. A prostaticmassage does not <strong>in</strong>crease the rate of isolation of gonococci or chlamydiae<strong>in</strong> cases of urethritis.Anorectal specimens are obta<strong>in</strong>ed by <strong>in</strong>sert<strong>in</strong>g a swab 4–5 cm <strong>in</strong>to the analcanal. For oropharyngeal specimens, the posterior pharynx and the tonsillarcrypts should be swabbed and plated immediately.Ideally the <strong>in</strong>oculation of specimens for the isolation of N. gonorrhoeae shouldbe made directly onto the culture medium <strong>in</strong> the cl<strong>in</strong>ic. Inoculated platesshould be placed <strong>in</strong> a candle jar or <strong>in</strong>to an atmosphere conta<strong>in</strong><strong>in</strong>g 5–10%carbon dioxide, with high humidity. If immediate plat<strong>in</strong>g and <strong>in</strong>cubation arenot possible, a transport medium such as Amies or Stuart transport mediumshould be used. The transport time should be as short as possible, and must1Van Dyck E, Meheus AZ, Piot P. <strong>Lab</strong>oratory diagnosis of sexually transmitted diseases. Geneva,World Health Organization, 1999.77


SEXUALLY TRANSMITTED DISEASESbe less than 12 hours <strong>in</strong> ambient temperatures up to 30 ∞C. Refrigeration is tobe avoided.Direct exam<strong>in</strong>ation and <strong>in</strong>terpretationMost studies have shown that the presence of four or more polymorphonuclear(PMN) leukocytes per oil-immersion field is strongly <strong>in</strong>dicative ofurethritis <strong>in</strong> men. This criterion is particularly useful to the cl<strong>in</strong>ician whohas to decide whether to treat patients with vague urethral compla<strong>in</strong>ts.In most cases of gonorrhoea <strong>in</strong> the male, the discharge is purulent, and numerouspolymorphonuclear leukocytes (>10 per oil-immersion field) can be seen<strong>in</strong> the urethral smear. However, this is not always the case <strong>in</strong> NGU, whichyields a less severe <strong>in</strong>flammatory reaction. Smears with more than 4 PMNleukocytes per oil-immersion field, and without <strong>in</strong>tracellular Gram-negativediplococci, are highly suggestive of NGU.A th<strong>in</strong>ly spread smear, prepared by roll<strong>in</strong>g a swab over a slide, should be heatfixedand methylene-blue or Gram-sta<strong>in</strong>ed. The presence of Gram-negative<strong>in</strong>tracellular diplococci <strong>in</strong> PMN leukocytes <strong>in</strong> a urethral smear is strongly suggestiveof gonorrhoea.Gram-sta<strong>in</strong>ed smears of <strong>in</strong>tra-urethral specimens from asymptomatic males,from bl<strong>in</strong>d rectal swabs, or from oropharyngeal samples are not recommended.However, microscopic exam<strong>in</strong>ation of purulent material obta<strong>in</strong>edunder anoscopy has a fairly high diagnostic value.Culture of Neisseria gonorrhoeaeInoculated plates with modified Thayer–Mart<strong>in</strong> (MTM) 1 agar (or New YorkCity medium (NYC)) 2 should be <strong>in</strong>cubated at 35 ∞C <strong>in</strong> a humid atmosphereenriched with carbon dioxide (candle jar), and should be observed dailyfor two days. <strong>Lab</strong>oratories process<strong>in</strong>g a large number of specimens for N.gonorrhoeae often prefer to use a non-selective chocolate agar enriched withIsoVitaleX, or an equivalent supplement, <strong>in</strong> addition to the selective MTM,because as many as 3–10% of gonococcal stra<strong>in</strong>s <strong>in</strong> a given area may be susceptibleto the concentration of vancomyc<strong>in</strong> used <strong>in</strong> selective media.1 Modified Thayer–Mart<strong>in</strong> agar is prepared by add<strong>in</strong>g at 50∞C a mixture of antimicrobials andIsoVitaleX, or an equivalent supplement, to chocolate agar prepared from GC agar or Columbiaagar as basal medium. Antimicrobial mixtures conta<strong>in</strong><strong>in</strong>g 3 or 4 antimicrobials are commerciallyavailable from several sources; VCN mixture conta<strong>in</strong>s vancomyc<strong>in</strong>, colist<strong>in</strong>, and nystat<strong>in</strong>; VCNTmixture also conta<strong>in</strong>s trimethoprim.The f<strong>in</strong>al concentrations of the antimicrobials <strong>in</strong> the prepared medium are:— vancomyc<strong>in</strong>: 3 mg/ml— colist<strong>in</strong>: 7.5 mg/ml— nystat<strong>in</strong>: 12.5IU/ml— trimethoprim lactate: 5mg/ml2Modified New York City medium is prepared by add<strong>in</strong>g 500ml of sterile GC agar base cooledto 50 ∞C, the follow<strong>in</strong>g supplements:— 50ml horse blood lysed by add<strong>in</strong>g 5ml/l sapon<strong>in</strong>,— sterile yeast autolysate,— an antimicrobial mixture conta<strong>in</strong><strong>in</strong>g vancomyc<strong>in</strong>, colist<strong>in</strong>, amphoteric<strong>in</strong>, and trimethoprim.The <strong>in</strong>gredients are commercially available from Oxoid Ltd, Wade Rd, Bas<strong>in</strong>gstoke, Hants RG248PW, England.78


BACTERIOLOGICAL INVESTIGATIONSGonococcal colonies may still not be seen after 24 hours. They appear after 48hours as grey to white, opaque, raised, and glisten<strong>in</strong>g colonies of differentsizes and morphology.Identification of Neisseria gonorrhoeaeA presumptive identification of N. gonorrhoeae isolated from urogenital specimensis based on a positive oxidase reaction and a Gram-sta<strong>in</strong>ed smearshow<strong>in</strong>g Gram-negative diplococci. Confirmation of the identification can beobta<strong>in</strong>ed by carbohydrate degradation assays or other tests, us<strong>in</strong>g methodsand media discussed extensively elsewhere. 1Antimicrobial susceptibility test<strong>in</strong>gThere is considerable geographical variation <strong>in</strong> the susceptibility of N. gonorrhoeaestra<strong>in</strong>s to benzylpenicill<strong>in</strong>. In some areas, such as sub-Saharan Africaor South-east Asia, most gonococcal stra<strong>in</strong>s are now b-lactamase-produc<strong>in</strong>g.Chromosomally mediated resistance to benzylpenicill<strong>in</strong> not based on b-lactamase production is also becom<strong>in</strong>g more common <strong>in</strong> many countries.However, the disc-diffusion test is not reliable <strong>in</strong> detect<strong>in</strong>g such stra<strong>in</strong>s.In areas where benzylpenicill<strong>in</strong>, ampicill<strong>in</strong> or amoxicill<strong>in</strong> is still used for thetreatment of gonococcal <strong>in</strong>fections, N. gonorrhoeae isolates (particularly fromcases of treatment failure) should be rout<strong>in</strong>ely screened for b-lactamase productionby one of the recommended tests, such as the Nitrocef<strong>in</strong> test. 2 For theNitrocef<strong>in</strong> test, a dense suspension from several colonies is prepared <strong>in</strong> a smalltube with 0.2ml sal<strong>in</strong>e; 0.025ml of Nitrocef<strong>in</strong> is then added to the suspensionand mixed for one m<strong>in</strong>ute. A rapid change <strong>in</strong> the colour, from yellow to p<strong>in</strong>kor red, <strong>in</strong>dicates that the stra<strong>in</strong> produces b-lactamase.Antimicrobial susceptibility test<strong>in</strong>g of N. gonorrhoeae by the disc-diffusionassay is not recommended <strong>in</strong> rout<strong>in</strong>e practice.Genital specimens from womenThe vag<strong>in</strong>al flora of premenopausal women normally consists predom<strong>in</strong>antlyof lactobacilli, and of a wide variety of facultative aerobic and anaerobicbacteria.Abnormal vag<strong>in</strong>al discharge may be due to:— vag<strong>in</strong>itis: Gardnerella vag<strong>in</strong>alis, Candida albicans;— bacterial vag<strong>in</strong>osis: overgrowth of anaerobes and Mobiluncus spp.;— cervicitis: Neisseria gonorrhoeae, Chlamydia trachomatis.Other bacteria, such as Enterobacteriaceae, are not proven causes of vag<strong>in</strong>itis.Vag<strong>in</strong>itis <strong>in</strong> prepubertal girls may be due to N. gonorrhoeae or C. trachomatis.1Van Dyck E, Meheus AZ, Piot P. <strong>Lab</strong>oratory diagnosis of sexually transmitted diseases. Geneva,World Health Organization, 1999.2The Nitrocef<strong>in</strong> reagent is obta<strong>in</strong>able from Oxoid Ltd, Wade Road, Bas<strong>in</strong>gstoke, Hants RG248PW, England, and consists of 1mg of Nitrocef<strong>in</strong> (SR112) and 1 vial of rehydration fluid (SR112A).The tube test can be replaced by a disc test, us<strong>in</strong>g Nitrocef<strong>in</strong>-impregnated paper discs (Cef<strong>in</strong>asediscs, available from BD Diagnostic Systems, 7 Loveton Circle, Sparks, MD 21152, USA).79


SEXUALLY TRANSMITTED DISEASESBacterial vag<strong>in</strong>osis (nonspecific vag<strong>in</strong>itis) is a condition characterized by anexcessive, malodorous, vag<strong>in</strong>al discharge associated with a significant<strong>in</strong>crease of Mobiluncus spp. and various obligate anaerobes, and a decrease <strong>in</strong>the number of vag<strong>in</strong>al lactobacilli. A m<strong>in</strong>imum diagnostic requirement forbacterial vag<strong>in</strong>osis is the presence of at least three of the follow<strong>in</strong>g signs:abnormal vag<strong>in</strong>al discharge, vag<strong>in</strong>al pH > 4.5, clue cells (epithelial cells withso many bacteria attached that the cell border becomes obscured), and a fishy,am<strong>in</strong>e-like odour when a drop of 10% potassium hydroxide is added to thevag<strong>in</strong>al secretions.Urethritis <strong>in</strong> women is also often caused by N. gonorrhoeae and C. trachomatis.Ascend<strong>in</strong>g <strong>in</strong>fections with N. gonorrhoeae, C. trachomatis, vag<strong>in</strong>al anaerobes,and facultative anaerobic bacteria can cause pelvic <strong>in</strong>flammatory disease(PID), with <strong>in</strong>fertility or ectopic pregnancy as late sequelae.Genital <strong>in</strong>fections with bacterial agents, <strong>in</strong>clud<strong>in</strong>g N. gonorrhoeae and C.trachomatis, dur<strong>in</strong>g pregnancy may result <strong>in</strong> complications such as prematuredelivery, prolonged rupture of membranes, chorio-amnionitis, and postpartumendometritis <strong>in</strong> the mother, and conjunctivitis, pneumonia, andamniotic <strong>in</strong>fection syndrome <strong>in</strong> the newborn.On special request, cervicovag<strong>in</strong>al specimens may be cultured for bacterialspecies, such as S. aureus (toxic shock syndrome), S. agalactiae (group B streptococci,neonatal <strong>in</strong>fection), Listeria monocytogenes (neonatal <strong>in</strong>fection), andClostridium spp. (septic abortion).Although <strong>in</strong>fections with C. trachomatis and with human herpesvirusare common, and can cause significant morbidity, their laboratory diagnosisrequires expensive equipment and reagents and will not be discussedhere.Collection and transport of specimensAll specimens should be collected dur<strong>in</strong>g a pelvic exam<strong>in</strong>ation us<strong>in</strong>g a speculum.The speculum may be moistened with warm water before use, but antisepticsor gynaecological exploration cream should not be used, s<strong>in</strong>ce thesemay be lethal to gonococci.For exam<strong>in</strong>ation for yeasts, G. vag<strong>in</strong>alis, and bacterial vag<strong>in</strong>osis, samples ofvag<strong>in</strong>al discharge may be obta<strong>in</strong>ed with a swab from the posterior fornix ofthe vag<strong>in</strong>a. Samples for gonococcal and chlamydial culture should be collected<strong>in</strong> the endocervix. After <strong>in</strong>sert<strong>in</strong>g the speculum, cervical mucus shouldbe wiped off with a cotton wool ball. A sampl<strong>in</strong>g swab (see page 77) shouldthen be <strong>in</strong>troduced <strong>in</strong>to the cervical canal and rotated for at least 10 secondsbefore withdrawal.Urethral, anorectal, and oropharyngeal specimens for gonococci may beobta<strong>in</strong>ed <strong>in</strong> a similar manner as from males.In all cases of pelvic <strong>in</strong>flammatory disease (PID), as a m<strong>in</strong>imum, the cervixshould be sampled for N. gonorrhoeae. Sampl<strong>in</strong>g from the fallopian tubes ismore reliable, but <strong>in</strong> most areas a cul-de-sac aspirate is the best sampleavailable.In <strong>in</strong>fants with ophthalmia neonatorum, conjunctival exudate should be collectedwith a swab or a loop.80


BACTERIOLOGICAL INVESTIGATIONSAmies and Stuart transport media are convenient for transport of cervical andvag<strong>in</strong>al samples, with the exception of specimens to be tested for C.trachomatis.Direct exam<strong>in</strong>ation and <strong>in</strong>terpretationDirect exam<strong>in</strong>ation of vag<strong>in</strong>al secretions is the method of choice for the etiologicaldiagnosis of vag<strong>in</strong>itis, but is much less useful for the diagnosis ofcervicitis.A wet mount is prepared by mix<strong>in</strong>g the vag<strong>in</strong>al sample with sal<strong>in</strong>e on a glassslide, after which a cover slip is added. A diluted preparation is preferredto ensure the separation of the cells, which may otherwise be clumpedtogether. Exam<strong>in</strong>e at a magnification of ¥400 for the presence of T. vag<strong>in</strong>aliswith typical movement, budd<strong>in</strong>g yeasts, and clue cells. C. albicans may formpseudomycelia, which may be observed occasionally <strong>in</strong> vag<strong>in</strong>al material. Cluecells are found <strong>in</strong> most women with bacterial vag<strong>in</strong>osis. A granular or dirtyappearance of the epithelial cell cytoplasm is a less objective criterion than theloss of the cell border. Microscopic exam<strong>in</strong>ation of a wet mount of cervicalspecimens is not recommended.Preparation of a Gram-sta<strong>in</strong>ed smear is the method of choice for the diagnosisof bacterial vag<strong>in</strong>osis. The smear should be prepared by gently roll<strong>in</strong>g,rather than smear<strong>in</strong>g, a swab over the glass slide. A normal vag<strong>in</strong>al smearconta<strong>in</strong>s predom<strong>in</strong>antly lactobacilli (large Gram-positive rods) and fewer than5 leukocytes per field. In typical smears from women with bacterial vag<strong>in</strong>osis,clue cells covered with small Gram-negative rods are accompanied by a mixedflora consist<strong>in</strong>g of very large numbers of small Gram-negative and Gramvariablerods and coccobacilli, and often Gram-negative curved rods, <strong>in</strong>the absence of larger Gram-positive rods. Only a few (10 cells per field) on the Gram-sta<strong>in</strong>edvag<strong>in</strong>al smear suggests trichomoniasis or cervicitis.Gram-sta<strong>in</strong><strong>in</strong>g is not particularly helpful for the diagnosis of gonococcal<strong>in</strong>fection <strong>in</strong> female patients. The exam<strong>in</strong>ation of Gram-sta<strong>in</strong>ed smears ofendocervical secretions for <strong>in</strong>tracellular Gram-negative diplococci has asensitivity of 50–70%, and a specificity of 50–90% for the diagnosis of gonococcal<strong>in</strong>fection, result<strong>in</strong>g <strong>in</strong> a poor predictive value of a positive test <strong>in</strong> populationswith a low prevalence of gonorrhoea. Gram-negative <strong>in</strong>tracellulardiplococci <strong>in</strong> cervical smears should be reported as such, and not as N.gonorrhoeae or gonococci. Over-<strong>in</strong>terpretation of cervical smears, which oftenconta<strong>in</strong> Gram-negative coccobacilli and bipolar sta<strong>in</strong>ed rods, must beavoided.The ma<strong>in</strong> <strong>in</strong>terest <strong>in</strong> a cervical smear is its validity for the diagnosis ofmucopurulent cervicitis: the presence of more than 10 polymorphonuclearleukocytes per oil-immersion field is a reasonably good <strong>in</strong>dication ofmucopurulent cervicitis, most often due to N. gonorrhoeae and/or C.trachomatis.The exam<strong>in</strong>ation of a Gram-sta<strong>in</strong>ed conjunctival smear is a sensitive andspecific technique for the diagnosis of gonococcal conjunctivitis. The presenceof <strong>in</strong>tracellular Gram-negative diplococci is diagnostic for gonococcalconjunctivitis.81


SEXUALLY TRANSMITTED DISEASESCultureCervical, rectal, urethral, conjunctival, and cul-de-sac specimens may be culturedfor N. gonorrhoeae us<strong>in</strong>g the methods specified on page 78. Specimensshould be processed as soon as they arrive <strong>in</strong> the laboratory or, preferably, <strong>in</strong>the cl<strong>in</strong>ic itself. Unlike <strong>in</strong> males, culture is essential for the diagnosis of gonococcal<strong>in</strong>fection <strong>in</strong> females. The sensitivity of a s<strong>in</strong>gle culture for the diagnosisof gonorrhoea <strong>in</strong> women is 80–90%. The sensitivity is lower for specimenstaken dur<strong>in</strong>g the peripartum period.Cultures for G. vag<strong>in</strong>alis or anaerobes are not recommended for the diagnosisof bacterial vag<strong>in</strong>osis, s<strong>in</strong>ce the organisms are recovered from 20–40% ofwomen without vag<strong>in</strong>al <strong>in</strong>fection. The presence of G. vag<strong>in</strong>alis <strong>in</strong> vag<strong>in</strong>aldischarge is <strong>in</strong> itself not an <strong>in</strong>dication for treatment, and only patients fulfill<strong>in</strong>gthe diagnostic criteria for bacterial vag<strong>in</strong>osis should be treated for thiscondition.As compared with microscopy, cultures <strong>in</strong>crease the detection of C. albicansby 50–100%. Culture methods are usually more efficient when the number oforganisms is low. However, low numbers of C. albicans can be found <strong>in</strong> thevag<strong>in</strong>a of 10–30% of women without signs or symptoms of vag<strong>in</strong>itis, and onlylarge numbers of C. albicans should be considered as evidence of vag<strong>in</strong>al candidiasis.Consequently, culture is not recommended. Cultures for G. vag<strong>in</strong>aliswill ma<strong>in</strong>ly detect asymptomatic carriers when performed <strong>in</strong> addition to a wetmount, and should not be performed.Specimens from genital ulcersGenital ulcers are a very common problem <strong>in</strong> many develop<strong>in</strong>g countries.Their etiological diagnosis and management are a challenge to the cl<strong>in</strong>icianas well as to the laboratory. Mixed <strong>in</strong>fections are common. Genital ulcerativelesions can be caused by a variety of sexually transmissible agents:— human herpesvirus— Treponema pallidum— Haemophilus ducreyi— Calymmatobacterium granulomatis, the agent of granuloma <strong>in</strong>gu<strong>in</strong>ale(Donovanosis)— Chlamydia trachomatis serovars L 1 , L 2 , L 3Genital herpes is the most common cause of genital ulcer disease <strong>in</strong> most<strong>in</strong>dustrialized countries, and is a cause of life-threaten<strong>in</strong>g complications <strong>in</strong>immunodeficient patients and neonates born to women with the <strong>in</strong>fection. Itslaboratory diagnosis will not be discussed here.Syphilis is still the most serious disease associated with genital lesions,s<strong>in</strong>ce it can give rise to severe late sequelae and to congenital syphilis. Whileserological tests play an important role <strong>in</strong> the diagnosis of all stagesof syphilis, only the dark-field exam<strong>in</strong>ation will be discussed here. Techniquesand <strong>in</strong>terpretation of serological tests for syphilis have been extensivelyreviewed elsewhere. 11Van Dyck E, Meheus AZ, Piot P. <strong>Lab</strong>oratory diagnosis of sexually transmitted diseases. Geneva,World Health Organization, 1999.82


BACTERIOLOGICAL INVESTIGATIONSChancroid (ulcus molle) is the major cause of genital ulceration <strong>in</strong> manydevelop<strong>in</strong>g areas. The cl<strong>in</strong>ical features <strong>in</strong>clude pa<strong>in</strong>ful, purulent ulcer(s)accompanied by pa<strong>in</strong>ful and occasionally suppurative <strong>in</strong>gu<strong>in</strong>al buboes. Latesequelae are not known to occur. The cl<strong>in</strong>ical differentiation from other genitalulcer diseases is difficult. Chancroid <strong>in</strong>creases the risk of acquir<strong>in</strong>g HIV<strong>in</strong>fection.Granuloma <strong>in</strong>gu<strong>in</strong>ale is characterized by extensive beefy, red, granulatedgenital ulcers. Bubo formation is rare.Chlamydial lymphogranuloma is typically associated with <strong>in</strong>gu<strong>in</strong>al and/orfemoral lymphadenopathy, and, less frequently, with small ulcers which healspontaneously. Its diagnosis is based on serological tests and isolation of C.trachomatis serovars L 1 , L 2 , L 3 .Collection of specimensTreponema pallidum: Protective surgical gloves should be worn. Squeezethe ulcer between two f<strong>in</strong>gers and clean the surface of the lesion withsal<strong>in</strong>e, us<strong>in</strong>g gauze swabs. Crusts should be removed if present. After wip<strong>in</strong>gaway the first drops of blood (if present), collect a sample of serous exudateby touch<strong>in</strong>g a completely clean glass slide to the surface of the lesion. Immediatelyplace a clean coverslip firmly on the drop of exudate. Alternatively,the specimen may be aspirated from the lesion, or from an enlargedlymph node, us<strong>in</strong>g a sterile needle and syr<strong>in</strong>ge. The preparation shouldbe exam<strong>in</strong>ed immediately by a microscopist experienced <strong>in</strong> dark-fieldmicroscopy.Haemophilus ducreyi: Specimens should be obta<strong>in</strong>ed from the base of the ulcerwith a swab and <strong>in</strong>oculated directly on to the isolation medium. Material mayalso be aspirated from <strong>in</strong>gu<strong>in</strong>al buboes, but isolation of H. ducreyi is less successfulthan from genital lesions. Transport media for H. ducreyi have not beenevaluated.If granuloma <strong>in</strong>gu<strong>in</strong>ale is suspected, ideally a biopsy of subsurface tissue froman area of active granulation should be made. Fresh smears should be madefrom a crushed piece of biopsy material. Alternatively, one may make a smearby scrap<strong>in</strong>g off the surface of the lesion.Direct exam<strong>in</strong>ationDemonstration of treponemas <strong>in</strong> lesion material is the method of choicefor the diagnosis of primary syphilis. Although T. pallidum can be sta<strong>in</strong>ed(for <strong>in</strong>stance with silver nitrate), dark-field microscopy is recommendedbecause it is more sensitive and specific. A microscope equipped with agood light source and a dark-field condenser must be available for dark-fieldexam<strong>in</strong>ation. Dark-field condensers block out the direct light rays, allow<strong>in</strong>gonly the peripheral rays (deflected by objects such as treponemes) to passthrough.Place a few drops of immersion oil on the condenser of a dark-field microscope.Lower the condenser slightly so that the oil is below the level of thestage. Place the slide on the microscope and raise the condenser until there isgood contact between the oil and the underside of the slide. Carefully avoidtrapp<strong>in</strong>g air bubbles <strong>in</strong> the oil.83


SEXUALLY TRANSMITTED DISEASESFig. 9. Appearance of T. pallidum under dark-field microscopy[Negative]Use the low-power objective (¥10) to br<strong>in</strong>g the specimen <strong>in</strong>to focus. Centre thelight <strong>in</strong> the field by adjust<strong>in</strong>g the centr<strong>in</strong>g screws located on the condenser, andfocus the condenser by rais<strong>in</strong>g or lower<strong>in</strong>g it until the smallest diameter of lightis obta<strong>in</strong>ed. Recentre the light if necessary. Then use the dry ¥40 objective tobr<strong>in</strong>g the specimen <strong>in</strong>to focus, and exam<strong>in</strong>e the slide carefully. The contrast willbe better when the microscopy is done <strong>in</strong> the dark. Avoid bright daylight.T. pallidum appears white, illum<strong>in</strong>ated on a dark background (Fig. 9). It is identifiedby its typical morphology, size, and movement. It is a th<strong>in</strong> (0.25–0.3 mm)organism, 6–16 mm long, with 8–14 regular, tightly wound deep spirals. Itexhibits quick and rather abrupt movements. It rotates relatively slowly aboutthe longitud<strong>in</strong>al axis (like a corkscrew). This rotation is accompanied bybend<strong>in</strong>g (twist<strong>in</strong>g) <strong>in</strong> the middle and is executed rather stiffly. Lengthen<strong>in</strong>gand shorten<strong>in</strong>g (like an elastic expander spiral) may be observed. Distortionmay occur <strong>in</strong> tortuous convolutions. When the organism is attached to, orobstructed by, heavier objects, the result<strong>in</strong>g vigorous struggl<strong>in</strong>g distorts thecoils. Other non-syphilis spirochaetes may be loosely coiled, thick, and coarse;the movements are different (not like a corkscrew), but take the form of a morewrith<strong>in</strong>g motion, with marked flexion and frequent relaxation of the coils.The demonstration of treponemes with morphology and motility characteristicof T. pallidum constitutes a positive diagnosis for primary and secondarysyphilis. Patients with a primary chancre, which is dark-field positive, maybe serologically negative. They normally become serologically reactive with<strong>in</strong>a few weeks.Failure to f<strong>in</strong>d the organism does not exclude a diagnosis of syphilis.Negative results may mean that:• An <strong>in</strong>sufficient number of organisms was present (a s<strong>in</strong>gle dark-fieldexam<strong>in</strong>ation has a sensitivity of no more than 50%).• The patient had already taken antimicrobials.84


BACTERIOLOGICAL INVESTIGATIONS• The lesion was approach<strong>in</strong>g natural resolution.• The lesion was not syphilitic.Whatever the result of the dark-field exam<strong>in</strong>ation, a blood sample shouldalways be taken for serological tests.In the diagnosis of granuloma <strong>in</strong>gu<strong>in</strong>ale, when acetone-fixed smears aresta<strong>in</strong>ed with Giemsa, typical, <strong>in</strong>tracellular, encapsulated bacilli can beseen with<strong>in</strong> histiocytes. The diagnosis of this disease is described <strong>in</strong> fullelsewhere. 1For the diagnosis of chancroid, a Gram-sta<strong>in</strong>ed smear is not recommended,s<strong>in</strong>ce the sensitivity and specificity are both less than 50%. For the diagnosisof chlamydial lymphogranuloma, Giemsa-sta<strong>in</strong>ed smears are not recommended.However, material from the ulcer should also be exam<strong>in</strong>ed by darkfieldmicroscopy to search for T. pallidum.CultureGonococci are occasionally isolated from genital ulcers, but their significance<strong>in</strong> such specimens is unclear. Apart from H. ducreyi, no other bacterialspecies—neither facultative aerobes nor obligate anaerobes—have beenshown to cause genital ulcer disease.Specimens to be exam<strong>in</strong>ed for H. ducreyi should be <strong>in</strong>oculated directly on toa selective, enriched agar plate. 2 The medium used should not be older thanone week. The plates should be <strong>in</strong>cubated at 33–35∞C <strong>in</strong> a candle jar with amoistened towel at the bottom. After 48–72 hours of <strong>in</strong>cubation, small, nonmucoid,yellow-grey, semi-opaque or translucent colonies appear that can bepushed <strong>in</strong>tact across the agar surface. The sensitivity of a s<strong>in</strong>gle culture forthe isolation of H. ducreyi is 70–80%.A presumptive diagnosis of H. ducreyi can be made on the basis of the characteristicmorphology of colonies on selective media, and the demonstrationof small Gram-negative, pleomorphic coccobacilli, often <strong>in</strong> s<strong>in</strong>gle cha<strong>in</strong>s(streptobacilli), parallel cha<strong>in</strong>s (“school of fish”), or clumps <strong>in</strong> the suspectcolonies. Although H. ducreyi is haem<strong>in</strong>-dependent, most cl<strong>in</strong>ical isolatesfail to grow on the media used for the determ<strong>in</strong>ation of X and V factorrequirement. Nearly all recent isolates from develop<strong>in</strong>g countries produceb-lactamase.1Van Dyck E, Meheus AZ, Piot P. <strong>Lab</strong>oratory diagnosis of sexually transmitted diseases. Geneva,World Health Organization, 1999.2Mueller–H<strong>in</strong>ton agar base, supplemented with 5% sterile horse blood heated to 75∞C, 1%IsoVitaleX, and 3g/ml vancomyc<strong>in</strong>.85


Purulent exudates, wounds,and abscessesIntroductionOne of the most commonly observed <strong>in</strong>fectious disease processes is theproduction of a purulent (sometimes seropurulent) exudate as the result ofbacterial <strong>in</strong>vasion of a cavity, tissue, or organ of the body. Such <strong>in</strong>fectionsmay be relatively simple, <strong>in</strong>nocuous “pimples” or a series of multiple pocketsof pus found <strong>in</strong> abscesses <strong>in</strong> one or more anatomical sites. The exudateconsists of white blood cells, predom<strong>in</strong>antly polymorphonuclear leukocytes,the <strong>in</strong>vad<strong>in</strong>g organisms, and a mixture of body fluid and fibr<strong>in</strong>. In some<strong>in</strong>stances, the exudate may be found as a coat<strong>in</strong>g on the surface of an organ,e.g. the surface of the bra<strong>in</strong> <strong>in</strong> acute bacterial men<strong>in</strong>gitis. In other cases, theexudate may be walled off by layers of fibr<strong>in</strong> and a network of tissue cells,e.g. a carbuncle or subcutaneous “boil”, while <strong>in</strong> still other cases the exudatemay be associated with an open wound, which therefore dra<strong>in</strong>s thick fluid orpus.Just as the anatomical site of exudate production can vary considerably, sotoo can the organisms <strong>in</strong>volved <strong>in</strong> the underly<strong>in</strong>g <strong>in</strong>fection. All bacteria thatare part of the normal flora, or that ga<strong>in</strong> access to the body, may be <strong>in</strong>volved<strong>in</strong> the production of an exudate. Some fungi, particularly those that are ableto multiply <strong>in</strong> body tissues, can also be <strong>in</strong>volved <strong>in</strong> the production ofan exudate. In contrast, a purulent exudate is rarely produced <strong>in</strong> a viral<strong>in</strong>fection.The bench microbiologist should be aware of the diversity of anatomicalsites and microorganisms <strong>in</strong>volved, and be prepared to make the appropriatemacroscopic and microscopic exam<strong>in</strong>ations and the proper primarymedia <strong>in</strong>oculations to recover the major organism(s) <strong>in</strong>volved. Oncethe organisms have been isolated <strong>in</strong> pure culture, the identificationprocess and antimicrobial susceptibility tests should be set up as soon aspossible.Communication between the cl<strong>in</strong>ician and the microbiologist is particularlyimportant <strong>in</strong> the diagnosis and management of patients with suppurative<strong>in</strong>fectious diseases. The microbiologist must collaborate with the physician toensure proper specimen collection and the expeditious delivery of the specimento the laboratory for prompt and proper process<strong>in</strong>g.Commonly encountered cl<strong>in</strong>ical conditions andthe most frequent etiological agentsSurgical specimensSurgical specimens may be obta<strong>in</strong>ed by aspiration of a localized abscess orother surgical procedures. The surgeon should be advised to obta<strong>in</strong> severalsmall representative tissue samples and any purulent exudate. If possible,cotton swabs should be avoided. The exudate should be collected us<strong>in</strong>g aneedle and syr<strong>in</strong>ge. If cotton swabs must be used, as much exudate as possibleshould be collected and dispensed <strong>in</strong>to appropriate conta<strong>in</strong>ers for dispatchto the laboratory. Upon receipt, the laboratory should review the <strong>in</strong>formation86


BACTERIOLOGICAL INVESTIGATIONSprovided and then plan cultures for the organisms likely to be found <strong>in</strong> theparticular specimen.A few examples of conditions and organisms found <strong>in</strong> different types ofsurgical specimens are given below:• The peritoneal cavity is likely to conta<strong>in</strong> Gram-negative enteric bacteria(Enterococci), Gram-negative anaerobic rods (Bacteroides fragilis), andclostridia.• A walled-off abscess may conta<strong>in</strong> any type of organism, either s<strong>in</strong>gle ormultiple species: Gram-positive cocci and Gram-negative bacilli are mostfrequently isolated. Anaerobic bacteria and amoebae may also need to beconsidered, depend<strong>in</strong>g on the abscess site.• Lymph nodes are frequently <strong>in</strong>volved <strong>in</strong> systemic <strong>in</strong>fections. They becomeswollen and often quite tender, and purulent exudate frequently accumulates.If the node is fluctuant, the liquid contents can be aspirated by aphysician. Lymph node biopsies or aspirates from children should be culturedfor Mycobacterium tuberculosis and other mycobacteria. In addition tobe<strong>in</strong>g cultured for staphylococci, streptococci, and Gram-negative entericbacteria, lymph nodes may be good specimens for the diagnosis of systemicand subcutaneous mycoses (histoplasmosis, sporotrichosis).• Sk<strong>in</strong> and subcutaneous tissue are prime targets for both abscesses andwound <strong>in</strong>fections. As a general rule, subcutaneous abscesses are caused bystaphylococci. Open, weep<strong>in</strong>g sk<strong>in</strong> lesions often <strong>in</strong>volve b-haemolyticstreptococci and/or staphylococci, as <strong>in</strong> impetigo. Another variety of sk<strong>in</strong>lesion requir<strong>in</strong>g some surgical <strong>in</strong>tervention, and often seen as a hospitalacquired<strong>in</strong>fection, is decubitus ulcer or bed sore. The bacteria are frequentlysk<strong>in</strong> commensals or <strong>in</strong>test<strong>in</strong>al flora that have proliferated <strong>in</strong> themost external part of the ulcer and create an unpleasant odour and appearance.Rout<strong>in</strong>e culture of those organisms is not cl<strong>in</strong>ically relevant. Theorganisms most commonly isolated from biopsy tissue are enteric bacilli;the same organisms may be found <strong>in</strong> cultures of the superficial exudate. Itis not always possible to evaluate the role of these organisms <strong>in</strong> decubitusulcers, but heal<strong>in</strong>g requires that the ulcer be kept clean, dry, and free ofbacteria. Occasionally organisms <strong>in</strong> a decubitus ulcer may f<strong>in</strong>d their way<strong>in</strong>to the blood stream, produc<strong>in</strong>g serious complications.• Burns, especially second- and third-degree burns, are prone to <strong>in</strong>fectionwith a variety of bacterial species. It is very important that carefulsurgical débridement be carried out prior to obta<strong>in</strong><strong>in</strong>g material forculture. Staphylococci and Pseudomonas aerug<strong>in</strong>osa are most commonlyencountered.• Exudates. Sometimes a serous or purulent fluid will collect <strong>in</strong> a cavity thatnormally possesses a very small amount of sterile fluid, e.g. the pericardialsac, pleural cavity, bursa, or jo<strong>in</strong>t. Needle aspiration under aseptic conditionswill yield a laboratory specimen from which the <strong>in</strong>fect<strong>in</strong>g organismmay be isolated and identified. Bacteria are usually the cause, but fungi orviruses may also be responsible. The <strong>in</strong>fections are usually monospecific,but mixed aerobic and anaerobic <strong>in</strong>fections do occur. Aspirates from thepleural cavity may yield pneumococci, streptococci, H. <strong>in</strong>fluenzae, anaerobicstreptococci, or anaerobic Gram-negative rods (Prevotella and Porphyromonas)or M. tuberculosis.Penetrat<strong>in</strong>g woundsAny lesion caused by a penetrat<strong>in</strong>g object that breaks the sk<strong>in</strong> is likely toconta<strong>in</strong> a mixture of microorganisms; these organisms are generally part ofthe sk<strong>in</strong> flora or of the normal microbial flora of soil and water. A penetrat<strong>in</strong>g87


PURULENT EXUDATES, WOUNDS, AND ABSCESSESwound <strong>in</strong>volv<strong>in</strong>g damage to the <strong>in</strong>test<strong>in</strong>es will lead to an even greater threatbecause the <strong>in</strong>test<strong>in</strong>al flora may contribute to <strong>in</strong>fection of the wound andperitoneal cavity.Penetrat<strong>in</strong>g or cutt<strong>in</strong>g wounds may be caused by sharp or blunt objects.Metal, glass, wood, etc. are frequently responsible for penetrat<strong>in</strong>g wounds,whether caused by accident or deliberately (e.g. stab or gunshot wounds).Tetanus result<strong>in</strong>g from a penetrat<strong>in</strong>g wound is a life-threaten<strong>in</strong>g disease <strong>in</strong>a non-immunized <strong>in</strong>dividual. Similarly, wound botulism may go undiagnosedif the physician and the microbiologist are not aware of this possibility.The diagnoses of tetanus and botulism are best made cl<strong>in</strong>ically, andlaboratory support should be provided by a central reference laboratory.People work<strong>in</strong>g with animals or their products are at risk of <strong>in</strong>fectionwith spores of Bacillus anthracis, which may ga<strong>in</strong> access through small woundsor sk<strong>in</strong> abrasions and produce the typical black eschar of anthrax. Othersoil organisms, such as Clostridium perfr<strong>in</strong>gens, may be <strong>in</strong>volved <strong>in</strong> deeppenetrat<strong>in</strong>g wounds and give rise to gas gangrene.Animal bites or scratches occur frequently <strong>in</strong> both urban and rural areas.The bite may be from a domestic pet, a farm animal, or a wild animal. Rabiesmust be the prime and immediate concern. Once the possibility of rabies hasbeen elim<strong>in</strong>ated, the other possible etiological agents are many and varied.Rabies diagnosis is too specialized to be discussed <strong>in</strong> this manual. 1The mouths of all animals conta<strong>in</strong> a heterogeneous flora consist<strong>in</strong>g ofaerobic and anaerobic bacteria, yeasts, protozoa, and viruses. Infections result<strong>in</strong>gfrom bites or scratches are predom<strong>in</strong>antly caused by bacteria. A primeexample is <strong>in</strong>fection by Pasteurella multocida, which often follows a dog or catbite if the bite has not been properly cleansed and treated. Human bitesmay sometimes result <strong>in</strong> a serious mixed <strong>in</strong>fection of aerobic and anaerobicbacteria.Nosocomial wound <strong>in</strong>fectionsOne of the ma<strong>in</strong> concerns <strong>in</strong> the care and treatment of hospitalized patientsis that they should not be harmed <strong>in</strong> the course of the diagnosis and treatmentof their illness. Unfortunately, 5–10% of hospitalized patients do acquirean <strong>in</strong>fection while <strong>in</strong> hospital. Nosocomial <strong>in</strong>fections are costly and canusually be avoided or greatly reduced. Many hospital-acquired <strong>in</strong>fectionsare known to occur <strong>in</strong> surgical departments. The rate of postoperative wound<strong>in</strong>fection varies from hospital to hospital, and with<strong>in</strong> a given hospital is likelyto be highest <strong>in</strong> patients who have undergone abdom<strong>in</strong>al, thoracic, ororthopaedic surgery. Surgical wound <strong>in</strong>fections may occur shortly aftersurgery or several days postoperatively. The site of <strong>in</strong>fection may be limitedto the suture l<strong>in</strong>e or may become extensive <strong>in</strong> the operative site. Staphylococcusaureus (usually benzylpenicill<strong>in</strong>-resistant, and now often meticill<strong>in</strong>resistant)is the biggest offender, followed closely by E. coli and other entericbacteria. Anaerobic bacteria from the patient’s large bowel may ga<strong>in</strong> access tothe operative site, mak<strong>in</strong>g a mixed <strong>in</strong>fection a serious and fairly frequentoccurrence <strong>in</strong> hospitals <strong>in</strong> which the postoperative wound care and <strong>in</strong>fectionprevention programmes are weak. Bacteroides fragilis and, occasionally,Clostridium perfr<strong>in</strong>gens may <strong>in</strong>vade the bloodstream, result<strong>in</strong>g <strong>in</strong> a systemicand frequently fatal postoperative <strong>in</strong>fection.1Mesl<strong>in</strong> F-X, Kaplan MM, Koprowski H, eds. <strong>Lab</strong>oratory techniques <strong>in</strong> rabies, 4th ed. Geneva,World Health Organization, 1996.88


BACTERIOLOGICAL INVESTIGATIONSAn <strong>in</strong>frequent but challeng<strong>in</strong>g <strong>in</strong>fection may follow dental or oral surgery,when a s<strong>in</strong>us tract from the <strong>in</strong>side works its way to the sk<strong>in</strong> surface onthe face or neck and the discharge conta<strong>in</strong>s the “sulfur” granules ofact<strong>in</strong>omycosis.Collection and transportation of specimensIt is not possible, here, to describe <strong>in</strong> detail the procedures for specimen collectionfrom each type of wound, abscess, etc. It should be obvious that thisis a task that requires close cooperation between the laboratory and the physician.In many <strong>in</strong>stances, there is only one opportunity to obta<strong>in</strong> a specimen;second specimens are unavailable <strong>in</strong> many cases. Therefore, proper collection,transport, and storage of these specimens are of the greatest importance, andcompromises should be avoided. Once a specimen has been obta<strong>in</strong>ed, packaged,and dispatched to the laboratory, it should be processed as soon aspossible. After the prelim<strong>in</strong>ary exam<strong>in</strong>ations have been completed and thecultures made, the rest of the specimen should be properly labelled, stoppered,and refrigerated, until it is certa<strong>in</strong> that no additional laboratory testsare needed.AbscessOnce an abscess, or multiple abscesses, have been found, the physician orsurgeon and the microbiologist should consult on what is to be done. Thetechnique for collect<strong>in</strong>g pus and pieces of the abscess wall is a surgical procedure.A syr<strong>in</strong>ge and needle are used to aspirate as much as possible of thepurulent material, which is then aseptically transferred to sterile specimenconta<strong>in</strong>ers. If such conta<strong>in</strong>ers are not available, the specimen should be kept<strong>in</strong> the syr<strong>in</strong>ge with the needle capped, and the syr<strong>in</strong>ge itself should be transportedto the laboratory. This material should be processed immediately bythe laboratory; both aerobic and anaerobic cultures can be made from a s<strong>in</strong>glespecimen.A similar situation exists when the surgeon encounters one or more walledoffabscesses <strong>in</strong> an organ, or <strong>in</strong> the thorax, abdomen, or pelvis, dur<strong>in</strong>g thecourse of a surgical procedure for another purpose. In anticipation of this,the laboratory should arrange to have stored, <strong>in</strong> the sterile surgical supplies,a kit for obta<strong>in</strong><strong>in</strong>g the contents of such abscesses so that specimens can bedelivered promptly to the laboratory for process<strong>in</strong>g. Every effort should bemade to avoid the use of swabs for collect<strong>in</strong>g a small amount of specimen,when a large amount is actually present. A swab can justifiably be used tocollect very small amounts of pus, or pus from sites that require care, e.g. fromthe eye. When pieces of tissue are obta<strong>in</strong>ed from the abscess wall, the laboratorytechnician should either gr<strong>in</strong>d the tissue, us<strong>in</strong>g a small amount of sterilebroth as a diluent, or m<strong>in</strong>ce the tissue <strong>in</strong>to very small pieces us<strong>in</strong>g sterilescissors. Aerobic and anaerobic cultures should be prepared as <strong>in</strong>dicated onpages 92–93.Infected lacerations, penetrat<strong>in</strong>g wounds,postoperative wounds, burns, and decubitus ulcersNo standard procedure for specimen collection can be formulated. However,certa<strong>in</strong> fundamental guidel<strong>in</strong>es should be followed to obta<strong>in</strong> the bestpossible specimen for laboratory analysis. After carefully clean<strong>in</strong>g the site, thesurgeon should look beneath the surface for collections of pus, devitalized89


PURULENT EXUDATES, WOUNDS, AND ABSCESSEStissue, the ooz<strong>in</strong>g of gas (crepitation), or any other abnormal sign. Segmentsof the tissue <strong>in</strong>volved that are to be used for cultures should be removed andplaced on sterile gauze for process<strong>in</strong>g. Pus or other exudate should be carefullycollected and placed <strong>in</strong> a sterile tube. Swabs may be used if necessary.S<strong>in</strong>us tract or lymph node dra<strong>in</strong>ageWhen a s<strong>in</strong>us tract or lymph node shows evidence of spontaneous dra<strong>in</strong>age,the dra<strong>in</strong>age material should be collected carefully, us<strong>in</strong>g a sterile Pasteurpipette fitted with a rubber bulb, and placed <strong>in</strong> a sterile tube. If discharge isnot evident, the surgeon should obta<strong>in</strong> the purulent material us<strong>in</strong>g a sterilesyr<strong>in</strong>ge and needle or probe. Aga<strong>in</strong>, swabs should only be used if a sterilePasteur pipette is not available.ExudatesThe abnormal accumulation of fluid with<strong>in</strong> a body cavity such as the pleuralspace, a jo<strong>in</strong>t, or the peritoneal space, requires a surgical procedure to aspiratethe accumulated material <strong>in</strong>to a sterile conta<strong>in</strong>er for subsequent deliveryto the laboratory for microbiology and cytology. In those cases where the accumulationpersists and an open dra<strong>in</strong> is put <strong>in</strong> place, it is necessary to collectthe dra<strong>in</strong>age fluid <strong>in</strong> an aseptic manner for subsequent culture and other tests.Macroscopic evaluationSpecimens of pus or wound discharge collected on swabs are difficult to evaluatemacroscopically, particularly when the swab is immersed <strong>in</strong> a transportmedium. Specimens of pus, received <strong>in</strong> a syr<strong>in</strong>ge or <strong>in</strong> a sterile conta<strong>in</strong>er,should be evaluated carefully by an experienced technician for colour, consistency,and odour.ColourThe colour of pus varies from green-yellow to brown-red. A red colour is generallydue to admixture with blood or haemoglob<strong>in</strong>. The aspirate from aprimary amoebic liver abscess has a gelat<strong>in</strong>ous consistency and a dark brownto yellowish brown colour. Pus from postoperative or traumatic wounds(burns) may be sta<strong>in</strong>ed blue-green by the pyocyan<strong>in</strong> pigment produced byPseudomonas aerug<strong>in</strong>osa.ConsistencyThe consistency of pus may vary from a turbid liquid to one that is very thickand sticky. Exudates, aspirated from a jo<strong>in</strong>t, the pleural cavity, the pericardialsac, or the peritoneal cavity, are generally liquid, with all possible gradationsbetween a serous exudate and frank pus.Pus orig<strong>in</strong>at<strong>in</strong>g from a dra<strong>in</strong><strong>in</strong>g s<strong>in</strong>us tract <strong>in</strong> the neck should be <strong>in</strong>spectedfor small yellow “sulfur” granules, which are colonies of the filamentousAct<strong>in</strong>omyces israelii. The presence of sulfur granules suggests a diagnosis ofcervicofacial act<strong>in</strong>omycosis. Small granules of different colours (white, black,red, or brown) are typical of mycetoma, a granulomatous tumour, generally<strong>in</strong>volv<strong>in</strong>g the lower extremities (e.g. madura foot), and characterized by mul-90


BACTERIOLOGICAL INVESTIGATIONStiple abscesses and dra<strong>in</strong><strong>in</strong>g s<strong>in</strong>uses. The coloured granules correspond toeither filamentous bacteria or fungal mycelium.Pus from tuberculous “cold abscesses” (with few signs of <strong>in</strong>flammation)is sometimes compared with soft cheese and called “caseum” or “caseouspus”.OdourA foul feculent odour is one of the most characteristic features of an anaerobicor a mixed aerobic–anaerobic <strong>in</strong>fection, although it may be lack<strong>in</strong>g <strong>in</strong> some<strong>in</strong>stances. The odour, together with the result of the Gram-sta<strong>in</strong>ed smear,should be reported at once to the cl<strong>in</strong>ician as it may be helpful <strong>in</strong> the empiricalselection of an appropriate antimicrobial. It will also help <strong>in</strong> determ<strong>in</strong><strong>in</strong>gwhether anaerobic cultures are needed.Microscopic exam<strong>in</strong>ationA smear for Gram-sta<strong>in</strong><strong>in</strong>g and exam<strong>in</strong>ation should be made for every specimen.In particular cases, or at the request of the cl<strong>in</strong>ician, a direct wet mountmay be prepared and Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g carried out.Gram-sta<strong>in</strong>ed smearUs<strong>in</strong>g a bacteriological loop, make an even smear of the most purulent partof the specimen on a clean slide. If only a swab is available, the slide shouldfirst be sterilized by be<strong>in</strong>g passed through the flame of a Bunsen burner andallowed to cool. The cotton swab should then be gently rolled over the glasssurface, without rubb<strong>in</strong>g or excessive pressure. Allow the slide to air-dry, protectedfrom <strong>in</strong>sects, or place it <strong>in</strong> the <strong>in</strong>cubator. Fix by heat, sta<strong>in</strong> and exam<strong>in</strong>ethe smear under the oil-immersion objective (¥100). Inspect carefully and notethe presence and the quantity (use +signs) of:— polymorphonuclear granulocytes (pus cells);— Gram-positive cocci arranged <strong>in</strong> clusters, suggestive of staphylococci;— Gram-positive cocci <strong>in</strong> cha<strong>in</strong>s, suggestive of streptococci or enterococci;— Gram-negative rods resembl<strong>in</strong>g coliform (Escherichia coli, Klebsiella, etc.),other Enterobacteriaceae (Proteus, Serratia, etc.), nonfermentative rods(Pseudomonas spp.), or obligate anaerobes (Bacteroides spp.);— large straight Gram-positive rods with square ends suggestive of Clostridiumperfr<strong>in</strong>gens, the pr<strong>in</strong>cipal agent of gas gangrene, or Bacillus anthracis,the agent of anthrax;— an extremely heavy and pleomorphic mixture of bacteria, <strong>in</strong>clud<strong>in</strong>g streptococci,Gram-positive and Gram-negative rods of various sizes, <strong>in</strong>clud<strong>in</strong>gfusiform rods; such a picture is suggestive of “mixed anaerobic flora” andshould be reported as such;— Candida or other yeast cells, which are seen as ovoid Gram-positivebudd<strong>in</strong>g spheres, often form<strong>in</strong>g branched pseudomycelia.Sulfur granules from act<strong>in</strong>omycosis or granules from a mycetoma should becrushed on a slide, Gram-sta<strong>in</strong>ed and <strong>in</strong>spected for th<strong>in</strong> branched and fragmentedGram-positive filaments.91


PURULENT EXUDATES, WOUNDS, AND ABSCESSESDirect microscopyWhen requested, or when a fungal or parasitic <strong>in</strong>fection is suspected, a wetpreparation should be exam<strong>in</strong>ed. If the pus is thick, a loopful should be mixed<strong>in</strong> a drop of sal<strong>in</strong>e. When look<strong>in</strong>g for fungi, a drop of 10% potassium hydroxideshould be used to clear the specimen. Apply a coverslip and, us<strong>in</strong>g the¥10 and ¥40 objectives, look especially for:— actively motile amoebae <strong>in</strong> aspirate from a liver abscess;— yeast cells of Histoplasma capsulatum (<strong>in</strong>clud<strong>in</strong>g the African var. duboisii,)Blastomyces dermatitidis (<strong>in</strong> endemic areas), Candida spp.;— fungal hyphae and bacterial filaments <strong>in</strong> crushed granules frommycetoma;— parasites, such as microfilariae, scolices or hooks of Ech<strong>in</strong>ococcus, eggs ofSchistosoma, Fasciola, or Paragonimus.Acid-fast sta<strong>in</strong><strong>in</strong>g (Ziehl–Neelsen)Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g should be performed when requested by the cl<strong>in</strong>ician.It is also advisable to make an acid-fast sta<strong>in</strong>ed preparation when the pusshows no bacteria or when only fa<strong>in</strong>tly sta<strong>in</strong>ed Gram-positive “coryneform”rods are seen on the Gram-sta<strong>in</strong>ed smear. Tubercle bacilli should be suspected,<strong>in</strong> particular, <strong>in</strong> pus or purulent exudate from the pleura, jo<strong>in</strong>ts, boneabscesses, or lymph nodes. Non-tuberculous (so-called “atypical”) acid-fastbacilli are sometimes found <strong>in</strong> gluteal abscesses at the site of deep <strong>in</strong>tramuscular<strong>in</strong>jections. Such abscesses are often caused by rapidly grow<strong>in</strong>g mycobacteriabelong<strong>in</strong>g to the Mycobacterium fortuitum–chelonei group. In the tropics,discharge scraped from the base of a necrotic sk<strong>in</strong> ulcer situated on a leg oran arm may be due to slow-grow<strong>in</strong>g acid-fast rods called M. ulcerans (Buruliulcer). M. mar<strong>in</strong>um is another tuberculous acid-fast rod, which may be found<strong>in</strong> chronic, ulcerative, nodular lesions on the hands, arms, and other exposedsk<strong>in</strong> surfaces <strong>in</strong> swimmers and fishermen.CultureIf bacteria or fungi are seen on microscopic exam<strong>in</strong>ation, appropriate culturemedia should be <strong>in</strong>oculated. Independently from the results of microscopy,all specimens of pus or exudate should preferably be <strong>in</strong>oculated onto am<strong>in</strong>imum of three culture media:— a blood agar plate for the isolation of staphylococci and streptococci;— a MacConkey agar plate for the isolation of Gram-negative rods; and— a tube of broth that can serve as enrichment medium for both aerobes andanaerobes, e.g. thioglycollate broth or cooked meat medium.The size of the <strong>in</strong>oculum should be determ<strong>in</strong>ed accord<strong>in</strong>g to the result of themicroscopic exam<strong>in</strong>ation, and may vary from one loopful to a few drops. Ifmassive numbers of organisms are seen on the Gram-sta<strong>in</strong>ed smear, the specimenmay even have to be diluted <strong>in</strong> a small amount of sterile broth beforeplat<strong>in</strong>g out. If a swab is used for the <strong>in</strong>oculation, it should be applied to asmall area of the plate and the rest of the surface streaked out with a loop. Ifthe swab is dry, it should first be moistened <strong>in</strong> a small quantity of sterile brothor sal<strong>in</strong>e. In all cases, the technique of <strong>in</strong>oculation should provide s<strong>in</strong>glecolonies for identification and susceptibility tests.92


BACTERIOLOGICAL INVESTIGATIONSPrior to <strong>in</strong>oculation, the blood agar plate should be dried for 20 m<strong>in</strong>utes <strong>in</strong>an <strong>in</strong>cubator to m<strong>in</strong>imize the risk of overgrowth by spread<strong>in</strong>g Proteus spp.The <strong>in</strong>oculated plate should be <strong>in</strong>cubated at 35∞C <strong>in</strong> a candle jar. Rout<strong>in</strong>ely,all media should be <strong>in</strong>cubated for two days and <strong>in</strong>spected daily for growth.If culture for fastidious organisms is requested, longer <strong>in</strong>cubation (1–2 weeksor more) will be necessary. If growth appears <strong>in</strong> the broth, it should be Gramsta<strong>in</strong>edand subcultured onto appropriate culture media. Additional culturemedia should be used if specially requested, or if <strong>in</strong>dicated by the results ofthe microscopic exam<strong>in</strong>ation, as <strong>in</strong> the follow<strong>in</strong>g examples:• If staphylococci have been seen, an additional mannitol salt agar is helpful<strong>in</strong> obta<strong>in</strong><strong>in</strong>g pure growth and <strong>in</strong> mak<strong>in</strong>g a prelim<strong>in</strong>ary dist<strong>in</strong>ction betweenS. aureus and other cocci.• If streptococci have been observed, their identification may be hastened byplac<strong>in</strong>g a differential bacitrac<strong>in</strong> disc on the <strong>in</strong>itial streak<strong>in</strong>g area.• If yeasts or fungi have been observed, the specimen should also be <strong>in</strong>oculatedonto two tubes of Sabouraud dextrose agar, one to be <strong>in</strong>cubated at35∞C, the other at room temperature, both to be observed for up to onemonth. (Blood agar is sufficient for the isolation of Candida spp.)• If acid-fast rods have been seen <strong>in</strong> the Ziehl–Neelsen sta<strong>in</strong>ed smear, up to3 tubes of Löwenste<strong>in</strong>–Jensen medium should be <strong>in</strong>oculated. If the specimenalso conta<strong>in</strong>s non-acid-fast bacteria, it should first be decontam<strong>in</strong>ated.Rapidly grow<strong>in</strong>g mycobacteria, such as M. fortuitum, may be killed by thedecontam<strong>in</strong>ation process; they produce growth with<strong>in</strong> 3–7 days on bloodagar and MacConkey agar. Branched, filamentous, partially acid-fast rods<strong>in</strong> pus from the pleura or from a bra<strong>in</strong> abscess will probably be Nocardiaasteroides, which grows on blood agar with<strong>in</strong> a few days.• Pus from patients with arthritis, pleuritis, osteitis, or cellulitis, particularlyfrom children under 5 years of age, should also be <strong>in</strong>oculated onto a chocolateagar plate for the recovery of H. <strong>in</strong>fluenzae.• Culture <strong>in</strong> a strictly anaerobic atmosphere is essential when the Gramsta<strong>in</strong>edsmear shows mixed anaerobic flora and also when the specimenproduces a typical foul odour. Anaerobic blood agar is also necessary forthe growth of Act<strong>in</strong>omyces. Anaerobic culture will be requested by thecl<strong>in</strong>ician when he or she suspects clostridial gas gangrene. Methods foranaerobic bacteriology are described on pages 98–102.IdentificationWith the exception of contam<strong>in</strong>ants from the environment or from the sk<strong>in</strong>(such as Staphylococcus epidermidis), all organisms isolated from wounds, pus,or exudates should be considered significant and efforts made to identifythem. Full identification, however, is not always necessary, particularly <strong>in</strong> thecase of mixed flora.Bacteria and fungi isolated from pus and exudates may belong to almost anygroup or species. Identification criteria are given here only for staphylococcicommonly associated with pus (pyogenic), and for two other pathogens, Pasteurellamultocida and Bacillus anthracis, which are rarely isolated from woundsor sk<strong>in</strong> <strong>in</strong>fections, but are very important for the management of the patient.A standard textbook of cl<strong>in</strong>ical microbiology should be consulted for a fulldescription of identification methods. In every case, the first step should beto exam<strong>in</strong>e well-separated colonies carefully, pick a s<strong>in</strong>gle colony of each type,prepare a Gram-sta<strong>in</strong>ed smear, and then characterize the organisms under themicroscope.93


PURULENT EXUDATES, WOUNDS, AND ABSCESSESStaphylococciStaphylococci are the bacteria most frequently associated with the productionof pus. Staphylococci grow well aerobically on blood agar and form opaquewhite to cream colonies, 1–2mm <strong>in</strong> diameter, after overnight <strong>in</strong>cubation. Theyare unique <strong>in</strong> grow<strong>in</strong>g on media with a high salt content, such as MSA. Theycan be differentiated from streptococci by their morphology and by the productionof catalase. Catalase production by staphylococci is shown by plac<strong>in</strong>git <strong>in</strong> a drop of 3% hydrogen peroxide onto the colonies deposited on a cleanglass slide. The appearance of bubbles of oxygen is an <strong>in</strong>dication of catalaseproduction.For cl<strong>in</strong>ical purposes, staphylococci can be divided <strong>in</strong>to those that producecoagulase and those that do not. The coagulase-produc<strong>in</strong>g staphylococcibelong to the species S. aureus, which is the species of greatest medical <strong>in</strong>terest.Of the several coagulase-negative species, only two will be consideredhere—S. epidermidis and S. saprophyticus.Although S. aureus is part of the commensal microbial flora of the nose (40%of healthy adults are positive), sk<strong>in</strong>, and <strong>in</strong>test<strong>in</strong>al tract, this species causesimpetigo, boils, abscesses, wound <strong>in</strong>fection, <strong>in</strong>fection of ulcers and burns,osteomyelitis, mastitis (breast abscess), pleural empyema, pyomyositis, toxicshock syndrome, and other types of pyogenic <strong>in</strong>fection.S. epidermidis is also a common commensal of the sk<strong>in</strong>, nose, and other mucousmembranes and possesses a very low pathogenicity. However, its presence <strong>in</strong>pus should not always be dismissed as sk<strong>in</strong> contam<strong>in</strong>ation. Despite its low<strong>in</strong>fectivity, S. epidermidis can cause sk<strong>in</strong> <strong>in</strong>fections at the site of an <strong>in</strong>-dwell<strong>in</strong>gcatheter, cannula, or other device. Infections with S. epidermidis are particularlytroublesome <strong>in</strong> cardiac and orthopaedic surgery <strong>in</strong>volv<strong>in</strong>g the <strong>in</strong>sertionof prosthetic devices (artificial heart valves or artificial hips).S. saprophyticus is recognized to be a common cause of ur<strong>in</strong>ary tract <strong>in</strong>fections<strong>in</strong> young women, be<strong>in</strong>g second only to E. coli <strong>in</strong> some populations.The dist<strong>in</strong>ctive features of the three ma<strong>in</strong> species of Staphylococcus are given<strong>in</strong> Table 22. A flow diagram for the prelim<strong>in</strong>ary identification of staphylococciis shown <strong>in</strong> Fig. 10.In view of the importance of the coagulase test <strong>in</strong> the identification of S. aureus,this test is described here <strong>in</strong> detail. Coagulase is an enzyme that causes plasmato clot. Staphylococcal coagulase exists <strong>in</strong> two forms: bound coagulase orTable 22. Differentiation of medically important species of StaphylococcusS. aureus S. epidermidis S. saprophyticusProduction of coagulase yes no noAcidification of mannitol on mannitol salt agar a acid (yellow) neutral (red) acid (yellow)Pigment of colonies a grey, cream white whiteor yellowIn vitro susceptibility to novobioc<strong>in</strong> susceptible susceptible resistant bDNase agar yes no noa Exceptions are possible.b Inhibition zone of less than 16 mm, us<strong>in</strong>g a 5-mg disc <strong>in</strong> the standardized disc-diffusion method.94


BACTERIOLOGICAL INVESTIGATIONSFig. 10. Flow diagram for the prelim<strong>in</strong>ary identification of humanStaphylococcus speciesclump<strong>in</strong>g factor, which is demonstrated <strong>in</strong> the slide test, and free coagulase,which is demonstrated <strong>in</strong> the tube test.• Slide test. On a clean slide, emulsify one or a few similar colonies ofstaphylococci <strong>in</strong> a drop of sal<strong>in</strong>e. The suspension must be fairly thick. Dipa straight wire <strong>in</strong>to plasma and use this to stir the bacterial suspension.Observe for clump<strong>in</strong>g with<strong>in</strong> 10 seconds. False-negative slide tests occurapproximately 10% of the stra<strong>in</strong>s of S. aureus. If the slide test is negativefor an isolate that seems to be pathogenic on other grounds (pigment, cl<strong>in</strong>icalsource), it should be re-exam<strong>in</strong>ed <strong>in</strong> the tube test.• Tube test. Dispense a few drops (0.5ml) of plasma <strong>in</strong>to a sterile 12 ¥75 mm tube, and add two drops of the pure culture <strong>in</strong> broth. A suspensionwith an equivalent density may also be prepared directly fromgrowth on blood agar. Incubate the tube at 35 ∞C for 4–18 hours and thenexam<strong>in</strong>e for clott<strong>in</strong>g.The plasma used <strong>in</strong> the coagulase test may be fresh human or rabbit plasmaobta<strong>in</strong>ed with ethylenediam<strong>in</strong>e tetraacetic acid (EDTA). It should be stored <strong>in</strong>95


PURULENT EXUDATES, WOUNDS, AND ABSCESSESthe refrigerator <strong>in</strong> small amounts (1ml), and its performance checked withcultures of S. aureus and S. epidermidis, run <strong>in</strong> parallel.Pasteurella multocidaA number of Gram-negative bacilli are transmitted by animal bites and cancause severe <strong>in</strong>fections <strong>in</strong> human be<strong>in</strong>gs, the most prevalent be<strong>in</strong>g Pasteurellamultocida. P. multocida is a commensal found <strong>in</strong> the normal mouth flora ofmany animals. A bite wound <strong>in</strong>fected with P. multocida may give rise to extensivecellulitis, which may extend to a jo<strong>in</strong>t, produc<strong>in</strong>g arthritis. Osteomyelitis,bacteraemia, and even men<strong>in</strong>gitis have been described.P. multocida should be looked for specifically <strong>in</strong> wound discharge if an animalbite is known or suspected of be<strong>in</strong>g the cause of the wound. P. multocida is avery small, Gram-negative, nonmotile coccobacillus. It grows well on bloodagar at 35∞C but is completely <strong>in</strong>hibited by the bile salts conta<strong>in</strong>ed <strong>in</strong> theenteric selective media, e.g. MacConkey agar. After overnight <strong>in</strong>cubation, thecolonies on blood agar are small, nonhaemolytic, translucent, and mucoid(due to the presence of a capsule <strong>in</strong> the virulent form).Biochemical identification is based on the follow<strong>in</strong>g characteristics:— fermentation of glucose without gas: P. multocida grows on Kligler ironagar with acidification of the butt;— oxidase test is weakly positive;— catalase-positive;— nitrate reduced to nitrite (0.1% potassium nitrate <strong>in</strong> nutrient broth);— urease-negative;— <strong>in</strong>dole-positive—test <strong>in</strong> tryptic soy broth (TSB) or on MIU after 48 hours<strong>in</strong>cubation;— highly sensitive to benzylpenicill<strong>in</strong> <strong>in</strong> the disc-susceptibility test.Bacillus anthracisThe genus Bacillus is composed of numerous species of aerobic, sporeform<strong>in</strong>g,Gram-positive rods, widely distributed <strong>in</strong> the soil. The species B.anthracis is of public health importance <strong>in</strong> sk<strong>in</strong> <strong>in</strong>fections. The other species,when isolated from wounds or pus, are generally contam<strong>in</strong>ants or, at most,opportunists.B. anthracis is a major pathogen of cattle, sheep, goats, and other domesticanimals. It also affects wild animals. Anthrax can affect human be<strong>in</strong>gs, particularlypeople <strong>in</strong> parts of Africa and Asia work<strong>in</strong>g or liv<strong>in</strong>g <strong>in</strong> close contactwith livestock. Human <strong>in</strong>fection may also derive from animal products conta<strong>in</strong><strong>in</strong>ganthrax spores, such as wool, sk<strong>in</strong>s, fur, and bones.The commonest form of human <strong>in</strong>fection is cutaneous anthrax, which mayprogress to septicaemia and men<strong>in</strong>gitis. The spore enters through damagedsk<strong>in</strong> and produces a vesicular lesion with a necrotic centre, surroundedby extensive oedema (“malignant pustule”). Large Gram-positive, squareended,capsulated rods without spores are seen <strong>in</strong> smears from the vesicularfluid.B. anthracis grows aerobically. On blood agar it produces large, flat, greyishcolonies, up to 5 mm <strong>in</strong> diameter, with a rough surface texture and irregularedges show<strong>in</strong>g hairy outgrowths (Medusa head). It is important at this stage96


BACTERIOLOGICAL INVESTIGATIONSto differentiate the highly pathogenic B. anthracis from the generally harmlesssaprophytic species.The prelim<strong>in</strong>ary dist<strong>in</strong>ction should be based on the absence of haemolysis,benzylpenicill<strong>in</strong> sensitivity, and the lack of motility <strong>in</strong> B. anthracis. In contrast,most of the saprophytic Bacillus species are motile and strongly haemolytic.These three features can form the basis of a presumptive identification. Fordef<strong>in</strong>itive diagnosis, a pure culture of the isolate should be sent immediatelyto the central veter<strong>in</strong>ary or public health laboratory.B. anthracis is a highly <strong>in</strong>fectious organism and specimens and cultures shouldbe handled with the greatest care to avoid contam<strong>in</strong>ation of the environmentand <strong>in</strong>fection of laboratory personnel.Susceptibility test<strong>in</strong>gAntimicrobials may not always be needed for the management of patientswith wounds, abscesses, or exudates. Proper surgical <strong>in</strong>cision, dra<strong>in</strong>age anddébridement are generally more important than antimicrobial drugs. Theresults of susceptibility tests should be made available, however, with<strong>in</strong> 48hours after receiv<strong>in</strong>g the specimen.Rout<strong>in</strong>e susceptibility tests should not be performed on bacteria that have aknown sensitivity pattern, such as streptococci, Pasteurella, and Act<strong>in</strong>omyces,which are almost without exception susceptible to benzylpenicill<strong>in</strong>s.For Enterobacteriaceae, non-fermentative Gram-negative rods, and staphylococci,the standardized disc-diffusion test (Kirby–Bauer) should be used. Onlyantimicrobials currently be<strong>in</strong>g used by the request<strong>in</strong>g physicians should betested. New and expensive antimicrobials should only be tested (or reported)on special request, or when the isolate is resistant to other drugs.Problems are often encountered when test<strong>in</strong>g the susceptibility of staphylococci,both S. aureus and S. epidermidis. Over 80% of isolates, even from thecommunity, produce b-lactamase and are resistant to benzylpenicill<strong>in</strong> andampicill<strong>in</strong>. Infections caused by benzylpenicill<strong>in</strong>-resistant staphylococci areoften treated with b-lactamase-resistant penicill<strong>in</strong>s of the meticill<strong>in</strong>-group(oxacill<strong>in</strong>, cloxacill<strong>in</strong>, etc.). The oxacill<strong>in</strong> disc (1mg) is currently recommendedfor test<strong>in</strong>g the susceptibility to this group. Oxacill<strong>in</strong> discs are stable, and aptto detect resistance to the whole group. This resistance is often of theheteroresistant type, i.e. it <strong>in</strong>volves only a part of the bacterial population. Asheteroresistance of staphylococci is easier to recognize at low temperatures,the <strong>in</strong>cubator temperature should not exceed 35∞C. A heteroresistant stra<strong>in</strong>shows, with<strong>in</strong> an otherwise def<strong>in</strong>ite zone of <strong>in</strong>hibition, a film of hazy growthor numerous small colonies that are often dismissed as contam<strong>in</strong>ants. If suchgrowth appears, a Gram-sta<strong>in</strong>ed smear is <strong>in</strong>dicated to exclude contam<strong>in</strong>ation.Heteroresistant stra<strong>in</strong>s are cl<strong>in</strong>ically resistant to all the b-lactam antimicrobials<strong>in</strong>clud<strong>in</strong>g cefalospor<strong>in</strong>s, carbapenems, and the meticill<strong>in</strong> group. For thisreason staphylococci need not be tested for susceptibility to cefalospor<strong>in</strong>s.There is complete cross-resistance between benzylpenicill<strong>in</strong> and ampicill<strong>in</strong>.Staphylococcal susceptibility to ampicill<strong>in</strong> should therefore not be testedseparately.97


Anaerobic bacteriologyIntroductionThis manual frequently refers to anaerobic bacterial <strong>in</strong>fections and anaerobicbacteria. The former may occur <strong>in</strong> virtually any body tissue and at any bodysite provided that the prevail<strong>in</strong>g conditions are suitable.The majority of anaerobic bacterial diseases are caused by endogenous bacteriathat are part of the normal body flora and that are perfectly compatiblewith health until someth<strong>in</strong>g happens to disturb the balance of the normalflora, or to allow the passage of bacteria from one anatomical site to another.Exogenous anaerobic bacteria, primarily Clostridium tetani, C. botul<strong>in</strong>um,and occasionally C. perfr<strong>in</strong>gens and other clostridial species, can ga<strong>in</strong> accessthrough wounds, caus<strong>in</strong>g tetanus, wound botulism, or gas gangrene.Abscesses of practically any organ, bacteraemia, peritonitis, thoracicempyema, cellulitis, and appendicitis are just a few conditions <strong>in</strong> whichanaerobic bacteria may play a very significant role <strong>in</strong> the disease process. It istherefore important that the microbiologist knows when and how to culturefor anaerobic bacteria <strong>in</strong> a given cl<strong>in</strong>ical specimen.Description of bacteria <strong>in</strong> relation to oxygenrequirementA perhaps over-simplistic, but operationally acceptable, description of medicallyimportant bacteria <strong>in</strong> relation to their oxygen requirements is asfollows:• Obligate aerobic bacteria require gaseous oxygen to complete their energyproduc<strong>in</strong>gcycle; these organisms cannot grow without a source of oxygen.Examples of obligate aerobic bacteria are Micrococcus spp. and Nocardiaasteroides.• Obligate anaerobic bacteria do not require oxygen for metabolic activity, and<strong>in</strong> fact oxygen is toxic to many of them. Energy is derived from fermentationreactions, which may produce foul-smell<strong>in</strong>g end-products. Examplesof such anaerobic bacteria are Bacteroides fragilis and Peptostreptococcusmagnus.• Facultative anaerobic bacteria are those for which there is no absolute requirementfor oxygen for growth or energy production; they can either utilizeoxygen or grow by anaerobic mechanisms. Such bacteria are most versatile,and are usually able to adapt to their environment, creat<strong>in</strong>g energy forgrowth and multiplication by the most effective mechanism. E. coli and S.aureus are examples of facultative anaerobic organisms.There are, <strong>in</strong> addition to the above, microaerophilic bacteria that grow bestat reduced oxygen tensions. Campylobacter jejuni is an example of a microaerophilicbacterium.<strong>Bacteriology</strong>Four major groups of anaerobic bacteria account for approximately 80% ofthe diagnosed anaerobic <strong>in</strong>fections. These are Bacteroides, Prevotella andPorphyromonas spp., Peptostreptococcus spp., and Clostridium spp. The most98


BACTERIOLOGICAL INVESTIGATIONSfrequently encountered species <strong>in</strong> each genus are: Bacteroides fragilis, Peptostreptococcusmagnus, and Clostridium perfr<strong>in</strong>gens. Specific methods for theisolation and identification of these three genera and species should also serveas a model for isolat<strong>in</strong>g and <strong>in</strong>itiat<strong>in</strong>g the identification process of other cl<strong>in</strong>icallyimportant anaerobic bacteria.Specimen collection and transport to the laboratoryThis has been covered throughly <strong>in</strong> previous sections. Swabs are to be avoidedfor the collection of specimens, as anaerobes are very sensitive to air anddry<strong>in</strong>g. Specimens for the culture of anaerobes should be taken carefully fromthe active site of <strong>in</strong>fection. The services of a surgeon may be required for thecollection of some specimens. This is particularly true of needle aspiration ofpus, obta<strong>in</strong><strong>in</strong>g tissue and/or pus specimens from <strong>in</strong>fected wounds, empyema,or dra<strong>in</strong><strong>in</strong>g abscesses.The specimen should be placed <strong>in</strong> a sterile, tightly closed conta<strong>in</strong>er, or if oneof these is not available, the entire aspirated specimen should be transportedimmediately to the laboratory <strong>in</strong> the syr<strong>in</strong>ge, with the needle capped or protectedby a rubber stopper.Establish<strong>in</strong>g an anaerobic environment for<strong>in</strong>cubat<strong>in</strong>g culturesA variety of methods exist for creat<strong>in</strong>g an anaerobic environment. One that issimple and <strong>in</strong>expensive is the use of an anaerobic jar made of thick glass orpolycarbonate, with a capacity of 2.5–3.5 litres, that is equipped with a securegas-proof lid which can be easily removed and replaced. After putt<strong>in</strong>g the<strong>in</strong>oculated Petri dishes <strong>in</strong>to the jar, an anaerobic atmosphere is generated by<strong>in</strong>troduc<strong>in</strong>g a commercially available disposable anaerobiosis-generat<strong>in</strong>gdevice, and clos<strong>in</strong>g the lid. Disposable devices for generat<strong>in</strong>g anaerobiosistake the form of flat, sealed, foil envelopes that release hydrogen and carbondioxide after addition of water. These devices, however, require a palladiumcatalyst fixed on the underside of the lid of the jar. The catalyst becomes <strong>in</strong>activateddur<strong>in</strong>g use and should be regenerated or replaced at regular <strong>in</strong>tervals,as recommended by the manufacturer. Disposable redox-<strong>in</strong>dicator strips,which change from blue (or red) to colorless <strong>in</strong> an anaerobic atmosphere, areavailable from a number of manufacturers.Tubes of broth cultures for anaerobes, such as thioglycollate broth or cookedmeat broth, need not be <strong>in</strong>cubated under anaerobic conditions, because theirformulations conta<strong>in</strong> reduc<strong>in</strong>g substances that will create an anaerobic environment.When the volume of broth is sufficient (10–12 ml per 15-mm diameterstandard screw-top tube) and the medium freshly prepared, anaerobicconditions are produced <strong>in</strong> the lower part of the tube. If not used on the dayof preparation, the tubes should be regenerated with the screw-top loosenedfor about 15 m<strong>in</strong>utes <strong>in</strong> a boil<strong>in</strong>g water-bath to remove dissolved oxygen, thescrew-top tightened, and the medium allowed to cool before <strong>in</strong>oculation.Anaerobic culture mediaAnaerobic cultures should be performed only when requested by thecl<strong>in</strong>ician, when the specimen has a foul smell, or when the result of theGram-sta<strong>in</strong>ed smear <strong>in</strong>dicates the possibility of an anaerobic <strong>in</strong>fection, e.g.99


ANAEROBIC BACTERIOLOGYthe presence of a mixed pleomorphic flora of Gram-positive and Gramnegativerods and cocci, the presence of Gram-negative fusiform rods, or thepresence of square-ended thick Gram-positive rods that may be Clostridium.Rout<strong>in</strong>e anaerobic cultures should not be done on ur<strong>in</strong>e, genital secretions,faeces, or expectorated sputum; the presence of anaerobic bacteria <strong>in</strong> thesespecimens is <strong>in</strong>dicative of contam<strong>in</strong>ation with the normal commensal flora ofthe respective specimen site. Cl<strong>in</strong>icians should be <strong>in</strong>formed that specimensconta<strong>in</strong><strong>in</strong>g normal flora are not acceptable for anaerobic cultures unless thereis strong justification.Ord<strong>in</strong>ary blood agar is a good plat<strong>in</strong>g medium for isolation of the most importantanaerobic pathogens. For isolation of the more fastidious species, a bloodagar base enriched with growth factors (haem<strong>in</strong> and menadione) is recommended.Such a base is commercially available as Wilk<strong>in</strong>s–Chalgren anaerobeagar.Anaerobic bacteria are often part of a complex microflora, also <strong>in</strong>volv<strong>in</strong>gaerobic organisms, and anaerobic blood agar may be made selective by theaddition of one or more specific antimicrobials. For example, the addition ofan am<strong>in</strong>oglycoside (neomyc<strong>in</strong>, kanamyc<strong>in</strong>) <strong>in</strong> a f<strong>in</strong>al concentration of 50mg/ml <strong>in</strong>hibits the majority of aerobic and facultative bacteria. A solution of theam<strong>in</strong>oglycoside is prepared by dissolv<strong>in</strong>g 500mg <strong>in</strong> 100ml of distilled water.Melt 100ml of anaerobic agar base and when it has cooled to 56 ∞C, add aseptically5ml of defibr<strong>in</strong>ated blood and 1ml of the antibiotic solution. Mix well,and aseptically pour about 15–18 ml <strong>in</strong>to sterile Petri plates. These platesshould be used as soon as possible, or kept <strong>in</strong> a refrigerator, preferably <strong>in</strong> aplastic bag or sleeve.Inoculation and isolation proceduresSpecimens from suspected anaerobic <strong>in</strong>fections should be <strong>in</strong>oculated withoutdelay onto the follow<strong>in</strong>g media:— an anaerobic blood agar to be <strong>in</strong>cubated <strong>in</strong> an anaerobic jar;— an aerobic blood agar to be <strong>in</strong>cubated <strong>in</strong> a candle jar;— a plate of MacConkey agar;— a tube of anaerobic broth (thioglycollate or cooked meat).The aerobic cultures should be <strong>in</strong>oculated and processed as usual and exam<strong>in</strong>edafter 24 and 48 hours for aerobic and facultative organisms. A small areaof the anaerobic blood agar plate should be <strong>in</strong>oculated and the <strong>in</strong>oculumstreaked out with a loop. The plates should be <strong>in</strong>cubated and the anaerobicjar opened after 48 hours for <strong>in</strong>spection. If growth is <strong>in</strong>sufficient, the platesmay be re<strong>in</strong>cubated for a further 24 or 48 hours. The broth culture should beheavily <strong>in</strong>oculated with a Pasteur pipette so as to distribute the <strong>in</strong>oculumthroughout the medium <strong>in</strong> the tube.After 48 hours, the growth on the anaerobic blood agar should be <strong>in</strong>spectedand compared with the growth on the aerobic plat<strong>in</strong>g media. Each colonytype should be exam<strong>in</strong>ed with Gram sta<strong>in</strong>. Bacteria with the same microscopicappearance that grow on aerobic and anaerobic agar are considered to befacultative anaerobes. Colonies that appear only on anaerobic agar are probableanaerobes and should be subcultured on two blood agar plates, one tobe <strong>in</strong>cubated anaerobically and one <strong>in</strong> a candle jar. If growth appears only<strong>in</strong> anaerobiosis, identification of a pure culture of the anaerobe should beattempted.100


BACTERIOLOGICAL INVESTIGATIONSIf growth is observed <strong>in</strong> the depths of anaerobic broth, it should be subculturedto aerobic and anaerobic blood agar and exam<strong>in</strong>ed <strong>in</strong> the sameway as the primary culture plates. As the liquid culture is <strong>in</strong>oculated witha larger volume of pus, it may be positive when the primary plates rema<strong>in</strong>sterile.Identification of medically important anaerobesBacteroides fragilis groupThis group <strong>in</strong>cludes several related species that belong to the normal flora ofthe <strong>in</strong>test<strong>in</strong>e and the vag<strong>in</strong>a. They are frequently <strong>in</strong>volved <strong>in</strong> abdom<strong>in</strong>al andpelvic mixed <strong>in</strong>fections and may also cause bacteraemia. B. fragilis is a nonmotileGram-negative rod, often show<strong>in</strong>g some pleomorphism, grow<strong>in</strong>grapidly on anaerobic blood agar. After 48 hours, the colonies are of moderatesize (up to 3 mm <strong>in</strong> diameter), translucent, grey-white, and non-haemolytic.Rapid identification is possible with the bile stimulation test. A pure cultureof the suspected organism is <strong>in</strong>oculated <strong>in</strong> the depth of two tubes of thioglycollatebroth, with one of the tubes conta<strong>in</strong><strong>in</strong>g 20% (2 ml <strong>in</strong> 10 ml) sterile (autoclaved)ox bile. After 24 hours of <strong>in</strong>cubation, the growth <strong>in</strong> the two tubesshould be compared: the growth of B. fragilis is clearly stimulated <strong>in</strong> the brothsupplemented with bile.Clostridium perfr<strong>in</strong>gensThe genus Clostridium conta<strong>in</strong>s many species of sporulat<strong>in</strong>g Gram-positiverods, some of which belong to the normal gut flora while others are found<strong>in</strong> dust and soil. The cl<strong>in</strong>ically most significant species is C. perfr<strong>in</strong>gens. Itis commonly associated with gas gangrene and may also cause bacteraemiaand other deep <strong>in</strong>fections. Unlike most other species of Clostridium, it isnon-motile and does not form spores <strong>in</strong> the <strong>in</strong>fected tissues or <strong>in</strong> youngcultures.C. perfr<strong>in</strong>gens grows rapidly <strong>in</strong> anaerobic broth with the production of abundantgas. On anaerobic blood agar, colonies of moderate size (2–3 mm) areseen after 48 hours. Most stra<strong>in</strong>s produce a double zone of haemolysis:an <strong>in</strong>ner zone of complete clear haemolysis, and an outer zone of partialhaemolysis.Rapid identification is possible with the reverse CAMP test, 1 which is performedas follows (see Fig. 11): 21. Prepare a blood agar plate with 5% thrice-washed sheep blood.2. Streak a pure culture of Streptococcus agalactiae along the diameter of theplate. Streak the suspected Clostridium culture <strong>in</strong> a l<strong>in</strong>e perpendicular to,but not touch<strong>in</strong>g, the S. agalactiae.3. Incubate <strong>in</strong> an anaerobic jar for 24 hours.C. perfr<strong>in</strong>gens forms an arrowhead-shaped area of enhanced haemolysis atthe junction of the two streaks. Reverse-CAMP-negative clostridia may bereported as “Clostridium spp. not C. perfr<strong>in</strong>gens”.1Reverse CAMP test: named after Christy, Adk<strong>in</strong>s and Munch-Peterson who first described thisreaction <strong>in</strong> group B streptococci.2Hansen MV & Elliot LP. New presumptive identification test for Clostridium perfr<strong>in</strong>gens: reverseCAMP test. Journal of cl<strong>in</strong>ical microbiology, 1980, 12:617–619.101


ANAEROBIC BACTERIOLOGYFig. 11. Reverse CAMP testPeptostreptococcusSeveral species of obligate anaerobic Gram-positive cocci belong to the commensalflora of the respiratory, digestive, and urogenital tracts. They are<strong>in</strong>volved, usually <strong>in</strong> association with other aerobic or anaerobic bacteria, <strong>in</strong>anaerobic abscesses, wound <strong>in</strong>fections, and even bacteraemia. The growth ofanaerobic cocci <strong>in</strong> laboratory media is usually slower than that of Bacteroidesor Clostridium and colonies are usually not apparent on blood agar until after48 hours of <strong>in</strong>cubation.Species identification is not needed <strong>in</strong> rout<strong>in</strong>e bacteriology. Gram-positivecocci that produce small, convex, white colonies on anaerobic blood agar, butdo not grow <strong>in</strong> aerobic conditions, may be presumptively identified as Peptostreptococcusspp.Antimicrobial susceptibility testsAntimicrobial susceptibility tests should not rout<strong>in</strong>ely be performed on anaerobicbacteria, <strong>in</strong> view of the present lack of agreement on a standardized discdiffusiontest.Most anaerobic <strong>in</strong>fections are caused by penicill<strong>in</strong>-sensitive bacteria, with theexception of <strong>in</strong>fections orig<strong>in</strong>at<strong>in</strong>g <strong>in</strong> the <strong>in</strong>test<strong>in</strong>al tract or the vag<strong>in</strong>a. Such<strong>in</strong>fections generally conta<strong>in</strong> Bacteroides fragilis, which produces b-lactamaseand is resistant to penicill<strong>in</strong>s, ampicill<strong>in</strong>s, and most cefalospor<strong>in</strong>s. Such <strong>in</strong>fectionscan be treated with cl<strong>in</strong>damyc<strong>in</strong>, metronidazole, or chloramphenicol.Am<strong>in</strong>oglycosides and qu<strong>in</strong>olones have no activity aga<strong>in</strong>st anaerobes, but theyare often used for the treatment of patients who have mixed <strong>in</strong>fections,because of their effectiveness aga<strong>in</strong>st aerobic bacteria, which are often part ofthe complex flora.102


Antimicrobial susceptibility test<strong>in</strong>gIntroductionAt a meet<strong>in</strong>g organized by WHO <strong>in</strong> Geneva <strong>in</strong> 1977, 1 concern was expressedabout the worldwide <strong>in</strong>crease <strong>in</strong> antimicrobial resistance associated with thegrow<strong>in</strong>g, and frequently <strong>in</strong>discrim<strong>in</strong>ate, use of antimicrobials <strong>in</strong> both humansand animals. In recent years, drug-resistant bacteria have given rise to severalserious outbreaks of <strong>in</strong>fection, with many deaths. This has led to a need fornational and <strong>in</strong>ternational surveillance programmes to monitor antibimicrobialresistance <strong>in</strong> bacteria by susceptibility test<strong>in</strong>g us<strong>in</strong>g reliable methods thatgenerate comparable data. The availability of microbiological and epidemiological<strong>in</strong>formation would help cl<strong>in</strong>icians <strong>in</strong> select<strong>in</strong>g the most appropriateantimicrobial agent for the treatment of a microbial <strong>in</strong>fection.If predictions are to be valid, the susceptibility test must be performed by anaccurate and reproducible method, the results of which should be directlyapplicable to the cl<strong>in</strong>ical situation. The ultimate criterion of the reliability ofany susceptibility test<strong>in</strong>g method is its correlation with the response of thepatient to antimicrobial therapy.The WHO meet<strong>in</strong>g considered that the modified disc-diffusion techniqueof Kirby–Bauer 2 , for which requirements had been established by WHO <strong>in</strong>1976, could be recommended for cl<strong>in</strong>ical and surveillance purposes <strong>in</strong> viewof its technical simplicity and reproducibility. The method is particularly suitablefor use with bacteria belong<strong>in</strong>g to the family Enterobacteriaceae, but itcan also be recommended as a general purpose method for all rapidlygrow<strong>in</strong>g pathogens. It has been adapted to the cl<strong>in</strong>ically most importantfastidious bacteria but not to strict anaerobes and mycobacteria. It is thereforerecommended that the details of this test be made available to laboratoryworkers. 3General pr<strong>in</strong>ciples of antimicrobial susceptibilitytest<strong>in</strong>gAntimicrobial susceptibility tests measure the ability of an antimicrobial agentto <strong>in</strong>hibit bacterial growth <strong>in</strong> vitro. This ability may be estimated by either thedilution method or the diffusion method.The dilution testFor quantitative estimates of antimicrobial activity, dilutions of the antimicrobialmay be <strong>in</strong>corporated <strong>in</strong>to broth or agar medium, which is then <strong>in</strong>oculatedwith the test organism. The lowest concentration that prevents growth1Surveillance for the prevention and control of health hazards due to antibiotic-resistant enterobacteria.Geneva, World Health Organization, 1978 (WHO Technical Report Series, No. 624).2WHO Expert Committee on Biological Standardization. Twenty-eighth report. Geneva, WorldHealth Organization, 1977 (WHO Technical Report Series, No. 610).3.A comparable method, based on similar pr<strong>in</strong>ciples and quality control requirements asthe Kirby–Bauer method, is the NEO-SENSITABS method, produced by ROSCO Diagnostica,Taastrup, Denmark. This method uses 9-mm colour-coded, antimicrobial tablets, <strong>in</strong>stead ofpaper discs. The tablet form results <strong>in</strong> an extraord<strong>in</strong>ary stability with a shelf-life of four years,even at room temperature. This <strong>in</strong>creased stability is very important for laboratories <strong>in</strong> tropicalcountries.103


ANTIMICROBIAL SUSCEPTIBILITY TESTINGafter overnight <strong>in</strong>cubation is known as the m<strong>in</strong>imum <strong>in</strong>hibitory concentration(MIC) of the agent. This MIC value is then compared with known concentrationsof the drug obta<strong>in</strong>able <strong>in</strong> the serum and <strong>in</strong> other body fluids to assessthe likely cl<strong>in</strong>ical response.The diffusion testPaper discs, impregnated with a specified amount of an antimicrobial, areplaced on agar medium uniformly seeded with the test organism. A concentrationgradient of the antimicrobial forms by diffusion from the disc and thegrowth of the test organism is <strong>in</strong>hibited at a distance from the disc that isrelated, among other factors, to the susceptibility of the organism.There is an approximately l<strong>in</strong>ear relation between log MIC, as measured by adilution test, and the <strong>in</strong>hibition zone diameter <strong>in</strong> the diffusion test. A regressionl<strong>in</strong>e express<strong>in</strong>g this relation can be obta<strong>in</strong>ed by test<strong>in</strong>g a large number ofstra<strong>in</strong>s by the two methods <strong>in</strong> parallel (see Fig. 12 and 13).Cl<strong>in</strong>ical def<strong>in</strong>ition of terms “resistant” and“susceptible”—the three-category systemThe result of the susceptibility test, as reported to the cl<strong>in</strong>ician, is the classificationof the microorganism <strong>in</strong> one of two or more categories of susceptibility.The simplest system comprises only two categories: susceptible andresistant. This classification, although offer<strong>in</strong>g many advantages for statisticaland epidemiological purposes, is too <strong>in</strong>flexible for the cl<strong>in</strong>ician to use.Therefore, a three-category classification is often adopted. The Kirby–Bauermethod and its modifications recognize three categories of susceptibility andFig. 12. Graphic representation of the relationship betweenlog 2 MIC and the <strong>in</strong>hibition zone diameter obta<strong>in</strong>ed by thediffusion test us<strong>in</strong>g discs conta<strong>in</strong><strong>in</strong>g a s<strong>in</strong>gle concentration ofantimicrobial104


BACTERIOLOGICAL INVESTIGATIONSFig. 13. Interpretation of zone sizes as susceptible, <strong>in</strong>termediateand resistant by their relationship to the MICit is important that both the cl<strong>in</strong>ician and the laboratory worker understandthe exact def<strong>in</strong>itions and the cl<strong>in</strong>ical significance of these categories.• Susceptible. An organism is called “susceptible” to an antimicrobial whenthe <strong>in</strong>fection caused by it is likely to respond to treatment with this antimicrobial,at the recommended dosage.• Intermediate susceptibility covers two situations. It is applicable to stra<strong>in</strong>sthat are “moderately susceptible” to an antimicrobial that can be used fortreatment at a higher dosage (e.g. b-lactams) because of its low toxicityor because the antimicrobial is concentrated <strong>in</strong> the focus of <strong>in</strong>fection(e.g. ur<strong>in</strong>e).The classification also applies to stra<strong>in</strong>s that show “<strong>in</strong>termediate susceptibility”to a more toxic antimicrobial (e.g. am<strong>in</strong>oglycoside) that cannot beused at a higher dosage. In this situation, the <strong>in</strong>termediate category servesas a buffer zone between susceptible and resistant.As most cl<strong>in</strong>icians are not familiar with the subtle, although cl<strong>in</strong>icallyimportant, dist<strong>in</strong>ction between <strong>in</strong>termediate and moderate susceptibility,many laboratories use the designation “<strong>in</strong>termediate” for report<strong>in</strong>gpurposes.• Resistant. This term implies that the organism is expected not to respondto a given antimicrobial, irrespective of the dosage and of the location ofthe <strong>in</strong>fection.In certa<strong>in</strong> situations, for example test<strong>in</strong>g the response of staphylococci tobenzylpenicill<strong>in</strong>, only the categories “susceptible” and “resistant” (correspond<strong>in</strong>gto the production of b-lactamase) are recognized.The ultimate decision to use a particular antimicrobial, and the dosage to begiven, will depend not only on the results of the susceptibility tests, but alsoon their <strong>in</strong>terpretation by the physician. Other factors, such as pathogenic significanceof the microorganism, side-effects and pharmacok<strong>in</strong>etic propertiesof the drug, its diffusion <strong>in</strong> different body sites, and the immune status of thehost, will also have to be considered.105


ANTIMICROBIAL SUSCEPTIBILITY TESTINGIndications for rout<strong>in</strong>e susceptibility testsA susceptibility test may be performed <strong>in</strong> the cl<strong>in</strong>ical laboratory for two ma<strong>in</strong>purposes:• to guide the cl<strong>in</strong>ician <strong>in</strong> select<strong>in</strong>g the best antimicrobial agent for an<strong>in</strong>dividual patient;• to accumulate epidemiological <strong>in</strong>formation on the resistance of microorganismsof public health importance with<strong>in</strong> the community.Susceptibility tests as a guide for treatmentSusceptibility tests should never be performed on contam<strong>in</strong>ants or commensalsbelong<strong>in</strong>g to the normal flora, or on other organisms that have no causalrelationship to the <strong>in</strong>fectious process. For example, the presence of Escherichiacoli <strong>in</strong> the ur<strong>in</strong>e <strong>in</strong> less than significant numbers is not to be regarded ascaus<strong>in</strong>g <strong>in</strong>fection, and it would be useless and even mislead<strong>in</strong>g to perform anantibiogram.Susceptibility tests should be carried out only on pure cultures of organismsconsidered to be caus<strong>in</strong>g the <strong>in</strong>fectious process. The organisms should also beidentified, as not every microorganism isolated from a patient with an <strong>in</strong>fectionrequires an antibiogram.Rout<strong>in</strong>e susceptibility tests are not <strong>in</strong>dicated <strong>in</strong> the follow<strong>in</strong>g situations:• When the causative organism belongs to a species with predictable susceptibilityto specific drugs. This is the case for Streptococcus pyogenes andNeisseria men<strong>in</strong>gitidis, which are still generally susceptible to benzylpenicill<strong>in</strong>.(However, there have recently been a few reports of sporadic occurrenceof benzylpenicill<strong>in</strong>-resistant men<strong>in</strong>gococci.) It is also the case forfaecal streptococci (enterococci), which, with few exceptions, are susceptibleto ampicill<strong>in</strong>. If resistance of these microorganisms is suspected on cl<strong>in</strong>icalgrounds, representative stra<strong>in</strong>s should be submitted to a competentreference laboratory.• If the causative organism requires enriched media, e.g. Haemophilus <strong>in</strong>fluenzaeand Neisseria gonorrhoeae. Disc-diffusion susceptibility tests may giveunreliable results, if the appropriate technique is not strictly followed. Theemergence of b-lactamase-produc<strong>in</strong>g variants of these species has led tothe <strong>in</strong>troduction of special tests, such as the <strong>in</strong> vitro test for b-lactamaseproduction, described on page 79. It will be the responsibility of the centraland regional laboratories to monitor the susceptibility of pneumococci,gonococci, and Haemophilus. If problems arise with resistant stra<strong>in</strong>s,the peripheral laboratories should be alerted and <strong>in</strong>structions should begiven on appropriate test<strong>in</strong>g methods and on alternative treatmentschemes.• In uncomplicated <strong>in</strong>test<strong>in</strong>al <strong>in</strong>fections caused by salmonellae (other thanS. typhi or S. paratyphi). Antimicrobial treatment of such <strong>in</strong>fections is notjustified, even with drugs show<strong>in</strong>g <strong>in</strong> vitro activity. There is now ampleevidence that antimicrobial treatment of common salmonella gastroenteritis(and <strong>in</strong>deed of most types of diarrhoeal disease of unknown etiology)is of no cl<strong>in</strong>ical benefit to the patient. Paradoxically, antimicrobials mayprolong the excretion and dissem<strong>in</strong>ation of salmonellae and may lead tothe selection of resistant variants.106


BACTERIOLOGICAL INVESTIGATIONSSusceptibility tests as an epidemiological toolRout<strong>in</strong>e susceptibility tests on major pathogens (S. typhi, shigellae) are usefulas part of a comprehensive programme of surveillance of enteric <strong>in</strong>fections.They are essential for <strong>in</strong>form<strong>in</strong>g the physician of the emergence of resistantstra<strong>in</strong>s (chloramphenicol-resistant S. typhi, co-trimoxazole-resistant andampicill<strong>in</strong>-resistant shigellae) and of the need to modify standard treatmentschemes. Although susceptibility test<strong>in</strong>g of non-typhoid salmonellaeserotypes caus<strong>in</strong>g <strong>in</strong>test<strong>in</strong>al <strong>in</strong>fection is not relevant for treat<strong>in</strong>g the patient,the appearance of multiresistant stra<strong>in</strong>s is a warn<strong>in</strong>g to the physician of theoveruse and misuse of antimicrobial drugs.Cont<strong>in</strong>ued surveillance of the results of rout<strong>in</strong>e susceptibility tests is an excellentsource of <strong>in</strong>formation on the prevalence of resistant staphylococci andGram-negative bacilli that may be responsible for cross-<strong>in</strong>fections <strong>in</strong> the hospital.Periodic report<strong>in</strong>g of the susceptibility pattern of the prevalent stra<strong>in</strong>sis an <strong>in</strong>valuable aid to form<strong>in</strong>g a sound policy on antimicrobial usage <strong>in</strong> thehospital by restriction and/or rotation of life-sav<strong>in</strong>g drugs, such as the am<strong>in</strong>oglycosidesand cefalospor<strong>in</strong>s.Choice of drugs for rout<strong>in</strong>e susceptibility tests <strong>in</strong>the cl<strong>in</strong>ical laboratoryThe choice of drugs used <strong>in</strong> a rout<strong>in</strong>e antibiogram is governed by considerationsof the antibacterial spectrum of the drugs, their pharmacok<strong>in</strong>etic properties,toxicity, efficacy and availability, as well as their cost to both the patientand the community. Among the many antimicrobial agents that could be usedto treat a patient <strong>in</strong>fected with a given organism, only a limited number ofcarefully selected drugs should be <strong>in</strong>cluded <strong>in</strong> the susceptibility test.Table 23 <strong>in</strong>dicates the antimicrobials to be tested <strong>in</strong> various situations. Thedrugs <strong>in</strong> the table are divided <strong>in</strong>to two sets. Set 1 <strong>in</strong>cludes the drugs that areavailable <strong>in</strong> most hospitals and for which rout<strong>in</strong>e test<strong>in</strong>g should be carriedTable 23. <strong>Basic</strong> sets of antimicrobials for rout<strong>in</strong>e susceptibility tests aStaphylococcus Enterobacteriaceae Pseudomonasaerug<strong>in</strong>osaIntest<strong>in</strong>al Ur<strong>in</strong>ary Blood & tissuesSet 1 benzylpenicill<strong>in</strong> ampicill<strong>in</strong> sulfonamide ampicill<strong>in</strong> piperacill<strong>in</strong>First choice oxacill<strong>in</strong> chloramphenicol trimethoprim chloramphenicol gentamic<strong>in</strong>erythromyc<strong>in</strong> co-trimoxazole co-trimoxazole co-trimoxazole tobramyc<strong>in</strong>tetracycl<strong>in</strong>e nalidixic acid ampicill<strong>in</strong> tetracycl<strong>in</strong>echloramphenicol tetracycl<strong>in</strong>e nitrofuranto<strong>in</strong> cefalot<strong>in</strong>nalidixic acid gentamic<strong>in</strong>tetracycl<strong>in</strong>eamoxy-clav bSet 2 gentamic<strong>in</strong> norfloxac<strong>in</strong> norfloxac<strong>in</strong> cefuroxime amikac<strong>in</strong>Additional drugs amikac<strong>in</strong> chloramphenicol ceftriaxone ciprofloxac<strong>in</strong>co-trimoxazole gentamic<strong>in</strong> ciprofloxac<strong>in</strong> ceftazid<strong>in</strong>ecl<strong>in</strong>damyc<strong>in</strong> amoxy-clav b piperacill<strong>in</strong>nitrofuranto<strong>in</strong>amikac<strong>in</strong>a Notes on the <strong>in</strong>dividual antimicrobial agents are given <strong>in</strong> the text.b Amoxycill<strong>in</strong> and clavulanic acid (<strong>in</strong>hibitor of b-lactamase).107


ANTIMICROBIAL SUSCEPTIBILITY TESTINGout for every stra<strong>in</strong>. Tests for drugs <strong>in</strong> set 2 are to be performed only at thespecial request of the physician, or when the causative organism is resistantto the first-choice drugs, or when other reasons (allergy to a drug, or itsunavailability) make further test<strong>in</strong>g justified. Many antimicrobials with goodcl<strong>in</strong>ical activity have been omitted from the table, but it must be emphasizedthat they are rarely needed <strong>in</strong> the management of the <strong>in</strong>fected patient. In veryrare cases, one or more additional drugs should be <strong>in</strong>cluded when there is aspecial reason known to the physician, or when new and better drugs becomeavailable. Periodic revision of this table is therefore desirable, and this shouldbe done after appropriate discussions with cl<strong>in</strong>ical staff. Many problems arise<strong>in</strong> practice, because cl<strong>in</strong>icians are not always aware that only one representativeof each group of antimicrobial agents is <strong>in</strong>cluded <strong>in</strong> rout<strong>in</strong>e tests. Theresult obta<strong>in</strong>ed for this particular drug may then be extrapolated to all, ormost, of the other members of the group. Difficulties arise <strong>in</strong> some countrieswhen the physician is familiar only with the commercial brand name of thedrug and not with its generic nonproprietary name. A serious effort shouldbe made to <strong>in</strong>form medical personnel about the <strong>in</strong>ternational nonproprietarynames of pharmaceutical substances, and to encourage their use. 11. The benzylpenicill<strong>in</strong> disc is used to test susceptibility to all b-lactamasesensitivepenicill<strong>in</strong>s (such as oral phenoxymethylpenicill<strong>in</strong> and pheneticill<strong>in</strong>).Isolates of staphylococci that fall <strong>in</strong>to the resistant categoryproduce b-lactamase and should be treated with a b-lactamase-resistantpenicill<strong>in</strong> G or with another antimicrobial, such as erythromyc<strong>in</strong>.2. The oxacill<strong>in</strong> disc is representative of the whole group of b-lactamaseresistantpenicill<strong>in</strong>s (<strong>in</strong>clud<strong>in</strong>g meticill<strong>in</strong>, nafcill<strong>in</strong>, cloxacill<strong>in</strong>,dicloxacill<strong>in</strong>, and flucloxacill<strong>in</strong>). There is good cl<strong>in</strong>ical evidence thatcross-resistance exists between the meticill<strong>in</strong> and the cefalospor<strong>in</strong> groups.Therefore, it is useless and mislead<strong>in</strong>g to <strong>in</strong>clude cefalot<strong>in</strong> <strong>in</strong> theantibiogram for staphylococci.Resistance to meticill<strong>in</strong> and related drugs is often of the heterogeneoustype, i.e. the majority of cells may be fully susceptible and produce a wide<strong>in</strong>hibition zone, while the resistant part of the population appears <strong>in</strong> theform of m<strong>in</strong>ute discrete colonies grow<strong>in</strong>g with<strong>in</strong> the <strong>in</strong>hibition zone. Thistype of resistance is more apparent when the temperature of the <strong>in</strong>cubatoris set at 35 ∞C 2 or when the <strong>in</strong>cubation time is prolonged.A serious disadvantage of meticill<strong>in</strong>, as a representative disc for the b-lactamase-resistant penicill<strong>in</strong>s, is its great lability even under conventionalstorage conditions. The oxacill<strong>in</strong> disc is much more resistant todeterioration and is therefore preferred for the standardized diffusiontest. The cloxacill<strong>in</strong> and dicloxacill<strong>in</strong> discs are not used as they may not<strong>in</strong>dicate the presence of a heteroresistant stra<strong>in</strong>.3. The results for the tetracycl<strong>in</strong>e disc may be applied to chlortetracycl<strong>in</strong>e,oxytetracycl<strong>in</strong>e, and other members of this group. However, most tetracycl<strong>in</strong>e-resistantstaphylococci rema<strong>in</strong> normally sensitive to m<strong>in</strong>ocycl<strong>in</strong>e.A disc of m<strong>in</strong>ocycl<strong>in</strong>e may thus be useful to test multiresistant stra<strong>in</strong>s ofstaphylococci.4. The result for the chloramphenicol disc may be extrapolated to thiamphenicol,a related drug with a comparable antimicrobial spectrum, butwithout known risk of aplastic anaemia.5. Only one representative of sulfonamide (sulfafurazole) is required <strong>in</strong> thetest.1International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative listNo. 9. Geneva, World Health Organization, 1996.2 Sahm DF et al. Current concepts and approaches to antimicrobial agent susceptibility test<strong>in</strong>g.In: Cumitech 25, Wash<strong>in</strong>gton, DC, American Society for Microbiology, 1988.108


BACTERIOLOGICAL INVESTIGATIONS6. The co-trimoxazole disc conta<strong>in</strong>s a comb<strong>in</strong>ation of trimethoprim and a sulfonamide(sulfamethoxazole). The two components of this synergisticcomb<strong>in</strong>ation have comparable pharmacok<strong>in</strong>etic properties and generallyact as a s<strong>in</strong>gle drug.7. Ampicill<strong>in</strong> is the prototype of a group of broad-spectrum penicill<strong>in</strong>s withactivity aga<strong>in</strong>st many Gram-negative bacteria. As it is susceptible to b-lactamase, it should not be used for test<strong>in</strong>g staphylococci. Generally, thesusceptibility to ampicill<strong>in</strong> is also valid for other members of this group:amoxycill<strong>in</strong>, pivampicill<strong>in</strong>, talampicill<strong>in</strong>, etc. (although amoxycill<strong>in</strong> istwice as active aga<strong>in</strong>st salmonellae and only half as active aga<strong>in</strong>st shigellaeand H. <strong>in</strong>fluenzae).8. Only cefalot<strong>in</strong> needs to be tested rout<strong>in</strong>ely as its spectrum is representativeof all other first-generation cefalospor<strong>in</strong>s (cefalex<strong>in</strong>, cefrad<strong>in</strong>e,cefalorid<strong>in</strong>e, cefazol<strong>in</strong>, cefapir<strong>in</strong>). Where second- and third-generationcefalospor<strong>in</strong>s and related compounds (cefamyc<strong>in</strong>s) with an expandedspectrum are available, a separate disc for some of these new drugs maybe justified <strong>in</strong> selected cases (cefoxit<strong>in</strong>, cefamandole, cefuroxime, cefotaxime,ceftriaxone). Although some cefalospor<strong>in</strong>s can be used to treatsevere staphylococcal <strong>in</strong>fections, the susceptibility of the <strong>in</strong>fect<strong>in</strong>g stra<strong>in</strong>can be derived from the result with oxacill<strong>in</strong> as already mentioned under2 above.9. Erythromyc<strong>in</strong> is used to test the susceptibility to some other members ofthe macrolide group (oleandomyc<strong>in</strong>, spiramyc<strong>in</strong>).10. Am<strong>in</strong>oglycosides form a group of chemically related drugs that <strong>in</strong>cludesstreptomyc<strong>in</strong>, gentamic<strong>in</strong>, kanamyc<strong>in</strong>, netilmic<strong>in</strong> and tobramyc<strong>in</strong>. Theirantimicrobial spectra are not always closely enough related to permitassumption of cross-resistance, but aga<strong>in</strong>st susceptible pathogens theseagents have been shown to be equally effective. Numerous studies havecompared the nephrotoxicity and ototoxicity of gentamic<strong>in</strong>, netilmic<strong>in</strong>and tobramyc<strong>in</strong>, but there is no conclusive evidence that any one of thedrugs is less toxic than the others. It is strongly recommended that eachlaboratory select a s<strong>in</strong>gle agent for primary susceptibility test<strong>in</strong>g. Theother agents should be held <strong>in</strong> reserve for treatment of patients with <strong>in</strong>fectionscaused by resistant organisms.11. Nitrofuranto<strong>in</strong> is limited to use only <strong>in</strong> the treatment of ur<strong>in</strong>ary tract <strong>in</strong>fections,and should not be tested aga<strong>in</strong>st microorganisms recovered frommaterial other than ur<strong>in</strong>e.Table 24 provides <strong>in</strong>formation on zone diameter limits for control stra<strong>in</strong>s.The modified Kirby–Bauer methodThe disc-diffusion method, orig<strong>in</strong>ally described <strong>in</strong> 1966, 1 is well standardizedand has been widely evaluated. Official agencies have recommended it, withm<strong>in</strong>or modifications, as a reference method which could be used as a rout<strong>in</strong>etechnique <strong>in</strong> the cl<strong>in</strong>ical laboratory.1Bauer AW et al. Antibiotic susceptibility test<strong>in</strong>g by a standardized s<strong>in</strong>gle disc method.American journal of cl<strong>in</strong>ical pathology, 1966; 45:493–496.109


ANTIMICROBIAL SUSCEPTIBILITY TESTINGTable 24. Zone diameter limits for control stra<strong>in</strong>s aAntimicrobial Disc potency Diameter of zone of <strong>in</strong>hibition (mm)S. aureus E. coli P. aerug<strong>in</strong>osa(ATCC 25923) (ATCC 25922) (ATCC 27853)amikac<strong>in</strong> 30 mg 20–26 19–26 18–26amoxy-clav b 20/10 mg 28–36 19–25 —ampicill<strong>in</strong> 10 mg 27–35 16–22 —benzylpenicill<strong>in</strong> 10IU 26–37 — —cefalot<strong>in</strong> 30 mg 29–37 15–21 —cefaloz<strong>in</strong> 30 mg 29–35 23–29 —ceftazidime 30 mg 16–20 25–32 22–29cefotaxime 30 mg 25–31 29–35 18–22ceftriaxone 30 mg 22–28 29–35 17–23cefuroxime 30 mg 27–35 20–26 —chloramphenicol 30mg 19–26 21–27 —ciprofloxac<strong>in</strong> 5 mg 22–30 30–40 25–33cl<strong>in</strong>damyc<strong>in</strong> 2 mg 24–30 — —co-trimoxazole 25mg 24–32 24–32 —erythromyc<strong>in</strong> 15 mg 22–30 — —gentamic<strong>in</strong> 10 mg 19–27 19–26 16–21nalidixic acid 30 mg — 22–28 —nitrofuranto<strong>in</strong> 300 mg 18–22 20–25 —norfloxac<strong>in</strong> 10 mg 17–28 28–35 22–29oxacill<strong>in</strong> 1mg 18–24 — —piperacill<strong>in</strong> 100mg — 24–30 25–33sulfonamide c 300mg 24–34 15–23 —tetracycl<strong>in</strong>e 30 mg 24–30 18–25 —tobramyc<strong>in</strong> 10 mg 19–29 18–26 19–25trimethoprim 5 mg 19–26 21–28 —vancomyc<strong>in</strong> 30 mg 17–21 — —a National Committee for Cl<strong>in</strong>ical <strong>Lab</strong>oratory Standards. Performance standards for antimicrobial disc susceptibilitytests. 6th ed. Vol. 21 No 1 (M2-A7 and M7-A5) and 11 th <strong>in</strong>formational supplement 2001 (M100-S11).b Amoxycill<strong>in</strong> and clavulanic acid (<strong>in</strong>hibitor of b-lactamase).c Sulfisoxazole.ReagentsMueller–H<strong>in</strong>ton agar1. Mueller–H<strong>in</strong>ton agar should be prepared from a dehydrated base accord<strong>in</strong>gto the manufacturer’s <strong>in</strong>structions. The medium should be such thatcontrol zone sizes with<strong>in</strong> the published limits are produced (see Table 24).It is important not to overheat the medium.2. Cool the medium to 45–50 ∞C and pour <strong>in</strong>to the plates. Allow to set on alevel surface, to a depth of approximately 4mm. A 9-cm plate requiresapproximately 25 ml of medium.3. When the agar has solidified, dry the plates for immediate use for 10–30m<strong>in</strong>utes at 35∞C by plac<strong>in</strong>g them <strong>in</strong> the upright position <strong>in</strong> the <strong>in</strong>cubatorwith the lids tilted.4. Any unused plates may be stored <strong>in</strong> a plastic bag, which should be sealedand placed <strong>in</strong> the refrigerator. Plates stored <strong>in</strong> this way will keep for 2weeks.110


BACTERIOLOGICAL INVESTIGATIONSTo ensure that the zone diameters are sufficiently reliable for test<strong>in</strong>g susceptibilityto sulfonamides and co-trimoxazole, the Mueller–H<strong>in</strong>ton agar musthave low concentrations of the <strong>in</strong>hibitors thymid<strong>in</strong>e and thym<strong>in</strong>e. Each newlot of Mueller–H<strong>in</strong>ton agar should therefore be tested with a control stra<strong>in</strong>of Enterococcus faecalis (ATCC 29212 or 33186) and a disc of co-trimoxazole. Asatisfactory lot of medium will give a dist<strong>in</strong>ct <strong>in</strong>hibition zone of 20mm ormore that is essentially free of hazy growth or f<strong>in</strong>e colonies.Antimicrobial discsAny commercially available discs with the proper diameter and potency canbe used. Stocks of antimicrobial discs should preferably be kept at -20∞C; thefreezer compartment of a home refrigerator is convenient. A small work<strong>in</strong>gsupply of discs can be kept <strong>in</strong> the refrigerator for up to 1 month. On removalfrom the refrigerator, the conta<strong>in</strong>ers should be left at room temperature forabout 1 hour to allow the temperature to equilibrate. This procedure reducesthe amount of condensation that occurs when warm air reaches the coldconta<strong>in</strong>er. If a disc-dispens<strong>in</strong>g apparatus is used, it should have a tight-fitt<strong>in</strong>gcover and be stored <strong>in</strong> the refrigerator. It should also be allowed to warm toroom temperature before be<strong>in</strong>g opened.Turbidity standardPrepare the turbidity standard by pour<strong>in</strong>g 0.6ml of a 1% (10g/l) solution ofbarium chloride dihydrate <strong>in</strong>to a 100-ml graduated cyl<strong>in</strong>der, and fill<strong>in</strong>g to100ml with 1% (10ml/l) sulfuric acid. The turbidity standard solution shouldbe placed <strong>in</strong> a tube identical to the one used for the broth sample. It can bestored <strong>in</strong> the dark at room temperature for 6 months, provided it is sealed toprevent evaporation.SwabsA supply of cotton wool swabs on wooden applicator sticks should be prepared.They can be sterilized <strong>in</strong> t<strong>in</strong>s, culture tubes, or on paper, either <strong>in</strong> theautoclave or by dry heat.ProcedureTo prepare the <strong>in</strong>oculum from the primary culture plate, touch with a loop thetops of each of 3–5 colonies, of similar appearance, of the organism to be tested.111


ANTIMICROBIAL SUSCEPTIBILITY TESTINGTransfer this growth to a tube of sal<strong>in</strong>e.When the <strong>in</strong>oculum has to be made from a pure culture, a loopful of theconfluent growth is similarly suspended <strong>in</strong> sal<strong>in</strong>e.Compare the tube with the turbidity standard and adjust the density of thetest suspension to that of the standard by add<strong>in</strong>g more bacteria or more sterilesal<strong>in</strong>e.Proper adjustment of the turbidity of the <strong>in</strong>oculum is essential to ensure thatthe result<strong>in</strong>g lawn of growth is confluent or almost confluent.Inoculate the plates by dipp<strong>in</strong>g a sterile swab <strong>in</strong>to the <strong>in</strong>oculum. Removeexcess <strong>in</strong>oculum by press<strong>in</strong>g and rotat<strong>in</strong>g the swab firmly aga<strong>in</strong>st the side ofthe tube above the level of the liquid.112


BACTERIOLOGICAL INVESTIGATIONSStreak the swab all over the surface of the medium three times, rotat<strong>in</strong>g theplate through an angle of 60∞ after each application. F<strong>in</strong>ally, pass the swabround the edge of the agar surface. Leave the <strong>in</strong>oculum to dry for a fewm<strong>in</strong>utes at room temperature with the lid closed.The antimicrobial discs may be placed on the <strong>in</strong>oculated plates us<strong>in</strong>g a pairof sterile forceps. It is convenient to use a template (Fig. 15) to place the discsuniformly.A sterile needle tip may also be used to place the antimicrobial discs on the<strong>in</strong>oculated plate.113


ANTIMICROBIAL SUSCEPTIBILITY TESTINGAlternatively, an antimicrobial disc dispenser can be used to apply the discsto the <strong>in</strong>oculated plate.A maximum of seven discs can be placed on a 9–10cm plate. Six discs may bespaced evenly, approximately 15 mm from the edge of the plate, and 1 discplaced <strong>in</strong> the centre of the plate. Each disc should be gently pressed down toensure even contact with the medium.The plates should be placed <strong>in</strong> an <strong>in</strong>cubator at 35∞C with<strong>in</strong> 30 m<strong>in</strong>utesof preparation. Temperatures above 35 ∞C <strong>in</strong>validate results for oxacill<strong>in</strong>/meticill<strong>in</strong>.Do not <strong>in</strong>cubate <strong>in</strong> an atmosphere of carbon dioxide.After overnight <strong>in</strong>cubation, the diameter of each zone (<strong>in</strong>clud<strong>in</strong>g the diameterof the disc) should be measured and recorded <strong>in</strong> mm. The results shouldthen be <strong>in</strong>terpreted accord<strong>in</strong>g to the critical diameters shown <strong>in</strong> Table 25.The measurements can be made with a ruler on the under-surface of the platewithout open<strong>in</strong>g the lid.114


BACTERIOLOGICAL INVESTIGATIONSIf the medium is opaque, the zone can be measured by means of a pair ofcalipers.A template (Fig. 14) may be used to assess the f<strong>in</strong>al result of the susceptibilitytests.115


ANTIMICROBIAL SUSCEPTIBILITY TESTINGTable 25. Interpretative chart of zone sizes for rapidly grow<strong>in</strong>g bacteria us<strong>in</strong>g themodified Kirby–Bauer technique aAntimicrobial agentDiameter of zone of <strong>in</strong>hibition (mm)Disc potency Resistant Intermediate Susceptibleamikac<strong>in</strong> 30mg 17amoxy-clav b 20/10 mg 18ampicill<strong>in</strong>, when test<strong>in</strong>g— Enterobacteriaceae 10mg 17— enterococci 10 mg 17benzylpenicill<strong>in</strong>, when test<strong>in</strong>g— staphylococci 10IU 29— enterococci 10IU 15cefalot<strong>in</strong> 30 mg 18cefaloz<strong>in</strong> 30 mg 18cefotaxime 30mg 23ceftazidime 30mg 18ceftriaxone 30mg 21cefuroxime sodium, cefamandole 30mg 18chloramphenicol 30mg


BACTERIOLOGICAL INVESTIGATIONSFig. 14. Template for the determ<strong>in</strong>ation of susceptibilityThe end-po<strong>in</strong>t of <strong>in</strong>hibition is judged by the naked eye at the edge where thegrowth starts, but there are three exceptions:• With sulfonamides and co-trimoxazole, slight growth occurs with<strong>in</strong> the<strong>in</strong>hibition zone; such growth should be ignored.• When b-lactamase-produc<strong>in</strong>g staphylococci are tested aga<strong>in</strong>st benzyl penicill<strong>in</strong>,zones of <strong>in</strong>hibition are produced with a heaped-up, clearly def<strong>in</strong>ededge; these are readily recognizable when compared with the sensitivecontrol, and, regardless of the size of the zone of <strong>in</strong>hibition, they shouldbe reported as resistant.• Certa<strong>in</strong> Proteus species may swarm <strong>in</strong>to the area of <strong>in</strong>hibition around someantimicrobials, but the zone of <strong>in</strong>hibition is usually clearly outl<strong>in</strong>ed andthe th<strong>in</strong> layer of swarm<strong>in</strong>g growth should be ignored.Interpretation of the zone sizesUs<strong>in</strong>g a template. When the zone sizes are compared with a template, a separatetemplate must be prepared for each <strong>in</strong>dividual antimicrobial agent (seeFig. 14). The result—susceptible, resistant, or <strong>in</strong>termediate—can be read atonce: “susceptible”, when the zone edge is outside the black circle; “resistant”,when there is no zone, or when it lies with<strong>in</strong> the white circle; and “<strong>in</strong>termediate”,when the edge of the zone of <strong>in</strong>hibition lies on the black circle.Us<strong>in</strong>g a ruler. When the zone sizes are measured <strong>in</strong> mm, the results should be<strong>in</strong>terpreted accord<strong>in</strong>g to the critical diameters given <strong>in</strong> Table 25.Direct versus <strong>in</strong>direct susceptibility testsIn the standardized method outl<strong>in</strong>ed above, the <strong>in</strong>oculum is prepared fromcolonies on a primary culture plate or from a pure culture. This is called an“<strong>in</strong>direct susceptibility test”. In certa<strong>in</strong> cases, where a rapid answer is important,the standardized <strong>in</strong>oculum may be replaced by the pathological specimenitself, e.g. ur<strong>in</strong>e, a positive blood culture, or a swab of pus. For specimensof ur<strong>in</strong>e, a microscopical exam<strong>in</strong>ation of the sediment should first be made <strong>in</strong>order to see if there is evidence of <strong>in</strong>fection, i.e. the presence of pus cellsand/or organisms. The ur<strong>in</strong>e may then be used as the <strong>in</strong>oculum <strong>in</strong> the standardtest. Likewise, susceptibility tests may be performed on <strong>in</strong>cubated bloodcultures show<strong>in</strong>g evidence of bacterial growth, or a swab of pus may be usedas a direct <strong>in</strong>oculum, when a Gram-sta<strong>in</strong>ed smear shows the presence of largenumbers of a s<strong>in</strong>gle type of organism. This is called a “direct susceptibilitytest”; its advantage over the <strong>in</strong>direct test is that a result is obta<strong>in</strong>ed 24 hoursearlier. The ma<strong>in</strong> disadvantage is that the <strong>in</strong>oculum cannot be properly controlled.When the susceptibility plate shows too light or too heavy growth, orwhen the culture is a mixture, the results should be <strong>in</strong>terpreted with caution,and the test repeated on pure cultures.117


ANTIMICROBIAL SUSCEPTIBILITY TESTINGTechnical factors <strong>in</strong>fluenc<strong>in</strong>g the size of the zone<strong>in</strong> the disc-diffusion methodInoculum densityIf the <strong>in</strong>oculum is too light, the <strong>in</strong>hibition zones will be larger even thoughthe sensitivity of the organism is unchanged. Relatively resistant stra<strong>in</strong>s maythen be reported as susceptible. Conversely, if the <strong>in</strong>oculum is too heavy, thezone size will be reduced and susceptible stra<strong>in</strong>s may be reported as resistant.Usually optimal results are obta<strong>in</strong>ed with an <strong>in</strong>oculum size that produces nearconfluent growth.Tim<strong>in</strong>g of disc applicationIf the plates, after be<strong>in</strong>g seeded with the test stra<strong>in</strong>, are left at room temperaturefor periods longer than the standard time, multiplication of the <strong>in</strong>oculummay take place before the discs are applied. This causes a reduction <strong>in</strong> the zonediameter and may result <strong>in</strong> a susceptible stra<strong>in</strong> be<strong>in</strong>g reported as resistant.Temperature of <strong>in</strong>cubationSusceptibility tests are normally <strong>in</strong>cubated at 35∞C for optimal growth. If thetemperature is lowered, the time required for effective growth is extended andlarger zones result. When a heterogeneous resistant stra<strong>in</strong> of Staphylococcusaureus is be<strong>in</strong>g tested aga<strong>in</strong>st meticill<strong>in</strong> (oxacill<strong>in</strong>), the resistant portion of thepopulation can be detected at 35 ∞C. At higher temperatures the entire cultureappears to be susceptible. At 35 ∞C or lower temperatures, resistant coloniesdevelop with<strong>in</strong> the zone of <strong>in</strong>hibition. These resistant colonies can be seenmore easily if the plate is left for several hours at room temperature beforethe result is read. Such colonies should always be identified to check whetherthey are contam<strong>in</strong>ants.Incubation timeMost techniques adopt an <strong>in</strong>cubation period of between 16 and 18 hours. Inemergencies, however, a provisional report may be made after 6 hours. Thisis not rout<strong>in</strong>ely recommended and the result should always be confirmed afterthe conventional <strong>in</strong>cubation time.Size of plate, depth of agar medium, and spac<strong>in</strong>gof the antimicrobial discsSusceptibility tests are usually carried out with 9–10cm plates and no morethan 6 or 7 antimicrobial discs on each plate. If larger numbers of antimicrobialshave to be tested, two plates, or one 14-cm diameter plate, is to be preferred.Excessively large <strong>in</strong>hibition zones may be formed on very th<strong>in</strong> media;the converse is true for thick media. M<strong>in</strong>or changes <strong>in</strong> the depth of the agarlayer have negligible effect. Proper spac<strong>in</strong>g of the discs is essential to avoidoverlapp<strong>in</strong>g of the <strong>in</strong>hibition zones or deformation near the edge of the plates(see Fig. 15).118


BACTERIOLOGICAL INVESTIGATIONSFig. 15. Template for uniform placement of susceptibility discson plates of 90mm diameterPotency of the antimicrobial discsThe diameter of the <strong>in</strong>hibition zone is related to the amount of drug <strong>in</strong>the disc. If the potency of the drug is reduced ow<strong>in</strong>g to deterioration dur<strong>in</strong>gstorage, the <strong>in</strong>hibition zone will show a correspond<strong>in</strong>g reduction <strong>in</strong> size.Composition of the mediumThe medium <strong>in</strong>fluences the size of the zone by its effect on the rate of growthof the organism, the rate of diffusion of the antimicrobial, and the activity ofthe agent. It is essential to use the medium appropriate to the particularmethod.The many factors <strong>in</strong>fluenc<strong>in</strong>g the zone diameters that may be obta<strong>in</strong>ed for thesame test organism clearly demonstrate the need for standardization of discdiffusionmethods. Only if the conditions laid down <strong>in</strong> a particular methodare closely followed can valid results be obta<strong>in</strong>ed. Alteration of any of thefactors affect<strong>in</strong>g the test can result <strong>in</strong> grossly mislead<strong>in</strong>g reports for thecl<strong>in</strong>ician.The precision and accuracy of the method should be monitored by establish<strong>in</strong>gthe quality control programme described below. Variations can then beimmediately <strong>in</strong>vestigated and corrective action taken to elim<strong>in</strong>ate them.119


ANTIMICROBIAL SUSCEPTIBILITY TESTINGQuality controlThe need for quality control <strong>in</strong> the susceptibilitytestThe f<strong>in</strong>al result of a disc-diffusion test is <strong>in</strong>fluenced by a large number ofvariables. Some of the factors, such as the <strong>in</strong>oculum density and the <strong>in</strong>cubationtemperature, are easy to control, but a laboratory rarely knows theexact composition of a commercial medium or the batch-to-batch variations<strong>in</strong> its quality, and it cannot take for granted the antimicrobial content of thediscs. The results of the test must therefore be monitored constantly by aquality control programme, which should be considered part of the procedureitself.The precision and accuracy of the test are controlled by the parallel use of aset of control stra<strong>in</strong>s, with known susceptibility to the antimicrobial agents.These quality control stra<strong>in</strong>s are tested us<strong>in</strong>g exactly the same procedure asfor the test organisms. The zone sizes shown by the control organisms shouldfall with<strong>in</strong> the range of diameters given <strong>in</strong> Table 24. When results regularlyfall outside this range, they should be regarded as evidence that a technicalerror has been <strong>in</strong>troduced <strong>in</strong>to the test, or that the reagents are at fault. Eachreagent and each step <strong>in</strong> the test should then be <strong>in</strong>vestigated until the causeof the error has been found and elim<strong>in</strong>ated.Standard procedure for quality controlThe quality control programme should test standard reference stra<strong>in</strong>s ofbacteria <strong>in</strong> parallel with the cl<strong>in</strong>ical cultures. These tests should preferablybe run every week, or with every fifth batch of tests, and, <strong>in</strong> addition,every time a new batch of Mueller–H<strong>in</strong>ton agar or a new batch of discsis used.Standard stra<strong>in</strong>s for quality controlStaphylococcus aureus (ATCC 25923)Escherichia coli (ATCC 25922)Pseudomonas aerug<strong>in</strong>osa (ATCC 27853)These cultures can be obta<strong>in</strong>ed from national culture collections. They arecommercially available <strong>in</strong> the form of pellets of desiccated pure cultures.Cultures for day-to-day use should be grown on slants of nutrient agar (trypticsoy agar is convenient) and stored <strong>in</strong> the refrigerator. They should be subculturedon to fresh slants every 2 weeks.Prepar<strong>in</strong>g the <strong>in</strong>oculumThe cultures may be <strong>in</strong>oculated <strong>in</strong>to any type of broth, and <strong>in</strong>cubated untilthe broth is turbid. Each broth should be streaked onto an agar plate and<strong>in</strong>cubated overnight. S<strong>in</strong>gle colonies should then be picked off and submittedto susceptibility tests as described on pages 111–115.120


BACTERIOLOGICAL INVESTIGATIONSFig. 16. Quality control chart for antimicrobial susceptibilitytest<strong>in</strong>gPlac<strong>in</strong>g antimicrobial discsAfter the <strong>in</strong>oculum has been streaked on to the plates, as described on page113, the appropriate discs should be applied. The discs to be selected for eachcontrol stra<strong>in</strong> are listed <strong>in</strong> Table 24.Read<strong>in</strong>g the platesAfter 16–18 hours <strong>in</strong>cubation, the diameters of the <strong>in</strong>hibition zones shouldbe measured with a ruler and recorded, together with the date of the test, ona special quality control chart. This chart should display data for eachdisc–stra<strong>in</strong> comb<strong>in</strong>ation. The chart is labelled <strong>in</strong> millimetres, with an <strong>in</strong>dicationof the range of acceptable zone sizes. An example of such a chart is shown<strong>in</strong> Fig. 16. When the results consistently fall outside the acceptable limits,action should be taken to improve the quality of the test.Grossly aberrant results, which cannot be expla<strong>in</strong>ed by technical errors <strong>in</strong> theprocedure, may <strong>in</strong>dicate contam<strong>in</strong>ation or sudden changes <strong>in</strong> the susceptibilityor growth characteristics of the control stra<strong>in</strong>. If this occurs, a fresh stockstra<strong>in</strong>should be obta<strong>in</strong>ed from a reliable source.121


Serological testsIntroductionSerological tests, unlike culture and microscopic <strong>in</strong>vestigations, provide only<strong>in</strong>direct evidence of <strong>in</strong>fection by detect<strong>in</strong>g bacterial antigens, or antibodiesproduced <strong>in</strong> response to them, <strong>in</strong> cl<strong>in</strong>ical material. Such tests are now widelyused <strong>in</strong> microbiology because of their high specificity and sensitivity.After an <strong>in</strong>itial <strong>in</strong>fection with pathogenic microorganisms, most patients willproduce both IgM and IgG antibodies. After a few weeks, the cells produc<strong>in</strong>gIgM antibodies switch to produc<strong>in</strong>g IgG antibodies, and subsequently onlyIgG antibodies will be present <strong>in</strong> the patient’s serum. A second <strong>in</strong>fection withthe same pathogens will elicit only an IgG response. Because the antibodyproduc<strong>in</strong>gcells have reta<strong>in</strong>ed the memory of the pathogen, the response willbe more rapid and usually stronger than the <strong>in</strong>itial response; this is ananamnestic response.The antibody level is usually designated by a “titre”. The diagnostic titreto be reported is the reciprocal value of the highest dilution of the patient’sserum <strong>in</strong> which antibodies are still detectable. For example, if antibodiesare detectable <strong>in</strong> serum diluted 1:1024 but not <strong>in</strong> further dilutions, the titre ofthe serum is 1024. Serum collected dur<strong>in</strong>g the acute phase of the <strong>in</strong>fection,when the disease is first suspected, is called the acute serum; serum drawndur<strong>in</strong>g convalescence, which is usually 2 weeks later, is called convalescentserum.Reaction to an antigen will occur regardless of the stage of <strong>in</strong>fection, althoughthis reaction will vary. The presence of IgG antibodies <strong>in</strong> a s<strong>in</strong>gle serumsample may <strong>in</strong>dicate past exposure to the agent and therefore cannot be usedto diagnose a current <strong>in</strong>fection. An antigen may also stimulate production ofantibodies that cross-react with other antigens. As these antibodies arenonspecific, tests <strong>in</strong>volv<strong>in</strong>g only s<strong>in</strong>gle serum samples may give rise to mis<strong>in</strong>terpretationof results. For the majority of serological tests, both acute andconvalescent sera should be tested, preferably together <strong>in</strong> the same test-run,to counteract variables <strong>in</strong>herent <strong>in</strong> the test procedure. An <strong>in</strong>crease <strong>in</strong> the antibodytitre of two doubl<strong>in</strong>g dilutions (e.g. from a dilution of 1:8 to a dilution1:32) is usually considered to be diagnostic of current <strong>in</strong>fection. This is calleda fourfold rise <strong>in</strong> titre. Test<strong>in</strong>g a s<strong>in</strong>gle serum sample may be useful only <strong>in</strong>special cases, such as for diagnosis of Mycoplasma pneumoniae <strong>in</strong>fection, wherehigh titres may <strong>in</strong>dicate a recent <strong>in</strong>fection, or when the test demonstrates thepresence of IgM antibodies and the result may be taken as evidence of acurrent <strong>in</strong>fection. The type of antigen–antibody reaction depends on thephysical state of the antigen.Quality control measuresThe reliability and consistency of serological test results are entirely dependenton the quality control measures undertaken before, dur<strong>in</strong>g and after eachtest. These quality control measures are extremely important as a falsepositiveor false-negative result might give rise to a medical decision or actionthat could harm the patient. Many variables may affect the quality of serologicaltest<strong>in</strong>g, <strong>in</strong>clud<strong>in</strong>g the experience of the laboratory personnel, thequality of the kits and equipment, the condition of the specimens, the controlsused <strong>in</strong> test-runs, and the <strong>in</strong>terpretation and report<strong>in</strong>g of results. After the test122


BACTERIOLOGICAL INVESTIGATIONShas been completed, discard used materials <strong>in</strong>to a conta<strong>in</strong>er filled with dis<strong>in</strong>fectant,and wash hands and bench surfaces with dis<strong>in</strong>fectant.EquipmentThe equipment <strong>in</strong> a serology laboratory <strong>in</strong>cludes water-baths, <strong>in</strong>cubators,refrigerators, freezers, pH meters, balances, centrifuges, microscopes, androtators. Monitor<strong>in</strong>g and rout<strong>in</strong>e ma<strong>in</strong>tenance of equipment is a vital part ofthe quality assurance programme <strong>in</strong> the serology laboratory. A rout<strong>in</strong>e ma<strong>in</strong>tenanceservice should be established with periodic <strong>in</strong>spection of all equipmentfor m<strong>in</strong>or adjustments. Records show<strong>in</strong>g dates of <strong>in</strong>spection,ma<strong>in</strong>tenance, and repair should be ma<strong>in</strong>ta<strong>in</strong>ed for each piece of equipment.The water-bath should be kept free of all foreign material and dra<strong>in</strong>ed andcleaned monthly. The temperatures of the water-bath should be strictly controlledand should not vary by more than ±1∞C; it should be checked andrecorded daily and dur<strong>in</strong>g use. A cover should be provided to prevent cool<strong>in</strong>gat the surface of the water. Mixtures of antigen and antibody should not be<strong>in</strong>cubated until the desired temperature has been ma<strong>in</strong>ta<strong>in</strong>ed for at least onehour. The water level should be the same as that of the fluid <strong>in</strong> the tubes orflasks that are placed <strong>in</strong> the water-bath.Microscopes are essential for the Venereal Disease Research <strong>Lab</strong>oratory(VDRL) test and the fluorescent treponemal antigen absorption (FTA-Abs)test, and must be ma<strong>in</strong>ta<strong>in</strong>ed <strong>in</strong> the best possible work<strong>in</strong>g order. After use,the eyepieces, objectives, and condenser of the microscope should be wipedclean of all oil and debris with a non-abrasive tissue. When not <strong>in</strong> use, themicroscope should be kept covered and protected aga<strong>in</strong>st moisture. The <strong>in</strong>tensityof the mercury lamp of the fluorescence microscope should be checkedrepeatedly with a light meter.The mechanical rotator for the VDRL and the rapid plasma reag<strong>in</strong> (RPR) testsshould be checked for speed dur<strong>in</strong>g use, and any change <strong>in</strong> speed that mayadversely affect the agglut<strong>in</strong>ation reaction should be corrected. The mechanicalrotator should be lubricated on a regular basis.MaterialsGlassware and needles used <strong>in</strong> serological tests should meet the specificationsrecommended <strong>in</strong> those tests.All chipped or scratched glassware, plates and slides should be discarded.The use of dirty or improperly cleaned glassware that may have residuesof organic material on it is a major cause of mislead<strong>in</strong>g results. The <strong>in</strong>structionsfor wash<strong>in</strong>g glassware should be clearly written out and displayed <strong>in</strong>the wash<strong>in</strong>g area. The basic steps should <strong>in</strong>clude pre-r<strong>in</strong>s<strong>in</strong>g, wash<strong>in</strong>g withan appropriate laboratory detergent, r<strong>in</strong>s<strong>in</strong>g with tap water followed bydistilled water, dry<strong>in</strong>g, and check<strong>in</strong>g to ensure that all detergent has beenremoved.All pipettes should be soaked upright <strong>in</strong> a detergent solution so that the solutionfills the <strong>in</strong>side of the pipette. Pipettes should then be r<strong>in</strong>sed for at least30 m<strong>in</strong>utes under runn<strong>in</strong>g water, followed by a r<strong>in</strong>se <strong>in</strong> distilled water. Glassplates used for the VDRL test must be cleaned thoroughly until all detergentand oil residues are removed. Prolonged soak<strong>in</strong>g <strong>in</strong> detergent solutionsshould be avoided as this may weaken and flake the ceramic r<strong>in</strong>gs on the123


SEROLOGICAL TESTSplates. Glass plates with paraff<strong>in</strong> r<strong>in</strong>gs should be cleaned us<strong>in</strong>g an appropriateorganic solvent (e.g. petrol ether).For the RPR and VDRL tests, calibrated needles are used for dispens<strong>in</strong>gantigen and diluent. The RPR test kit <strong>in</strong>cludes a dispens<strong>in</strong>g needle, and theseneedles should be checked before use. Check the needle by determ<strong>in</strong><strong>in</strong>g thenumber of drops/ml: a 20-gauge needle should deliver 90 drops/ml. RPRneedles that are not work<strong>in</strong>g properly should be discarded. Wash the needleswith distilled water after use. To prepare the two needles for the VDRL test,break the po<strong>in</strong>ts with a pair of pliers. Check the needles by determ<strong>in</strong><strong>in</strong>g thenumber of drops/ml: an 18-gauge needle must deliver 60 drops/ml, and a 21-or 22-gauge needle deliver 100 drops/ml. Any needle <strong>in</strong> the VDRL test kit thatdoes not deliver the exact number of drops should be discarded, or adjustedby either press<strong>in</strong>g or ream<strong>in</strong>g the end of the needle. Wash the needles withwater, 70% ethanol and acetone after use.ReagentsChemicals used <strong>in</strong> serology must be of reagent quality and must meet thespecifications of the particular procedure. They should be stored <strong>in</strong> accordancewith the manufacturers’ <strong>in</strong>structions.High-quality distilled water with a pH of 7.0 should be used for the preparationof reagents. Distilled water should be stored <strong>in</strong> a heat-resistant glass orplastic bottle with a tightly fitt<strong>in</strong>g lid and be properly labelled and dated.Sal<strong>in</strong>e is used either as sal<strong>in</strong>e or as a buffered solution, such as phosphatebufferedsal<strong>in</strong>e. In humid climates, sodium chloride should be dried <strong>in</strong> a hotairoven for 30 m<strong>in</strong>utes at 160–180 ∞C to remove any moisture. The salt shouldbe dissolved <strong>in</strong> distilled or dem<strong>in</strong>eralized water and stored <strong>in</strong> a heat-resistantglass or plastic bottle with a tightly fitt<strong>in</strong>g lid and be properly labelledand dated. When buffered sal<strong>in</strong>e is prepared, the pH must be determ<strong>in</strong>edbefore use.Sera that conta<strong>in</strong> particulate debris should be centrifuged at 3000g for 10m<strong>in</strong>utes, and the supernatant used for test<strong>in</strong>g. Haemolysed or contam<strong>in</strong>atedsera should be discarded. If <strong>in</strong>activated serum is required for a test, heat theserum at 56 ∞C for 30 m<strong>in</strong>utes. If the serum has not been used 4 hours afterthe <strong>in</strong>itial <strong>in</strong>activation, it should be re-<strong>in</strong>activated by heat<strong>in</strong>g at 56∞C for 10m<strong>in</strong>utes before test<strong>in</strong>g. Br<strong>in</strong>g all sera to room temperature before test<strong>in</strong>g.A detailed description of some of the serological procedures rout<strong>in</strong>ely performed<strong>in</strong> many medical laboratories will be discussed <strong>in</strong> this chapter. These<strong>in</strong>clude serological tests for the <strong>in</strong>vestigation of syphilis, the Wright test forthe diagnosis of brucellosis, and the antistreptolys<strong>in</strong> O test for the diagnosisof post-streptococcal disease.Each description refers to the use of a commercial test kit. As these test kitsare available from a number of manufacturers, the user should carefully readthe detailed <strong>in</strong>structions conta<strong>in</strong>ed <strong>in</strong> each package <strong>in</strong>sert.124


BACTERIOLOGICAL INVESTIGATIONSSerological reactionsFlocculation or precipit<strong>in</strong> reactionsIn flocculation tests, the antigen is <strong>in</strong> solution and the <strong>in</strong>teraction with the antibodywill result <strong>in</strong> the formation of a precipitate, which can be observed eitherunder the microscope or with the naked eye. When the reagents are mixed,the <strong>in</strong>itial comb<strong>in</strong>ation of antigen and antibody occurs almost immediately.However, subsequent formation of larger visible clumps requires an hour ormore and is temperature-dependent. The reaction is fastest <strong>in</strong> the zone ofequivalence, where the antigen–antibody ratio is optimal. The tube with thequickest formation of a precipitate is a good <strong>in</strong>dication of equivalence. Themost widely used flocculation tests are the VDRL and the RPR test. Both areused for the diagnosis of syphilis (caused by Treponema pallidum), and for othertreponemal <strong>in</strong>fections.Flocculation tests provide qualitative evidence of an antigen–antibody reactionbut do not <strong>in</strong>dicate whether one or more types of antigen–antibody reactionsare <strong>in</strong>volved. If, however, the reactions are <strong>in</strong>vestigated us<strong>in</strong>ga semisolid gel, the different antigens and antibodies are likely to diffuseat different migration rates, and it may be possible to dist<strong>in</strong>guish differentreactions.Agglut<strong>in</strong>ation reactionsIn agglut<strong>in</strong>ation tests, the reagent, which may be an antigen or an antibody,is fixed or absorbed to a micro-particle. A variety of particles can be used ascarriers of the reagent, e.g. latex particles, gelat<strong>in</strong> particles, microbeads, bacteriaor red blood cells. This technique is also called passive agglut<strong>in</strong>ation.When red blood cells are used as carriers the tests are called coagglut<strong>in</strong>ationtests. When mixed with a specific antiserum, the cells or particles form a latticenetwork that results <strong>in</strong> clump<strong>in</strong>g and leaves a clear supernatant. If an antiserumof known specificity is used, the test for the identification of unknownmicroorganisms or their antigens can be applied. This test may be performedon a slide, and the result<strong>in</strong>g agglut<strong>in</strong>ation read macroscopically or under thelow-power objective of microscope. The agglut<strong>in</strong>ation reaction is also used toestimate the titre of antibacterial agglut<strong>in</strong><strong>in</strong>s <strong>in</strong> the serum of patients withunknown diseases. A rise <strong>in</strong> titre dur<strong>in</strong>g an illness strongly suggests a causalrelationship.Agglut<strong>in</strong>ation is accelerated at higher temperatures (35–56∞C) and by movement(e.g. shak<strong>in</strong>g, stirr<strong>in</strong>g or centrifug<strong>in</strong>g), which <strong>in</strong>creases the contactbetween antigen and antibody. The agglut<strong>in</strong>ation process requires the presenceof salts. A potentially serious problem with agglut<strong>in</strong>ation tests is prozonereaction: if too much antibody is present, the lattice will not form and agglut<strong>in</strong>ationwill be <strong>in</strong>hibited. A prozone reaction gives the impression that antibodyis absent; this error, however, can be avoided by test<strong>in</strong>g serial dilutionsof the serum.There is a commonly used agglut<strong>in</strong>ation test that uses Staphylococcus aureus,which conta<strong>in</strong>s a prote<strong>in</strong>, Prote<strong>in</strong> A, on its surface. This prote<strong>in</strong> b<strong>in</strong>ds to theFc fragment of IgG antibodies. IgG antibody-coated staphylococci producevisible agglut<strong>in</strong>ation <strong>in</strong> the presence of a specific antigen. The test is ma<strong>in</strong>lyused to identify organisms cultured from cl<strong>in</strong>ical specimens or to detect bacterialantigens <strong>in</strong> body fluids of <strong>in</strong>fected patients (cerebrosp<strong>in</strong>al fluid <strong>in</strong> thecase of men<strong>in</strong>gitis).125


SEROLOGICAL TESTSAgglut<strong>in</strong>ation tests are used for the diagnosis of Epste<strong>in</strong>-Barr virus (<strong>in</strong>fectiousmononucleosis), rotavirus, rubella, and for the detection of bacterial antigens(Haemophilus and Streptococcus A and B, among others).Fluorescent antibody testsIn immunofluorescence tests, the immunoreagent (antigen or antibody) isattached to a fluorescent dye, such as fluoresce<strong>in</strong> or rhodam<strong>in</strong>e, and the reactionbetween the antigen and the antibody is detected by fluorescencemicroscopy. In the direct antigen-detection test, fluoresce<strong>in</strong>-conjugated antibodiesare used to reveal the presence of a specific antigen. The test is a valuableaid <strong>in</strong> the rapid identification of Chlamydia trachomatis, C. psittaci,Rickettsia spp., Streptococcus pyogenes, Bordetella pertussis, Corynebacterium diphtheriae,Legionella pneumophila, and other organisms <strong>in</strong> cl<strong>in</strong>ical specimens.In the <strong>in</strong>direct fluorescent antibody (IFA) test, serial dilutions of a patient’sserum are allowed to react with the specific antigen, and antihuman IgG orIgM antibodies conjugated to fluoresce<strong>in</strong> are added to make the reactionvisible. For example, <strong>in</strong> the serodiagnosis of syphilis, Treponema pallidumantigen is fixed to a slide, overlaid with the patient’s serum, and then washed.Fluoresce<strong>in</strong>-labelled antihuman immunoglobul<strong>in</strong> is then placed on the preparation,which is washed and exam<strong>in</strong>ed by fluorescence microscopy. If thepatient’s serum conta<strong>in</strong>s specific antibodies to Treponema pallidum, brightlyfluorescent spirochaetes are seen. If the spirochaetes do not fluoresce, no specificantitreponemal antibodies are present <strong>in</strong> the patient’s serum. The IFA testcan also be used to identify other bacteria, <strong>in</strong>clud<strong>in</strong>g mycobacteria, and thisprocedure is often more sensitive than the direct immunofluorescence test,because more fluoresce<strong>in</strong>-labelled antibodies will attach to each antigen site.Serological tests for syphilisThe serological tests for the diagnosis of syphilis <strong>in</strong>clude non-treponemal andtreponemal tests. The non-treponemal tests are the VDRL and the RPR tests.The antigens used <strong>in</strong> these tests are prepared from non-treponemal antigens,such as cardiolip<strong>in</strong>–lecith<strong>in</strong>, and they detect the antibody-like substancereag<strong>in</strong>, which is present <strong>in</strong> the sera of many patients with syphilis, and mayoccasionally be detected <strong>in</strong> the sera of patients with other acute and chronicdiseases. These tests are practical, <strong>in</strong>expensive, and reproducible, althoughthey are not absolutely specific. They may confirm the diagnosis of early orlate symptomatic syphilis or provide diagnostic evidence of latent syphilis.This test is superior to the treponemal tests as a follow-up <strong>in</strong>vestigation aftertreatment. Moreover, the VDRL test is an effective tool <strong>in</strong> epidemiological<strong>in</strong>vestigations of syphilis and other treponemal diseases.The treponemal tests use Treponema pallidum antigens to detect specific antibodiesthat have developed <strong>in</strong> serum <strong>in</strong> response to syphilis <strong>in</strong>fection. Theprocedures are used to verify the specificity of positive reactions <strong>in</strong> nontreponemaltests. The fluorescent treponemal antibody absorption test (FTA-Abs) and the Treponema pallidum haemagglut<strong>in</strong>ation test (TPHA) are highlyspecific and sensitive but they cannot differentiate between active and pastsyphilis <strong>in</strong>fections; neither can they be used for evaluat<strong>in</strong>g therapeuticresponse.126


BACTERIOLOGICAL INVESTIGATIONSVDRL testThe VDRL test uses cardiolip<strong>in</strong>–lecith<strong>in</strong>-coated cholesterol particles. Inactivatedserum or cerebrosp<strong>in</strong>al fluid and VDRL antigen emulsion are mixedus<strong>in</strong>g a rotat<strong>in</strong>g mach<strong>in</strong>e for a prescribed period of time. The VDRL particleswill flocculate if reag<strong>in</strong> is present <strong>in</strong> the serum or cerebrosp<strong>in</strong>al fluid.The VDRL test is strongly reactive for early syphilis <strong>in</strong>fection. After effectivetreatment the titre falls gradually and usually becomes non-reactive with<strong>in</strong>1–2 years. In the late phase of the disease the serum may rema<strong>in</strong> reactive at alow titre (e.g. 1:8 or less) for many years, even after effective treatment. Reactivitymay cease spontaneously <strong>in</strong> about 20–30% of untreated patients dur<strong>in</strong>gthe latent phase of the disease, and even more often dur<strong>in</strong>g the late phase.False-positive results may be observed because of the similarity of the VDRLantigen with normal host tissue. Although false-positive reactions can sometimesbe observed <strong>in</strong> the serum of healthy persons, they are often associatedwith a specific disease or follow<strong>in</strong>g vacc<strong>in</strong>ation. Acute false-positive reactionsoften have low titres (1:8 or less) and are ma<strong>in</strong>ly seen <strong>in</strong> persons with viralor bacterial <strong>in</strong>fections (atypical pneumonia, psittacosis, <strong>in</strong>fectious mononucleosisand <strong>in</strong>fectious hepatitis), dur<strong>in</strong>g pregnancy or after recent vacc<strong>in</strong>ation.Prolonged false-positive reactions usually have high titres that are caused byautoantibodies (rheumatoid factors) <strong>in</strong> patients with lepromatous leprosy,tuberculosis, immune disorders (e.g. lupus erythematosus, collagenosis,rheumatic diseases, Sjögren syndrome, dysgammaglobul<strong>in</strong>aemia) and occasionallymalaria, or <strong>in</strong> those who are dependent on hero<strong>in</strong>. Reactive or weaklyreactive VDRL test results should not be considered conclusive evidence ofsyphilis <strong>in</strong> a patient and a non-reactive VDRL test by itself does not rule outthe diagnosis of syphilis. Any test sample giv<strong>in</strong>g a reactive or weakly reactiveresult <strong>in</strong> the absence of cl<strong>in</strong>ical evidence of syphilis should therefore be subjectedto a treponemal test such as FTA-Abs or TPHA.Materials and reagents provided <strong>in</strong> the VDRL test kitBuffered sal<strong>in</strong>e solutionControl sera set (non-reactive, weakly reactive and reactive)VDRL antigenAdditional materials and reagents required for the VDRL testAbsolute alcohol and acetoneAgglut<strong>in</strong>ation slide, approximately 5 ¥ 7.5cm with wells 16mm <strong>in</strong> diameterand 1.75mm deep, for cerebrosp<strong>in</strong>al fluid testsAliquot vialsDistilled or deionized waterGlass plate with 12 paraff<strong>in</strong> or ceramic r<strong>in</strong>gs approximately 14mm <strong>in</strong> diameterfor serum testsHumidity coverHypodermic needles without bevels: 18-gauge for serum tests, and 21- or22-gauge for cerebrosp<strong>in</strong>al fluid testsInterval timerLight microscope with ¥10 ocular and ¥10 objectiveMechanical rotator, circumscrib<strong>in</strong>g a circle 2cm <strong>in</strong> diameter, at a speed of180rev/m<strong>in</strong>, on a horizontal plane, with an automatic timerpH meterSerological pipettes: 5.0ml, 1.0ml and 0.2mlSterile sal<strong>in</strong>e solutions (0.85% and 10%)Syr<strong>in</strong>ge, Luer-type, 1 or 2ml127


SEROLOGICAL TESTSVDRL antigen emulsion bottles, 30-ml, round, glass-stoppered, narrowmouth,approximately 35mm <strong>in</strong> diameter with flat <strong>in</strong>ner bottom surfaceWater-bath (56 ∞C)Rehydration of VDRL antigen and control seraThe VDRL antigen is an alcoholic solution of lipids (cardiolip<strong>in</strong> and lecith<strong>in</strong>)and cholesterol. These substances are not soluble <strong>in</strong> water. VDRL antigen isunstable and a fresh suspension must be prepared on the day of use. Pour thecontents of the antigen ampoule <strong>in</strong>to the storage vial. Ensure that the vialis tightly capped and store <strong>in</strong> the dark at 15–30 ∞C. Withdraw antigen asrequired.After the bottle of buffered sal<strong>in</strong>e has been opened, it should be stored <strong>in</strong> therefrigerator. Discard if turbidity appears.Rehydrate the control sera with 3ml of distilled or deionized water. Dividethe rehydrated sera that are surplus to the day’s use <strong>in</strong>to suitable aliquot portions(one day’s use) and store at -20∞C for up to one month. Do not thawand refreeze. Store the sera to be used for the day <strong>in</strong> the refrigerator at 2–8∞C.Preparation of VDRL antigen emulsion1. Allow the antigen and buffered sal<strong>in</strong>e to reach room temperature.Check the pH of the buffered sal<strong>in</strong>e and discard if outside the range of pH6.0 ± 0.1.2. Pipette 0.4ml of buffered sal<strong>in</strong>e <strong>in</strong>to an antigen emulsion bottle and gentlytilt the bottle so that the buffered sal<strong>in</strong>e covers the bottom the bottle.3. Measure 0.5ml of antigen solution us<strong>in</strong>g a 1-ml pipette graduated to thetip, and add the antigen as follows:• Keep the pipette <strong>in</strong> the upper one third of the bottle. Do not let it touchthe sal<strong>in</strong>e.• While rotat<strong>in</strong>g the bottle manually <strong>in</strong> a circle approximately 5cm <strong>in</strong>diameter, add the antigen drop by drop to the buffered sal<strong>in</strong>e.• Allow approximately 6 seconds to add the antigen, then discharge therema<strong>in</strong><strong>in</strong>g antigen <strong>in</strong> the pipette <strong>in</strong>to the bottle.• Cont<strong>in</strong>ue rotation of the bottle for 10 seconds.4. Add 4.1ml of buffered sal<strong>in</strong>e to the bottle, allow<strong>in</strong>g it to flow down theside of the bottle.5. Place the glass stopper <strong>in</strong> the bottle and shake the bottle up and downapproximately 30 times <strong>in</strong> 10 seconds.6. Let the antigen emulsion stand for at least 10 m<strong>in</strong>utes before us<strong>in</strong>g. Swirlgently prior to use. The antigen emulsion may be used for the next 8 hours.7. If cerebrosp<strong>in</strong>al fluid is to be tested, dilute the antigen emulsion a further1:2 with an equal volume of 10% sal<strong>in</strong>e solution. Shake the bottle gentlyfor 10 seconds and allow to stand for a m<strong>in</strong>imum of 5 m<strong>in</strong>utes and amaximum of 2 hours before us<strong>in</strong>g.VDRL qualitative test1. Us<strong>in</strong>g a 1.0ml pipette, mix the <strong>in</strong>activated serum several times then add0.05ml to the first well of the VDRL glass plate.2. Spread the serum with a circular motion of the pipette tip so that it coversthe entire <strong>in</strong>ner surface of the paraff<strong>in</strong> or ceramic well. Use only cleanplates that allow the serum to cover evenly the entire surface with<strong>in</strong> theparaff<strong>in</strong> or ceramic well.128


BACTERIOLOGICAL INVESTIGATIONS3. Take a syr<strong>in</strong>ge with an 18-gauge needle and, hold<strong>in</strong>g it vertically, carefullyadd 1 drop of antigen (1/60ml) to the serum. Do not allow the needle totouch the serum.4. Place the plates on the mechanical rotator under a humidity cover androtate for 4 m<strong>in</strong>utes. If a mechanical rotator is not available rotate the cardby hand with a steady circular motion for 4 m<strong>in</strong>utes.5. Exam<strong>in</strong>e the plate immediately after rotation us<strong>in</strong>g a microscope with a¥10 ocular and a ¥10 objective.6. Read the reactions as follows:Medium and large clumps R ReactiveSmall clumps W Weakly reactiveNo clump<strong>in</strong>g or very slight roughness N Non-reactiveSerum that produces weakly reactive or rough non-reactive results should beretested with the semi-quantitative test as prozone reactions are occasionallyencountered.VDRL semi-quantitative test1. Prepare a two-fold serial dilution of <strong>in</strong>activated serum <strong>in</strong> 0.85% sal<strong>in</strong>e(1:2, 1:4, 1:8, 1:16, 1:32).2. Test each serum dilution us<strong>in</strong>g the qualitative test procedure.3. Report the results <strong>in</strong> terms of the highest serum dilution that producesa reactive (not weakly reactive) result <strong>in</strong> accordance with the follow<strong>in</strong>gexamples:DilutionReportUndilutedserum 1:2 1:4 1:8 1:16 1:32W N N N N N Weakly reactive, undilutedR W N N N N Reactive, undilutedR R W N N N Reactive, 1:2 dilutionR R R W N N Reactive, 1:4 dilutionW W R R W N Reactive, 1:8 dilutionN (rough) W R R R N Reactive, 1:16 dilutionW: weakly reactive; R: reactive; N: non-reactive.4. If reactive results are obta<strong>in</strong>ed up to dilution 1:32, prepare further twofoldserial dilutions <strong>in</strong> 0.85% sal<strong>in</strong>e (1:64, 1:128 and 1:256) and retest us<strong>in</strong>g thequalitative test procedure.RPR testThe antigen suspension <strong>in</strong> the RPR test conta<strong>in</strong>s charcoal particles to allowfor macroscopically visible flocculation. The ma<strong>in</strong> differences between theRPR test and the VDRL test are that it uses a stabilized antigen, cards <strong>in</strong>steadof plates, and serum as well as plasma, and the serum does not need to beheated. As only a small amount of sample is required, plasma or serum fromcapillary blood can also be used. The RPR test cannot be used to test cerebrosp<strong>in</strong>alfluid.129


SEROLOGICAL TESTSIn the RPR test the antigen is ready for immediate use. It requires no priorpreparation or dilution. Unopened antigen reagent has a shelf-life of one year;storage <strong>in</strong> a refrigerator is recommended. Once opened, the antigen reagentma<strong>in</strong>ta<strong>in</strong>s its reactivity for 3 months when stored <strong>in</strong> the refrigerator <strong>in</strong> itsplastic dispenser. The RPR test is slightly more sensitive than the VDRL testand it is easier and quicker to perform. False-positive reactions occur slightlymore often with the RPR test than with the VDRL test. Some commercial kitsrequire a mechanical rotator for mix<strong>in</strong>g the reagents, whereas others can berotated manually.Materials and reagents provided <strong>in</strong> the RPR test kitAntigen delivery needle to deliver 60 drops/ml of the antigen suspensionControl sera, positive and negativeDisposable droppers to deliver 50ml of serum or plasmaPlastic-coated RPR test cards, each with two rows of five wellsPrepared RPR antigen suspensionStirrersAdditional materials and reagents required for the RPR testDisposable dropperGrease pencilHumidity coverMechanical rotator, circumscrib<strong>in</strong>g a circle 2cm <strong>in</strong> diameter, at a speed of180rev/m<strong>in</strong>, on a horizontal plane, with an automatic timerSterile sal<strong>in</strong>e (0.85%)RPR qualitative test1. Remove the reagent kit from the refrigerator and allow the reagents towarm to room temperature.2. Reconstitute the control serum by add<strong>in</strong>g the recommended volume of distilledwater.3. <strong>Lab</strong>el each well on the RPR card with the laboratory number of a sampleto be tested, <strong>in</strong>clud<strong>in</strong>g wells for positive, weakly positive and negativecontrol sera.4. Use the disposable dropper to add 50 ml of unheated serum or plasma tothe correspond<strong>in</strong>g well. Use a new dropper for each sample.5. Gently shake the antigen suspension and add one free-fall<strong>in</strong>g drop to eachwell us<strong>in</strong>g the antigen delivery needle provided. Carefully mix the antigensuspension and serum. Use a new stirrer for each sample. Spread to coverthe area of the well.6. Place the card on the mechanical rotator under a humidity cover and rotatefor 8 m<strong>in</strong>utes. If a mechanical rotator is not available rotate the card byhand with a steady circular motion for 2 m<strong>in</strong>utes, then place it <strong>in</strong> a moistchamber conta<strong>in</strong><strong>in</strong>g wet tissue or filter-paper for 6 m<strong>in</strong>utes. Remove thecard and rotate briefly to obta<strong>in</strong> the f<strong>in</strong>al read<strong>in</strong>g. Take care to avoid crosscontam<strong>in</strong>ationof samples.7. Remove the card from the rotator and exam<strong>in</strong>e it macroscopically <strong>in</strong> a goodlight. The positive control serum should show clearly visible agglut<strong>in</strong>ation.The negative control serum should show no agglut<strong>in</strong>ation. A brief rotationand tilt<strong>in</strong>g of the card by hand can help to differentiate weakly reactivefrom non-reactive samples.8. Record the test results:• Small to large flocculated clumps: reactive• Even turbidity of the particle suspension: non-reactive9. Prepare serial dilutions of any reactive sera to estimate the antibody titre.130


BACTERIOLOGICAL INVESTIGATIONSRPR semi-quantitative test1. Remove the reagent kit from the refrigerator and allow the reagents towarm to room temperature.2. <strong>Lab</strong>el a row of 5 wells on the RPR card with the laboratory number foreach sample to be tested.3. Use the disposable dropper to add 1 drop of sal<strong>in</strong>e (0.85%) to each well.Do not spread.4. Use a new dropper to add 1 drop of the serum sample to the first well.Mix by draw<strong>in</strong>g up and down the dropper 5–6 times (avoid bubble formation).5. Transfer 50ml of the mixed sample (1:2 dilution) to the next well. Mix.Repeat the procedure up to the 5th well (1:32 dilution). Discard 50ml fromthe last dilution.6. Spread the diluted samples over the entire area of the test well start<strong>in</strong>gwith the highest dilution. Use a new stirrer for each sample.7. Gently shake the antigen add 1 free-fall<strong>in</strong>g drop to each well us<strong>in</strong>g theantigen delivery needle provided. Carefully mix the antigen suspensionand serum. Spread to cover the area of the well. Use a new stirrer for eachsample.8. Place the card on the mechanical rotator under a humidity cover androtate for 8 m<strong>in</strong>utes. If a mechanical rotator is not available rotate the cardby hand with a steady circular motion for 2 m<strong>in</strong>utes, then place it <strong>in</strong> amoist chamber conta<strong>in</strong><strong>in</strong>g wet tissue or filter-paper for 6 m<strong>in</strong>utes.Remove the card and rotate briefly to obta<strong>in</strong> the f<strong>in</strong>al read<strong>in</strong>g. Take careto avoid cross-contam<strong>in</strong>ation of samples.9. Remove the card from the rotator and exam<strong>in</strong>e it macroscopically <strong>in</strong> agood light. The highest dilution to conta<strong>in</strong> macroscopic agglut<strong>in</strong>ation isthe titre of the sample.10. If the sample is positive at 1:32, the dilution series should be extended.Prepare a 1:16 dilution <strong>in</strong> sal<strong>in</strong>e (0.85%) and perform a serial dilutionseries as described previously.Fluorescent treponemal antibody absorptiontest (FTA-Abs)The antigen used for the FTA-Abs test consists of Treponema pallidum (Nicholsstra<strong>in</strong>) which is fixed with acetone on a slide. Lyophilized T. pallidum cellsreconstituted <strong>in</strong> sal<strong>in</strong>e can also be used. Inactivated patient serum is <strong>in</strong>cubatedwith a sorbent consist<strong>in</strong>g of Reiter treponemes for absorption of nonspecifictreponemal group antibodies. After absorption, patient serum is added to theslide. Specific antibodies <strong>in</strong> the serum b<strong>in</strong>d to the surface of the treponemalcells. After r<strong>in</strong>s<strong>in</strong>g, a conjugate of antihuman antibodies with a fluorescentsta<strong>in</strong> (fluoresce<strong>in</strong> isothiocyanate) is added to the treponemes. The conjugatewill b<strong>in</strong>d to the antibodies that have bound to the treponemes and can be visualizedby fluorescence microscopy.Reactivity can be observed three weeks after <strong>in</strong>fection and is permanent <strong>in</strong>untreated patients. It may be observed several years after successful drugtreatment <strong>in</strong> the early phase of the disease and may be permanent <strong>in</strong> patientswho receive adequate drug therapy only <strong>in</strong> the late phase of the disease. Apositive reaction <strong>in</strong> the FTA-Abs test <strong>in</strong>dicates a high probability of syphilitic<strong>in</strong>fection. False-negative results are exceptional and may be due to poorquality antigen. False-positive results may be caused by group antibodies thatwere not elim<strong>in</strong>ated dur<strong>in</strong>g absorption procedures or by unsatisfactoryreagents. False-positive results have also been reported <strong>in</strong> patients with131


SEROLOGICAL TESTShepatic cirrhosis, balanitis, collagenosis, herpes gestationis, lupus erythematosus,and very occasionally <strong>in</strong> pregnant women and healthy persons, forunknown reasons.Cross-reactivity between T. pallidum and Borrelia burgdorferi (Lyme disease) hasbeen demonstrated. In particular, specimens with a disproportionately highantibody titre <strong>in</strong> an FTA-Abs test, compared with other serological syphilistests, should be tested for antibodies aga<strong>in</strong>st Borrelia.The ma<strong>in</strong> advantages of the FTA-Abs test is its high specificity and sensitivityas well as the early onset of reactivity. The results are reliable and may bedecisive <strong>in</strong> doubtful cases. However, the FTA-Abs test is time-consum<strong>in</strong>g andexpensive; it requires highly tra<strong>in</strong>ed personnel to carry it out and to read theresults. It should therefore be used only as a confirmatory test <strong>in</strong> cases wherethe diagnosis is <strong>in</strong> doubt.Materials and reagents provided <strong>in</strong> the FTA-Abs test kitBuffer solutionControl sera, positive and negativeFluoresce<strong>in</strong>-labelled antihuman immunoglobul<strong>in</strong> (conjugate)Lyophilized extract of Reiter treponemes (sorbent)T. pallidum smears fixed to slidesAdditional materials and reagents required for the FTA-Abs testCoverslipsFluorescence microscope with UV illum<strong>in</strong>ation (¥40 objective)Mount<strong>in</strong>g mediumPhosphate-buffered sal<strong>in</strong>e, pH 7.2 (PBS)Tween 80 (2%)-PBSFTA-Abs test1. Remove the reagent kit from the refrigerator and allow the reagents towarm to room temperature.2. Allow the required number of slides to warm to room temperature for 15m<strong>in</strong>utes.3. Dilute 50ml of serum with 0.2ml of sorbent and mix. Dilute positivecontrol and negative control sera <strong>in</strong> parallel, 1:5 <strong>in</strong> buffer solution and1:5 <strong>in</strong> sorbent.4. Cover the smear on one slide with 10ml of buffer solution (conjugatecontrol) and the smear on a second slide with 10ml of sorbent (sorbentcontrol).5. On the rema<strong>in</strong><strong>in</strong>g slides cover the smears with 10ml each of serum dilutionand control serum dilutions.6. Place the slides <strong>in</strong> a moist chamber for 30 m<strong>in</strong>utes at 37∞C. Wash the slidesfor 5 m<strong>in</strong>utes <strong>in</strong> Tween-PBS solution. Repeat each wash. R<strong>in</strong>se <strong>in</strong> distilledwater, then dra<strong>in</strong> and leave to dry <strong>in</strong> a slide box.7. Cover the smears on all slides with 10ml of antihuman immunoglobul<strong>in</strong>diluted <strong>in</strong> buffer solution accord<strong>in</strong>g to the manufacturer’s <strong>in</strong>structions.8. Place the slides <strong>in</strong> a moist chamber for 30 m<strong>in</strong>utes at 37∞C. Wash the slidesfor 5 m<strong>in</strong>utes <strong>in</strong> Tween-PBS. Repeat each wash. R<strong>in</strong>se <strong>in</strong> distilled water,then dra<strong>in</strong> and leave to dry <strong>in</strong> a slide box.9. Cover each smear with 2 drops of mount<strong>in</strong>g medium and a coverslip.10. Check that the conjugate, sorbent and negative serum controls do notfluoresce:132


BACTERIOLOGICAL INVESTIGATIONS• No fluorescence or slightly greenish treponemes: negative reaction• Vary<strong>in</strong>g degree of green fluorescence: positive reactionThe degree of fluorescence can be graded as:Non-reactive 0Borderl<strong>in</strong>e 1+, 2+, 3+Reactive 4+A reaction of 2+ or greater is regarded as <strong>in</strong>dicative of T. pallidum <strong>in</strong>fection.Febrile agglut<strong>in</strong><strong>in</strong>s testsPhysicians who treat patients with <strong>in</strong>explicable fever often request a series ofserological tests, collectively known as febrile agglut<strong>in</strong><strong>in</strong>s tests, to demonstrate<strong>in</strong>fections with Brucella (Wright test), Salmonella typhi (Widal test) andsome rickettsias (Weil–Felix reaction). The tests measure agglut<strong>in</strong>at<strong>in</strong>g antibodiesdirected aga<strong>in</strong>st an O surface antigen and/or an H flagella antigen ofthe suspected organism, or, <strong>in</strong> the case of the Weil–Felix reaction, a crossreact<strong>in</strong>gsurface antigen of two stra<strong>in</strong>s of Proteus vulgaris.The Widal and Weil–Felix tests are no longer recommended for the screen<strong>in</strong>gof patients as they pose a considerable number of technical and <strong>in</strong>terpretationalproblems. A negative reaction will not exclude active <strong>in</strong>fection as the<strong>in</strong>fection may be <strong>in</strong> the <strong>in</strong>cubation period and the patient has not yet produceddetectable antibodies aga<strong>in</strong>st the organism. The prozone phenomenonalso results <strong>in</strong> a negative reaction; this can be prevented by us<strong>in</strong>g serial dilutionsof the serum. A positive reaction with a given antigen may not be diagnostic,as the patient may exhibit a rise <strong>in</strong> heterologous agglut<strong>in</strong><strong>in</strong>s dur<strong>in</strong>g thecourse of the illness. Such reactions are known as nonspecific anamnestic reactionsbecause the patient has responded to an antigenic stimulus with productionof nonspecific agglut<strong>in</strong><strong>in</strong>s. This makes serological diagnosis based ona s<strong>in</strong>gle high antibody titre too uncerta<strong>in</strong>, and only seroconversion with afourfold or greater rise <strong>in</strong> titre on serial dilutions of sera should be acceptedas an <strong>in</strong>dication of a recent <strong>in</strong>fection.Most patients with acute brucellosis will have an agglut<strong>in</strong><strong>in</strong> titre of 1:320 orgreater by the end of the second week of illness. Even one year after treatment,20% of patients will cont<strong>in</strong>ue to have a significant Brucella agglut<strong>in</strong><strong>in</strong>titre. High Brucella agglut<strong>in</strong><strong>in</strong> titres have also been recorded <strong>in</strong> patients withFrancisella tularensis and Yers<strong>in</strong>ia entero-colitica <strong>in</strong>fections, and <strong>in</strong> patients whohave recently had a Brucella or cholera vacc<strong>in</strong>ation or been tested with brucellerg<strong>in</strong>sk<strong>in</strong> test. They have also occasionally been recorded <strong>in</strong> abattoirworkers.Because blood culture may not demonstrate the organism for many weeks, ifever, the Brucella agglut<strong>in</strong><strong>in</strong> determ<strong>in</strong>ations can support a presumptive diagnosisof acute brucellosis. Isolation of the organism, usually from blood, providesdef<strong>in</strong>itive proof of <strong>in</strong>fection. However, <strong>in</strong> suspected cases where bloodculture does not show <strong>in</strong>fection, sternal bone marrow aspirate may be culturedto confirm the diagnosis. Patients with localized brucellosis may beafebrile and may not have significant levels of Brucella agglut<strong>in</strong><strong>in</strong> titre. In thesecases, the <strong>in</strong>fection should be suspected on epidemiological grounds and bydetection of calcified lymph nodes on X-ray, but the diagnosis should be confirmedby culture.133


SEROLOGICAL TESTSThe rapid slide test is a screen<strong>in</strong>g test designed to detect agglut<strong>in</strong><strong>in</strong>s, whereasthe tube test is a confirmatory test designed to measure the agglut<strong>in</strong><strong>in</strong> quantitatively.Any positive result obta<strong>in</strong>ed with the slide test should be verifiedwith the tube test.Materials and reagents provided <strong>in</strong> the febrile agglut<strong>in</strong><strong>in</strong>s test kitAntigen suspensions (B. abortus, B. melitensis) <strong>in</strong> bottles fitted with droppersNegative control serumPositive control serumAdditional materials and reagents required for the febrileagglut<strong>in</strong><strong>in</strong>s testApplicator sticksGlass plateGrease pencilPipettes, 50–1000 mlRulerSterile sal<strong>in</strong>e (0.85%)Test-tubes and test-tube racksTimerWater-bath, temperature-controlledFebrile agglut<strong>in</strong><strong>in</strong>s slide testThis test is preferred to the tube test as it is less complicated.1. The serum sample must be clear and free of visible fat. It should not showhaemolysis or be contam<strong>in</strong>ated by bacteria. It should not be heat <strong>in</strong>activated,as this may destroy some of the thermolabile agglut<strong>in</strong><strong>in</strong>s.2. Prepare the glass plate by draw<strong>in</strong>g up rows of 2.5-cm squares with theruler and the grease pencil. Each row of 5 squares is sufficient to test oneantigen aga<strong>in</strong>st serum dilutions up to 1:320.3. Use a 0.2ml pipette to add 0.08, 0.04, 0.02, 0.01, and 0.005ml of serum to arow of squares on the glass plate.4. Place 1 drop of the appropriate well-mixed antigen suspension for the slidetest on each drop of serum.5. Mix the serum–antigen mixture with an applicator stick, start<strong>in</strong>g from thehighest serum dilution. The f<strong>in</strong>al dilutions are correlated approximately tothe macroscopic tube test dilutions and are counted as 1:20, 1:40, 1:80,1:160 and 1:320, respectively.6. Hold the glass plate with both hands and gently rotate it 15–20 times.Exam<strong>in</strong>e the serum–antigen mixture macroscopically for agglut<strong>in</strong>ationwith<strong>in</strong> 1 m<strong>in</strong>ute <strong>in</strong> a good light. Reactions occurr<strong>in</strong>g later may be due tothe reactants dry<strong>in</strong>g on the slide and should be verified with the tube test.7. Record results as follows:Complete agglut<strong>in</strong>ation 4+Approximately 75% of the cells are clumped 3+Approximately 50% of the cells are clumped 2+Approximately 25% of the cells are clumped 1+Trace or no agglut<strong>in</strong>ation —Febrile agglut<strong>in</strong><strong>in</strong>s tube testPrepare serial dilutions of serum and the control sera <strong>in</strong> the follow<strong>in</strong>gmanner:134


BACTERIOLOGICAL INVESTIGATIONS1. Place 8 test-tubes <strong>in</strong> a rack for each serum to be tested.2. Pipette 1.9ml of sal<strong>in</strong>e (0.85%) <strong>in</strong>to the first tube of each row and 0.5ml<strong>in</strong>to each of the rema<strong>in</strong><strong>in</strong>g tubes.3. Add 0.1ml of the serum to tube 1 conta<strong>in</strong><strong>in</strong>g 1.9ml of sal<strong>in</strong>e.4. Mix well with a pipette and transfer 0.5ml to tube 2. Mix thoroughly.5. Cont<strong>in</strong>ue down the row of rubes add<strong>in</strong>g 1 drop of serum dilution untiltube 7. Mix thoroughly. Discard 0.5ml from tube 7 after mix<strong>in</strong>g thoroughly.Tube 8 is the antigen control tube.6. Add 0.5ml of the respective antigen to each of the 8 tubes. Shake the racksto mix the antigen and antiserum. The resultant dilutions are 1:20 through1:1280, respectively.7. Incubate <strong>in</strong> a water-bath at 37 ∞C for 48 hours or accord<strong>in</strong>g to the manufacturer’s<strong>in</strong>structions.8. Exam<strong>in</strong>e the tubes macroscopically for agglut<strong>in</strong>ation with<strong>in</strong> 1 m<strong>in</strong>ute <strong>in</strong> agood light aga<strong>in</strong>st a black background. The tubes should not be shaken.Positive reactions show obvious agglut<strong>in</strong>ation (granulation); negative reactionsshow a cloudy suspension without agglut<strong>in</strong>ation. The highest degreeof dilution of serum <strong>in</strong> a tube show<strong>in</strong>g agglut<strong>in</strong>ation is the titre.Discard an antigen if it does not agglut<strong>in</strong>ate with a known positive controlserum, or if it agglut<strong>in</strong>ates with a known negative control serum.Agglut<strong>in</strong><strong>in</strong>s may be found <strong>in</strong> healthy <strong>in</strong>dividuals, and s<strong>in</strong>gle sera with titresof less than 80 are of doubtful significance. False-positive results may occurwith sera from patients <strong>in</strong>fected with Francisella tularensis or vacc<strong>in</strong>atedaga<strong>in</strong>st Vibrio cholerae. It is not possible to differentiate between B. abortus andB. melitensis <strong>in</strong>fections us<strong>in</strong>g this test.Antistreptolys<strong>in</strong> O (ASO) testStreptococcal <strong>in</strong>fections are very common <strong>in</strong> all populations, and a high percentageof people will have antibodies aga<strong>in</strong>st streptococci. The b-haemolyticgroup A streptococci produce two haemolys<strong>in</strong>s: oxygen-labile streptolys<strong>in</strong> Oand oxygen-stable haemolys<strong>in</strong> S. Only reduced (non-oxidized) streptolys<strong>in</strong> Ois immunogenic and is used for the test. The antistreptolys<strong>in</strong> O test is basedon the fact that patients with Streptococcus pyogenes (group A streptococcal)<strong>in</strong>fections develop antibodies that <strong>in</strong>hibit the haemolytic activity of streptolys<strong>in</strong>O. The antibodies are usually long-last<strong>in</strong>g and a s<strong>in</strong>gle <strong>in</strong>creased titreis not an <strong>in</strong>dication of a current <strong>in</strong>fection. Only a fourfold or greater rise <strong>in</strong>titre on successive serum samples taken 10–14 days apart should be considered<strong>in</strong>dicative of recent <strong>in</strong>fection. This test is ma<strong>in</strong>ly used <strong>in</strong> the diagnosis ofacute rheumatic fever, acute glomerulonephritis and other post-streptococcaldiseases.There are two types of commercial antistreptolys<strong>in</strong> O test kits:• The ASO latex slide agglut<strong>in</strong>ation test is used to screen sera to identifythose with raised ASO titres (200IU or higher).• The ASO tube test is a haemolysis <strong>in</strong>hibition test that is used to determ<strong>in</strong>eASO antibody titre <strong>in</strong> serum samples that are positive <strong>in</strong> the ASO latexslide agglut<strong>in</strong>ation test. A titre of less than 50IU does not confirm the diagnosisof acute rheumatic fever.135


SEROLOGICAL TESTSMaterials and reagents provided <strong>in</strong> the ASO latex slide agglut<strong>in</strong>ationtest kitDisposable cards, with 6 wells eachDisposable dropperPositive control serumSensitized latex reagent (with streptolys<strong>in</strong> O)Additional materials required for the ASO latex slide agglut<strong>in</strong>ation testApplicator sticksASO latex slide agglut<strong>in</strong>ation test1. Dilute the serum 1:20.2. Place 1 drop of the serum solution <strong>in</strong> a well on the disposable card.3. Use a new dropper to add 1 drop of sensitized latex reagent.4. Use an applicator stick to mix the two drops and spread them over theentire well.5. Exam<strong>in</strong>e for agglut<strong>in</strong>ation with<strong>in</strong> 2 m<strong>in</strong>utes.A positive reaction appears as a f<strong>in</strong>e flocculation (agglut<strong>in</strong>ation) with<strong>in</strong> 2m<strong>in</strong>utes.A negative reaction shows no agglut<strong>in</strong>ation.If the flocculation appears with<strong>in</strong> 2 m<strong>in</strong>utes, the serum should be titrated withthe antistreptolys<strong>in</strong> O tube test.Materials and reagents provided <strong>in</strong> the ASO tube test kitPositive control serumReduced streptolys<strong>in</strong> O antigen (dried preparation)Sheep red blood cellsStandard antistreptolys<strong>in</strong> O antibody (dried preparation, 20IU/bottle)Streptolys<strong>in</strong> O buffer (25¥ concentrated solution)Additional materials required for the ASO tube testDistilled waterPipettes (1ml, 2ml)Test-tubesWater-bathASO tube test1. Reconstitute the reduced streptolys<strong>in</strong> O antigen (dried preparation)with the appropriate volume of distilled water (stated on the bottlelabel) to give a potency of 2 IU equivalent per ml. The solutionshould be used with<strong>in</strong> 6 hours of reconstitution as it does not conta<strong>in</strong>preservatives.2. Reconstitute the standard antistreptolys<strong>in</strong> O antibody (dried preparation,20IU/bottle) with 10ml of streptolys<strong>in</strong> O buffer. The solution can bestored for six months at 4∞C provided it does not become contam<strong>in</strong>ated.3. Dilute the streptolys<strong>in</strong> O buffer (25¥ concentrated solution) with 480mlof distilled water before use. Diluted buffer should be discarded after oneweek.136


BACTERIOLOGICAL INVESTIGATIONS4. Wash and centrifuge 1ml of sheep red blood cells three times <strong>in</strong> streptolys<strong>in</strong>O buffer and pipette the supernatant fluid off. Add streptolys<strong>in</strong> Obuffer to give an 8% cell suspension.5. Allow the reagents and serum samples to reach room temperature.6. Make a 1:10 dilution of patient serum <strong>in</strong> a test-tube (0.1ml serum + 0.9ml streptolys<strong>in</strong> O buffer). Prepare 2 master dilutions from the 1:10 dilutionas shown <strong>in</strong> the table below:Serum Buffer Dilution0.2ml (1:10) 1.8ml 1:1001.0ml (1:100) 0.5ml 1:1507. Prepare the follow<strong>in</strong>g dilution series with streptolys<strong>in</strong> O buffer for eachof these master dilutions:Tube Serum Buffer Dilution Reduced streptolys<strong>in</strong> O1 0.2ml (1:10) 0.8ml 1:50 0.5ml2 0.5ml (1:100) 0.5ml 1:200 0.5ml3 0.5ml (1:200) 0.5ml 1:400 0.5ml4 0.5ml (1:400) 0.5ml 1:800 0.5ml5 0.5ml (1:150) 0.5ml 1:300 0.5ml6 0.5ml (1:300) 0.5ml 1:600 0.5ml7 0 1.5ml — 08 0 1.0ml — 0.5ml8. Rearrange the tubes <strong>in</strong> ris<strong>in</strong>g dilutions: 1:50, 1:200, 1:300, 1:400, 1:600,1:800.9. Add 1.5ml of buffer to control tube 7 and 1ml of buffer to control tube 8.10. Add 0.5ml of reduced streptolys<strong>in</strong> O to all test-tubes, except control tube7.11. Mix and refrigerate at 4 ∞C for two hours to allow the antibody–antigenreaction to take place.12. Add 0.5ml of the 8% cell suspension to each tube, <strong>in</strong>clud<strong>in</strong>g control tubes7 and 8, mix and <strong>in</strong>cubate <strong>in</strong> a water-bath at 37 ∞C for 30 m<strong>in</strong>utes.13. Centrifuge the tubes at 1000 g for 2 m<strong>in</strong>utes and observe for haemolysis.Control tube 7 should show no haemolysis and control tube 8 should becompletely haemolysed.14. The ASO titre is determ<strong>in</strong>ed as the highest dilution show<strong>in</strong>g no sign ofhaemolysis:• If there is haemolysis <strong>in</strong> all tubes, report the result as “ASO titre lessthan 200IU”.• If there is no haemolysis <strong>in</strong> the tubes with a higher serum dilution,report the result as “ASO reactive with the titre”.Bacterial antigen testsLatex agglut<strong>in</strong>ation and coagglut<strong>in</strong>ation tests for bacterial antigens are usedto identify microorganisms or their antigens <strong>in</strong> cultures or <strong>in</strong> cl<strong>in</strong>ical specimens.Latex agglut<strong>in</strong>ation tests use polymer particles as solid-phase support;coagglut<strong>in</strong>ation tests use red blood cells as solid-phase support. Latex agglut<strong>in</strong>ationtests are available to detect a number of different polysaccharide anti-137


SEROLOGICAL TESTSgens of bacteria that cause men<strong>in</strong>gitis <strong>in</strong>clud<strong>in</strong>g Haemophilus <strong>in</strong>fluenzae (typeb), S. pneumoniae (omnivalent), N. men<strong>in</strong>gitidis (group A, B, C, Y and W135),E. coli (type K1), and S. agalactiae (group B). Latex agglut<strong>in</strong>ation tests are usefulfor identify<strong>in</strong>g streptococci from Lancefield groups A, B, C, D, F and G.Moreover, latex agglut<strong>in</strong>at<strong>in</strong>g sera are available for use <strong>in</strong> qualitative slideagglut<strong>in</strong>ation tests and quantitative tube agglut<strong>in</strong>ation tests for serologicalidentification and typ<strong>in</strong>g of Streptococcus groups A–D, N. men<strong>in</strong>gitidis, H.<strong>in</strong>fluenzae, Salmonella, Shigella, Vibrio cholerae, etc.A threshold level of the antigen is required to detect polysaccharide antigens<strong>in</strong> cl<strong>in</strong>ical samples. The threshold level is usually exceeded if organisms canbe seen <strong>in</strong> Gram-sta<strong>in</strong>ed preparations, although this may not always be thecase. The number of bacteria found <strong>in</strong> the cerebrosp<strong>in</strong>al fluid of patients withN. men<strong>in</strong>gitidis <strong>in</strong>fection is significantly lower that that for other types of Neisseriaspp. <strong>in</strong>fection and therefore the threshold level of polysaccharide antigensis reached less frequently.Several serogroups of N. men<strong>in</strong>gitidis may cause men<strong>in</strong>gitis. While serogroupsA, C, Y, and W135 each have a stable antigen that can be detected with a s<strong>in</strong>glepolyvalent reagent, the serogroup B antigen is relatively unstable and considerablymore difficult to detect. It is also <strong>in</strong>dist<strong>in</strong>guishable from the K1 polysaccharideantigen of E. coli, which is the ma<strong>in</strong> cause of E. coli men<strong>in</strong>gitis <strong>in</strong>newborn babies. However, if the Gram-sta<strong>in</strong>ed preparation demonstratesGram-negative diplococci, <strong>in</strong>fection is most likely to be due to N. men<strong>in</strong>gitidisgroup B; if the Gram-sta<strong>in</strong>ed preparation demonstrates Gram-negative rods,<strong>in</strong>fection is probably due to E. coli.For some of the tests a polysaccharide antigen is extracted from the organismbefore test<strong>in</strong>g. This extraction may be carried out chemically or enzymatically.Four different tests can be used for the detection of the antigen:• In the slide-agglut<strong>in</strong>ation tests, the antigen is added to latex particles orstaphylococcal cells coated with specific antibodies. The mixture is rotatedby hand with a steady circular motion for 1–2 m<strong>in</strong>utes and the reaction isobserved macroscopically for agglut<strong>in</strong>ation.• In the ELISA tests, a solution of sample and antigen is first passed over amembrane coated with an antibody (this antibody is usually monoclonal).Subsequently, the membrane is covered with a solution of a second(monoclonal) antibody conjugated with an enzyme. The presence of theantigen–antibody enzyme complex on the membrane is detected by itsreaction with a chromogenic substrate that is added <strong>in</strong> solution.• In the gold immunoassay, a solution of sample and antigen is left to diffuseon a membrane, which is then exam<strong>in</strong>ed.• In the optical immunoassay, antibodies are attached to a silicon wafer withreflective properties. When the antigen reacts with the specific antibody onthe wafer, a change <strong>in</strong> the surface layer occurs, which causes a change <strong>in</strong>the light reflection.Typical procedures for latex agglut<strong>in</strong>ation orcoagglut<strong>in</strong>ation tests1. For cell-bound antigens: use a sterilized loop to transfer well-isolatedcolonies to a drop of sal<strong>in</strong>e on a slide and mix carefully to obta<strong>in</strong> a slightlyopalescent emulsion. If the sal<strong>in</strong>e emulsion shows clump<strong>in</strong>g, it usually<strong>in</strong>dicates a rough (R) stra<strong>in</strong> <strong>in</strong>stead of a smooth (S) stra<strong>in</strong>, and the cells willfail to agglut<strong>in</strong>ate with the antibody. If no clump<strong>in</strong>g appears, add thereagent and proceed from step 4.138


BACTERIOLOGICAL INVESTIGATIONSFor extracted antigen: use a sterilized loop to transfer well-isolated coloniesto a small test-tube conta<strong>in</strong><strong>in</strong>g extraction solution and emulsify them. Incubatethe emulsion at 35 ∞C or accord<strong>in</strong>g to the manufacturer’s <strong>in</strong>structions.For cl<strong>in</strong>ical specimens (CSF, ur<strong>in</strong>e): heat the specimen to boil<strong>in</strong>g-po<strong>in</strong>t oraccord<strong>in</strong>g to the manufacturer’s <strong>in</strong>structions. Cool and centrifuge at2000 g for 5–10 m<strong>in</strong>utes.2. Place 1 drop of the antibody-coated particles on the slide.3. Place 1 drop of the antigen suspension beside the antibody-coatedparticles.4. Mix the 2 drops on the slide and spread <strong>in</strong> a square.5. Rotate the slide by hand <strong>in</strong> a steady circular motion for 1 m<strong>in</strong>ute. Take carethat the mixture does not spill outside the boundaries of the square.6. Exam<strong>in</strong>e the slide macroscopically for agglut<strong>in</strong>ation after the time specified<strong>in</strong> the manufacturer’s <strong>in</strong>structions. For best visibility hold the slidenear a bright light and view aga<strong>in</strong>st a dark background.7. A positive result is recorded when the antigen mixed with the antibodyshows agglut<strong>in</strong>ation, i.e. the suspension shows clump<strong>in</strong>g or is granularto the po<strong>in</strong>t of curdl<strong>in</strong>g. Agglut<strong>in</strong>ation is best seen by tilt<strong>in</strong>g the slideslightly so that the fluid dra<strong>in</strong>s down towards the lower boundary ofthe square.139


This page <strong>in</strong>tentionally left blank


Part IIEssential media and reagents


IntroductionWith just a few diagnostic materials, a laboratory can make an importantcontribution to <strong>in</strong>dividual patient care through accurate etiological diagnosis.In most develop<strong>in</strong>g countries bacteriological laboratory practice is hamperedby a shortage of culture media and basic reagents, which are very costly toimport. However, the number of culture media and reagents that have to bepurchased can be reduced to the essential ones, through rational selection, ashas been the case with essential drug lists. Additionally, some simple mediaand reagents can be produced or prepared locally. Application of these twoapproaches would greatly reduce the necessity for foreign exchange and makemore readily available the laboratory material necessary for patient care andepidemiological studies.This chapter has been prepared to enable health laboratory managers toconcentrate their resources on the most relevant media and reagents. Itcomprises two sections both composed of a series of lists.142


Pathogens, media and diagnosticreagentsExpected pathogensPathogens are listed accord<strong>in</strong>g to a number of factors:— frequency of isolation,— cl<strong>in</strong>ical relevance,— severity of disease,— epidemic potential,— cost–benefit ratio of isolation and/or identification.The list<strong>in</strong>g is by no means absolute and will vary from country to countryor from laboratory to laboratory, depend<strong>in</strong>g on the local disease pattern, thelaboratory capacity, and the resources available.Media and diagnostic reagent priority grad<strong>in</strong>gsA certa<strong>in</strong> degree of flexibility has been <strong>in</strong>corporated by adopt<strong>in</strong>g a prioritygrad<strong>in</strong>g for media and diagnostic reagents as follows:Grade 1: High priorityGrade 2: Intermediate priorityGrade 3: Low priorityMedia and diagnostic reagents are priority graded accord<strong>in</strong>g to the list<strong>in</strong>gof the pathogens for which they are used for isolation and identification.However, there may be differences. If the medium is used broadly for morethan one pathogen, it may score higher than any one pathogen for which it isused.Grade 1: High priority media and diagnostic reagents should be available <strong>in</strong>all laboratories that practise general diagnostic bacteriology. They are mostoften for general purpose use, easy to prepare and few <strong>in</strong> number.Grade 2: Intermediate priority media and diagnostic reagents are additionaluseful substances that make laboratory diagnosis more complete and moreuseful for epidemiological studies, although they may not be essential fordirect patient care, e.g. the group<strong>in</strong>g antisera for men<strong>in</strong>gococci.Grade 3: Low priority media and diagnostic reagents are substances thatare of value only occasionally for patient care, but which are useful for teach<strong>in</strong>g,research, and special <strong>in</strong>vestigations by a reference laboratory. Thiscategory applies to media and diagnostic reagents that are too expensive forgeneral use, or that are needed for the isolation and identification of organismsthat occur rarely or are difficult to isolate and therefore often notcost-effective.For common laboratory <strong>in</strong>vestigations, the listed pathogens, and the requiredmedia and diagnostic reagents, together with a suggested priority grad<strong>in</strong>g,are to be found below. The priority grad<strong>in</strong>g should be adapted for each laboratoryaccord<strong>in</strong>g to local circumstances.143


PATHOGENS, MEDIA AND DIAGNOSTIC REAGENTSBloodExpected pathogensBacteroides fragilisBrucellaBurkholderia pseudomalleiCandida albicans and Cryptococcus neoformansHaemophilus <strong>in</strong>fluenzaeNeisseria men<strong>in</strong>gitidisNon-fermenters other than Pseudomonas aerug<strong>in</strong>osaOther EnterobacteriaceaePseudomonas aerug<strong>in</strong>osaSalmonella typhi and non-typhiStaphylococcus aureusStreptococci (S. pyogenes, S. pneumoniae, viridans streptococci)Media and diagnostic reagentsBlood-culture brothPriority grad<strong>in</strong>gTryptic soy broth (TSB) can be replaced by any rich broth,e.g. bra<strong>in</strong>–heart <strong>in</strong>fusion broth, addition of sodiumpolyanethol sulfonate (SPS), 0.25g/l, optional 1“Anaerobic” blood culture broth: thioglycollate broth orSchaedler broth or Wilk<strong>in</strong>s–Chalgren anaerobe broth 2Isolation mediaSubculture on blood agar, chocolate agar and MacConkey agar 1Diagnostic reagentsBacitrac<strong>in</strong> disc 1Coagulase plasma 1b-Lactamase test reagent 1Optoch<strong>in</strong> disc 1Oxidase reagent 1Salmonella agglut<strong>in</strong>at<strong>in</strong>g antisera 1V and XV factors 2Haemophilus <strong>in</strong>fluenzae type b antiserum 3Neisseria men<strong>in</strong>gitidis agglut<strong>in</strong>at<strong>in</strong>g serum (polyvalent andspecific groups A, B, C) 3Cerebrosp<strong>in</strong>al fluidExpected pathogensCryptococcus neoformansEnterobacteriaceaeHaemophilus <strong>in</strong>fluenzaeListeria monocytogenes144


ESSENTIAL MEDIA AND REAGENTSMycobacterium tuberculosisNeisseria men<strong>in</strong>gitidisStreptococcus agalactiaeStreptococcus pneumoniaeMedia and diagnostic reagentsIsolation mediaPriority grad<strong>in</strong>gBlood agar (with streak of Staphylococcus) 1Chocolate agar 1MacConkey agar 1Löwenste<strong>in</strong>–Jensen medium 2Sabouraud dextrose agar 2Diagnostic reagentsIndia <strong>in</strong>k 1b-Lactamase test reagent 1Optoch<strong>in</strong> disc 1Oxidase reagent 1V and XV factors 2Haemophilus <strong>in</strong>fluenzae type b antiserum 3Neisseria men<strong>in</strong>gitidis agglut<strong>in</strong>at<strong>in</strong>g serum (polyvalent andspecific groups A, B, C) 3Rapid diagnostic testsTest kit for rapid diagnosis of bacteria caus<strong>in</strong>g men<strong>in</strong>gitis 3Ur<strong>in</strong>eExpected pathogensCandida albicansEnterococciEscherichia coliMycobacterium tuberculosisOther EnterobacteriaceaeOther staphylococciPseudomonas and other non-fermentersStaphylococcus saprophyticusMedia and diagnostic reagentsIsolation and quantitative mediaPriority grad<strong>in</strong>gBlood agar 1Brolac<strong>in</strong> agar (can be replaced by purple lactose agar,145


PATHOGENS, MEDIA AND DIAGNOSTIC REAGENTSMacConkey agar, agar without crystal violet, or eos<strong>in</strong>methylene-blue agar) 1CLED agar 1Identification media and diagnostic reagentsb-Glucuronidase tablet (PGUA) for identification of E. coli 1For Gram-negative rods:Kligler iron agar (KIA) 1Kovacs reagent for <strong>in</strong>dole 1motility–<strong>in</strong>dole–urease (MIU) medium 1oxidase reagent 1lys<strong>in</strong>e–decarboxylase broth (Möller) 2ONPG test 2Simmons citrate agar 2For staphylococci and enterococcicatalase test (H 2 O 2 ) 1coagulase plasma 1bile–aescul<strong>in</strong> agar (for enterococci) 2novobioc<strong>in</strong> (5mg) disc for differentiat<strong>in</strong>gnegative-coagulase staphylococci 3StoolExpected pathogensAeromonas and PlesiomonasCampylobacter spp.Escherichia coli (enteropathogenic, enterotoxigenic, entero<strong>in</strong>vasive,and enterohaemorrhagic)Non-typhoid Salmonellae spp. and EdwardsiellaSalmonella typhi and S. paratyphiShigellaVibrio cholerae serogroup O1, non-cholerae vibriosYers<strong>in</strong>ia enterocoliticaMedia and diagnostic reagentsTransport mediaPriority grad<strong>in</strong>gCary–Blair medium (for all pathogens) 1Buffered glycerol sal<strong>in</strong>e (not for Vibrio or Campylobacter) 2Enrichment mediaSelenite F broth 1Alkal<strong>in</strong>e peptone water 2146


ESSENTIAL MEDIA AND REAGENTSIsolation mediaDeoxycholate–citrate agar (can be replaced by Salmonella-Shigellaagar, xylose–lys<strong>in</strong>e–deoxycholate agar (XLD) 1MacConkey agar (with crystal violet) 1TCBS agar 1Campylobacter medium: Columbia agar base or any blood agarbase with lysed blood and antibiotic supplement, or charcoalbasedmedia 2Prelim<strong>in</strong>ary media and diagnostic reagentsKligler iron agar (KIA) (may be replaced by triple sugar ironagar (TSI) but only for enteric pathogens) 1Kovacs reagent for <strong>in</strong>dole 1Motility–<strong>in</strong>dole–urease (MIU) medium (may be replaced bymotility test medium + peptone urea broth) 1Oxidase reagent 1Specific media and diagnostic reagentsAndrade peptone water (or phenol red broth base) 2Lys<strong>in</strong>e–decarboxylase broth (Möller) 2ONPG test 2Simmons citrate agar 2Vibriostatic compound O:129 disc 2Agglut<strong>in</strong>at<strong>in</strong>g antiseraPriority grad<strong>in</strong>gSalmonella: O antiserum polyvalent (A–I and Vi) 1O-factor antisera: O:2 (A), O:4 (B), O:9 (D), Vi 2H-factor antisera: H:a, H:b, H:d, H:i, H:m, H:2 3phase <strong>in</strong>version H-antisera: H:b, H:i, H:1,2 3Shigella:dysenteriae polyvalent, flexneri polyvalent,boydii polyvalent, sonnei polyvalent 1dysenteriae type 1 (Shiga) 1Vibrio cholerae: O1 antiserum polyvalent 1subtypes B (Ogawa), C (Inaba), O:139 3Haemophilus <strong>in</strong>fluenzae type b 3Neisseria men<strong>in</strong>gitidis polyvalent 3s<strong>in</strong>gle factor A, B, C 3Upper respiratory tractExpected pathogensCandida albicans (oropharynx)Corynebacterium diphtheriae (throat and nose)Haemophilus <strong>in</strong>fluenzae (ear and s<strong>in</strong>us)Moraxella catarrhalis (ear and s<strong>in</strong>us)Neisseria men<strong>in</strong>gitidisPseudomonas147


PATHOGENS, MEDIA AND DIAGNOSTIC REAGENTSStaphyloccoccus aureus (ear and s<strong>in</strong>us)Streptococcus pneumoniae (ear and s<strong>in</strong>us)Streptococcus pyogenes (group A, throat)Media and diagnostic reagentsIsolation mediaPriority grad<strong>in</strong>gBlood agar (prepared from a glucose-free base) 1Chocolate agar 2Löffler coagulated serum or Dorset egg medium 2Tellurite blood agar 2Modified Thayer–Mart<strong>in</strong> medium (for gonococci andmen<strong>in</strong>gococci) 3Diagnostic reagentsBacitrac<strong>in</strong> disc 1Catalase and coagulase reagents 1Optoch<strong>in</strong> disc 1Carbohydrate degradation media for Neisseria spp. 2Oxidase reagent 2V and XV factors (discs or strips) 2Tributyr<strong>in</strong> 3Rapid diagnostic testsGroup<strong>in</strong>g kit for haemolytic streptococci 3Lower respiratory tractExpected pathogensCandida albicansEnterobacteriaceaeHaemophilus <strong>in</strong>fluenzaeKlebsiella pneumoniaeMoraxella catarrhalisMycobacterium tuberculosisStaphylococcus aureusStreptococcus pneumoniaeMedia and diagnostic reagentsIsolation mediaPriority grad<strong>in</strong>gBlood agar 1Chocolate agar 1MacConkey agar 1Löwenste<strong>in</strong>–Jensen medium 2148


ESSENTIAL MEDIA AND REAGENTSSabouraud dextrose agar 3Selective blood agar for Haemophilus (bacitrac<strong>in</strong> or vancomyc<strong>in</strong>) 3Diagnostic reagentsCoagulase plasma 1Optoch<strong>in</strong> disc 1Oxidase reagent 2V and XV factors (discs or strips) 2Tributyr<strong>in</strong> 3Urogenital specimens for exclusion of sexuallytransmitted diseases (STDs)Expected pathogensCandida albicans (microscopic exam<strong>in</strong>ation)Chlamydia trachomatisGardnerella vag<strong>in</strong>alis (microscopic exam<strong>in</strong>ation) 1Haemophilus ducreyiNeisseria gonorrhoeaeTreponema pallidum (dark-field microscopy)Media and diagnostic reagentsTransport mediaPriority grad<strong>in</strong>gAmies transport medium or Stuart transport medium 1Isolation mediaModified Thayer–Mart<strong>in</strong> (MTM) medium orNew York City (NYC) medium 1Mueller–H<strong>in</strong>ton chocolated horse-blood agar+ vancomyc<strong>in</strong> + IsoVitaleX for H. ducreyi 3Identification reagentsNitrocef<strong>in</strong> test or other b-lactamase test reagent 1Oxidase reagent 1Pus and exudatesExpected pathogensBacillus anthracisBacteroides and other strict anaerobes1Gardnerella vag<strong>in</strong>alis is an <strong>in</strong>dicator organism for vag<strong>in</strong>osis, but not a pathogen.149


PATHOGENS, MEDIA AND DIAGNOSTIC REAGENTSClostridium perfr<strong>in</strong>gensEnterobacteriaceaeMycobacterium tuberculosis, M. ulceransOther Mycobacterium spp.Pasteurella multocidaPseudomonas and other non-fermentersStaphylococcus aureusStreptococcus pyogenesStreptococcus (other species)Media and diagnostic reagentsIsolation mediaPriority grad<strong>in</strong>gBlood agar 1MacConkey agar 1Mannitol salt agar 2Thioglycollate broth (with <strong>in</strong>dicator) (can be replaced bycooked meat medium, Schaedler broth, Wilk<strong>in</strong>s–Chalgren broth) 2Tryptic soy broth (TSB) 2Diagnostic reagentsCatalase test (H 2 O 2 ) 1Coagulase plasma 1Oxidase reagent 1Hydrogen generator for anaerobic jar 2List of recommended media and diagnosticreagents for the <strong>in</strong>termediate microbiologicallaboratoryCulture mediaRecommended medium Alternatives Priority grad<strong>in</strong>gBile–aescul<strong>in</strong> agar 1Blood agar (see tryptic soyagar) 1Brolac<strong>in</strong> agar purple lactose agar, CLED agar 1Kligler iron agar (KIA) 1Löffler coagulated serum Dorset egg medium 1Löwenste<strong>in</strong>–Jensen medium 1MacConkey agar (with crystal eos<strong>in</strong> methylene-blue agarviolet) 1MacConkey agar (withoutcrystal violet) 1Motility–<strong>in</strong>dole–urease (MIU) motility test medium + urea brothmedium + peptone (tryptone) water 1Mueller–H<strong>in</strong>ton agar 1Sabouraud dextrose agar 1Deoxycholate citrate agar Salmonella–Shigella (SS) agar 1Tryptic soy agar (TSA) Columbia agar 1150


ESSENTIAL MEDIA AND REAGENTSRecommended medium Alternatives Priority grad<strong>in</strong>gTryptic soy broth (TSB) bra<strong>in</strong>–heart <strong>in</strong>fusion broth 1TCBS 1Transport medium (Amies) transport medium (Stuart orCary–Blair) 1Andrade peptone water phenol red broth 2Decarboxylase broth (Möller) 2Mannitol salt agar (MSA) 2Selenite F broth 2Simmons citrate agar 2Thioglycollate medium (with Schaedler broth, Wilkens–<strong>in</strong>dicator)Chalgren anaerobe broth,cooked meat medium 2DNase agar 3Inhibitors or antimicrobials for use <strong>in</strong> media oras reagentsChloramphenicol (for isolation of fungi) 1Gonococcal antimicrobial supplement: vancomyc<strong>in</strong>, colist<strong>in</strong>, nystat<strong>in</strong>(trimethoprim): VCN (VCNT) 1Campylobacter antimicrobial supplement 2Tellurite solution (for isolation of Corynebacterium diphtheriae) 2Bacitrac<strong>in</strong> (for isolation of Haemophilus spp.) 3Vancomyc<strong>in</strong> (for isolation of Haemophilus ducreyi or H. <strong>in</strong>fluenzae) 3Enrichments for culture mediaIsoVitaleX (Polyvitex, Vitox, supplement B, supplement VX,supplement CVA) 2Sodium polyanethol sulfonate (SPS) 3Diagnostic discs, tablets or stripsBacitrac<strong>in</strong> disc 1Nitrocef<strong>in</strong> disc (Cef<strong>in</strong>ase) or reagent 1ONPG test 1Optoch<strong>in</strong> disc 1Oxidase reagent 1PGUA (b-glucuronidase) 1V and XV factors 2Novobioc<strong>in</strong> (5mg) disc 3PYR test 3Tributyr<strong>in</strong> 3Vibriostatic compound O:129 disc 3Diagnostic kitsRapid serodiagnostic kit for identification of bacteria caus<strong>in</strong>gmen<strong>in</strong>gitis 3Serological group<strong>in</strong>g kit for haemolytic streptococci 3151


PATHOGENS, MEDIA AND DIAGNOSTIC REAGENTSMiscellaneous diagnostic reagentsBarium sulfate standard (for Kirby–Bauer method) 1Gram-sta<strong>in</strong> reagents 1Hydrogen peroxide (H 2 O 2 ) (catalase) 1Kovacs reagent (for <strong>in</strong>dole) 1Oxidase reagent (dimethyl-p-phenylenediam<strong>in</strong>e) 1Plasma (for coagulase test and germ-tube test) 1Ziehl–Neelsen sta<strong>in</strong> 1Buffered glycerol–sal<strong>in</strong>e (for transportation of stool) 2Carbohydrates: glucose, lactose, maltose, mannitol, sucrose 2Hydrogen generator for anaerobic jar 2India <strong>in</strong>k (for capsule detection) 2Lys<strong>in</strong>e (for decarboxylase test) 2Sensitivity-test<strong>in</strong>g discsAntimicrobials <strong>in</strong>cluded <strong>in</strong> the WHO list of essentialdrugs (2002)amoxicill<strong>in</strong>ampicill<strong>in</strong>benzylpenicill<strong>in</strong>chloramphenicolciprofloxaz<strong>in</strong>co-trimoxazole (sulfamethoxazole–trimethoprim)cloxacill<strong>in</strong>erythromyc<strong>in</strong>gentamic<strong>in</strong>kanamyc<strong>in</strong>nalidixic acidnitrofuranto<strong>in</strong>sulfonamidetetracycl<strong>in</strong>e (or doxycycl<strong>in</strong>e)trimethoprimReserved antimicrobialsamoxy-clavamikac<strong>in</strong>cefalot<strong>in</strong>cefazol<strong>in</strong>cefotaximeceftazidimeceftriaxonecefuroximeciprofloxac<strong>in</strong> or other fluoqu<strong>in</strong>olonescl<strong>in</strong>damyc<strong>in</strong>piperacill<strong>in</strong>vancomyc<strong>in</strong>152


ESSENTIAL MEDIA AND REAGENTSAgglut<strong>in</strong>at<strong>in</strong>g antiseraPriority grad<strong>in</strong>gSalmonella: O antiserum polyvalent (A–I and Vi) 1O-factor antisera: O:2 (A), O:4 (B), O:9 (D), Vi 2H-factor antisera: H:a, H:b, H:d, H:i, H:m, H:2 3phase <strong>in</strong>version H-antisera: H:b, H:i, H:1,2 3Shigella:dysenteriae polyvalent, flexneri polyvalent,boydii polyvalent, sonnei polyvalent 1dysenteriae type 1 (Shiga) 1Vibrio cholerae: O1 antiserum polyvalent 1subtypes B (Ogawa), C (Inaba), O:139 3Haemophilus <strong>in</strong>fluenzae: type b 3Neisseria men<strong>in</strong>gitidis: polyvalent 3s<strong>in</strong>gle factor A, B, C 3153


Selected further read<strong>in</strong>gAugust MJ et al. Quality control and quality assurance practices <strong>in</strong> cl<strong>in</strong>ical microbiology.Cumitech, 1990, 3A:1–14.<strong>Basic</strong>s of quality assurance for <strong>in</strong>termediate and peripheral laboratories, 2nd ed. Alexandria,WHO Regional Office for the Eastern Mediterranean, 2000.Baron EJ, F<strong>in</strong>egold SM. Diagnostic microbiology, 8th ed. St Louis, MO, The C.V. MosbyCompany, 1990.Blazevic DJ et al. Practical quality control procedures for the cl<strong>in</strong>ical microbiology laboratory.Cumitech, 1976, 3:1–12.Cheesbrough M. Medical laboratory manual for tropical countries. Vol. II: Microbiology.London, Tropical Health Technology/Butterworths, 1989.Coll<strong>in</strong>s CH, Lyne PM. Microbiological methods, 5th ed. London, Butterworths, 1985.Gillies RP, Paul J. <strong>Bacteriology</strong> illustrated. Ed<strong>in</strong>burgh, Churchill Liv<strong>in</strong>gstone, 1983.Howard BJ et al. Cl<strong>in</strong>ical and pathogenic microbiology. St Louis, MO, The C.V. MosbyCompany, 1987.Koneman EW. Color atlas and textbook of diagnostic microbiology, 5th ed. Philadelphia,Lipp<strong>in</strong>cott, 1997.Miller JM. Quality control <strong>in</strong> microbiology. Atlanta, GA, Centers for Disease Control andPrevention, 1987.Miller JM, Wentworth BB. Methods for quality control <strong>in</strong> diagnostic microbiology. Wash<strong>in</strong>gton,DC, American Public Health Association, 1985.Montefiore DG et al. Tropical microbiology. Ed<strong>in</strong>burgh, Churchill Liv<strong>in</strong>gstone, 1984.Murray P et al. Manual of cl<strong>in</strong>ical microbiology, 8th ed. Wash<strong>in</strong>gton, DC, AmericanSociety for Microbiology, 2003.Stokes EJ et al. Quality control. In: Cl<strong>in</strong>ical bacteriology, 7th ed. London, Edward Arnold,1993.Turk DC et al. A short textbook of medical microbiology. London, Hodder & Stoughton,1983.Summanen P et al. Wadsworth anaerobic bacteriology manual. Belmont, CA, Star Publish<strong>in</strong>gCompany, 1993.154


IndexNote: Page numbers <strong>in</strong> bold type <strong>in</strong>dicate ma<strong>in</strong> discussions.Abscesses 86, 87, 89, 93, 98liver 92lung 66–67Acid-fast sta<strong>in</strong>, see Ziehl–Neelsensta<strong>in</strong><strong>in</strong>gAc<strong>in</strong>etobacterIwoffi 10–12, 24spp. 60, 70Acquired immunodeficiency syndrome(AIDS) 20, 37, 61, 76Act<strong>in</strong>omyces israelii 90, 93Act<strong>in</strong>omycosis 89, 90Acute bronchitis 66Aeromonas spp. 38, 53, 146Aescul<strong>in</strong> agar, see Bile–aescul<strong>in</strong> agarAfrican trypanosomiasis 26Agglut<strong>in</strong>at<strong>in</strong>g antisera 147, 153Agglut<strong>in</strong>ation tests 28, 56–59, 63,125–126, 135–139Agglut<strong>in</strong><strong>in</strong>s tests, febrile 133–135AIDS, see Acquired immunodeficiencysyndromeAlbert sta<strong>in</strong> 64Album<strong>in</strong>, bov<strong>in</strong>e 73Alcohol 21Alkal<strong>in</strong>e bile salt agar 42Alkal<strong>in</strong>e peptone water 40–42, 146American Type Culture Collection 14Amies transport medium 40, 62, 77, 81,149, 151Amikac<strong>in</strong> 107, 110, 116, 152Am<strong>in</strong>oglycosides 100, 109Amoeba 26, 87, 92Amoebic dysentery 41Amoxicill<strong>in</strong> 109, 152Amoxy-clav 107, 110, 116, 152Amphoteric<strong>in</strong> B 42, 78Ampicill<strong>in</strong> 107, 109, 110, 116, 152Anaemia, aplastic 108Anaerobes 10, 80, 87, 98–102necrotiz<strong>in</strong>g ulcerative pharyngitis 61stab cultures 15, 24surgical specimens 91, 93wound <strong>in</strong>fections 88Anaerobic jars 8, 44Andrade peptone water 64, 147, 151Aneurysms, <strong>in</strong>fected 20Animal bites/scratches 88, 96Anorectal specimens, collection 77Anthrax (see also Bacillus anthracis) 96–97Antibiograms (see also Susceptibilitytests)blood cultures 24Antibiotic discs, see Antimicrobial discsAntibiotic susceptibility test<strong>in</strong>g,see Susceptibility test<strong>in</strong>gAntibodies 122Anticoagulant, blood collection 22Antigens 77, 122diagnostic 12–13latex agglut<strong>in</strong>ation test 137, 138–139VDRL test 128Antimicrobial discs 13–14, 103, 104–105,108–121potency 119recommended 151, 152Antimicrobial resistance 17, 62, 97,101–121, 108Antimicrobial susceptibility, def<strong>in</strong>ition104–105Antimicrobial susceptibility test<strong>in</strong>g,see Susceptibility test<strong>in</strong>gAntimicrobials (see also Drugs)enteric disease therapy 39generic names 108media/reagent use 151susceptibility test<strong>in</strong>g discs 103,104–105, 108–121, 151–152Antiseraagglut<strong>in</strong>at<strong>in</strong>g 147, 153diagnostic 12–13external quality assessment 17–18Antistreptolys<strong>in</strong> O (ASO) test 135–137Arab<strong>in</strong>ose 53Arcobacter butzleri 39, 54Argen<strong>in</strong>e 38, 54Arthritis 76, 93, 96ASO, see Antistreptolys<strong>in</strong> O testAspirates 80, 86–87, 92Autoclaves, quality control 8Bacillus anthracis 88, 91, 93, 96–97, 149Bacitrac<strong>in</strong> 148, 151Bacteraemia 20–21, 24, 37, 101, 102Bacteria, oxygen requirement 98<strong>Bacteriology</strong>, quality assurance 2–18Bacteriuria, screen<strong>in</strong>g test 32Bacteroidesfragilis 12, 21, 87, 88, 91, 144identification 99, 101, 102stock stra<strong>in</strong> 16melan<strong>in</strong>ogenicus, see Prevotellamelan<strong>in</strong>ogenicaspp. 98–99, 149Balanitis 132Balanoposthitis 76Barium sulfate 12, 152Barthol<strong>in</strong>itis 76Bed sores 87, 89–90Benzalkonium chloride, see ZephiranBenzylpenicill<strong>in</strong> 79, 97, 106–108, 110,116, 152155


INDEXBile–aescul<strong>in</strong> agar 11, 23, 29, 64, 146,150Bile stimulation test 101Bismuth sulfite agar (BSA) 44, 48Bites, animal/human 88, 96Blastomyces dermatitidis 92Bl<strong>in</strong>d subcultures, blood samples 23Blood agar 27–29,anaerobic specimens 100Corynebacterium diphtheriae 64CSF specimens 27Haemophilus <strong>in</strong>fluenzae 29, 149priority grad<strong>in</strong>g 144–145, 148–150,155sputum culture 69Streptococcus pyogenes culture 63surgical specimens 92–93Blood specimens 20–24collection 20–22culture 21, 22–24diagnostic reagents/media 144expected pathogens 144Body cavities, purulent exudates 87, 90Bordetella pertussis 126Borrelia burgdorferi 132Bottles, blood-culture 22–23Botulism, wound 88, 98Bra<strong>in</strong> heart <strong>in</strong>fusion broth 144, 151Branhamella catarrhalis, see MoraxellacatarrhalisBrolac<strong>in</strong> agar 145, 150Bromothymol blue–lactose–cyst<strong>in</strong>e agar34, 145, 150Bronchitis 66Bronchopneumonia 67Brothanaerobes culture 99, 100, 101, 144,151blood culture 22thioglycollate 12, 23, 38, 92, 144, 150tryptic soy (TSB) 22, 27, 96, 144, 150,151Wilk<strong>in</strong>s–Chalgren 100, 144, 151Brucellaabortus 23, 135melitensis 133, 135spp. 16, 17, 23, 59, 133, 135, 144Brucellosis 20, 133BSA, see Bismuth sulfite agarBuboes, <strong>in</strong>gu<strong>in</strong>al 83Burkholderia pseudomallei 17, 21, 144Burns 87, 89–90Calcium alg<strong>in</strong>ate 77Calibrated loop technique, ur<strong>in</strong>especimens 32–33Calymmatobacterium granulomatis 76, 82CAMP test 23reverse 28, 64, 101–102Campylobacterantimicrobial supplement 151coli 38, 50, 54, 55fetus 54, 55hyo<strong>in</strong>test<strong>in</strong>alis 54, 55jejuni 38, 50, 54, 55lari 54, 55media 147spp. 7, 41, 42, 50, 98enteric <strong>in</strong>fections 37, 38, 146, 147identification 54, 55<strong>in</strong>cubation 43–44upsaliensis 54, 55Cancer, cervical 76Candidaalbicans 12, 21, 61, 144–149<strong>in</strong> sputum 69STDs 76, 79, 81, 82stock stra<strong>in</strong> 10, 70, 71spp. 61, 62, 93Candidiasis, oral 61–62Candle jars 43, 69, 100Carbapenem 97Carbohydrate degradation 79, 148Carbohydrates 152Carbohydrate utilization test 28Carbol fuchs<strong>in</strong> 50Carbon dioxide 28, 77Cardiolip<strong>in</strong> lecith<strong>in</strong> 126, 127Carriers, upper respiratory tract<strong>in</strong>fections 62Cary–Blair transport medium 40–41,146, 151Castaneda bottle 23Catalase test 13, 29, 46, 52, 64, 96, 146,148, 150, 152Causal agentsbacteraemia 21diarrhoeal disease 37–39fungaemia 21men<strong>in</strong>gitis 25pharyngitis 61–62purulent exudates 87STDs 76–77tonsillitis 61CCFA, see Cefoxit<strong>in</strong>–cycloser<strong>in</strong>e–fructoseagarCefalex<strong>in</strong> 109Cefalospor<strong>in</strong>s 97, 109Cefalot<strong>in</strong> 107, 109, 110, 116, 152Cefaloz<strong>in</strong> 110, 116, 152Cefamandole 109Cefamyc<strong>in</strong> 109Cefapir<strong>in</strong> 109Cefotaxime 109, 116, 152Cefoxit<strong>in</strong> 109Cefoxit<strong>in</strong>–cycloser<strong>in</strong>e–fructose (CCFA)agar 42, 50Cefrad<strong>in</strong>e 109Ceftazidime 107, 110, 116, 152Ceftriaxone 107, 110, 116, 152Cefuroxime 107, 109, 110, 152Cellobiose 53Cellulitis 93, 96Centrifuges, quality control 8Cerebrosp<strong>in</strong>al fluid (CSF) 25–29diagnostic reagents/media 145156


INDEXdiagnostic tests 29, 125, 127–129, 145expected pathogens 144–145macroscopic <strong>in</strong>spection 26men<strong>in</strong>gitis 27microscopic exam<strong>in</strong>ation 26–28Neisseria men<strong>in</strong>gitidis 138pathogen identification 28–29specimen collection/transport 25specimen culture 27–29susceptibility test<strong>in</strong>g 29Cervical cancer 76Cervicitis 76, 79, 81Cervicofacial act<strong>in</strong>omycosis 90Cervicovag<strong>in</strong>al specimens (see alsoSexually transmitted diseases)collection 80culture 82<strong>in</strong>terpretation 81–82microscopic exam<strong>in</strong>ation 81transport 81CFUs, see Colony-form<strong>in</strong>g unitsChancre 84Chancroid 76, 83, 85Childrenbacterial pharyngitis 61diarrhoeal diseases 37neonates 21, 25, 80, 82surgical specimens 93ur<strong>in</strong>e specimens 31Chlamydiaspp. 66, 83trachomatis 76, 77, 79–80, 82, 83, 126,149Chloramphenicol 107, 108, 110, 116, 151,152Chlorhexid<strong>in</strong>e 21Chlortetracycl<strong>in</strong>e 108Chocolate agar 11, 27–28, 69, 78, 145,148Cholera 38, 41Chorio-amnionitis 76, 80Chromosal resistance 79Chronic bronchitis 66Ciprofloxac<strong>in</strong> 107, 110, 116, 152Citrate 22, 25, 51Citrobacterfreundii 10, 12, 17, 51spp. 25Classification, Salmonella spp. 54–55CLED agar, seeCyst<strong>in</strong>e–lactose–electrolytedeficientagarCl<strong>in</strong>damyc<strong>in</strong> 107, 110, 116, 152Cl<strong>in</strong>ical relevance 4–5Clostridiumbifermentans 42botul<strong>in</strong>um 98difficile 39, 41, 42, 43, 50perfr<strong>in</strong>gens 10, 21, 88, 101–102, 150sordelli 42spp. 21, 24, 42, 80, 98–99, 100tetani 98Cloxacill<strong>in</strong> 97, 108, 152Clue cells 81Coagulase plasma 13, 70, 144, 146, 149,150Coagulase test, Staphylococcus aureus94–96Colist<strong>in</strong> 78, 151Colitis 20, 38–39Collagenosis 127, 132Collectionanaerobic specimens 99anorectal specimens 77blood specimens 20–22cervicovag<strong>in</strong>al specimens 80CSF specimens 25genital ulcer specimens 83pharyngeal specimens 62sputum specimens 68stool specimens 40surgical specimens 89–90urethral specimens 77–78ur<strong>in</strong>e specimens 30–32Colony-form<strong>in</strong>g units (CFUs) 34–35Concentration, m<strong>in</strong>imal <strong>in</strong>hibitory (MIC)5, 71, 104–105Conjunctivitis 76, 80, 81Conta<strong>in</strong>ers, ur<strong>in</strong>e specimens 30Contam<strong>in</strong>ationanaerobic cultures 100blood cultures 21, 24Control stra<strong>in</strong>sbacteria 14susceptibility test<strong>in</strong>g 110, 120Cooked meat broth, anaerobes 99, 101Cooked meat medium 92, 150, 151Corynebacteriumdiphtheriae 61, 65, 126, 147carriers 62culture/identification 64–65mitis 64Coryneform rods 92Cost–benefit ratio, diagnostic tests 2Co-trimoxazole 107, 109, 110, 116, 152Crepitation 90Criteria, quality assurance 4–6Cross-reactivity 59, 132Cross-resistance, staphylococci 97Cryptococcus neoformans 4, 21, 25, 26, 28,144CSF, see Cerebrosp<strong>in</strong>al fluidCulture media (see also Media) 7–8,10–12blood specimens 22–23CSF specimens 27–28dehydrated 7–8order<strong>in</strong>g/storage 7–8, 10performance tests 11–12preparation 8priority grad<strong>in</strong>g 143, 150–151quality control 10–12selection 7stool specimens 41–42, 44, 48storage 7–8, 10ur<strong>in</strong>e specimens 33–34157


INDEXCultures 13–15, 27, 29anaerobic 61, 91, 93, 99–101blood specimens 22–24Candida albicans 82cervicovag<strong>in</strong>al specimens 182Corynebacterium diphtheriae 64–65CSF specimens 27–28external quality assessment 16, 17Gardnerella vag<strong>in</strong>alis 82genital ulcer specimens 85Mycobacterium tuberculosis 72–75Neisseria gonorrhoeae 78–79, 82preservation 14–16sputum specimens 69–70stab cultures 15, 24, 29stock 10, 14–16Streptococcus pyogenes 63, 63surgical specimens 92–93susceptibility test<strong>in</strong>g 120ur<strong>in</strong>e specimens 32–35URT specimens 63–65Cyst<strong>in</strong>e–lactose–electrolyte-deficient(CLED) agar 33, 146Cyst<strong>in</strong>e trypticase agar (CTA) 15Cystitis 30Cytomegalovirus 76Cytotox<strong>in</strong> 39DCA, see Deoxycholate citrate agarDecarboxylase 11Decarboxylase broth 151Decontam<strong>in</strong>ation procedures,Mycobacterium tuberculosis cultures67, 72–74Decubitus ulcers 87, 89–90Def<strong>in</strong>itionsantimicrobial resistance/susceptibility104–105quality assessment 4quality assurance terms 2quality control 3–4Dehydrated media 7–8Dehydrolase 11Dental surgery 89Deoxycholate citrate agar (DCA) 7, 11,42, 44, 48, 147, 150Dermatitis 76Dextrose oxidation/fermentation(see also Glucose) 11Diagnostic discs, see AntimicrobialdiscsDiagnostic kits, recommended 151Diagnostic reagents, see ReagentsDiagnostic sensitivity 5–6, 13, 83Diagnostic specificity 6, 13, 83Diagnostic tests (see also Tests)error sources 2quality assurance 2–18Diarrhoeal diseases 37–39, 41Dicloxacill<strong>in</strong> 108Diffusion test, antimicrobial resistance104Dilution, serological tests 131–133, 137Dilution test, antimicrobial resistance103–104Dimethyl-p-phenylenediam<strong>in</strong>e(oxidase reagent) 52Diphtheria (see also Corynebacteriumdiphtheriae) 61, 64–65Disc-diffusion technique, seeKirby–Bauer disc-diffusiontechniqueDiscs, antimicrobial 13–14, 103, 104–105,107–121, 151–152Dis<strong>in</strong>fection, sk<strong>in</strong> 21, 25Dispatch (see also Transport)Mycobacterium tuberculosis cultures75pharyngeal specimens 62sputum specimens 68Distilled water, serological tests 124DNAse agar 94, 151Donovanosis, see Granuloma <strong>in</strong>gu<strong>in</strong>aleDorset egg medium 64, 151Doxycycl<strong>in</strong>e 152Drugs (see also Antimicrobials)nonproprietary names 108susceptibility test<strong>in</strong>g 107–109WHO list of essential 152Dysenteriae polyvalent antiserum 147,153Dysentery 37–38, 41Edwardsiella tarda 51, 146Egg yolk agar base 64Elek test (<strong>in</strong>-vitro toxigenic test) 38, 64ELISA test 39, 138Encephalitis 25Endocarditis 20Endometritis 76, 80Endovascular <strong>in</strong>fections 20Enrichmentculture media 151stool specimens 41–42, 146Enteric bacteria, colony morphology48Enteric <strong>in</strong>fections (see alsoStool specimens) 37–38Enterobacteragglomerans, see Pantoea agglomeranscloacae 7, 10, 15, 25, 28, 45–46, 48, 60,69–71spp. 21, 48Enterobacteriaceae 4, 7, 10, 15, 28,144–145, 148, 150colony morphology 48identification 45–50Kirby–Bauer technique 103men<strong>in</strong>gitis 25<strong>in</strong> pharynx 60, 148sputum cultures 69, 70, 71stab cultures 15susceptibility test<strong>in</strong>g 107, 116Enterococci 145Enterococcus faecalis 11, 63, 64Enterocolitis 20, 38158


INDEXEpidemiology 107Epididymitis 76, 77Epiglottitis 60Epste<strong>in</strong>–Barr virus 126Equipmentanaerobic jars 8, 44blood-culture 22–23care of 7operat<strong>in</strong>g temperature records 9quality control 8–9serological tests 123Error sources, diagnostic tests 2Erythrocytes 41Erythromyc<strong>in</strong> 71, 107, 109, 110, 116, 152Escherichiacoli 11–12, 17, 88, 91, 145bronchopneumonia 67colony morphology 48control stra<strong>in</strong>s 14, 110diarrhoeal disease 38, 41b-glucuronidase test (PGUA)35–36latex agglut<strong>in</strong>ation test 138men<strong>in</strong>gitis 25, 138performance tests 10–11<strong>in</strong> pharynx 60Shigella differentiation 50–51, 59stool specimens 37–38, 41, 146susceptibility test<strong>in</strong>g 120ur<strong>in</strong>ary tract <strong>in</strong>fection 30, 35–36,94wound <strong>in</strong>fections 88fergusonii 38hermanii 38Essential drugs, WHO list 152Ethylenediam<strong>in</strong>e tetraacetic acid (EDTA)95Exudates, purulent, see Purulentexudates; Surgical specimensFacultative anaerobic bacteria 98Faecal specimens, see Stool specimensFalse negatives, blood cultures 21False positives, FTA(Abs) test 131–132Fasciola hepatica 92Febrile agglut<strong>in</strong><strong>in</strong>s tests 133–135Femalesgenital specimens 79–82ur<strong>in</strong>e specimens 31Fevers 37, 133–135Filter-paper dip-strip method, ur<strong>in</strong>especimens 33–34Flexneri polyvalent antiserum 147, 153Flocculation reactions, serological tests125Floramixed anerobic 4normal pharyngeal 60–61Flucloxacill<strong>in</strong> 108Fluorescence microscopy 123, 131–132Fluorescent treponemal antibodyabsorption (FTA-Abs) test 123,124, 126, 127, 131–133Francisella tularensis 133Fungaemia 20–21Fungi 10fungaemia 20–21men<strong>in</strong>gitis 25–28pharyngitis 61surgical specimens 92, 93Fusobacterium spp. 61Fusospirochaetal complex 61, 62Gardnerella vag<strong>in</strong>alis 76, 79, 80, 82, 149Gas gangrene 88, 93, 98, 101Gastroenteritis 37–38Gelat<strong>in</strong>ase 11, 48Generic names, antimicrobials 108Genital herpes 76, 82Genital specimens 77, 79–82Genital ulcers 82–5Gentamic<strong>in</strong> 107, 109, 110, 116, 152Ghost cells 41Giemsa sta<strong>in</strong> 85Glasswareequipment 8serological tests 123–124Glomerulonephritis 61, 135Glucose 27, 46, 52, 63Glucuronic acid 35b-Glucuronidase test, Escherichia coli 13,35–36, 146, 151Gluteal abscesses 92Glycerol, long-term preservation 14Gold immunoassay 138Gonococcal antimicrobial supplement151Gonococcal pharyngitis 61Gonococcal urethritis 77Gonococci, culture preservation 16Gonococcus, see Neisseria gonorrhoeaeGonorrhoea 61, 78, 81Gram-negative organisms 10, 20Bacillus anthracis 96CSF cultures 27men<strong>in</strong>gitis 28, 29piperacill<strong>in</strong> 116respiratory tract <strong>in</strong>fection 61sputum specimens 69stool cultures 45, 47surgical specimens 87, 91, 96ur<strong>in</strong>e cultures 34Gram-positive organisms 10, 20, 27–28,91CSF cultures 27sputum specimens 69, 70stool cultures 46–47surgical specimens 91, 95ur<strong>in</strong>e cultures 34Gram-sta<strong>in</strong>ed smears(see also Gram sta<strong>in</strong><strong>in</strong>g) 64bacterial vag<strong>in</strong>osis 81CSF specimens 26–27sputum specimens 69surgical specimens 91, 92, 93ur<strong>in</strong>e specimens 32159


INDEXGram sta<strong>in</strong><strong>in</strong>g (see also Gram-sta<strong>in</strong>edsmears) 13, 26, 31, 77, 152anaerobes 100, 101Granulocytopenia 61Granuloma <strong>in</strong>gu<strong>in</strong>ale (donovanosis) 76,82, 83, 85Growth factors 64, 100Gunshot wounds 88H factor antisera 147, 153Haemagglut<strong>in</strong>ation tests, stool cultures53–54Haem<strong>in</strong> 85, 100Haemolys<strong>in</strong> 23, 63, 135Haemolysisalpha 11, 28, 50, 70antibiotic susceptibility 29beta 11, 28, 63, 64performance test<strong>in</strong>g 10–11reverse CAMP test 101b-Haemolytic streptococci 61, 63–64group<strong>in</strong>g kit 148Haemophilusducreyi 76, 82, 83, 85, 149<strong>in</strong>fluenzae 10–11, 25, 28, 144, 147, 148agglut<strong>in</strong>at<strong>in</strong>g antisera 145, 147, 153latex agglut<strong>in</strong>ation test 138lower respiratory tract <strong>in</strong>fections66, 67, 69, 70, 71surgical specimens 93susceptibility tests 106para<strong>in</strong>fluenzae 10, 11spp. 16, 60, 63, 126HBV, see Hepatitis B virusHEA, see Hektoen enteric agarHeart <strong>in</strong>fusion agar 42, 48Hektoen enteric agar (HEA) 42, 48Hepatitis B virus (HBV) 76Hero<strong>in</strong> 127Herpes, genital 82Herpesvirus, human (HSV) 76, 77, 80, 82Heteroresistance 97Histoplasma capsulatum 92HIV, see Human immunodeficiency virusHospital-acquired <strong>in</strong>fection, seeNosocomial <strong>in</strong>fectionHot-air ovens, quality control 8HPV, see Human papilloma virusHSV, see Herpesvirus; HumanherpesvirusHuman herpesvirus 76, 77, 80, 82Human immunodeficiency virus (HIV)20, 37, 61, 76, 83Human papilloma virus (HPV) 76Hydrogen generator 44, 150, 152Hydrogen peroxide 44, 152Hydrogen sulfide 46, 51Hyphae, fungal 92Iatrogenic <strong>in</strong>fection 20Identification (see also Interpretation)anaerobic bacteria 101–102Bacillus anthracis 93, 96–97Bacillus fragilis 101Clostridium perfr<strong>in</strong>gens 101–102Corynebacterium diphtheriae 64–65CSF pathogens 28–29Neisseria gonorrhoeae 79Pasteurella multocida 93, 96Peptostreptococcus spp. 102Salmonella spp. 44–46, 50–51sputum pathogens 70Staphylococcus spp. 94–96stool pathogens 44–59Streptococcus pyogenes 63surgical specimen pathogens 93–97ur<strong>in</strong>e pathogens 32–36Vibrio cholerae 47–48, 52–53Yers<strong>in</strong>ia enterocolitica 47, 52–53, 59IFA, see Indirect fluorescent antibodytestImmunocompromised patients 20, 60,82diarrhoea 37oral candidiasis 61Immunofluorescence assay 77Incubationanaerobic specimens 99–102blood cultures 23Campylobacter spp. 43–44Clostridium difficile 43Kirby–Bauer method 114stool specimens 43–45susceptibility tests 118Vibrio cholerae 43Yers<strong>in</strong>a spp. 43Incubators, quality control 8India <strong>in</strong>k 145, 152Indirect fluorescent antibody (IFA)test 126Indole 46, 51Indole test 96Infants, ur<strong>in</strong>e specimens 31Infertility 76, 80Influenza 67Inhibitors, media/reagent use 151Inoculationanaerobic specimens 100–101stool specimens 41–43surgical specimens 92–93susceptibility test<strong>in</strong>g 111–114, 118,120–121ur<strong>in</strong>e specimens 33–34Inspection, equipment 8Intensive-care departments, <strong>in</strong>fections67Intermediate susceptibility 105Interpretationcervicovag<strong>in</strong>al cultures 81Mycobacterium tuberculosis cultures 74sputum cultures 69–70test results 3urethral cultures 78ur<strong>in</strong>e cultures 34–35Iod<strong>in</strong>e 21Isolation, enteric pathogens 42–44160


INDEXIsolation media 43, 144–149IsoVitaleX 78, 149, 151Jarsanaerobic 8, 44candle 43, 69, 100Kanamyc<strong>in</strong> 100, 109, 152Kirby–Bauer disc-diffusion technique(modified) 13, 71, 97<strong>in</strong>terpretative chart 116susceptibility test<strong>in</strong>g 103, 104–105,109–119Kits, diagnostic 151Klebsiellapneumoniae 10–11, 13, 17, 67, 148spp. 48, 60, 91Kligler’s iron agar (KIA) 11, 23, 51, 54priority grad<strong>in</strong>g 146, 147, 150stool specimens 44–49Kovacs reagent for <strong>in</strong>dole 46, 146, 147,152<strong>Lab</strong>oratoriesappropriate resources use 39–40operations manual 6Lacerations, <strong>in</strong>fected 89–90b-Lactamase production 71, 79, 85, 97,106, 108test reagent 144–145Lactobacilli, vag<strong>in</strong>al 80Lactose 44–45, 46Lactose non-ferment<strong>in</strong>g bacteria 44–45Latex agglut<strong>in</strong>ation tests 63, 135–139Lecith<strong>in</strong>ase 42, 50Legionella pneumophila 66, 126Legionnaire disease 66Leigh & Williams method, ur<strong>in</strong>e cultures33Leprosy 127Leptospirosis 20Leukocyte esterase 32LeukocytesCSF specimens 25–27polymorphonuclear 78stool specimens 41ur<strong>in</strong>e specimens 32Lipase 42, 50Listeria monocytogenes 21, 80, 144men<strong>in</strong>gitis 25, 28, 29Liver abscesses 92Löffler coagulated serum 64, 148, 150Loop technique, calibrated 32, 33Löwenste<strong>in</strong>–Jensen medium 28, 67, 72,93, 145, 148, 150Lower respiratory tract <strong>in</strong>fections 66–75common 66–68culture/<strong>in</strong>terpretation 69–70, 72–74diagnostic reagents 149expected pathogens 148media 148–149specimen collection/process<strong>in</strong>g 68–69susceptibility test<strong>in</strong>g 70–71Lumbar puncture 25Lung abscesses 66–67Lyme disease 132Lymph nodesspontaneous dra<strong>in</strong>age 90surgical specimens 87Lymphogranuloma venereum 76Lyophilization 14Lys<strong>in</strong>e 46, 151Lys<strong>in</strong>e decarboxylase 46, 152Lys<strong>in</strong>e decarboxylase broth 146, 147MacConkey agar 11anaerobes 100CSF cultures 27, 28priority grad<strong>in</strong>g 144–148, 150stool cultures 42, 47–48, 50surgical cultures 92, 93ur<strong>in</strong>e cultures 33–34Macroscopic evaluationCSF specimens 26sputum specimens 68–69surgical specimens 90–91Ma<strong>in</strong>tenanceequipment 8, 123stock cultures 14–16Malaria 127Malesurethritis 77–79ur<strong>in</strong>e specimens 31Malonate broth 11Maltose 64Mannitol 51–52, 70Mannitol salt agar 11, 23, 70, 93, 150,151Manuals, laboratory operations 6–7Mastitis 94MaterialsASO tests 136febrile agglut<strong>in</strong><strong>in</strong>s test 134FTA-Abs test 132RPR test 130serological tests 123–124VDRL test 127Measles 67Media (see also Culture media) 7–12, 42,142anaerobic specimens 99–101blood specimens 22–23, 144Corynebacterium diphtheriae culture 64CSF specimens 27–28, 145essential 141–53exudates/pus 92–93, 150lower respiratory tract specimens69–70, 148–149Mycobacterium tuberculosis culture 74Neisseria gonorrhoeae culture 78priority grad<strong>in</strong>gs 143, 150–151quality control 10–12sputum specimens 67, 69–71stool specimens 41–42, 146–147storage 10Streptococcus pyogenes culture 63161


INDEXsurgical specimens 92–93susceptibility test<strong>in</strong>g 110–111upper respiratory tract specimens 64ur<strong>in</strong>e specimens 33, 145–146urogenital specimens 149Medusa head 96Mellibiosa 53Menadione 100Men<strong>in</strong>gitis 25–28, 86anthrax 96Escherichia coli 138neonates 21, 25Pasteurella multocida 96pathogens 138viral 76Men<strong>in</strong>gococcus, see Neisseria men<strong>in</strong>gitidisMetacill<strong>in</strong>, resistance to 17, 62, 97, 108Methyl red/Voges Prosgauer 11Methylene blue 8, 41, 64, 77Meticill<strong>in</strong>-resistant Staphylococcus aureus(MRSA) 17, 62Metronidazole 102MIC, see M<strong>in</strong>imal <strong>in</strong>hibitoryconcentrationMicroaerophilic bacteria 98Microscopesma<strong>in</strong>tenance 123quality control 8Microscopic exam<strong>in</strong>ationcervicovag<strong>in</strong>al specimens 81CSF specimens 26–28genital ulcer specimens 83–85pharyngeal specimens 62respiratory tract <strong>in</strong>fections 62sputum specimens 69STD specimens 78, 81, 83–85surgical specimens 86, 91–92Treponema pallidum 83–85urethral specimens 78Microscopy, dark field 50, 82, 83MIL, see Motility–<strong>in</strong>dole–lys<strong>in</strong>e mediumMIU, see Motility-<strong>in</strong>dole-urease mediumM<strong>in</strong>eral oil 15M<strong>in</strong>imal <strong>in</strong>hibitory concentration (MIC)5, 71, 104–105M<strong>in</strong>ocycl<strong>in</strong>e 108Mobiluncus spp. 76, 79–80Monitor<strong>in</strong>g, equipment 8Mononucleosis, <strong>in</strong>fectious 126Moraxella catarrhalis 10, 60, 66, 69, 70, 71,147, 148Morganella 51Morphology, common enteric bacteriacolonies 48Motility–<strong>in</strong>dole–lys<strong>in</strong>e medium (MIL)44, 45–46, 47Motility–<strong>in</strong>dole–urease medium (MIU)146–147, 150MRSA, see Meticill<strong>in</strong>-resistantStaphylococcus aureusMTM, see Thayer–Mart<strong>in</strong> mediumMueller–H<strong>in</strong>ton agar 11, 14, 20, 24, 54,71, 110–111, 120, 150Mueller–H<strong>in</strong>ton chocolate horse bloodagar 149, 150Mycetoma 90–92Mycobacteria, HIV/AIDS 37, 87, 92, 93,126, 150Mycobacteriumbovis 74chelonei 92fortuitum 92, 93mar<strong>in</strong>um 92tuberculosis 25, 66, 72–75, 87, 92, 145,148, 150ulcerans 92, 150Mycoplasmahom<strong>in</strong>is 76pneumoniae 66, 122Mycoses, lymph nodes 87N-acetyl-L-cyste<strong>in</strong>e-sodium hydroxide(NALC) 72, 73Naegleria fowleri 26Nafcill<strong>in</strong> 108NALC, see N-acetyl-L-cyste<strong>in</strong>e-sodiumhydroxideNalidixic acid 107, 110, 116, 152Nasopharyngitis 60Necrotiz<strong>in</strong>g ulcerative pharyngitis(V<strong>in</strong>cent ang<strong>in</strong>a) 61, 62Needles, serological tests 124Neisseriacatarrhalis, see Moraxella catarrhalisgonorrhoeae 10, 12, 76, 77, 79–80, 81,149culture 78–79, 82identification 79susceptibility test<strong>in</strong>g 79, 106men<strong>in</strong>gitidis 10, 12, 21, 25, 28, 29,144–145, 147agglut<strong>in</strong>at<strong>in</strong>g antisera 144–145, 147,153carriers 62latex agglut<strong>in</strong>ation test 138susceptibility 106Neomyc<strong>in</strong> 100Neonatal <strong>in</strong>fection 80, 82Neonatal men<strong>in</strong>gitis 21, 25Netilmyc<strong>in</strong> 109New York City medium 78, 149NGU, see Nongonococcal urethritisNitrate broth 11Nitrate reduction tests 32, 64, 96Nitrocef<strong>in</strong> test 79, 149, 151Nitrofuranto<strong>in</strong> 107, 109, 110, 116, 152o-Nitrophenyl-b-D-galactopyranoside(ONPG) test 13, 51, 146, 147, 151p-Nitrophenyl-b-Dglucopyranosiduronicacid(PGUA) test 13, 35–36, 151Nocardia asteroides 93Nongonococcal urethritis (NGU) 77, 78Nonproprietary names, drugs 108Non-trepanomal tests 126–131Non-tuberculous acid-fast bacilli 92162


INDEXNorfloxac<strong>in</strong> 107, 110, 116Normal flora, pharynx 60–61Nosocomial <strong>in</strong>fections 21, 67, 88–89Novobioc<strong>in</strong> 146, 151Nystat<strong>in</strong> 78, 151O antiserum polyvalent 147, 153Obligate bacteria, aerobic/anaerobic 98Oleandomyc<strong>in</strong> 109ONPG, see o-Nitrophenyl-b-DgalactopyranosidetestOperat<strong>in</strong>g temperature, equipment 9Operations manuals 6–7Opthalmia neonatorum 80Optoch<strong>in</strong> discs 13, 23, 28, 69, 70, 144,145, 148, 149, 151Oral candidiasis 61–62Oral surgery 89Order<strong>in</strong>g procedures, dehydrated media7–8Ornith<strong>in</strong>e 11, 28, 51Ornith<strong>in</strong>e decarboxylase 51–52Otitis media 60, 76Ovens, hot-air 8Oxacill<strong>in</strong> 71, 97, 107, 108, 110, 116Oxidase reaction 79, 96Oxidase reagents 13, 51, 144–153Oxidase test, stool specimens 49Oxygen, bacteria requirement 98Oxytetracycl<strong>in</strong>e 108Pantoea agglomerans 21Paragonimus westermani 92Parasitic <strong>in</strong>fection, surgical specimens 92Pasteurella multocida 88, 150identification 93, 96Pathogens 143blood 144CSF 144–145enteric disease 37–39, 42lower respiratory tract 148pus/exudates 149–150STDs 149stool 146upper respiratory tract 147–148ur<strong>in</strong>e 145Pelvic <strong>in</strong>flammatory disease (PID) 76, 80Penicill<strong>in</strong>s, susceptibility test<strong>in</strong>g 108Peptone urea broth 147, 150Peptone water 11, 51Peptostreptococcus spp. 67, 98–99, 102Performance testsculture media 11–12prepared media 10sta<strong>in</strong>s/reagents 12, 13Pericardial sac, exudates 87Peritoneal cavity, purulent exudate 87,90Petroff procedure, see Sodium hydroxideprocedurePGUA, see p-Nitrophenyl-b-Dglucopyranosiduronicacid testPharyngitis 60–65, 76Pharynx, normal flora 60–61Phenol red broth 147, 151Phenylalan<strong>in</strong>e 11, 51Phenylalan<strong>in</strong>e deam<strong>in</strong>ase 51pH test<strong>in</strong>g 10Piperacill<strong>in</strong> 107, 110, 116, 156Pivampicill<strong>in</strong> 109Plasma, Staphylococcus aureus coagulasetest 95–96, 152Plesiomonas shigelloides 51, 53, 59, 146Pleural cavity, exudates 87, 90Pleural effusion 66, 67Pleurisy 66Pneumococcus, see StreptococcuspneumoniaePneumonia 61, 66, 67–68atypical 127Corynebacterium trachomatis 76, 80Polymorphonuclear leukocytes 78Polymyx<strong>in</strong> B susceptibility test 53, 54Polysaccharides 63Polyvidone iod<strong>in</strong>e 21Polyvitex 151Porphyromonas spp. 87, 98Potassium hydroxide 80, 92Precipit<strong>in</strong> reactions, see FlocculationreactionsPregnancy 80, 127, 132Preservation, stock cultures 14–16Prevotella melan<strong>in</strong>ogenica 67, 87Prevotella spp. 98Priority grad<strong>in</strong>gs, media/reagents143–152Proctitis 76Propionibacterium acnes 21, 24Prostatitis 30, 76Prote<strong>in</strong> A 125Proteusmirabilis 10–12spp. 10–12, 21, 48, 51, 117vulgaris 133Providentia spp. 48, 51Prozone reaction 129, 133Pseudobacteraemia 21Pseudomembranous colitis 39Pseudomonasaerug<strong>in</strong>osa 10–11, 87, 90, 110, 144bronchopneumonia 67susceptibility tests 107, 116, 120cepacia 17pseudomalei, see Burkholderiapseudomaleispp. 22, 91, 145, 147, 150<strong>in</strong> pharynx 60sputum specimens 69, 70Public health, enteric disease 39Pulmonary tuberculosis 66, 67–68Purple lactose agar 145, 150Purulent exudates 77, 86–97, 149–150abscesses 67, 89collection/transport 86–87, 89culture 89, 92–93diagnostic reagents/media 150163


INDEXexpected pathogens 149–150pathogen identification 93–97wound <strong>in</strong>fections 87–88Pus 86, 89, 91, 93lung abscesses 67macroscopic evaluation 90–91Pyelonephritis 20, 30Pyocyan<strong>in</strong> 90Pyogenic bacteria 68Pyomyositis 94PYR, see Pyrrolidonyl-b-naphthylamidetestPyrrolidonyl-b-naphthylamide (PYR)test 64, 151Quality assessment 4, 16–18Quality assurance 2–18external 4<strong>in</strong>ternal 3–4Quality controldef<strong>in</strong>ition 3–4equipment 7, 8<strong>in</strong>ternal 6–16prepared media 10–12serological tests 122–124stock stra<strong>in</strong>s 10susceptibility tests 120–121Quality criteria, microbiology 4–6Quantitative culturesserological tests 129, 131ur<strong>in</strong>e specimens 32–35Qu<strong>in</strong>olones 102Rabies 88Rapid diagnostic testsCSF specimens 145, 151URT specimens 148Rapid plasma reag<strong>in</strong> (RPR) test 123–124,126, 129–131Reagents 142, 150–153ASO tests 136blood specimens 144CSF specimens 145febrile agglut<strong>in</strong><strong>in</strong>s test 134FTA-Abs test 132Kirby–Bauer method 110–111lower respiratory tract 149miscellaneous diagnostic 152performance tests 11–12, 13priority grad<strong>in</strong>gs 143pus/exudates 150recommended 150–151RPR test 130serological tests 124stool specimens 147susceptibility test<strong>in</strong>g 110–111upper respiratory tract 148ur<strong>in</strong>e specimens 146urogenital specimens 149VDRL test 127–128Reag<strong>in</strong> 126, 127Records, equipment operat<strong>in</strong>gtemperature 9Rectal swabs, collection 40Reference laboratories, use of 16Refrigerators, quality control 8Reiter syndrome 76Reliability, diagnostic tests 2, 5, 16Reproducibility, diagnostic tests 2, 5Resistanceantimicrobial 101–121metacill<strong>in</strong> and related drugs 17, 62,97, 108Respiratory tract <strong>in</strong>fections, see Lowerrespiratory tract; Upperrespiratory tractResults, report<strong>in</strong>g 18Reverse CAMP test 28, 64, 101–102Rhamnose 51, 53Rheumatic disease 127Rheumatic fever 61, 135Rickettsia spp. 126, 133Rotavirus, diarrhoea 39RPR, see Rapid plasma reag<strong>in</strong> testRubella 17, 126Sabouraud dextrose agar 28, 70, 93, 145,149–151Saccharose 64Safety, Mycobacterium tuberculosiscultures 74–75Sal<strong>in</strong>e 112, 124, 127, 128, 132Salmonellaarizonae 51choleraesuis 51groups C and D 58non-typhi 144paratyphi 17, 46, 51, 58, 146spp. 10–12, 25, 37, 40, 41, 43, 106,146agglut<strong>in</strong>at<strong>in</strong>g antisera 144, 147,153colony morphology 48identification 44–46, 50–51nomenclature 54–55serological identification 54–58typhi 17, 21, 42, 51, 107, 133, 144, 146typhimurium 10–12Salmonella–Shigella agar 7, 11, 42–44, 48,147, 150Salmonellosis 37, 41Salp<strong>in</strong>gitis 76Schaedler broth 92, 144Screen<strong>in</strong>g, ur<strong>in</strong>e specimens 32Selenite F broth 11, 41, 146, 151Sensitivity, diagnostic 5–6, 13, 83Sensitivity test<strong>in</strong>g, see Susceptibilitytest<strong>in</strong>gSepticaemia 20, 96Sera 122, 131quality assessment 17–18serological tests 124Serological tests 12–13, 122–139Salmonella spp. 54–58syphilis 126–133Serratia marcescens 10, 21, 51, 91164


INDEXSexually transmitted diseases (STDs)76–85causal agents 76–77diagnostic reagents/media 149expected pathogens 149specimen collection/transport 77–78,80–81, 83specimen culture 78–79, 82, 85susceptibility tests 79Shigellaboydii 38, 46dysenteriae 38, 42, 47flexneri 10–12, 36, 38, 46sonnei 38, 51spp. 10–12, 16, 17, 20, 37–38, 146agglut<strong>in</strong>at<strong>in</strong>g antisera 147, 153f<strong>in</strong>al identification 50–52identification 44–47latex agglut<strong>in</strong>ation test 138serological identification 59stool specimens 41, 42, 43, 46–47, 51susceptibility tests 107, 109Shigellosis 41Shock, septic 20Silver nitrate 83Simmons citrate agar 11, 23, 51, 146–147,151S<strong>in</strong>us tract, spontaneous dra<strong>in</strong>age 90S<strong>in</strong>usitis 60Sjögren syndrome 127Sk<strong>in</strong> dis<strong>in</strong>fectionblood collection 21CSF collection 25Sk<strong>in</strong> <strong>in</strong>fections 87–88, 92, 94Slide agglut<strong>in</strong>ation tests 28, 63, 138Slide clump<strong>in</strong>g test 95Smears, see Gram-sta<strong>in</strong>ed smearsSodium citrate 73Sodium hydroxide procedure (Petroff),Mycobacterium tuberculosis cultures72–73Sodium metabisulfite–sodium pyruvate42Sodium polyanethol sulfonate (SPS) 22,144, 151Sonnei polyvalent antiserum 147, 151Sorbitol 63Soy case<strong>in</strong> agar, see Tryptic soy agarSpecificity, diagnostic 6, 13, 83, 122, 126,132Specimen collection, see CollectionSpecimen preparationblood 22–23CSF 26Specimen transport, see TransportSpiramyc<strong>in</strong> 109Spirochaetes 61, 84, 126SPS, see Sodium polyanethol sulfonateSputum specimens 72–74collection 68culture/<strong>in</strong>terpretation 69–70macroscopic evaluation 68–69microscopic exam<strong>in</strong>ation 69pulmonary tuberculosis 67, 67–68transport 75Stab cultures 15, 24, 29Stab wounds 88Sta<strong>in</strong>s (see also Gram sta<strong>in</strong><strong>in</strong>g;Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g)Albert 64Giemsa 85performance tests 12, 13Standardization, disc-diffusion methods119Standard stra<strong>in</strong>s, quality control 120Staphylococcusaureus 10, 12, 21, 80, 94–96, 144, 148bronchopneumonia 67carriers 62identification 70<strong>in</strong> pharynx 60–61sputum specimens 69susceptibility test<strong>in</strong>g 120wound <strong>in</strong>fections 88epidermidis 20, 21, 24, 60, 94–96saprophyticus 94–96, 145spp. 11–12, 25, 145surgical specimens 87, 93, 94–96susceptibility test<strong>in</strong>g 97, 107vancomyc<strong>in</strong> 116STDs, see Sexually transmitted diseasesSterility test<strong>in</strong>g, prepared media 10Stock cultures 10, 14–16Stool specimens 37–59anaerobic cultures 100collection and transport 40enrichment and <strong>in</strong>oculation 41–43expected pathogens 146laboratory resource use 39–40media 42, 146–147pathogen identification 7, 42–43,44–59reagents 147serological identification 54–59visual exam<strong>in</strong>ation 41Storagedehydrated media 7–8prepared media 10stock cultures 14–16Streptococcusagalactiae 10, 21, 25, 28, 29, 64, 145groups A and B 61, 63, 126, 135mitis 10pneumoniae 10, 21, 25, 66, 67, 69, 70,71, 145, 148antibiotic susceptibility 28latex agglut<strong>in</strong>ation test 138men<strong>in</strong>gitis 25upper respiratory tract <strong>in</strong>fections60, 148pyogenes 10, 21, 61, 62, 63–64, 126, 135carriers 62culture/identification 63pharyngitis 61priority grad<strong>in</strong>g 144, 148, 150susceptibility 106165


INDEXspp. 10, 15, 23, 61, 144ASO test 135–137culture preservation 16surgical specimens 87, 91, 93, 150Streptolys<strong>in</strong> O 135Streptomyc<strong>in</strong> 109Str<strong>in</strong>g test, stool specimens 49–50Strips, diagnostic 151Stuart transport medium 40, 62, 77, 81,149, 151Subcultures, blood samples 23Subcutaneous tissue, <strong>in</strong>fections 87Sucrose fermentation 48, 51–53Sulfamethoxazole 109Sulfonamide 107, 108, 110, 116, 152Sulfur granules 89Supplements 151Surgical specimens 86–87collection/transport 89culture 92–93macroscopic evaluation 90–91microscopic exam<strong>in</strong>ation 91–92pathogen identification 93–97susceptibility test<strong>in</strong>g 97Surveys, quality assessmentprogrammes 17Susceptibility test<strong>in</strong>g 13–14, 103–121anaerobic specimens 102basic antimicrobials 107–109benzylpenicill<strong>in</strong> 108, 110, 116CSF cultures 29direct vs <strong>in</strong>direct 117general pr<strong>in</strong>ciples 103–105<strong>in</strong>direct 117Neisseria gonorrhoeae 79plate size 118–119recommended discs 152sputum cultures 70–71stool cultures 54surgical specimens 97throat specimens 65treatment guide 106ur<strong>in</strong>e cultures 36Syphilis (see also Trepanoma pallidum) 76,82, 83–85serological tests 13, 125, 126–133Tablets, diagnostic 151Talampicill<strong>in</strong> 109TCBS, see Thiosulfate citrate bile saltssucrose agarTellurite agar 42, 48, 64, 148, 151Tellurite discs 13, 23Tellurite taurocholate gelat<strong>in</strong>e agar(TTGA) 42, 48Temperatureequipment operat<strong>in</strong>g records 9susceptibility tests 118Term<strong>in</strong>ology, microorganisms 5Testsagglut<strong>in</strong>ation 56–59, 125–126, 135–139antimicrobial susceptibility 13–14,103–121ASO 135–137diffusion/dilution 103–104febrile agglut<strong>in</strong><strong>in</strong>s 133–135FTA-Abs 123, 124, 126, 127, 131–135media performance 11–12ONPG 13, 51, 146, 147, 151PGUA 13, 35–36rapid diagnostic 145, 148, 151RPR 123–124, 126, 129–131serological 12–13, 122–139stool specimens 49–50Tetanus 88, 98Tetracycl<strong>in</strong>e 71, 107, 108, 110, 116Thayer–Mart<strong>in</strong> medium (MTM),modified 12, 61, 78, 148, 149Thiamphenicol 108Thioglycollate broth 12, 23, 38, 92, 144,150, 151Thiosulfate citrate bile salts sucrose(TCBS) agar 12, 42, 47–48, 147,151Throat swabscollection 62culture/identification 63–65gonococcal pharyngitis 61Thrombophlebitis 20Tobramyc<strong>in</strong> 107, 109, 110, 116Tonsillitis 60, 61Toxicity assays 38, 64Toxigenicity 64Toxic shock 20, 80Transport (see also Dispatch)anaerobic specimens 99cervicovag<strong>in</strong>al specimens 81CSF specimens 25respiratory tract specimens 62sputum specimens 68STD specimen media 149stool specimens 40, 146surgical specimens 89urethral specimens 77–78urogenital specimens 81Transport media 81Amies 40, 41, 62, 66, 77, 81, 149, 151Buffered glycerol sal<strong>in</strong>e 146, 152Cary–Blair 40–41, 146, 151Stuart 40, 62, 77, 81, 149, 151Treatment, susceptibility tests as guide106Treponemapallidum 76, 82, 83–85, 125–126, 149v<strong>in</strong>centii 61Tributyr<strong>in</strong> 70, 148–151Trichomonas vag<strong>in</strong>alis 77, 81Trimethoprim 78, 107, 110, 116, 152Triple sugar iron agar 12, 70, 147Trisodium phosphate 26, 73Trypanosomiasis, African 26Tryptic soy agar (TSA) 15, 63, 150Tryptic soy broth (TSB) 22, 27, 96, 144,150, 151Tubercle bacillus, see Mycobacteriumtuberculosis166


INDEXTuberculosispulmonary 66, 67–68VDRL test 127Tuberculous men<strong>in</strong>gitis 27–28Turbidity standardKirby–Bauer technique 111–112susceptibility test<strong>in</strong>g 111Typhoid fever 20, 37Ulcerative pharyngitis, necrotiz<strong>in</strong>g(V<strong>in</strong>cent ang<strong>in</strong>a) 61, 62Ulcus molle, see ChancroidUpper respiratory tract <strong>in</strong>fections 60–65carriers 62causal agents 61–62diagnostic reagents/media 148direct microscopy 62expected pathogens 147–148pathogen culture/identification 63–65Urea medium 12, 44–45, 76, 77Ureaplasma urealyticum 77Urease 12, 45, 47, 51, 53Ureteritis 30Urethral specimenscollection/transport 77–78<strong>in</strong>terpretation 78Urethritis<strong>in</strong> men 77–79<strong>in</strong> women 80Ur<strong>in</strong>ary tract <strong>in</strong>fection (UTI) 30, 35, 94Ur<strong>in</strong>e 30–36culture/<strong>in</strong>terpretation 32–35, 100diagnostic reagents/media 145–146expected pathogens 145screen<strong>in</strong>g 32specimen collection 30–32Urogenital specimens 149UTI, see Ur<strong>in</strong>ary tract <strong>in</strong>fectionVag<strong>in</strong>itis 76, 79, 81Vag<strong>in</strong>osis 76, 79–82Vancomyc<strong>in</strong> 78, 110, 116, 149, 151, 152VCN mixture 78, 151VDRL, see Venereal Disease Research<strong>Lab</strong>oratory testVenepuncture, blood collection 21Venereal Disease Research <strong>Lab</strong>oratory(VDRL) test 123–124, 125syphilis 126, 127–129Ventricular puncture 25V-factor 13, 144–151Vibriocholerae 10, 16, 38, 146agglut<strong>in</strong>at<strong>in</strong>g antisera 147, 153identification 47–48, 52–53media 41, 42, 43fluvialis 38, 53furniss 53hollisiae 38, 53mimicus 38, 53parahaemolyticus 38, 47–49vibriostatic compound O:129 disc 147,151V<strong>in</strong>cent ang<strong>in</strong>a, see Necrotiz<strong>in</strong>gulcerative pharyngitisViral diarrhoea 41Viral men<strong>in</strong>gitis 27Vitox 151Voges–Prosgauer agar 11, 52, 53Water-baths, quality control 8, 123Weil–Felix reaction, rickettsias 133White blood cells, see LeukocytesWidal test, Salmonella typhi 6, 133Wilk<strong>in</strong>s–Chalgren anaerobe broth 100,144, 151WoundsClostridium spp. 98nosocomial <strong>in</strong>fections 88–90penetrat<strong>in</strong>g 87–90, 96Wright test, Brucella 133XLD, see Xylose–lys<strong>in</strong>e–deoxycholateagarXV-factor 13, 85, 144–145, 148–149, 151Xylose–lys<strong>in</strong>e–deoxycholate (XLD) agar42–44, 48, 147Yeasts (see also Fungi) 26, 69Yers<strong>in</strong>iaenterocolitica 17, 39, 133, 146colony morphology 48identification 47, 52–53, 59media 41, 42, 43frederiksenii 53<strong>in</strong>termedia 53kristensenii 53pseudotuberculosis 53Zephiran–trisodium phosphateprocedure 73–74Ziehl–Neelsen sta<strong>in</strong><strong>in</strong>g 74, 152CSF specimens 27, 28diagnostic specificity 6pulmonary tuberculosis 67sputum specimens 67surgical specimens 92, 93Zone diameters, disc-diffusionsusceptibility test<strong>in</strong>g 104–105,110–111, 116–119167

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!